Table of Contents

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Washington, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the


Securities Exchange Act of 1934

(Amendment No. )

Filed by the RegistrantFiled by a Partyparty other than the Registrant

Check the appropriate box:

     

CHECK THE APPROPRIATE BOX:

 

Preliminary Proxy Statement

☐  

Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2))

Definitive Proxy Statement

☒  

 

Definitive Proxy Statement

☐  

Definitive Additional Materials

☐  

Soliciting Material Pursuant to §240.14a-12

under §240.14a-12

AMN Healthcare Services, Inc.

LOGO

AMN HEALTHCARE SERVICES, INC.

(Name of Registrant as Specified in itsIn Its Charter)


(Name of Person(s) Filing Proxy Statement, if Other Thanother than the Registrant)

PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

required

Fee paid previously with preliminary materials

Fee computed on table belowin exhibit required by Item 25(b) per Exchange Act Rules14a-6(i)(1) and0-11. 0-11


Table of Contents

Notice of Annual Meeting
& Proxy Statement


Table of Contents

A Letter from Our CEO & Independent Board Chairman

 

AMN Healthcare is well positioned to continue to meet the needs of healthcare organizations in an era of workforce shortages.

Dear AMN Healthcare Shareholders,

On behalf of the Board and AMN Healthcare, thank you for the trust and confidence you have placed in us during this extraordinary time for the healthcare industry. In 2022, AMN Healthcare delivered record financial performance by supporting our clients, clinicians and communities as they navigated high service demand and workforce shortages. We believe our strong culture, our team’s ability to execute on our strategy combined with the platform we have created in healthcare, will continue to create value and make a positive impact on society.

Evolution of AMN as the Total Talent Solutions Leader

Our success over the years has been predicated on listening carefully to clients’ needs throughout dramatic changes in the healthcare industry – rising costs, healthcare reform, a major recession, an unprecedented pandemic, an aging population, and workforce shortages that today reach crisis proportions. To meet these challenges, AMN Healthcare has refined and continually strengthened our workforce solutions by investing in our existing services and platforms while also expanding into new solutions through strategic acquisitions and internal investments.

The results over time have been the creation of an entirely new type of company in the healthcare industry – a diversified, integrated total healthcare talent services organization. We strive to be recognized as the most trusted, innovative, and influential force in helping healthcare organizations provide a quality patient care experience that is more human, more effective, and more achievable. AMN Healthcare today places tens of thousands of nurses, physicians, allied health professionals, executives, and other professionals who are necessary to quality patient care and the business of healthcare. We invest in the improvement of the professional and personal lives of clinicians, particularly engaging many avenues of support for their mental health and wellbeing.

The value that we bring to our strategic partnerships with our clients has grown throughout the company’s history and will continue to be our priority. As workforce shortages and other systemic challenges persist, and as an aging populace needs greater and more complex healthcare services, the healthcare industry’s total talent needs for integrated staffing, precision planning and technology innovations become increasingly essential. AMN Healthcare is well positioned to continue to meet these needs for years to come. In 2022, we delivered record revenue of $5.24 billion, net income of $444.1 million and adjusted EBITDA of $846.7 million.(1) As a result of these strong partnerships between our clients, healthcare professionals and our team members, our total shareholder return outperformed a number of our peers.

AMN’s Culture is Foundational to Our Success

The commitment to help create a more just and inclusive society for all is a foundation of AMN Healthcare’s culture. AMN Healthcare has created a truly inclusive and diverse company, where 69% of our corporate team members are women and 45% are from historically underrepresented communities. Our commitment to advancing diversity extends to our upper ranks, where 63% of all corporate leaders are women and 29% of our leaders are BIPOC. In the boardroom, 56% of our Board of Directors are women and 33% are BIPOC, and in total, 67% of our Board have identities that were historically excluded from corporate Boards, which places AMN Healthcare among the highest levels of Board diversity in the healthcare industry and publicly

  

(1) Title of each class of securities to which transaction applies:

 

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐  

Fee paid previously with preliminary materials.

☐  

Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:


A Letter from our Independent Board Chairman and our CEO

Dear Fellow Shareholders,

On behalf of AMN Healthcare Services and its Board of Directors, we are pleased to invite you to attend our Annual Meeting of Shareholders on April 22, 2020 at our offices in Dallas, Texas. Throughout the past year, we have further advanced our position as the leader and trusted partner for total talent solutions to healthcare organizations. We made significant progress in our mission to deliver the best talent and insights to help healthcare organizations optimize their workforce, give healthcare professionals opportunities to do their best work towards quality patient care and create a values-based culture of innovation where our team members can achieve their goals.

Purpose, Profit and Culture

We recognize the integral role that our corporate purpose and culture play in the Company’s ability to generate sustainable profits and make a positive impact in society. We have established a performance and values-based culture that aligns our business strategy with the development of our greatest assets, our people. To this end, we have an active strategy to enhance diversity, equality, and inclusion in our workplace, workforce, and marketplace.

Diversity, Equality & Inclusion

Diversity, equality, and inclusion is a foundational element of AMN’s culture and helps us sustain a competitive advantage. We are among a unique group of companies with 44% female representation on our Board and 50% of our executive team from historically underrepresented groups. This diversity extends through our organization from our team members to our affiliate partners and suppliers. AMN strives to be a catalyst for change in the healthcare and staffing industries and in our communities by regularly publishing and participating in surveys and white papers that highlight diversity issues. In 2019, and for the third consecutive year, AMN was recognized by the Bloomberg Gender Equality Index and the Human Rights Campaign’s Corporate Equality Index.

Sustainable Long-Term Growth

Our strategy and our actions every day are grounded in the belief that we can achieve our mission by unlocking the strength of the diverse backgrounds, experiences, and perspectives of all our stakeholders. We believe this philosophy and approach will help us prepare for anticipated risks, create a platform for long-term growth and demonstrates the effective leadership and governance principles that sustainable-minded investors seek.

Thank you for your continued support and investment in AMN Healthcare, and we hope to see you at our 2020 Annual Meeting.

Sincerely,

LOGO

LOGO

Douglas D Wheat

Chairman of the Board

    Susan R. Salka

    Chief Executive Officer

“Inclusion for me is an action verb. I am proud that we have initiated a strategic action plan to promote and achieve true diversity, equality, and inclusion – to make our company, our industry, and the world around us better.”

Susan Salka


TABLE OF CONTENTS

  Page  
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

PROXY STATEMENT SUMMARY

1

PROPOSAL 1: ELECTION OF OUR DIRECTORS

6

CORPORATE GOVERNANCE

18

Overview of Our Corporate Governance Program

18

Our Annual Shareholder Outreach Summary

19

Our Human Capital Management Strategy

20

Our Corporate Social Responsibility Program

21

Our Board’s Role in Risk Oversight

23

Director Independence

26

Board Leadership Structure

27

Policies and Procedures Governing Conflicts of Interest and Related Party Transactions

28

Our Board’s Aggregate Tenure Policy

29

Board Meetings and Annual Meeting Attendance by Board Members

29

Committees of the Board

29

Executive Sessions ofNon-Management Directors

32

Communications with the Board of Directors

32

DIRECTOR COMPENSATION AND STOCK OWNERSHIP GUIDELINES

33

Director Cash Compensation

33

Director Equity Compensation

33

Director Compensation Table

34

Director Equity Ownership Requirement

34

COMPENSATION COMMITTEE REPORT

35

COMPENSATION DISCUSSION AND ANALYSIS

36

Introduction

36

Executive Summary

36

Response to 2019Say-on-Pay Vote

41

Our Compensation Program Philosophy and Objectives

42

Our Compensation Program Oversight

43

Components of Our Compensation Program

46

Our 2019 Compensation Program and Results

49

Equity Ownership Requirements, Clawback and No Pledging Policies

54

Tax Deductibility of Executive Compensation

55

Overview of Our 2020 Executive Compensation Program

55

EXECUTIVE COMPENSATION DISCLOSURE

57

OurNon-Director Executive Officers

57

Summary Compensation Table

58

Grants of Plan-Based Awards

60


  Page  

Outstanding Equity Awards at Fiscal Year End

61

Option Exercises and Stock Vested

63

Nonqualified Deferred Compensation

63

Termination of Employment and Change in Control Arrangements

64

CEO PAY RATIO

68

PROPOSAL 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION

69

REPORT OF THE AUDIT COMMITTEE

71
PROPOSAL 3: RATIFICATION OF THE SELECTION OF OUR INDEPENDENT PUBLIC ACCOUNTING FIRM72
PROPOSAL 4: REDUCE THE THRESHOLD NECESSARY TO CALL A SPECIAL SHAREHOLDERS MEETING73

PROPOSAL 5: SHAREHOLDER PROPOSAL

74

SECURITY OWNERSHIP AND OTHER MATTERS

76

Security Ownership of Certain Beneficial Owners and Management

76

Section 16(a) Beneficial Ownership Reporting Compliance

78

Shareholder Proposals for the 2021 Annual Meeting of Shareholders

78

Annual Report

78

Delivery of Proxy Statement, Annual Report or Notice of Internet Availability

78

Other Business

79

GENERAL INFORMATION

80
EXHIBIT A: STOCKHOLDER NOMINEE REQUIREMENTSA-1
EXHIBIT B:NON-GAAP RECONCILIATIONB-1
ANNEX A: Proposed Bylaw AmendmentAX-1


LOGO

Notice of Annual Meeting of Shareholders

Meeting Date

Wednesday, April 22, 2020

Time

8:30 a.m. (Central Time)

Location

8840 Cypress Waters Blvd., Suite 300

Dallas, Texas 75019

    Record Date    

Monday, February 24, 2020

The Annual Meeting of Shareholders (the “Annual Meeting”) of AMN Healthcare Services, Inc. will be held at our office located at 8840 Cypress Waters Boulevard, Suite 300, Dallas, Texas 75019 on Wednesday, April 22, 2020, at 8:30 a.m. Central Time, or at any subsequent time that may be necessary by any adjournment or postponement of the Annual Meeting. The purpose of the meeting is to:

(1)

elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified,

(2)

approve, bynon-binding advisory vote, the compensation of our named executive officers,

(3)

ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020,

(4)

approve a proposal to reduce the threshold necessary to call a special shareholders meeting; and

(5)

transact such other business, including consideration of a shareholder proposal if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

The Board of Directors has fixed the close of business on February 24, 2020 as the record date for determining the shareholders of the Company entitled to notice of and to vote at the Annual Meeting and at any adjournment or postponement thereof. Representation of at least a majority of the voting power represented by all outstanding shares is required to constitute a quorum at the Annual Meeting. Accordingly, it is important that your shares be represented at the Annual Meeting.

We will be using the Securities and Exchange Commission’s Notice and Access model (“Notice and Access”), which allows us to make proxy materials available electronically, as the primary means of furnishing proxy materials. We believe Notice and Access provides shareholders with a convenient method to access our proxy materials and vote. It also allows us to conserve natural resources which aligns with our Corporate Social Responsibility strategy by reducing our environmental footprint as well as reducing the costs associated with printing and distributing our proxy materials. On or about March 11, 2020, we will commence mailing by sending a Notice of Internet Availability of Proxy Materials to our shareholders with instructions on how to access our proxy statement and 2019 Annual Report, including the financial statements set forth in our annual report on Form 10-K, online and how to cast your vote. The Notice also contains instructions on how to receive a paper copy of the proxy statement and 2019 Annual Report.

March 11, 2020

By Order of the Board of Directors,

LOGO

Denise L. Jackson

Chief Legal Officer and Corporate Secretary

YOUR VOTE IS IMPORTANT

WE URGE YOU TO VOTE BY TELEPHONE OR INTERNET, IF AVAILABLE TO YOU, OR IF YOU RECEIVE THESE PROXY MATERIALS BY MAIL, PLEASE COMPLETE, SIGN, DATE, AND RETURN THE PROXY CARD PROMPTLY. PLEASE NOTE THAT IF YOUR SHARES ARE HELD BY A BANK, BROKER, OR OTHER RECORDHOLDER AND YOU WISH TO VOTE THEM AT THE MEETING, YOU MUST OBTAIN A LEGAL PROXY FROM THAT RECORDHOLDER.


              PROXY  STATEMENT SUMMARY              

Proxy Statement Summary

The summary below highlights certain information that may be found elsewhere in this proxy statement. We encourage you to read the entire proxy statement before casting your vote. Our proxy statement and related materials are first being made available to our shareholders on or about March 11, 2020.

Our Financial Performance

LOGO

(1)

More information on our adjusted EBITDA, which refers to our adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of our 20192022 net income to adjusted EBITDA, can be found atExhibit BA to this proxy statement (pageB-1) 113).

2023 Proxy Statement1

Table of Contents

A Letter from Our Total Return(²) vs. Russell 2000 and S&P 500

CEO & Independent Board Chairman

 

traded companies. The dedication of the AMN Healthcare culture has been widely recognized, including with the 2022 National Association of Corporate Directors (NACD) Diversity, Equity & Inclusion Award, along with many years of inclusion in the Bloomberg Gender-Equality Index and the Human Rights Campaign Corporate Equality Index. AMN Healthcare has significantly expanded its investment and accomplishments in establishing a diverse, equitable and inclusive corporate team, resulting in greater innovation and more expansive viewpoints and experiences to better serve our clients and enable our healthcare professionals to provide quality patient care.

Our culture of diversity, equality, equity and inclusion reaches far beyond our virtual corporate walls. Our core business seeks to reduce inequality and drive health equity. Our Language Services division breaks down language and communication barriers for millions of patients through real-time interpretation. We are enhancing access to healthcare services through our provision of teletherapy services and our international nurse division brings much needed qualified nurses to communities who otherwise may be left behind.

Vision – Present and Future

The vision of AMN Healthcare’s executive and board leadership, continues to be that AMN empowers the future of care as a long-term, vital partner for the complex and challenging realities that the healthcare industry faces today. We thank Susan Salka, who retired as AMN’s CEO in 2022, for her visionary leadership.

This post-pandemic era presents opportunities along with challenges, and AMN Healthcare is well positioned to capture those opportunities to deliver long-term value to its stakeholders. Enhanced healthcare workforce sustainability and engagement are goals we can achieve through growing partnerships between AMN Healthcare and our industry partners. Technology-enabled total talent solutions can mitigate pressures on healthcare organizations while driving better outcomes for care providers and their patients and improved performance for our company. We invest in the future by expanding our network of healthcare professionals overseas. We bolster our platforms through innovative solutions for the growing number of patients who are English learners or hearing impaired and telehealth for the rising demand for therapists and other clinicians in our schools. We will continue to focus on driving strong outcomes in our existing services while driving innovation that will result in improved patient outcomes, performance success for AMN Healthcare and our clients, and healthier communities where all can thrive.

These topics and other issues of shareholder interest are discussed further within this proxy statement and may be addressed at our 2023 Annual Meeting of Shareholders on Wednesday, May 17, 2023, at 1:00 p.m. Central Time. We will conduct our 2023 meeting virtually. We cordially invite you to join us and have included instructions for participating in our virtual shareholder meeting under the General Information Section of this proxy statement.

Gratefully Yours,

LOGOLOGO
LOGOLOGO

This post-pandemic era presents opportunities along with challenges, and AMN Healthcare is well positioned to capture those opportunities to deliver long-term value to its stakeholders.

 

(2)

The total returns reflected are as of December 31, 2019 and calculated by combining share price appreciation and dividends paid to show the total return to shareholders expressed as an annual percentage. Sources include: S&P Dow Jones Indices and FactSet.

 






DOUGLAS D. WHEAT

AMN HEALTHCARE SERVICES, INC.  

Chairman of the Board

CARY GRACE

2020 Proxy Statement

  1

President and Chief Executive Officer


            PROXY STATEMENT  SUMMARY               

Director Nominees

This year’s slate of director nominees to the Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (the “Company” or “AMN”) includes a new director, Ms. Teri G. Fontenot, who was appointed to the Board in September 2019. The addition of Ms. Fontenot, who is a former chief financial officer of three health systems and CEO of Women’s Hospital in Baton Rouge, Louisiana, supports our ongoing Board refreshment strategy and further strengthens and diversifies the aggregate skills, experiences and characteristics of our Board. Please find a list of all director nominees below. Additional information for each nominee can be found under “Election of Our Directors (Item 1)” beginning on page 6.

Name  Age   

Director

Since

   

 

Professional

Background

 

  

Board

Committees

 
Mark G. Foletta   59    2012   

 

Executive Vice President and

Chief Financial Officer, Tocagen Inc.

 

   Audit (Chair) 
Teri G. Fontenot   66    2019   

 

Former CEO of Women’s Hospital

 

   Audit 
R. Jeffrey Harris   65    2005   

Former Of Counsel at

Apogent Technologies, Inc.

  

 

 

 

 

Corporate Governance
& Compliance (Chair);
Executive

 

 

 
 
 

 

Michael M.E. Johns, M.D.   78    2008   

Professor in the School of Medicine,

Emory University

  

 

 

 

 

Compensation;
Corporate Governance
& Compliance

 

 

 
 
 

 

Daphne E. Jones   61    2018   

 

Former Senior Vice President –

Digital/Future of Work, GE Healthcare

 

   Audit; Compensation 
Martha H. Marsh   71    2010   

 

Former President and CEO,

Stanford Hospital and Clinics

 

   Compensation (Chair) 
Susan R. Salka   55    2003   

 

Chief Executive Officer,

AMN Healthcare Services, Inc.

 

   Executive 
Douglas D. Wheat   69    1999   

 

Managing Partner,

Wheat Investments, LLC

 

   

Board (Chairman);

Executive

 

 

                   

2  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


              PROXY  STATEMENT SUMMARY              

Our Key Executive Compensation Practices

            Practice             

Description
  

Balanced Approach

to Performance-

based Pay

2

Table of Contents

A Letter from Our CEO & Independent Board Chairman

AMN: LEADER & INNOVATOR IN TOTAL TALENT SOLUTIONS POSITIONED TO EMPOWER THE FUTURE OF CARE

Record Revenue of
$5.24B in 2022
Performance-based awards are tied to the achievementOver 250,000
Healthcare Professional
Placements
in 2022
Recognized
for Workplace
Equality on Human
Rights Campaign
Corporate Equality
Index
2018 – 2022
Ranked#91 on Fortune
Magazine’s 2022 List
of financial objectives, including revenue, adjusted EBITDA margin, adjusted EBITDA margin growth
Fastest Growing Companies
Named by
Newsweek as
one of America’s
Most Responsible
Companies
2020 – 2023
Diluted EPS of$9.90 and
Adjusted Diluted EPS of

$11.90 in 2022(1)
Recognized for
Workplace Equity
on Bloomberg
Gender-Equality
Index
2018 – 2023
Cary Grace joins
AMN Healthcare as its
President
and total shareholder return, as well as strategic leadership objectives.Chief
Executive Officer
WinnerNACD Diversity,
Equity & Inclusion Award
Public Company – Mid-Cap 2022
  

Three-Year

Performance Periods

(1)

More information on our adjusted diluted EPS, and Vest Schedules

The performance periods and vest schedules fora reconciliation of our equity awards span three years2022 GAAP diluted net income per share to promote a long-term approachadjusted diluted EPS can be found at Exhibit A to the achievement of strategic and financial objectives.this proxy statement (page 113).
  

Balanced Mix of

Pay Components

2023 Proxy Statement
Target compensation mix is not overly weighted toward annual incentive awards and balances cash and long-term equity awards in accordance with certain financial ornon-financial metrics that align with our short and long-term strategic goals.3

Table of Contents

CEOOur Aspiration

Compensation

at Risk

In 2019, approximately 80% of our CEO’s target compensation was variable and at risk.

We strive to be recognized as the most trusted, innovative, and influential force in helping healthcare organizations provide a quality patient care experience that is more human, more effective, and more achievable.

Our Mission

Equity Ownership

GuidelinesDELIVER

 

CEOg 5x salary

Named executive officersg 2x salary

Other members of the CEO Committee (CEO’s direct reports)g 1.5x salary

Executive

Compensation

Philosophy

Reflects our commitment to equal pay principles and a values-based culture.

“Double-Trigger”

Change-in-Control

Arrangements

Beginning in 2019, our equity agreements include “double-trigger” mechanisms to align with our executive severance agreements, which have historically includeddouble-trigger” mechanisms.

AMN HEALTHCARE SERVICES, INC.  

GIVE

 

2020 Proxy StatementCREATE

the best talent and insights to help healthcare organizations optimize their workforce 

  3


            PROXY STATEMENT  SUMMARY               

healthcare professionals opportunities to do their best work towards quality patient care
 

Our Key Corporate Governance Policies

            Practice             

Description

Proxy Access

Our Bylaws contain meaningful proxy access features that are consistent with market practice and were developed through shareholder conversations.

Majority Voting in Uncontested Elections

Director nominees must receive the affirmative votea values-based culture of a majority of the votes cast in order to be elected to the Board in uncontested elections.

Director Resignation

Policy

Our Director Resignation Policy requires an incumbent director to tender his or her resignation if he or she receives more votes “Against” his or her election than votes “For” his or her election in an uncontested election. The Corporate Governance and Compliance Committee and the Board, which we refer to asinnovation where our Governance and Compliance Committee, would then consider and take appropriate action on such offer of resignation in accordance with this Policy.

Board Aggregate

Tenure Policy

Our Board has committed that it will maintain an average tenure for independent board directors of less than ten years.

No “Poison Pill”

We do not have a stockholder rights plan or “poison pill” and no shareholder rights plan shall be adopted unless it is approved by a majority of the independent directors of the Board that find such action is consistent with the exercise of their fiduciary responsibilities.

Annual Election of

Directors

All directors must be nominated andre-elected each year.

Shareholder

Engagement

Program

We engage in a formal outreach program to provide us an opportunity to gain valuable insight from our shareholders on corporate governance matters that are most important to them. To consistently act in the best long-term interests of our shareholders, we continuously evaluate and act on, when appropriate, shareholder feedback.

Human Rights Policy

To further our core values and reflect our commitment to human rights in our relationships with our clients, team members vendors and communities, we have adopted a Human Rights Policy.

Recent Recognition

LOGO

4  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


              PROXY  STATEMENT SUMMARY              

How to Vote your Shares

WHENWHERE

Wednesday, April 22, 2020 at

8:30 a.m. Central Standard Time

8840 Cypress Waters Blvd., Suite 300

Dallas, Texas 75019

ONLINECALLMAILIN PERSONcan achieve their goals
    

Our Purpose

Helping to achieve personal and professional goals every day.

www.proxyvote.com

 

We Value:

1 (800)690-6903CUSTOMER FOCUS

c/o Broadridge

51 Mercedes Way Edgewood, NY 11717

8840 Cypress Waters Blvd., Suite 300We put people first, whether the customer is internal or external. We strive to go above and beyond in what we bring to every professional relationship, not just meeting, but exceeding, expectations at every turn.

Dallas, TX 75019RESPECT

We value everyone’s unique contribution, and as such, we treat everyone with the highest level of personal and professional courtesy, consideration, and care.

TRUST

Our relationships are honest, authentic, and open. We pride ourselves on the fact that we keep our commitments. Our word is our promise.

CONTINUOUS IMPROVEMENT

We know that even our best efforts and our most robust solutions can always be better. We never settle for ‘good enough’ and constantly seek opportunities and proactively embrace changes to improve.

PASSION

We love what we do – and it shows. Passion makes the difference between just doing something – and doing it well. It’s the fire that drives our purpose and our daily lives.

INNOVATION

Innovation is a mindset. We work to stay future-focused and committed to bringing new ideas to life that generate differentiated value for everyone.

  

LOGO

4

Table of Contents

Table of Contents

RECOMMENDATIONS     

  
2023 Proxy Statement5

Table of Contents

Notice of Annual Meeting of Shareholders

DATE AND TIMELOCATIONRECORD DATE
May 17, 2023www.virtualshareholdermeeting.com/AMN2023March 21, 2023
1:00 p.m. (Central Time)

VOTING MATTERS

  RECOMMENDATIONPAGE
1.To elect nine directors to the Board of Directors16
2.To approve, by non-binding advisory vote, the compensation of our named executive officers58
3.To ratify the appointment of KPMG LLP to be our independent registered public accounting firm for the fiscal year ending December 31, 2023101
4.To consider a shareholder proposal if properly presented at the 2023 Annual Meeting103

We will also take action upon any other business as may properly come before the 2023 Annual Meeting and any adjournments or postponements of that meeting.

HOW TO VOTE YOUR SHARES

ONLINECALLMAILDURING THE MEETING
Please follow the internet votinginstructions sent to you and visitwww.proxyvote.com, any timeup until 11:59 p.m. (Eastern Time) on May 16, 2023.Please follow the telephonevoting instructions sent to you and visit

www.proxyvote.com,

call 1 (800) 690-6903, any time up until

11:59 p.m. (Eastern Time) on April 21, 2020.

May 16, 2023.

Please follow the telephone voting instructions sent

to you and call

1 (800)690-6903,

any time up until

11:59 p.m. (Eastern Time)

on April 21, 2020.

If you receivereceived printed copies of our proxy materials,please mark, date and sign your proxy card per the instructions and return it by mail in thepre-addressed envelope provided with your proxy materials.provided. The proxy card must be received prior to the 20202023 Annual Meeting to be counted.

In personYou can also cast your vote at the 2020 Annualour Virtual Shareholder Meeting. Even if you plan to attend, we encourage you to vote in advance by Internet, telephone or mail so your vote will be counted if for some reason you are unable to attend.

Our Board’s Voting Recommendations

    
  Item    Description of Proposal  For      Against      Page     
          
  

1

  

Election of eight director nominees

  LOGO   

 

  

 

6

 

  

2

  

Approval, on an advisory basis, compensation of our

named executive officers

  LOGO   

 

  

 

69

 

  

3

  

Ratify the appointment of the independent auditor

  LOGO   

 

  

 

72

 

  

4

  

Reduce the threshold necessary to call a special

shareholders meeting to 15%

  LOGO   

 

  

 

73

 

  

5

  

Shareholder proposal – Make Shareholder Right to Call

Special Meeting More Accessible

   

 

  LOGO  

 

74

 

YOUR VOTE IS IMPORTANT. PLEASE NOTE THAT IF YOUR SHARES ARE HELD BY A BANK, BROKER, OR OTHER RECORDHOLDER AND YOU WISH TO VOTE THEM AT THE MEETING, YOU MUST OBTAIN A LEGAL PROXY FROM THAT RECORDHOLDER.

We will be using the Securities and Exchange Commission’s Notice and Access model (“Notice and Access”), which allows us to make proxy materials available electronically, as the primary means of furnishing proxy materials. We believe Notice and Access provides shareholders with a convenient method to access our proxy materials and vote. It also allows us to conserve natural resources which aligns with our Environmental, Social, and Governance strategy by reducing our environmental footprint as well as reducing the costs associated with printing and distributing our proxy materials. On or about April 4, 2023, we will commence mailing by sending a Notice of Internet Availability of Proxy Materials to our shareholders with instructions on how to access our proxy statement and 2022 Annual Report, including the financial statements set forth in our annual report on Form 10-K, online and how to cast your vote. The Notice also contains instructions on how to receive a paper copy of the proxy statement and 2022 Annual Report.

April 4, 2023
By Order of the Board of Directors,

DENISE L. JACKSON
Chief Legal Officer and Corporate Secretary

6

Table of Contents

Our Strategy and Talent Solutions

 

AMN

We are the leader and innovator in total talent solutions for the healthcare sector in the United States. We are passionate about all aspects of our mission:

PURPOSE-DRIVEN, VALUES-BASED
ORGANIZATION
Committed to Serving AllOur Stakeholders
LEADER AND INNOVATOR IN TOTALHEALTHCARE SERVICES, INC.  TALENT SOLUTIONS
Well Positioned to Serve GrowingHealth Systems and Diverse Care Settings
EXPERIENCED, DIVERSE AND DEEPLEADERSHIP TEAM
Driving Digital Enablement thatBenefits Healthcare Professionals and Clients

Our talent solutions enable our clients to manage and optimize their workforce, simplify staffing complexity, increase efficiency, and elevate the patient experience. Our comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, telehealth and virtual care management, analytics, and related services to build and manage all or part of our clients’ healthcare workforce needs. We offer temporary, project, and permanent career opportunities to our healthcare professionals, from nurses, doctors, and allied health professionals to healthcare leaders and executives in a variety of settings across the nation to help them achieve their personal and professional goals.

 

NURSE &
ALLIED SOLUTIONS

 

 

PHYSICIAN &
2020 Proxy StatementLEADERSHIP SOLUTIONS

 

 

TECHNOLOGY &
  5WORKFORCE SOLUTIONS


PROPOSAL 1:  ELECTION OF OUR DIRECTORS    

PROPOSAL 1

ELECTION OF OUR DIRECTORS

The Board is elected by the shareholders to oversee their interest in the overall success of the Company’s strategy, business operations and financial strength. The Board serves as the Company’s ultimate decision-making body to the extent set forth in our Certificate of Incorporation and Amended and RestatedBy-laws (the “Bylaws”). It also selects and oversees our senior executives, who, in turn, oversee ourday-to-day business and related affairs.

Board Composition Evaluation and Director Nomination Processes

The Corporate Governance and Compliance Committee understands the vital role that a strong board composition with a diverse set of skills and continuous refreshment play in effective oversight. The Committee is committed to maintain a diverse board to more effectively manage complex corporate issues by leveraging different experiences to support the Company’s long-term objectives and business strategy. With this purpose in the mind, the Committee seeks out candidates with unique skills, experiences and characteristics, including individuals representing historically underrepresented groups and from different careers, industries, races, ethnicities or genders that align with our long-term strategic objectives. To ensure this alignment and in response to the Company’s shareholder discussions on Board refreshment, in 2018, the Committee established a more robust process by which it would regularly evaluate the Board’s collective composition relative to the Company’s strategic objectives and potential director candidates.

To kick off the process, the Corporate Governance and Compliance Committee mapped the collective composition of the then-current Board to the skills and experiences it considered necessary to support the Company’s long-term strategic objectives. It then established a pool of potential director candidates derived from various sources, including recommendations from shareholders and consultants, many of whom are industry experts that match certain key skills, experiences and characteristics the Committee identified as critical to the Company’s long-term strategic objective and from which the Committee could engage candidates quickly depending on the occurrence of certain events necessitating new or additional directors, such as retirements, changing market conditions or strategic objectives and newly considered enterprise risks. The Committee then regularly evaluates its potential candidate pool and adds and eliminates individuals based on the factors listed above as well as the candidates’ changing biographical information and availability.

LOGO

WORKFORCE STAFFING

6    Travel Nursing

  Allied Healthcare

  Local Staffing

  Rapid Response

  Revenue Cycle Solutions

  School Staffing

  Labor Disruption

  International Staffing and Permanent Placement

 

WORKFORCE STAFFING

AMN HEALTHCARE SERVICES, INC.    Physician Staffing

  Interim Leadership

LEADERSHIP SEARCH

  Executive Search

  Academic Leadership

  Clinical Leadership

PHYSICIAN SEARCH

  Retained Search for Physicians and Advanced Practices

 

TALENT MANAGEMENT

  2020 Proxy Statement  Vendor Management Systems

  Recruitment Solutions

  Float Pool Management

  Scheduling & Staff Planning

VIRTUAL CARE

  Language Services

  Teleservices Platforms


>60%
  

of revenue from these segments is derived from managed services programs (MSPs)

2023 Proxy Statement7

Table of Contents

Our Strategy and Talent Solutions

We aim to deliver long-term sustainable value to our stakeholders. Every day, we help our clients and healthcare providers drive access to care, health and wellness. We continue to embed Diversity, Equality, Equity, and Inclusion (“DEI”) in our DNA, inspiring innovation, strengthening engagement, and driving health equity in the communities we serve. In partnership with our team members, healthcare professionals, clients, suppliers and others, we are committed to advancing a healthy, just, equitable, and sustainable world where all can thrive. We have aligned our environmental, social and governance (“ESG”) strategy with the United Nations’ Sustainable Development Goals and report in alignment with Sustainability Accounting Standards Board (“SASB”), Global Reporting Initiative (“GRI”), and Taskforce for Climate Related Financial Disclosure (“TCFD”) frameworks which we discuss in detail on page 35 of this Proxy Statement and within our 2022 ESG Report that can be found on the Corporate Social Responsibility page of our Company website https://www.amnhealthcare.com/about/corporate-social-responsibility/.

 

AMN HEALTHCARE EVOLUTION FROM STAFFING COMPANY TO LEADER IN TOTAL TALENT SOLUTIONS

Nurse & Allied Staffing

2010: Nursefinders | 2015: Onward | 2019: AdvancedMedical | 2022: Connetics

Vendor Management Systems

2013: ShiftWise | 2015: Medefis | 2019: b4health

Language Interpretation

2020: Stratus Video

Leadership Solutions

2015: The First String | 2016: B.E. Smith | 2018: PhillipsDiPisa/Leaders for Today

Scheduling & Predictive Workforce Analytics

2014: Avantas

Teletherapy and Virtual Care

2019: Advanced Medical | 2021: Synzi

Revenue Cycle Solutions

2016: Peak | 2018: MedPartners


8

PROPOSAL 1:  ELECTION  OF OUR DIRECTORS


Table of Contents

BelowOur Strategy and Talent Solutions

Our Business Strategy

Our strategy is a summarydesigned to support growth in (i) expansion of the process by whichmarkets we serve; (ii) the Governancenumber, scope and Compliance Committee activelysize of customer relationships and continuously evaluates its collective composition(iii) opportunities afforded to our healthcare professionals. Driving increased adoption of our existing talent solutions will deepen and potential director candidates priorbroaden our customer relationships. We will continue to nominating such director candidatesinnovate, develop, and invest in new, complementary service and technology solutions to add to our talent solutions portfolio and enhance the Boarddigital experience for review, approvalclinicians and appointment.clients. We believe this strategy will enable us to expand our strategic customer relationships, while driving more recurring revenue with an improved margin mix that will be less sensitive to economic cycles.

2022 Accomplishments

 
RECORD REVENUE of
$5.24B
RECORD ADJUSTED
DILUTED EPS(1)of
$11.90

RECORD NET INCOME of
$444.1M

and RECORD ADJUSTED EBITDA(1) of
$846.7M

MORE THAN
$12B
SPEND UNDER MANAGEMENT
THROUGH VMS AND MSP SOLUTIONS
AMN
PASSPORT
DOWNLOADED BY 97% OF OUR
NURSE AND ALLIED HEALTHCARE
PROFESSIONALS ON ASSIGNMENT

250,000

HEALTHCARE PROFESSIONAL
PLACEMENTS

(1)More information on our adjusted diluted EPS and adjusted EBITDA, which refers to our adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of our 2022 GAAP diluted net income per share to adjusted diluted EPS and 2022 net income to adjusted EBITDA, can be found at Exhibit A to this proxy statement (page 113).
2023 Proxy Statement9

Table of Contents

Our Strategy and Talent Solutions

Recent Recognition

NACD

Winner – Diversity, Equity & Inclusion Award – Public
Company – Mid-Cap 2022

BLOOMBERG

Gender-Equality Index
2018-2023

HUMAN RIGHTS CAMPAIGN

Corporate Equality Index
2018-2022

NEWSWEEK

America’s Most Responsible Companies
2020-2023

FORBES

America’s Best Large Employers; 2022America’s Best Employers for Women
2022

Advancing ESG Initiatives

GOVERNANCEDIVERSITY, EQUALITY,
EQUITY AND INCLUSION

Materiality Assessment to prioritizeESG issues

56% women and 33% BIPOCrepresentation on our Board

Enhanced TCFD & ESG Reporting

$961 million in diverse and/or smallbusiness spend

39% participation in EmployeeResource Groups

69% of our team members arewomen and 45% of ourteam members are fromunderrepresented communities

HEALTHSUSTAINABILITY

Team member health insurancepremium waivers and enhanced401(k) contributions

Over 250,000 healthcareprofessional placements in 2022

14 million patient encounters whereour 3,000+ interpreters(1) bridgedlanguage barriers, enabling accessand improving health outcomes

 34% reduction in Scope 1 & 2 GHGefrom 2019 baseline levels

 Measured full Scope 1, 2, and 3Greenhouse Gas Emissions for2020-2022

 Measured full Scope 3 GreenhouseGas Emissions for 2020-2022

(1)Includes both our team members as well as independent contractors.
10

Table of Contents

Proxy Voting Roadmap

The summary below highlights certain information that may be found elsewhere in this proxy statement. We encourage you to read the entire proxy statement before casting your vote. Our proxy statement and related materials are first being made available to our shareholders on or about April 4, 2023.


 

PROPOSAL 1

Election of Our Directors

Our Board recommends that you vote FOR this proposal. (page 16)

Directors at a Glance

This year’s slate of director nominees to the Board of Directors (the Board) of AMN Healthcare Services, Inc. (the Companyor AMN) includes a new addition, Cary Grace, who was appointed as the Company’s President and Chief Executive Officer and a member of the Board on November 28, 2022. Ms. Grace is a proven executive that will continue AMN’s exceptional growth and impact, by building on our operational and organizational strengths. Ms. Grace brings to the Board more than three decades of experience developing and executing profitable growth strategies for leading financial service organizations across health care, banking, investment management, alternative capital, M&A and insurance. A list of all director nominees is reflected below. Additional information for each nominee can be found under “Election of Directors (Proposal 1)” beginning on page 16.

Name AgeDirector
Since
Other Public
Company Boards
Board
Committees
Jorge A. Caballero  IND 6620210 A    G 
Mark G. Foletta  IND 6220122 A 
Teri G. Fontenot  IND 6920192 A    G 
Cary Grace
President and Chief Executive Officer, AMN Healthcare Services, Inc.
5420220 E 
R. Jeffrey Harris  IND 6820050

 S    C 

 G    E 
Daphne E. Jones  IND 6520182 A    C 
Martha H. Marsh  IND 7420101 S    C 
Rear Admiral Dr. Sylvia Trent-Adams, PHD, RN, FAAN  IND 5720200 C    G 
Douglas D. Wheat (Chairman)  IND 7219992 S    E 

AAudit CommitteeGCorporate Governance and Compliance Committee           evaluatesSSearch Committee           Chair
CCompensation Committee           EExecutive CommitteeINDIndependent

2023 Proxy Statement11

Table of Contents

Proxy Voting Roadmap

Current Board Composition

The illustration below summarizes the key experience, qualifications, and attributes of our director nominees and highlights the balanced mix of experience of our Board as a whole. This is a high-level summary that is not intended to be an exhaustive list of the director nominees’ skills or contributions to the Board.

Our Key Corporate Governance Practices

PracticeDescription
Proxy AccessOur Bylaws contain meaningful proxy access features that are consistent with market practice and were developed through shareholder conversations.
Majority Voting in Uncontested ElectionsDirector nominees must receive the affirmative vote of a matrix that maps the collective skills, experiences and characteristicsmajority of the Boardvotes cast in order to be elected to the skills, experiencesBoard in uncontested elections.
Board Diversity / “Rooney Rule”Our Board has committed that when considering candidates to fill an open seat on the Board, the pool of candidates from which Board nominees are chosen includes candidates from historically underrepresented communities.
Director Resignation PolicyOur Director Resignation Policy requires an incumbent director to tender their resignation if they receive more votes “Against” their election than votes “For” their election in an uncontested election.
Board Aggregate Tenure PolicyOur Board has committed that it will maintain an average tenure for independent board directors of less than ten years. As of December 31, 2022, our average board tenure was nine years.
No “Poison Pill”We do not have a shareholder rights plan or “poison pill” and characteristicsno shareholder rights plan shall be adopted unless it considers necessaryis approved by a majority of the independent directors of the Board.
Annual Election of DirectorsAll directors must be nominated and re-elected each year.
Shareholder EngagementProgramWe engage in a formal outreach program to supportgain valuable insight from our shareholders on corporategovernance matters that are most important to them. To consistently act in the Company’sbest long-term growthinterests of our shareholders, we continuously evaluate and act on shareholder feedback when appropriate.
Stock Ownership GuidelinesWe require senior executives and non-employee directors to maintain significant holdings of our common stock to promote alignment with the interests of our shareholders.
Code of EthicsWe have established a code of ethics that applies to our Senior Financial Officers to ensure adherence to best practices and advancement of the values-based culture we strive to maintain.

12

Table of Contents

Proxy Voting Roadmap

 

PROPOSAL 2

Advisory Vote on Executive Compensation

Our Board recommends that you vote FOR this proposal. (page 58)

Our Financial Performance

(1)More information on adjusted EBITDA, which refers to our adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of our 2022 net income to adjusted EBITDA can be found at Exhibit A to this proxy statement (page 113).

Our Total Return vs. Russell 2000

2023 Proxy Statement13

Table of Contents

Proxy Voting Roadmap

Pay Aligned with Financial Performance

(1)CEO compensation represented Ms. Salka’s total compensation in 2022, since Ms. Grace did not join the Company until November 28, 2022.

Say-on-Pay Results

In 2022, we received 90% of votes in favor of our Say-on-Pay proposal (based on shares voting). Since 2014, our Say-on-Pay results have averaged 95% (based on shares voting), which we believe reflects our pay-for-performance philosophy and level of engagement with our shareholders.

14

Table of Contents

Proxy Voting Roadmap

Key Executive Compensation Practices

PracticeDescription
Executive Compensation PhilosophyCommitment to equal pay principles and a values-based culture to which leaders are held accountable through a portion of their annual cash incentive award.
Balanced Approach to Performance-based PayPerformance-based awards are tied to the achievement of financial objectives, including revenue, adjusted EBITDA, total shareholder return, as well as strategic leadership and business strategyESG-related objectives.
Three-Year Performance Periods and engagesVest SchedulesThe performance periods and vest schedules for our equity awards span a three-year period to promote a long-term approach to the achievement of strategic and financial objectives.
Balanced Mix of Pay ComponentsTarget compensation mix is not overly weighted toward annual incentive awards and balances cash and long-term equity awards in discussions on whether additional skills, experiencesaccordance with certain financial or characteristics should be identifiednon-financial metrics that align with our short and iflong-term strategic goals.
Equity Ownership Guidelines

CEO  5x salary

Named executive officers  2x salary

Other members of the considerationCEO Committee (CEO’s direct reports)  1.5x salary

“Double-Trigger” Change-in-ControlArrangementsExecutive equity and severance agreements include “double-trigger” mechanisms.
No Tax Gross UpsNo tax gross ups included in executive compensation program.

 

PROPOSAL 3

Ratification of additional director candidates is advisable;the Selection of Our Independent Public Accounting Firm

Our Board recommends that you vote FOR this proposal.(page 101)

 

PROPOSAL 4

Shareholder Proposal

Our Board recommends that you vote AGAINST this proposal.(page 103)

2023 Proxy Statement15

Table of Contents

Corporate Governance

 

(2)

If it determines that additional director candidates may be reasonably necessary, the Committee discusses and prioritizes the skills, experiences and characteristics it desires to target based on the Company’s long-term growth objectives and business strategy; and 

PROPOSAL 1

 

Election of Our Directors

The board of directors recommends that shareholders vote “FOR” each of the director nominees
 (3)

Once certain skills, experiences and characteristics are identified, the Committee considers potential director candidates from its pool of candidates, reviews recommended director nominees that possess the skills, experiences and characteristics desired, and recommends the nominees to the Board for approval.

Since establishing the processes described above, the Board has appointed two new directors. In July 2018, the Board appointed Daphne E. Jones, an accomplished executive with extensive experience in strategic, entrepreneurial and global use technologies in the healthcare sector. Ms. Jones’ contributions to the Board have been evident through its strategic oversight of the execution of the Company’s digital and strategic initiatives. In September 2019, the Board appointed Ms. Teri G. Fontenot, an executive with extensive experience in healthcare leadership, women’s healthcare, corporate finance, economic policy and healthcare policy. Our Board is proud to be among a unique group of companies with 44% female representation.

Additional information regarding how shareholders can nominate a director candidate for election at our 2021 Annual Meeting of Shareholders can be found inExhibit A to this proxy statement. Our Board is committed to continue to seek out highly qualified candidates with diverse backgrounds, skills and experience to further strengthen our Board‘s collective composition and strategically support the Company’s strategic objectives. A collective summary of our Board’s current composition, skills and experiences is set forth below.

Our Nominees for the Board of Directors

EightNine directors are to be elected at our 20202023 Annual Meeting of Shareholders to hold office until our next annual meeting or until their successors are duly elected and qualified, or until the director retires, resigns, is removed or becomes disqualified.

The proxy will be voted in accordance with the directions stated on the card, or, if no directions are stated, for election of each of the eightnine nominees listed below. Upon the recommendation of the Board’s Corporate Governance and Compliance Committee (the “Governance and Compliance Committee”), the Board has nominated for

election the eightnine directors listed below, all of whom are currently serving as directors on our Board. The director nominees for election are willing to be duly elected and to serve. If any such nominee is not a candidate for election at the Annual Meeting, an event that the Board does not anticipate, the proxies may be voted for a substitute nominee(s). The business experience, board service, qualifications and affiliations of our director nominees are set forth below.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  7


PROPOSAL 1:  ELECTION OF OUR DIRECTORS    

Our Directors’ Skills Matrix

LOGO

The Board of Directors recommends that shareholders vote

“FOR���

each of the following nominees

8  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

Mark G. Foletta

Director Since 2012

Age: 59

Audit Committee Chair

Financial Expert

LOGO

Finance

Enterprise Risk Management

Board Leadership

Mergers & Acquisitions

Healthcare Industry

C-Suite Leadership

Strategy

Executive Vice President and Chief Financial Officer

Tocagen Inc.

Experience and Qualifications

The Board has concluded that Mr. Foletta is qualified to serve on the Board, because he brings considerable audit, financial, healthcare and enterprise risk management experience as both an executive officer and director of healthcare companies. The Board has designated Mr. Foletta as a financial expert for its Audit Committee, for which he serves as Chairman. Since February 2017, Mr. Foletta has served as Executive Vice President and Chief Financial Officer of Tocagen Inc. Mr. Foletta served as the Interim Chief Financial Officer of Biocept, Inc., a publicly-traded diagnostics company, from August 2015 to July 2016, and he also served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from March 2006 until October 2012. While at Amylin, Mr. Foletta assisted with developing and launching the organization’s initial enterprise risk management assessment. From March 2000 to March 2006, Mr. Foletta served as Vice President, Finance and Chief Financial Officer of Amylin. Mr. Foletta received a Bachelor of Arts from the University of California, Santa Barbara. He is also a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.

Board Experience

Since November 2014, Mr. Foletta has served on the Board of DexCom, Inc., a publicly-traded company, where he is the Lead Director. From February 2013 through June 2018, Mr. Foletta served as a director of Regulus Therapeutics Inc., and was Chairman of its Audit Committee and a member of its Nominating and Governance Committee. While at Regulus and DexCom, Mr. Foletta helped oversee and guide the launch of each organization’s initial enterprise risk management assessment. Additionally, Mr. Foletta serves as a director of Viacyte, Inc., a privately held company. He previously served as a director and Chairman of the Audit Committee of Ambit Biosciences Corporation (sold in 2014), and also served as a director of Anadys Pharmaceuticals, Inc. (sold in 2011).

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  9


PROPOSAL 1:  ELECTION OF  OUR DIRECTORS

Teri G. Fontenot

Director Since 2019

Age: 66

Audit Committee

Financial Expert

LOGO

Finance

Enterprise Risk Management

Board Leadership

Mergers & Acquisitions

Healthcare Industry

C-Suite Leadership

Strategy

Former President & Chief Executive Officer of

Woman’s Hospital

Experience and Qualifications

The Board has concluded that Ms. Fontenot is qualified to serve on the Board because she brings considerable audit, financial and healthcare experience both as an executive officer and director of healthcare companies. The Board has determined that Ms. Fontenot qualifies as a financial expert and appointed her as a member of its Audit Committee. Since March 2019, Ms. Fontenot has served as CEO Emeritus of Woman’s Hospital, the largest independently-owned women’s and infant’s hospital in the United States providing comprehensive subspecialty services to women. From 1996 to March 2019, Ms. Fontenot served as President and CEO of Woman’s Hospital. From 1992 to 1996, Ms. Fontenot served as the Chief Financial Officer and Executive Vice President of Woman’s Hospital. Under her leadership, Woman’s Hospital became the largest birthing hospital and neonatal intensive care unit in Louisiana. Prior to joining Woman’s Hospital in 1992, Ms. Fontenot served as Chief Financial Officer of three other hospitals located in Louisiana and Florida and is a Certified Public Accountant (inactive).

Board Experience

Ms. Fontenot has served on numerous healthcare boards at a local, state and national level, including the Board of Directors of the Louisiana Hospital Association, and the American Hospital Association where she served as Chairperson in 2012. She is on the American College of Healthcare Executives Board of Governors and a member of its Audit Committee, and she held asix-year term on the Advisory Committee on Research on Women’s Health for the National Institutes of Health. Ms. Fontenot is also a director on the board of the Baton Rouge Water Company, a private company, and a director on the board of Companion Animal Alliance, a not-for profit agency. From 2007 to 2019, Ms. Fontenot served on the board of directors of the Sixth District Federal Reserve Bank of Atlanta, including as its Audit Committee chair for two years. Ms. Fontenot currently serves on the board of directors and a member of the audit committees for LHC Group, Inc. and Amerisafe. Inc. and she was a member of the board of directors of Landauer (a formerly publicly-held company) until its sale in 2017. She is a Fellow of the American College of Healthcare Executives, where she presents frequently on women’s health and leadership topics.

10  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

R. Jeffrey Harris

Director Since 2005

Age: 65

Corporate Governance and

Compliance Committee

Chair

Executive Committee

LOGO

Corporate Governance

Strategy

Legal

C-Suite Leadership

Healthcare Industry

Mergers & Acquisitions

Former Of Counsel at          

Apogent Technologies, Inc.          

Experience and Qualifications

The Board has concluded that Mr. Harris is qualified to serve on the Board because he brings considerable mergers and acquisitions experience, which is a key component of AMN’s strategy. Additionally, Mr. Harris has experience serving as a director on public company compensation and corporate governance committees, which is essential to designing and maintaining our executive compensation programs and guiding our corporate governance strategies. Mr. Harris served as Of Counsel at Apogent Technologies, Inc. from December 2000 through 2003, and as Vice President, General Counsel and Secretary from 1988 to 2000, when the company was named Sybron International.

Board Experience

Since 2002, Mr. Harris has been involved as an investor in, and a director of, early stage companies. Mr. Harris served on the Board of Sybron Dental Specialties from April 2005 until it was acquired by Danaher Corporation in 2006. Mr. Harris served on the Board of Playtex Products, Inc. from 2001 until Energizer Holdings acquired it in October 2007. Mr. Harris was director of Prodesse, Inc., an early stage biotechnology company, from 2002 until 2009, whenGen-Probe Incorporated acquired it. Mr. Harris also served as director of Apogent Technologies, Inc. from 2000 to 2004, when it was acquired by Fisher Scientific International, Inc. From 2008 until 2018, he served as a director of Guy & O’Neill, Inc. He currently serves on the Board of Brookfield Academy, anon-profit entity, and is Chairman of the Board and aco-founder of BrightStar Wisconsin Foundation, Inc., anon-profit economic development corporation. Additionally, Mr. Harris is a director of Okanjo Partners, Inc., anearly-stage technology company.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  11


PROPOSAL 1:  ELECTION OF  OUR DIRECTORS

Michael M.E. Johns, M.D.

Director Since 2008

Age: 78

Corporate Governance and

Compliance Committee

Compensation

Committee

LOGO

Board Leadership

Strategy

C-Suite Leadership

Healthcare Industry

Professor,

Emory University School of Medicine

Experience and Qualifications

The Board has concluded that Dr. Johns is qualified to serve on the Board because he has extensive“C-suite” healthcare leadership experience and is a recognized healthcare thought leader. This expertise is valuable in shaping our strategy to deliver innovative and expanded service offerings as a healthcare workforce solutions company. Dr. Johns is a Professor in the School of Medicine at Emory University, where he also served as Chancellor from October 2007 through August 2012. Dr. Johns served as Interim Executive Vice President of Health Affairs for Emory University and as Interim Chairman and CEO of Emory Healthcare from September 1, 2015 through January 31, 2016. He served as the Interim Executive Vice President for Medical Affairs and Interim Chief Executive Officer of the University of Michigan Health System from June 2014 through March 2015. From 1996 to 2007, Dr. Johns served as Executive Vice President for Health Affairs and Chief Executive Officer of the Robert W. Woodruff Health Sciences Center of Emory University. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. Dr. Johns is a member of The National Academy of Medicine of the National Academy of Science.

Board Experience

Dr. Johns serves on the Board of Directors of Intelligent Fingerprinting, a privately held company, as well as several philanthropic entities. He is also a member of the Board of Regents of the Uniformed Services University for the Health Sciences, University of Michigan Medical Center and Vanderbilt University Medical Center. Dr. Johns served on the Board of the Genuine Parts Company from 2000 until April 2015, and at various times during his tenure, was a member of its Compensation, Governance and Nominating Committee and its Audit Committee. He also served on the Board and the Compensation Committee of Johnson & Johnson from 2005 to 2014 and served as a member of the Board of West Health Institute, a non-profit medical research organization. From 1996 to 2007, Dr. Johns served as Chairman of the Board of Directors of Emory Healthcare.

12  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

Daphne E. Jones

Director Since 2018

Age: 61

Audit Committee

Compensation Committee

LOGO

Digital / Technology

Healthcare Industry

C-Suite Leadership

Strategy

Former Senior Vice President – Digital/Future of Work

GE Healthcare

Experience and Qualifications

The Board has concluded that Ms. Jones is qualified to serve on the Board because she brings considerable information technology, global digital technology use, data management and privacy experience as a seasoned“C-suite” executive with extensive experience in multinational corporations. Ms. Jones’ digital use and technology expertise and experience will be critical to our successful execution of our digital strategies. Ms. Jones served as the Senior Vice President - Digital/Future of Work for GE Healthcare, the healthcare business of GE, from May 2017 to October 2017 and prior to that she served as the Senior Vice President - Chief Information Officer for GE Healthcare Diagnostic Imaging and Services since August 2014. Prior to joining GE Healthcare, Ms. Jones was the Senior Vice President, Chief Information Officer for Hospira, Inc., a provider of pharmaceuticals and infusion technologies, from October 2009 through June 2014. Previously she served as Chief Information Officer at Johnson & Johnson from 2006 to 2009 and served in various information technology roles with Johnson & Johnson from 1997 through 2006. Ms. Jones began her career in sales and systems engineering at IBM.

Board Experience

Ms. Jones serves on the board of Masonite International Corp, where she is a member of the Audit Committee. She also serves on the board of directors for Barnes Group Inc. and Destiny Transformations Group, LLC. Ms. Jones previously served on the board of the Thurgood Marshall College Fund, anot-for-profit organization and the nation’s largest organization exclusively representing the Black College Community.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  13


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

Martha H. Marsh

Director Since 2010

Age: 71

Compensation Committee

Chair

LOGO

Board Leadership

Strategy

C-Suite Leadership

Healthcare Industry

Former President and CEO,

Stanford Hospital and Clinics

Experience and Qualifications

The Board has concluded that Ms. Marsh is qualified to serve on the Board because she has extensive“C-suite” leadership and expertise in the healthcare industry. Ms. Marsh’s experience and understanding of the challenges and opportunities of large healthcare facilities are immensely useful in directing our strategy to innovate and provide enhanced and expanded workforce solutions service offerings to meet our clients’ evolving needs. Ms. Marsh served as President and CEO of Stanford Hospital and Clinics for eight years, from April 2002 until her retirement in August 2010. Previously, Ms. Marsh served as the CEO of UC Davis Medical Center and the Chief Operating Officer of the UC Davis Health System from 1999 to 2002. Prior to that time, she served as the Senior Vice President for Professional Services and Managed Care at the University of Pennsylvania Health System, and before that as President and CEO of Matthew Thornton Health Plan in Nashua, New Hampshire.

Board Experience

From 2012 through 2019, Ms. Marsh served as a director of Owens & Minor, Inc. as the Chairperson of the Governance and Nominating Committee and also served on its Compensation and Benefits Committee. Since October 2015, she has served as a director of Edwards Lifesciences Corporation and is a member of its Compensation and Governance Committee. She also serves on the Board and the Compensation Committee of Teichert, a privately-held company. Prior to Thoratec Corporation’s acquisition by St. Jude Medical in 2015, she had served on Thoratec’s Board. Ms. Marsh is a past Chair of the Board of Trustees for the California Hospital Association and the California Association of Hospitals and Health Systems and a former director of Ascension Healthcare Network, a privately-held company.

14  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

Susan R. Salka

Director Since 2003

Age: 55

Executive Committee

LOGO

Healthcare Industry

Board Leadership

C-Suite Leadership

Mergers & Acquisitions

Corporate Governance

Finance

Strategy

Chief Executive Officer

AMN Healthcare Services, Inc.

Experience and Qualifications

Ms. Salka has served as our President since May 2003 and our CEO since May 2005. The Board has concluded that Ms. Salka is qualified to serve on the Board because she has nearly three decades of healthcare services industry experience, including 30 years of experience with us in various roles, including Chief Financial Officer and Chief Operating Officer. During her service to the Company, she has helped grow our business both organically and through acquisitions into the national industry leader we are today. Prior to joining us, Ms. Salka worked at BioVest Partners, a venture capital firm, and at Hybritech, a subsidiary of Eli Lilly & Co., which Beckman Coulter later acquired.

Board Experience

Ms. Salka is recognized as a leader in corporate governance and currently serves as a director of McKesson Corp., including as Chairperson of its Corporate Governance Committee and as a member of its Compensation Committee. Ms. Salka served on the Board and the Audit Committee of Beckman Coulter from 2007 until 2011, when Danaher Corporation acquired it. Additionally, she served on the Board of Playtex Products, Inc. from 2001 until Energizer Holdings acquired it in October 2007.

Diversity, Equality and Inclusion

Under Ms. Salka’s leadership, AMN has become the largest and most diversified total talent solutions company in healthcare. Ms. Salka is passionate about corporate social responsibility, diversity, inclusion, and equality. She participates in many of the company’s community initiatives, including the annual medical and community development trip to Guatemala. As one of the top 25 New York Stock Exchange (“NYSE”) female CEOs, she is also an advocate for promoting women in leadership and the boardroom. AMN is part of the Bloomberg Gender Equality Index and Human Rights Campaign Foundation Corporate Equality Index. Ms. Salka serves on the Executive Committee of the Healthcare Leadership Council, a coalition of CEOs from the nation’s top healthcare companies dedicated to improving healthcare delivery and accessibility by working with each other and legislators.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  15


PROPOSAL 1:  ELECTION  OF OUR DIRECTORS

Douglas D. Wheat

Director Since 1999

Age: 69

Board Chair

Executive Committee

LOGO

Healthcare Industry

Legal

Mergers & Acquisitions

Board Leadership / Governance

Corporate Finance

Strategy

Managing Partner

Wheat Investments, LLC

Experience and Qualifications

The Board has concluded that Mr. Wheat is qualified to serve on the Board because he possesses significant healthcare staffing industry knowledge as well as extensive expertise in corporate finance and mergers and acquisitions. Such knowledge and expertise are critical to the successful design and implementation of our growth strategy. He is currently the Managing Partner of Wheat Investments, a private investment firm. From 2007 to 2015, Mr. Wheat was the founding and Managing Partner of the private equity company Southlake Equity Group. From 1992 until 2006, Mr. Wheat was President of Haas Wheat & Partners. Prior to the formation of Haas Wheat, Mr. Wheat was a founding member of the merchant banking group Donaldson, Lufkin & Jenrette specializing in leveraged buyout financing. From 1974 to 1984, Mr. Wheat practiced corporate and securities law in Dallas, Texas. Mr. Wheat received both his J.D. and B.S. degrees from the University of Kansas.

Board Experience

Mr. Wheat is the Chairman of the Board of Overseas Shipholding Group and the Chairman of the Board of International Seaways, Inc. He previously served as Vice Chairman of Dex Media, Inc. and as Chairman of SuperMedia prior to its merger with Dex One. Mr. Wheat has also previously served as a member of the Board of Directors of several other companies, including, among others: (1) Playtex Products (of which he also served as Chairman), (2)Dr. Pepper/Seven-Up Companies, Inc., (3) Dr. Pepper Bottling of the Southwest, Inc., (4) Walls Industries, Inc., (5) Alliance Imaging, Inc., (6) Thermadyne Industries, Inc., (7) Sybron International Corporation, (8) Nebraska Book Corporation, (9) ALC Communications Corporation, (10) Mother’s Cookies, Inc., and (11) Stella Cheese Company.

16  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 1:  ELECTION OF OUR DIRECTORS

RETIRING DIRECTOR

We would like to recognize and thank Mr. Stern who will be retiring from the Board effective upon the conclusion of our Annual Meeting.

Andrew M. Stern

During Mr. Stern’s nearly 19 years of board service to the Company, he has offered immeasurable insights on healthcare policy, administration and operational priorities. The Company and the Board thank Mr. Stern for his dedicated leadership and service and wish him the best in his future endeavors.

LOGO

Director Since 2001

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  17


            CORPORATE GOVERNANCE                

CORPORATE GOVERNANCE

Overview of Our Corporate Governance Program

Our Board and executive leaders believe that strong and effective corporate governance is essential to our success. A cornerstone of our corporate governance program is providing transparent disclosure to our stakeholders on an ongoing and consistent basis. Our approach integrates all components of effective governance, including a strong ethical culture, a comprehensive enterprise risk management program, a formal shareholder engagement program, sound financial, regulatory and legal compliance functions and corporate social responsibility. Our holistic strategy focuses on delivering long-term shareholder value and has been recognized for the highest standards of governance. AMN aligns with the Investor Stewardship Group’s (“ISG”) Corporate Governance Framework for U.S. Listed Companies. Below is an illustration how certain of our governance practices directly support each of the ISG principles.

ISG Principle

AMN’s Practice

Boards are accountable to

shareholders.

•   We provide proxy access to our shareholders with features that are consistent with market practices and that incorporated shareholder input.

•   Our directors stand for election annually, with a majority voting standard in uncontested director elections. Directors that do not receive majority support must tender their resignation for consideration by the Board.

Shareholders should be

entitled to voting rights in

proportion to their economic

interest.

•   We have one class of common stock, with each share carrying equal voting rights. We believe in a “one share,one-vote” standard.

•   We do not have a “poison pill.”

Boards should be

responsive to shareholders

and be proactive in order to

understand their

perspectives.

•   Our robust shareholder outreach program allows us to solicit ongoing feedback from our shareholders on corporate governance matters most important to them.

•   The Board regularly considers and acts upon feedback received from our shareholders. A detailed discussion of the specific actions that the Board has taken in 2019 in response to shareholder feedback is located in the “Our Annual Shareholder Outreach Summary” section below.

Boards should have a

strong, independent

leadership structure.

•   We have a strong, independent Board Chairman and independent committee chairs with clearly defined responsibilities.

•   Our Board regularly reviews its leadership structure and composition at least annually and discusses its appropriateness in this proxy statement.

•   Key Board committees are completely independent and include: Corporate Governance and Compliance; Audit; and Compensation.

Boards should adopt

structures and practices

that enhance their

effectiveness.

•   88% of our director nominees are independent.

•   Our directors reflect a diverse set of experiences and skills that are relevant to our long-term business strategy and our refreshment strategy is continuously evaluated.

•   50% of our director nominees are diverse from gender, race or ethnicity standpoint.

•   Annual Board and committee-level assessments are conducted withbi-annual individual director interviews to ensure effectiveness.

•   Our Board has committed that it will maintain an average tenure for independent board directors of less than ten years.

•   Our Board has access to management and outside consultants to ensure effectiveness.

Boards should develop

management incentive

structures that are aligned

with the long-term strategy

of the company.

•   Target compensation mix is not overly weighted toward annual incentive awards and balances cash and long-term equity awards in accordance with certain financial andnon-financial metrics that align with our short and long-term strategic goals.

•   Our executive severance agreements and equity awards contain “double trigger” mechanics.

•   We have stock ownership requirements for our named executive officers that require ownership of unrestricted shares.

•   Our executive compensation programs are aligned with shareholder returns and promote a values-based culture.

18  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


              CORPORATE  GOVERNANCE              

Our Annual Shareholder Outreach Summary

We understand that we must earn and maintain our shareholders’ continued support by adhering to the highest standards of corporate governance and social responsibility. To this end, five years ago, we initiated a formal shareholder corporate governance outreach program to supplement our financial-related outreach and gain further insight into the views of our shareholders. Our engagement efforts have evolved into a robust program where we take a customized approach to each shareholder. We believe this facilitates more meaningful and ongoing dialogue on relevant topicswe have a slate of director nominees that allow usare well-positioned to build stronger shareholder relationships and a more successful company.

With a formal outreach strategy and clear objectives in place, we sent letters to our top shareholders in 2019 representing approximately 64% of our outstanding Common Stock. We look forward to the opportunity to connect withrepresent our shareholders and find these engagements to be enlightening and productive. Each shareholder we met with expressed appreciation for our proactive interest in their views, and we certainly appreciated their time and insight. Collectively, our discussions focused on the following topics:

Human Capital Strategy

Board

Refreshment

Social &

Governance

Issues

Diversity, Equality

& Inclusion

Gender Pay

Equality

Although each shareholder’s particular focus can differ, AMN’s mission, long-term strategy, pay for performance approach to executive compensation and emphasis on corporate governance and social responsibility were well received. One of the focuses of our engagement with a large shareholder is tackling gender pay equality in the U.S. healthcare system, and we look forward to continuing our engagement on this important issue. Further information surrounding our shareholder engagement program is formalized in our Corporate Governance Guidelines, which we refer to as our Governance Guidelines, and post on our Company website atwww.amnhealthcare.investorroom.com/governance-guidelines.

The following chart summarizes some of the specific actions our Board has taken in recent years in response to feedback received from shareholders. In February 2019, our Board committed to maintain an average tenure for independent directors of less than ten years, commencing in 2020. Additionally, in response to shareholder feedback on board refreshment and in an effort to continue to diversify our Board’s collective composition to most effectively supportoversee the Company’s long-term strategic objectives, our Governancestrategy, business operations and Compliance Committee reviewed itsfinancial strength.

AMN Healthcare Board composition evaluation and director candidate nomination process, which has resulted in the appointments of Ms. Daphne Jones and Ms. Teri Fontenot to the Board in 2018 and 2019, respectfully. The Board’s composition evaluation and director nomination processes are described in the “Board Composition Evaluation and Director Nomination Processes” section located on page6 above.Directors

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  19


            CORPORATE GOVERNANCE                

Response to Shareholder Feedback

Corporate

Social
Responsibility

  New disclosures in our proxy statement and on our website to highlight our commitment to Corporate Social Responsibility.

  Expanded approach to GRI reporting and changed the publication of our CSR report from abi-annual to an annual basis aligned with the release of our Proxy Statement and Annual Report.

Board

Composition

and

Refreshment

  Appointed Ms. Daphne Jones and Ms. Teri Fontenot to the Board;

  Committed to maintain an aggregate board tenure for independent directors with an average tenure of less than ten years; and

  Incorporated individual interviews into the director evaluation process on a bi-annual basis for increased accountability.

Human Capital

Management

Strategy

  Implemented company-wide retention and investment initiatives.

  Established a formal Diversity, Equality & Inclusion philosophy and multifaceted program.

Executive

Compensation

  Instituted “double trigger” mechanics for newly granted equity awards.

Diversity,

Equality &

Inclusion

  Revised Governance Guidelines to affirm our commitment to a diverse Board;

  Published white papers and surveys that highlight diversity issues; and

  Expanded diversity sourcing, candidate metrics, unconscious bias training, and employee resource groups across the enterprise.

Pay

Equality

  Implemented a process to ensure pay equality without regard to legal classification across our organization.

Our Human Capital Management Strategy

An essential element of our approach to effective corporate governance and social responsibility is our Human Capital Management Strategy. Our team members are critical assets that we must continually invest in and strategically manage to maximize their long-term value and potential. With this objective in mind, we identify and monitor a variety of risks and opportunities that are central to our long-term strategic objectives, such as, among others, our diversity, equality and inclusion program, team member engagement, professional development and employee health and safety to ensure we are delivering on our commitment to promote a values-based culture that is centered around business ethics and professional integrity. Our Board and executive management team is committed to fostering a strong ethical corporate culture and expect all team members to fulfill their responsibilities in accordance with the highest standards of professional and personal conduct.

Some actions that we have taken to uphold this commitment to further develop our Human Capital Management Strategy are listed below.

Refreshed our Code of Conduct and Ethics (“Code of Conduct”) that is based on the Company’s core values of respect, trust, passion, innovation, customer focus and continuous improvement and contains examples and questions that help our team members put our core values into practice.

20  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


            CORPORATE GOVERNANCE                

Evolved our formal Diversity, Equality and Inclusion Philosophy focusing our efforts on the workplace, workforce and marketplace and reflected on the Company’s website atwww.amnhealthcare.com/diversity-equality-inclusion.

Adopted a Human Rights Policy and a Vendor Code of Conduct that is incorporated into our Code of Conduct.

Launched a Corporate Social and Responsibility webpage that illustrates information and resources applicable to our strategy and the social objectives that we strive to achieve.

Evaluated and amended the Governance Guidelines to reflect corporate governance and human capital management best practices. The Governance Guidelines function as a critical component to the overall framework for the governance of our Human Capital Strategy.

As discussed above, our Board and its committees regularly and carefully review these and other key governance documents to ensure they contain what we believe to be best practices the best practices and policies in support of our objectives and the values based culture we strive to promote. We publish these documents, among others, under the “Corporate Governance” section of the “Investors Relations” page on the Company’s website atwww.amnhealthcare.com. We also make these materials available in print to any shareholder upon request. Our Board closely monitors corporate governance developments and modifies the Governance Guidelines, Executive Compensation Philosophy, the Code of Conduct and our Code of Ethics for Senior Financial Officers regularly.

Our Corporate Social Responsibility Program

Corporate social responsibility (“CSR”) represents our commitment to economic and social progress by creating a positive impact on the health and development of our team members, healthcare professionals, local and global communities, and stakeholders at large while advancing the quality of our company through engagement in the world around us. CSR is fundamental to AMN’s aspiration to be the most trusted and utilized total talent solution partner for healthcare organizations in the country. Accordingly, we recognize that certain environmental, social and governance (“ESG”) issues can have real financial impacts over the long-term. This is why we are proactively working to better understand, manage and report more robustly and transparently on the ESG risks and opportunities that are relevant to our business and the industries we serve.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  21


            CORPORATE GOVERNANCE                

For sustainability disclosure purposes, we have primarily leveraged the standards issued by the Global Reporting Initiative (“GRI”) because it provides a comprehensive framework that allows us to present all facets of our CSR program. We publish updates in our CSR report on an annual basis and took an opportunity last year to expand our reporting under the GRI framework in an effort to increase transparency surrounding our impact on our stakeholders and the world around us. Accordingly, we are excited to release our 2019 CSR report in March 2020. It will be available to view or download on AMN’s new CSR webpage we recently launched on the company’s website atwww.amnhealthcare.com/corporate-social-responsibility. Below is an illustration of AMN’s holistic CSR ecosystem, its key components and the stakeholders we serve.

LOGO

Our dedication to build an industry-leading CSR program is further demonstrated by our high ESG ratings and our commitment to the United Nations Sustainable Development Goals (“SDGs”). In 2019, we achieved an “AA” ESG rating from MSCI ESG Research, which places us in the top 12% of companies within the health care provider and services industry. Under ISS’ ESG QualityScore, our Governance rating is “1” on a1-10 scale, with 1 being the highest score, a rating of “2” for the Social category and a “3” rating for Environment. We are supportive of the objectives of the SDGs and actively engage with shareholders on those relevant to our business and industry, such as (1) good health and well-being, (2) gender equality, and (3) decent work and economic growth.

22  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


            CORPORATE GOVERNANCE                

To further demonstrate our commitment to continuously improve our disclosures surrounding sustainability, we want to acknowledge that we are listening to our shareholders requests by making progress towards more robust reporting that aligns with the Sustainability Accounting Standards Board (SASB”) and the Task Force on Climate-related Financial Disclosures. Below we have reflected our industry specific disclosure topics that SASB has identified as most likely to impact the operating performance or financial condition of the typical company in the Professional and Commercial Services Industry as well as the initiatives or recognition we have received for our efforts to manage these opportunities.

LOGO

Our Board’s Role in Risk Oversight

The Board as a whole is responsible for overseeing our risk exposure as part of determining a business strategy that generates long-term shareholder value. The Board shapes our enterprise-wide risk capacity, appetite and tolerance levels that provide the foundation for our overall business strategy and direction, and believes that overseeing processes for assessing and managing the various risks we face is one of its most important responsibilities to our stakeholders.

Purposeful and appropriate risk-taking in certain areas is important for us to be competitive and to achieve our long-term goals. Our enterprise risk governance framework reflects a collaborative process whereby the Board, executive management and other team members apply a consistent, rigorous approach to our strategic planning and operational decisions across the Company that is designed to balance the opportunities and threats to our business and consider the steps we are willing to take to capitalize on any business opportunities while mitigating against the key risks. The Board believes that oversight of risk management is a vital element of its responsibility. As a result, it meets with executive management at regular Board meetings and, if necessary, at other times to discuss the strategy and success in addressing our identified key risks.

As part of our annual strategic planning process, we maintain an Enterprise Risk Management Committee that assists the Board in identifying key risks. We typically focus on five to seven risks annually, which may relate to, among other things, business operations, competitive landscape, engagement and retention of quality healthcare professionals, talent management, technology systems, security and innovation. The Enterprise Risk Management

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  23


            CORPORATE GOVERNANCE                

Committee also assists the Board in determining our risk tolerance in light of our (1) existing risk capacity, (2) appetite, if any, to take on additional risk or lessen our risk, (3) risk velocity and (4) mitigation factors. The Board’s determination of our key risks and our tolerance for each ultimately influence how we operate our business, including how we marshal our resources and make strategic and operational decisions.

To ensure that the Company operates within its risk appetite, executive management and other leaders establish and support a culture of integrity, ethical behavior and risk awareness for our team members. We also have designed and maintain internal processes and an internal control environment that further facilitates the identification and management of risks.

In addition to the foregoing, each of the Board’s standing committees’ responsibilities are designed to focus attention on risk areas implicated by its area of expertise, and each committee reports regularly to the Board on its identification and assessment of such risks. All committees play significant roles in carrying out the risk oversight function that typically focus in their areas of expertise. Below is an illustration of which committees, or the full Board, are responsible for overseeing the Company’s key risks identified by the Board.

LOGO

AUDIT COMMITTEE RISK OVERSIGHT

The Audit Committee assists the Board in fulfilling its oversight responsibilities of our compliance with financial ethical requirements and certain other financially-related rules and regulations, as well as our processes to manage our business, financial, technology security and enterprise risk. In performing these functions, the Audit Committee meets periodically with the independent auditor, management, and internal auditors (including in private sessions) to review their work and confirm that they are properly discharging their respective responsibilities.

Among other things, the Audit Committee’s responsibilities include:

Overseeing the work of our independent auditors,

Reviewing and discussing with management significant technology strategic initiatives, operations and risks, including, business continuity planning, project performance, technical operations performance, major technology architecture decisions, internal IT controls and related regulatory risks, significant technology investments and trends in technology that may affect the Company’s strategic plans,

Reviewing and discussing with management key technology strategic initiatives and risks, including information security and cybersecurity incidents and any related disclosure obligations,

Reviewing and discussing with management the Company’s processes to manage major financial risk exposures to the Company and the steps management has or plans to take to monitor, control and manage such exposures, including our risk assessment and risk management guidelines and policies,

24  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


            CORPORATE GOVERNANCE                

Approving procedures for receiving complaints regarding accounting, internal accounting controls or auditing matters, and reviewing evidence of material violations of securities laws, breaches of fiduciary duty related to financial reporting and other financially-related disclosures,

Reviewing and discussing with management, our chief internal auditor, independent auditors orin-house counsel, as appropriate, any legal, regulatory or compliance matters that could have a significant effect on our financial statements, and

Reviewing the results of significant financial or accounting investigations, examinations or reviews performed by regulatory authorities and management’s responses.

In 2019, the Audit Committee didincumbent directors should not identify any significant deficiencies or material weaknesses in the Company’s internal controls. In addition, the Audit Committee determined that our processes to manage our enterprise, business and financial risks are effective and comply with applicable legal and ethical requirements as well as our internal policies and procedures.

COMPENSATION COMMITTEE OVERSIGHT

The Compensation Committee is responsible for analyzing the risks associated with our compensation and human capital management practices. Among other things, the Compensation Committee’s responsibilities include:

Establishing the Company’s executive compensation philosophy and principles to ensure they (i) reflect the Company’s commitment to equal pay principles and its values-based culture, (ii) are designed and operating effectively to appropriately attract, incent and retain talent, and (iii) align with long-term shareholder interests;

Reviewing on an annual basis the corporate goals and objectives relevant to CEO compensation, evaluate the CEO’s performance in light of those goals and objectives, and determine and approve the CEO’s compensation level based on this evaluation,

Reviewing and make recommendations to the Board on an annual basis with respect to the compensation of all of the Company’s executive officers,

Setting the composition of the group of peer companies used for comparison of executive compensation,

Overseeing the design and management of the various long-term incentive compensation, equity, savings, health and welfare plans that cover our employees,

Reviewing, and recommending to the Board, the compensation for ournon-employee directors; and

Overseeing the Company’s human capital management program strategy, including its talent recruitment, retention and engagement and inclusion initiatives.

Risk Related to Executive Compensation

The Compensation Committee designs our incentive compensation to reward officers and other key employees for committing to and delivering on financial goals that we believe are challenging, yet (i) reasonably achievable, (ii) require revenue and profitability performance to reach the target level, and (iii) require significant revenue and profitability growth to reach the maximum level. The financial performance required to reach the maximum level of compensation is developed within the context of budget planning and, while difficult to achieve, is not viewedexpect to be at such an aggressive level that it would induce bonus-eligible employeesre-nominated annually. In determining whether to take inappropriate risks that could threaten our financial and operating stability.

The Compensation Committee believesrecommend a director for re-election, the use of a long-term incentive award program with targets that span a three-year performance period balances risk and reward by discouraging excessive risk that could threaten our long-term value, but at the same time encourages innovation to build our value in the short- and long-term. The Compensation Committee also reviews our program for design features that have been identified by experts as having the potential to encourage excessive risk-taking, such as: (A) too much focus on equity, (B) compensation mix overly weighted toward short-term results, (C) highly leveraged payout curves and steep payout cliffs at specific performance levels that could encourage short-term actions to meet payout thresholds, and (D) unreasonable goals or thresholds. After its consideration of the foregoing factors, the Compensation Committee has determined that our compensation programs and policies do not create risks that are reasonably likely to have a material adverse effect on us.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  25


            CORPORATE GOVERNANCE                

CORPORATE GOVERNANCE AND COMPLIANCE COMMITTEE OVERSIGHT

The Governance and Compliance Committee considers the risks associated withneeds of the Company and the diversity of the Board and believes that our corporate governance practices, leadership succession process, ethicsdirectors should satisfy several qualifications, including but not limited to, demonstrated integrity, the director’s overall engagement in board activities, the results of the annual Board evaluation and compliance programs,other attributes that are discussed further in our Corporate Governance Guidelines (the “Governance Guidelines”) and in the “Evaluation of Board Composition and Director Nomination Process” section below.

Director Nominee Snapshot

INDEPENDENT
DIRECTOR TENURE
AGEGENDER DIVERSITYRACIAL DIVERSITYINDEPENDENCE
Average 9 yearsAverage 65 years56% Female33% BIPOC89% Independent Directors
16

Table of Contents

Corporate Governance

The Board represents a range of characteristics, skills and experiences in areas that are relevant to and contribute to the Board’s oversight of the Company’s strategic objectives and to reflect a diversity of personal backgrounds. Diversity of race, ethnicity, gender and age are taken into account in director nominations. We believe a diverse organization, including our healthcare, clinicalBoard, leads to innovation and employment regulatory compliance practices,successful outcomes. Below, we include the demographic information for each director nominee and quality programs. Amongdescribe the key experiences, qualifications, skills and attributes the director nominee brings to the Board that, for reasons discussed in the chart below, are important to our businesses and strategic objectives. The Board considered these key experiences, qualifications, skills and attributes and the nominees’ other things,qualifications in determining to recommend that they be nominated for election.

HEALTHCARE INDUSTRY

We generally seek directors who have knowledge of and experience in the healthcare industry, which is useful in understanding the needs, regulatory requirements and complexities of our clients and healthcare professionals.

C-SUITE LEADERSHIP

We believe that directors who have served in executive positions are important because they have the experience and perspective to analyze, shape and oversee our strategy and the growth and preservation of shareholder value.

FINANCE/AUDIT

AMN is committed to strong financial discipline, effective allocation of capital and accurate disclosure practices. We believe that financial expertise on the Board is instrumental to our success.

LEGAL/RISK MANAGEMENT

We operate in a constantly changing and increasingly complex regulatory environment. Directors with regulatory compliance oversight and enterprise risk management experience play an important role in the Board’s ability to oversee our enterprise risk management program and legal and compliance risks.

MERGERS & ACQUISITIONS

We believe that our ability to achieve our long-term growth objectives will require a combination of organic growth and growth by acquisition. We believe that M&A expertise on the Board provides valuable insight and oversight of our growth strategies and achievement of financial goals.

HUMAN CAPITAL MANAGEMENT

We have a large and diverse workforce which represents one of our key resources as well as one of our largest expenses. We believe experience in managing a large workforce is important to ensure that AMN has sufficient talent, robust development and retention practices and maintains our commitment to diversity, equity and inclusion.

GOVERNMENT/POLICY ADVOCACY

We operate in a changing healthcare industry. State and federal government experience and an understanding of policy development enhance the Board’s ability to provide effective oversight of government policy and regulatory risk.

DIGITAL/TECHNOLOGY

Our business has become increasingly complex as we have accelerated our digital transformation and expanded our service offerings to include more telehealth and technology related solutions. This digital transformation requires a sophisticated level of technology resources and infrastructure as well as technological expertise, and, accordingly, we believe digital transformation expertise on the Board contributes to our success.

2023 Proxy Statement17

Table of Contents

Corporate Governance

Skills and Experience

  
Skill, Competency or
Attribute
CaballeroFolettaFontenotGraceHarrisJonesMarshTrent-
Adams
Wheat
HEALTHCARE INDUSTRY  
C-SUITE LEADERSHIP   
FINANCE/AUDIT    
LEGAL/RISK MANAGEMENT    
MERGERS & ACQUISITIONS     
HUMAN CAPITAL MANAGEMENT     
GOVERNMENT/POLICY ADVOCACY       
DIGITAL/TECHNOLOGY       
DEMOGRAPHIC BACKGROUND       
Tenure1103017412223
GenderMMFFMFFFM
RACE/ETHNICITY        
African American or Black       
Hispanic or Latinx        
White   
18

Table of Contents

Corporate Governance

Evaluation of Board Composition & Director Nomination Process

Our Governance and Compliance Committee understands the vital role that a strong board composition with a diverse set of skills and continuous refreshment plays in effective oversight. The Governance and Compliance Committee is committed to maintaining a diverse board to effectively manage complex corporate issues by leveraging different experiences to support the Company’s long-term objectives and business strategy. With this purpose in mind, the Governance and Compliance Committee seeks out candidates with skills, experiences, and characteristics, including individuals representing historically underrepresented groups, that when working collectively will fulfill its oversight responsibilities and continue to guide the Company into the future.

As part of the Board’s refreshment strategy and director candidate identification and nomination processes, the Governance and Compliance Committee actively and continuously evaluates its collective composition to identify and prioritize director characteristics, skills, and experiences prior to nominating a new director candidate to the Board for review, approval and appointment. Below is an illustration of the Governance and Compliance Committee’s responsibilities include:

Overseeing matters of corporate governance, including preparingregular Board refreshment and recommendingdirector candidate identification process.

REVIEWS

The Boards current composition and tenure relative to the Company’s strategic objectives

IDENTIFIES

The characteristics, skills, and experiences most critical to the Company’s long-term strategic objectives

ALIGNS

Desired characteristics, skills, and experiences for future director candidates to ensure a diverse Board

When assessing and prioritizing desired characteristics, skills and backgrounds, the Governance Guidelines,

Overseeing director succession practices, including identifying potential director candidates forand Compliance Committee considers, among other things, the BoardBoard’s current skill set and recommending director nominees to the Board for approval,

Reviewing our leadership succession programs and processes and our CEO succession plans,

Reviewing the organization, implementation and effectiveness of the Company’snon-financial compliance and quality programs, includingtenure, the Company’s employment, healthcarelong-term strategic plan and clinical compliance practicesobjectives, shareholder discussions, current and risk oversight of the credentialing of candidatespast board service, commitment to ensure that the Company is placing qualified healthcare professionals,

Reviewing any significant events investigated under our compliance and ethics programscorporate social responsibility and the Company’s Code of Conduct (other than financial matters or misconduct that are reviewed bydirector feedback provided in connection with the Audit Committee), andBoard’s annual evaluation process.

Overseeing the Company’s shareholder outreach program relating to corporate governance matters.

The Governance and Compliance Committee reviewsthen establishes a diverse pool of potential director candidates who possess the Company’s practicesdesired characteristics, skills, and approach with respect to corporate governanceexperiences; the director candidate slates are identified from various databases and regulatory compliance to ensure that its corporate governancesources, including recommendations from shareholders, management and compliance structures provide a foundation for achieving long-term shareholder value. This responsibility goes hand in hand with its oversight of the Company’s leadership succession process to not expose the Company to leadership gapsdirectors, consultants, and the consequences flowing from such gaps.

industry experts. The Governance and Compliance Committee may also reviews and discussesengage a third party to conduct or assist with our management relevant quality metrics, performance improvement, compliance with certification standards and related laws and regulations as well as our enterprise risk management processes relating to the quality of our services and compliance with regulatory requirements.search or evaluation. The Governance and Compliance Committee believesregularly evaluates its potential candidate pool and adds and eliminates individuals based on factors such as candidates’ professional affiliations and availability, director retirements, changing market conditions or strategic objectives and/ or newly considered enterprise risks. When considering candidates to fill an open seat on the Company’s sound corporate governance practices, ethics and compliance infrastructure, comprehensive leadership success program and extensive quality programs are designed to shield the Company from risk that is reasonably likely to have a material adverse effect on us.

Director Independence

The Board, has adopted categorical standards for director independence, which we set forth in the Governance Guidelines and make available on our website. Under these standards, a director will not be considered independent if:

(1)

the director does not qualify as independent under Rule 303A.02(b) of the NYSE Listed Company Manual,

(2)

the director or an immediate family member is a partner of, or of counsel to, a law firm that performs substantial legal services for us on a regular basis, or

(3)

the director or an immediate family member is a partner, officer or employee of an investment bank or consulting firm that performs substantial services for us on a regular basis for which it receives compensation.

26  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


            CORPORATE GOVERNANCE                

The Board does not consider the following relationships to be material relationships that would impair a director’s independence:

(1)

the director or an immediate family member is an executive officer of another company that does business with us and the annual sales to, or purchases from, us are less than 1% of the annual revenues of the company for which he or she serves as an executive officer,

(2)

the director or an immediate family member is an executive officer of another company which is indebted to us, or to which we are indebted, and the total amount of either company’s indebtedness to the other is less than 1% of the total consolidated assets of the company for which he or she serves as an executive officer and such indebtedness is not past due, or

(3)

the director or an immediate family member serves as an officer, director or trustee of a charitable organization, and our discretionary charitable contributions to the organization are less than 1% of its total annual charitable receipts.

The Board has determined that director nominees Mark G. Foletta, Teri G. Fontenot, R. Jeffrey Harris, Dr. Michael M.E. Johns, Martha H. Marsh, Daphne E. Jones and Douglas D. Wheat all meet our categorical standards for director independence and the applicable rules and regulations of the NYSE and federal securities laws regarding director independence. Our CEO is the only member of our Board who the Board has not deemed independent.

When making director independence determinations, the Board considered a business relationship between LHC Group, Inc., of which Ms. Fontenot is an independent director, and the Company. We discuss this relationship in more detail in the “Certain Transactions” section below. The Board considered the nature of this relationship, the annual amount of payments we receive from LHC Group, the fact that the nature of this relationship resulted solely from Ms. Fontenot’s role as an independent director of LHC Group, Inc., and determined that the relationship did not preclude the Board from making an independence determination for Ms. Fontenot and that the relationship fell within our standards of independence.

Board Leadership Structure

We separate the roles of Chairman of the Board and the Chief Executive Officer. Our CEO, Ms. Salka, is responsible for working with the Board in setting our strategic direction and ourday-to-day leadership and performance, while the Chairman of the Board, Mr. Wheat, leads the Board in overseeing our strategy, provides guidance to our CEO and presides over meetings of the Board. At this time the Board believes that having separate roles:

(1)

increases the independent oversight of the Company and enhances the Board’s objective evaluation of our CEO,

(2)

provides our CEO with an experienced sounding board in the Chairman, and

(3)

provides an independent spokesperson for the Company.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  27


            CORPORATE GOVERNANCE                

Policies and Procedures Governing Conflicts of Interest and Related Party Transactions

The Governance Guidelines, our Code of Conduct and the Company’s Related Party Transactions Policy adopted by the Board in December 2019 collectively establish the Company’s procedures related to conflicts of interest and related party transactions.

Under these policies, directors and executive officers must promptly notify the Company’s Chief Legal Officer of any potential “related party transaction” that the Company would be required to disclose publicly under Item 404 of RegulationS-K promulgated under the Securities Exchange Act of 1934. Potential related party transactions involving the Chief Legal Officer must be disclosed to the CEO. If the Chief Legal Officer or CEO, as the case may be, determines that a potential related party transaction would be an actual related party transaction, if consummated, such matter must be referred to the Governance and Compliance Committee for reviewensures that the pool of candidates from which Board nominees are chosen includes candidates from historically underrepresented groups who would bring diversity to the Board. Any search firm or third-party consultant asked to provide an initial list of potential candidates is also required to include such candidates.

2023 Proxy Statement19

Table of Contents

Corporate Governance

Board Refreshment

We prioritize effective and approval. The Committee may approve the transaction if it determines that consummationaligned Board composition, supplemented by a thoughtful approach to refreshment. It is essential to have a qualified group of the transaction is in the best interests of the Company’s shareholders.

Further, our policies require our directors and executive officers to avoid any action, position or interest that conflicts with an interestappropriate mix of the Company or gives the appearance of a conflict. Any potential conflict of interest involving our directors or executive officers must be reported in advanceskills, experience and attributes to the Chief Legal Officer, with potential conflicts of interest involving the Chief Legal Officer having to be reported in advance to the CEO. If the Chief Legal Officer or CEO, as the case may be, determines that an actual conflict of interest may exist, then the matter must be referred to the Governance and Compliance Committee for review. If the Governance and Compliance Committee determines that an actual conflict exists, the Company is required to implement guidelines and procedures necessary to remove the conflict.

Any conflict of interest issue involving any other employee is reviewed by an attorney in our Legal Department. If the attorney believes that an actual conflict of interest issue exists, then the attorney submits the conflict of interest issue to our Chief Legal Officer. If our Chief Legal Officer determines that an actual conflict exists, then the Chief Legal Officer decides what steps should be taken to remove the conflict.

Certain Transactions

In December 2019, the Governance and Compliance Committee evaluated a potential transaction involving the Company and Randstad North America pursuant to which the Company and Randstad North America would agree to jointly pursue and service third parties’ contingent staffing needs.oversee AMN’s strategic objectives. The Governance and Compliance Committee evaluated this transactioncontinuously reviews the Board’s composition, taking into consideration the characteristics of the existing directors, both individually and as a potential “related party transaction” under Item 404 of RegulationS-K because Ms. Rebecca Henderson holds the position of CEO of Randstad Global Businesses, and Ms. Henderson is the spouse of the Company’s former President of Professional Services and Staffing, Mr. Ralph Henderson, who was an executive officer and will retire from the Company on or around May 1, 2020. While the nature of the transaction does not currently contemplate any direct payments between the parties in excess of $120,000, the Governance and Compliance Committee believed the transaction will likely benefit each of the Company and Randstad in excess of this amount and evaluated the transaction under the Company’s Related Party Transaction Policy. The Company understands that Ms. Henderson is not directly compensated on the basis of the financial performance of Randstad North America, which is a Randstad portfolio company for which she is not responsible.

After reviewing and considering the terms of this proposed transaction, the Governance and Compliance Committee determined that its consummation is in the best interests of the Company’s shareholders, and it is being negotiated on anarm’s-length basis between the parties. The Governance and Compliance Committee also determined that, based on its review of the processes and guidelines in place to limit Mr. Henderson’s involvement in the proposed transaction, consummation of the proposed transaction and the Company’s performance under the transaction does not constitute a conflict of interest involving Mr. Henderson. Subsequent to the review of this proposed transactiongroup. Ongoing strategic board succession planning, led by the Governance and Compliance Committee, the parties entered into a definitive agreement on January 20, 2020 and are currently performing the terms of such agreement.

In determining whether directors are independent, the Board considered Ms. Fontenot’s role as an independent director at LHC Group, Inc. In 2019, we continued a commercial relationship with LHC Group that existed before

28  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


            CORPORATE GOVERNANCE                

Ms. Fontenot joined the Board under which LHC Group provides home health contingent staffing services to the Company. The approximately $1.8 million in fees that we received from LHC Group in 2019 were negotiated on anarm’s-length basis and are within the categorical independence standardsensures that the Board continues to maintain an appropriate mix of objectivity, skills and experiences to provide fresh perspectives and effective oversight and guidance to management, while leveraging the institutional knowledge and historical perspective of our longer-tenured directors. Currently, 50% of our Board has adopted. The relationship does not prevent Ms. Fontenot from qualifying as an independent director under the categorical independence standards,served less than five (5) years, and the Board considers Ms. Fontenothas an aggregate tenure of nine (9) years. Each of the five directors that we have added to bethe Board over the past five years have brought additional skills and perspectives to the Board and strengthened the Board’s ability to support and oversee the Company’s long-term strategic objectives. These five directors all represent gender, race and ethnicities that have been historically underrepresented on boards.

Daphne E. Jones –
Experience with strategic, entrepreneurial, and global use technologies in the healthcare sector.
Teri G. Fontenot –
Experience in healthcare leadership, corporate finance, economic policy and healthcare.
Sylvia
Trent-Adams –
Experience in directing and coordinating major federal health programs, as well as strategic planning and leadership of a healthcare institution.
Jorge A.
Caballero –

Accomplished global executive with extensive experience in audit, financial, risk management and mergers and acquisitions.
Cary Grace –
A proven executive with large organizations with significant experience developing and executing profitable growth strategies.

Onboarding and Continuing Education

Our director onboarding process is designed to provide new directors with information, context, and perspectives that enables new directors to effectively contribute to the Board’s work. During the initial months after joining the Board, new directors have individual meetings with each of our current directors, including specific committee-focused meetings with the chair of each committee. New directors are also invited to attend all committee meetings to assist in their development. Each new director is also assigned an independent director.experienced AMN Healthcare board member to share feedback, provide perspective on boardroom activities and dynamics, help with meeting preparation, and act as a resource between meetings.

In addition to providing new directors with a library of resources that includes governance, finance and core background documents, key business executives and functional leaders from across the organization meet with new directors to increase their understanding of AMN’s businesses, operations, culture and values. Throughout their tenure directors participate in informal meetings with other directors and senior leaders to share ideas, build stronger working relationships, gain broader perspective and strengthen their working knowledge of our business, strategy, performance and culture.

We encourage and facilitate director participation in continuing education programs and each director is provided membership in the National Association of Corporate Directors as well as subscriptions to other governance publications and resources. In 2022, individual directors also participated in issue-focused educational programs in areas including ESG, cyber and climate, some receiving certifications. Periodic educational sessions are also provided to members of the Board through the Company by both internal and external resources on subjects that would assist them in discharging their duties. For example, in 2022 board members received educational briefings on topics including, but not limited to, ESG and Stakeholder Capitalism, Social Issues and Crisis Communication and Investor Perspectives.

20

Table of Contents

Corporate Governance

Board Tenure Policy

Our Board’s Aggregate Tenure Policy

In February 2019, our Board adopted an aggregate board tenure policy that reflects its commitment to consistently evaluate the composition of our Board to ensure that it collectively possesses the necessary experience, skills, knowledge, and level of engagement necessary to serve the best interests of our shareholders. The terms of the followingThis policy, werewhich is set forth below, was developed in part based on insight and feedback we received directly from shareholders in connection with our ongoing corporate governance shareholder engagement efforts.

The Board believes that directors should not expect to bere-nominated annually. In determining whether to recommend a director forre-election, the Governance and Compliance Committee considers the needs of the Company and the diversity of the Board as a whole, the director’s participation in and contributions to the activities of the Board, the results of the annual Board evaluation and past meeting attendance.

The Board does not believe in a specific limit for the overall length of time an independent director may serve. Directors who have served on the Board for an extended period can provide valuable insight into the operations and future of the Company based on their experience with, and understanding of, the Company’s history, policies, and objectives. The Board also believes that new directors will strengthen the diversity of the Board, provide fresh perspectives and provide value as the Company evolves. To achieve this balance, effective in 2020, the Board will maintain an average Board tenure for independent board directors of less than ten years.

Upon the conclusion of the Annual Meeting, theThe average aggregate tenure for our Board’s independent directors will be slightly less than 9is approximately nine (9) years.

Shareholder Recommendations and Nominations

The Governance and Compliance Committee considers shareholder recommendations of qualified director candidates when such recommendations are submitted in writing to the Company’s Corporate Secretary at 2999 Olympus Blvd., Suite 500, Dallas, Texas 75019 Attn: Denise L. Jackson, Chief Legal Officer and Corporate Secretary. When evaluating any such shareholder recommendations, the Governance and Compliance Committee uses the evaluation methodology that is described in the “Evaluation of Board Meetings andComposition & Director Nomination Process” above. To have a director nominee considered for election at our 2024 Annual Meeting Attendance by Board Members

We expect eachof Shareholders, a shareholder must submit the nomination in writing to the attention of our directorsCorporate Secretary and also satisfy the requirements set forth in our Bylaws regarding shareholder director nominees no later than February 17, 2024 and no sooner than January 18, 2024, assuming the date of the 2024 Annual Meeting of Shareholders does not change by more than 30 days from the first anniversary of the prior year’s annual meeting. To have a director nominee included in our 2024 proxy statement for election, a shareholder must submit the nomination in writing to attendthe attention of our Corporate Secretary and also satisfy the requirements set forth in the “proxy access” provisions of our Bylaws no earlier than November 6, 2023 and no later than December 6, 2023. In addition, a shareholder who intends to solicit proxies in support of director nominees submitted under the advance notice provisions of our Bylaws must provide the notice required under Rule 14a-19 promulgated by the SEC under the Exchange Act to our Corporate Secretary no later than March 18, 2024.

The Company received no recommendations for director nominees or director nominations from any shareholder for election to be held at the Annual Meeting.

2023 Proxy Statement21

Table of Contents

Corporate Governance

Board and Committee Self-Evaluation Process

In line with our value of continuous improvement, each meetingdirector conducts an evaluation of the performance of the Board and each committee for which they serve on an annual basis. Additionally, on a biennial basis, the Chair of our Governance and Compliance Committee conducts individual conversations with each director. Each step of the committees on which he or she serves. We also expect our directors to attend ourBoard’s annual meetings. Ourevaluation process is further illustrated below.

Director Independence

The Board has an excellent recorddetermined that director nominees Jorge A. Caballero, Mark G. Foletta, Teri G. Fontenot, R. Jeffrey Harris, Sylvia Trent-Adams, Martha H. Marsh, Daphne E. Jones, and Douglas D. Wheat all meet our categorical standards for director independence described in our Governance Guidelines and the applicable rules and regulations of attendance and engagement.During 2019,the New York Stock Exchange (“NYSE”) regarding director independence. Our CEO is the only member of our Board whom the Board has not deemed independent.

When making director independence determinations, the Board considered business relationships between LHC Group, Inc. and Orlando Health, Inc., both clients of the Company. Ms. Fontenot serves as an independent director of Orlando Health, Inc., and served as an independent director of LHC Group, Inc. from 2019 until its sale to United Healthcare in February 2023. We discuss these relationships in more detail in the “Certain Transactions” section below. The Board considered the nature of these related party relationships and the annual amount of payments we receive from each LHC Group, Inc. and Orlando Health, Inc. The Board determined that neither relationship precluded the Board from making an independence determination for Ms. Fontenot and that the related party relationships fell within our standards of independence.

Set forth below is a brief description of the backgrounds and qualifications of each director. These, along with the skills and experience described earlier in this section, led the Board to conclude that the director should be nominated for election at the 2023 Annual Meeting.

22

Table of Contents

Corporate Governance

Director Biographies

Director Since: 2021

Committee: Audit Committee
(Financial Expert); Corporate
Governance & Compliance
Committee

Skills & Qualifications:

Finance/
Audit

Legal/Risk
Management

Mergers &
Acquisitions


Jorge A. Caballero | 66

Qualification Highlights

●  

Managing Partner of Deloitte’s Business Tax Services U.S.- India practice (2016–2019)

●  

New Jersey Tax Managing Partner of Deloitte (2003–2011)

●  

Assistant Vice President of Tax of Beneficial Corporation, a consumer finance company that was acquired by Household International, Inc. in 1998 (1983–1986)

Board Experience

●  

Deloitte Tax LLP, a global professional services firm and one of the Big Four accounting firms, where he was the Chief Diversity Officer (2009–2016)

●  

United Way of Essex and West Hudson in New Jersey, a non-profit organization where he served as the chair of Board of Directors and Finance Committee (2003–2019)

●  

The College of New Jersey, where he served as the chair of the Board of Directors, Finance Committee, and Audit and Risk Management Committee (2007–2019)

●  

Jersey Battered Women’s Service, a private, non-profit agency, where he served as the chair of the Finance, Human Resources, and Infrastructure Committees (1993–2001)


Mr. Caballero brings to the Board significant public company accounting and financial reporting expertise and a top-level perspective in organizational management. Mr. Caballero’s career has provided him with practical knowledge of executive management of complex, global businesses and extensive experience in a wide range of financial and accounting matters including management of global financial operations, financial oversight, risk management and the alignment of financial and strategic initiatives. Mr. Caballero also brings deep corporate governance experience through his work with public and private companies and in his board leadership positions at Deloitte and extensive experience in mergers and acquisitions, a critical component to AMN’s growth strategy. The Board has determined that Mr. Caballero qualifies as an audit committee financial expert and has appointed him to the Audit Committee.

2023 Proxy Statement23

Table of Contents

Corporate Governance

Director Since: 2012

Committee: Audit Committee (Chair)
(Financial Expert)

Skills & Qualifications:

Finance/
Audit

Legal/Risk
Management

Healthcare
Industry

C-Suite
Leadership


Mark G. Foletta | 62

Qualification Highlights

●  

Executive Vice President and Chief Financial Officer of Tocagen Inc., a brain cancer biotechnology company, from February 2017 until its acquisition by Forte Biosciences, Inc. in March 2020

●  

Interim Chief Financial Officer of Biocept, Inc., a publicly traded diagnostics company (August 2015 to July 2016)

●  

Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. (March 2006 – October 2012)

●  

Vice President, Finance and Chief Financial Officer of Amylin (March 2000 – March 2006)

●  

Certified Public Accountant (inactive) and a member of the Corporate Directors Forum

●  

Assisted with developing and launching the initial enterprise risk management assessment at Amylin Pharmaceuticals and guided the launch of the initial risk management assessment at both Regulus and DexCom

Board Experience

●  

DexCom, Inc., a publicly traded diabetes care technology company, since November 2014, where he is the Lead Independent Director

●  

Enanta Pharmaceuticals, a publicly traded biotechnology company, where he is the Chair of the Audit Committee (June 2020 – present)

●  

Regulus Therapeutics Inc., where he served as Chair of the Audit Committee and a member of the Nominating and Governance Committee (February 2013 – June 2018)

●  

Viacyte, Inc., a privately held company

●  

Ambit Biosciences Corporation, where he served as Chair of the Audit Committee (sold in 2014)

●  

Anadys Pharmaceuticals, Inc. (sold in 2011)


Mr. Foletta brings to the Board considerable audit, financial, healthcare and enterprise risk management experience as both an executive officer and director of healthcare companies. Mr. Foletta’s prior experience as a public company CFO provides the Board with extensive public company accounting and financial reporting expertise to guide AMN’s commitment to strong financial discipline, effective allocation of capital and accurate disclosure practices. The Board has designated Mr. Foletta as an audit committee financial expert, and he serves as the Chair of the Audit Committee.

24

Table of Contents

Corporate Governance

Director Since: 2019

Committee: Audit Committee
(Financial Expert); Corporate
Governance & Compliance
Committee

Skills & Qualifications:

Finance/
Audit

Government/
Policy Advocacy

Human Capital
Management

Healthcare
Industry

C-Suite
Leadership


Teri G. Fontenot | 69

Qualification Highlights

●  

President and CEO of Woman’s Hospital, the largest independently-owned women’s and infant’s hospital in the United States providing comprehensive subspecialty services to women (March 1996 – March 2019)

●  

Chief Financial Officer and Executive Vice President of Woman’s Hospital (1992 – 1996)

●  

Chief Financial Officer of three other hospitals located in Louisiana and Florida prior to joining Woman’s Hospital in 1992

●  

Certified Public Accountant (inactive)

●  

Held a six-year term on the Advisory Committee on Research on Women’s Health for the National Institutes of Health

Board Experience

●  

Amerisafe, Inc., a publicly traded specialty provider of workers’ compensation insurance, where she serves on the Audit and Governance Committees (June 2016 - present)

●  

Orlando Health, Inc., a not-for-profit organization (September 2021-present)

●  

Baton Rouge Water Company (2009-Present) and Dynamic Infusion Therapy (May 2021-present) both privately held companies

●  

LHC Group, Inc., a publicly traded in-home healthcare services company, where she served on the Clinical Quality and Corporate Development Committees and as Chair of the Audit Committee (2019 until its sale to United Healthcare in February 2023)

●  

Landauer (a formerly publicly traded company), where she served on its Audit and Governance Committee, until its sale in 2017

●  

PELITAS, a privately held company (June 2021 until its sale in 2022)

●  

Sixth District Federal Reserve Bank of Atlanta, including as its Audit Committee chair for two years (2004 - 2009)

●  

Served on numerous healthcare boards at a local, state and national level, including the Board of Directors of the Louisiana Hospital Association, and the American Hospital Association where she served as Chairperson (2012)


Ms. Fontenot brings substantial operational and strategic experience in the healthcare industry as a former chief executive officer and chief financial officer of four healthcare institutions and as the chair of an insurance provider. Ms. Fontenot’s more than 30 years in healthcare and finance leadership provides valuable insights into AMN Healthcare’s strategic discussions regarding the dynamic economic environment and healthcare industry and continued development of client-centric total talent solutions. The Board has determined that Ms. Fontenot qualifies as an audit committee financial expert and appointed her as a member of the Audit Committee.

2023 Proxy Statement25

Table of Contents

Corporate Governance

Director Since: 2022

Committee: Executive Committee

Skills & Qualifications:

C-Suite
Leadership

Digital/
Technology

Human Capital
Management

Healthcare
Industry

Mergers &
Acquisitions

Finance/
Audit

Legal/Risk
Management

Cary Grace | 54

Qualification Highlights

●  

President and CEO of AMN Healthcare Services, Inc.

●  

Chief Executive Officer of the Global Retirement, Investment and Human Capital Solutions business at Aon PLC from 2016 to January 2020

●  

Led Aon’s Global M&A integration, its Enterprise Client Management function as well as its digitally enabled private health exchanges; served on the Policy and Governance Team, the Operating Committee and was a named executive officer of the corporation

●  

More than 14 years at Bank of America, where she led several institutional and private banking businesses, including their $9 billion Mass Affluent Client Business

Board Experience

●  

State Farm Insurance, a mutual company offering auto, home, life and health insurance as well as investment services, since 2022

●  

League, Inc. a privately held digital platform and technology company empowering consumer health engagement, since 2020

●  

FinTech Evolution Acquisition Group (2021-March 2023); served as Chair of its Audit Committee


Ms. Grace brings to the Board more than three decades of experience developing and executing profitable growth strategies for leading professional and financial services organizations across human capital, banking, investments, health, and mergers and acquisitions. Ms. Grace’s extensive experience in leading initiatives and services with a focus on digital enablement provides valuable insight and leadership as AMN continues to evolve and develop technology related and enabled solutions for clients and clinicians. Ms. Grace is also a passionate advocate for diversity and inclusion and with deep knowledge of environmental, social and governance (ESG) in business, causes closely tied to AMN’s purpose and values and a key differentiator providing competitive advantage.


26

Table of Contents

Corporate Governance

Director Since: 2005

Committee: Corporate Governance
& Compliance Committee (Chair);
Executive Committee; Search
Committee

Skills & Qualifications:

Legal/Risk
Management

Healthcare
Industry

Mergers &
Acquisitions

C-Suite
Leadership


R. Jeffrey Harris | 68

Qualification Highlights

●  

Of Counsel at Apogent Technologies, Inc., a laboratory, life science and diagnostic products company (December 2000 - 2003)

●  

Vice President, General Counsel and Secretary at Apogent Technologies, Inc. (1988 - 2000), when the company was named Sybron International

Board Experience

●  

Sybron Dental Specialties (April 2005 - 2006) until it was acquired by Danaher Corporation

●  

Playtex Products, Inc. (2001 - October 2007) until it was acquired by Energizer Holdings

●  

Prodesse, Inc., an early-stage biotechnology company (2002 - 2009), until it was acquired by Gen-Probe Incorporated (2009)

●  

Apogent Technologies, Inc. (2000 - 2004) until it was acquired by Fisher Scientific International, Inc.

●  

Guy & O’Neill, Inc., a privately held private label and contract manufacturing company (2008 - 2018)

●  

Chairman (2013-2021), president, board member and a co-founder of BrightStar Wisconsin Foundation, Inc., a non-profit economic development corporation

●  

Okanjo Partners, Inc., an early-stage technology company


Mr. Harris brings considerable mergers and acquisitions experience to the Board, which is a key component of AMN’s growth strategy. Mr. Harris’ legal, regulatory and corporate governance expertise provides valuable insights to the Board and Management as we operate in a constantly changing and increasingly complex regulatory environment and strive to deliver industry-leading results supported by strong governance and compliance practices. Mr. Harris serves as the Chair of the Corporate Governance & Compliance Committee.

Director Since: 2018

Committee: Audit Committee;
Compensation Committee

Skills & Qualifications:

Digital/
Technology

C-Suite
Leadership

Healthcare
Industry


Daphne E. Jones | 65

Qualification Highlights

●  

Senior Vice President, Digital/Future of Work for GE Healthcare, the healthcare business of GE (May 2017 - October 2017)

●  

Senior Vice President, Chief Information Officer for GE Healthcare Diagnostic Imaging and Services (August 2014 - May 2017)

●  

Senior Vice President, Chief Information Officer for Hospira, Inc., a provider of pharmaceuticals and infusion technologies (October 2009 - June 2014)

●  

Chief Information Officer at Johnson & Johnson (2006 to 2009); served in various information technology roles with Johnson & Johnson (1997 - 2006)

●  

Founder, The Board Curators, LLC (July 2021 -present)

●  

Founder, Destiny Transformations Group, LLC (April 2018 - present)

Board Experience

●  

Masonite International Corp., a publicly traded global designer, manufacturer, and distributor of internal and external doors for the construction and renovation industry, where she serves as a member of the Corporate Governance and Nominating Committee (February 2018 - present)

●  

Barnes Group Inc., a publicly traded engineered products and industrial technologies company, where she serves on the Audit Committee (September 2019 - present)

●  

Thurgood Marshall College Fund, a not-for-profit organization and the nation’s largest organization exclusively representing the Black College Community


Ms. Jones brings to the Board considerable information technology, global digital technology use, data management and privacy experience as a seasoned “C-Suite” executive with extensive experience in multinational corporations. Ms. Jones’ digital use and technology expertise and experience provides valuable insights in leading innovative change, technological advancement and strategic growth and is critical to our successful execution of our technology and digital strategies.

2023 Proxy Statement27

Table of Contents

Corporate Governance

Director Since: 2019

Committee: Compensation
Committee (Chair); Search Committee

Skills & Qualifications:

C-Suite
Leadership

Human Capital
Management

Healthcare
Industry


Martha H. Marsh | 74

Qualification Highlights

●  

President and CEO of Stanford Hospital and Clinics for eight years until her retirement (April 2002 -August 2010)

●  

CEO of UC Davis Medical Center and the Chief Operating Officer of the UC Davis Health System (1999 - 2002)

●  

Senior Vice President for Professional Services and Managed Care at the University of Pennsylvania Health System

●  

President and CEO of Matthew Thornton Health Plan in Nashua, New Hampshire

●  

Former Chair of the Board of Trustees for the California Hospital Association and the California Association of Hospitals and Health Systems

Board Experience

●  

Edwards Lifesciences Corporation, a publicly traded structural heart disease and critical care monitoring company, where she serves as Lead Director and is a member of its Compensation and Governance Committee (2015 - present)

●  

Owens & Minor, Inc., a publicly traded healthcare services and logistics company, from 2012 through 2019; also served as a member of its Compensation and Benefits Committee and as Chairperson of its Governance and Nominating Committee

●  

Teichert, a privately held company, where she is a member of the Compensation Committee

●  

Thoratec Corporation until it was acquired by St. Jude Medical in 2015

●  

Former Director of Ascension Healthcare Network, a privately held company


With more than 40 years of experience in the healthcare industry, including as CEO or other C Suite Executive of multiple healthcare systems and facilities, Ms. Marsh provides the Board with experience and understanding of the challenges and opportunities of the large healthcare facilities, like the ones we serve, that are immensely useful in directing our strategy to innovate and provide enhanced and expanded talent solution service offerings to meet our clients’ evolving needs. Ms. Marsh’s experience in executive leadership and service on several public company boards also provides the Board with valuable experience in public company governance and top-level perspective in organizational management and execution of corporate strategy. Ms. Marsh serves as the Chair of our Compensation Committee.

28

Table of Contents

Corporate Governance

Director Since: 2020

Committee: Compensation
Committee; Corporate Governance
& Compliance Committee

Skills & Qualifications:

Healthcare
Industry

C-Suite
Leadership

Government/
Policy Advocacy

Human Capital
Management


Sylvia Trent-Adams | 57

Qualification Highlights

●  

President, University of North Texas Health Science Center at Fort Worth (since September 2022)

●  

Executive Vice President and Chief Strategy Officer of the University of North Texas Health Science Center at Fort Worth (October 2020 –September 2022)

●  

Served in the U.S. Public Health Service Commissioned Corps from 1992 - 2020, which included service as Deputy Surgeon General and Acting Surgeon General of the United States

●  

Held leadership roles in the U.S. Department of Health and Human Services, including as Principal Deputy Assistant Secretary for Health

Board Experience

●  

University of Minnesota School of Nursing, Board of Visitors

●  

Institute for Healthcare Improvement, an independent not-for-profit organization, focused on advancing and sustaining better outcomes in health and healthcare

●  

One Safe Place, a non-profit organization


Dr. Trent-Adams is an active C-Suite healthcare leader which provides the Board with valuable insights as AMN continues to evolve to serve the more diverse needs of our clients and the complexities of large growing health systems and to proactively anticipate their needs driven by changes in care delivery, reimbursement, and other factors. Dr. Trent-Adams’ experience serving in high levels of the federal government health service and understanding of the drivers and development of public policy enhances the Board’s ability to provide effective oversight of clinical quality, government policy and regulatory risk, all of which are critical to the successful design and implementation of our growth strategy.

Director Since: 1999

Committee: Board Chair;
Executive Committee; Search
Committee (Chair)

Skills & Qualifications:

Legal/Risk
Management

Finance/
Audit

Mergers &
Acquisitions


Douglas D. Wheat | 72

Qualification Highlights

●  

Managing Partner of Wheat Investments, a private investment firm

●  

Founding and Managing Partner of Southlake Equity Group (2007 - 2015)

●  

President of Haas Wheat  & Partners (1992 - 2006)

●  

A founding member of the merchant banking group Donaldson, Lufkin & Jenrette specializing in leveraged buyout financing

●  

Practiced corporate and securities law in Dallas, Texas (1974 - 1984)

Board Experience

●  

Overseas Shipholding Group, a publicly traded ocean transportation services company, where he serves as Chairman (2014 - present)

●  

International Seaways, Inc., a publicly traded oil and gas tanker company, where he serves as Chairman (2016 - present)

●  

Former member of the Board of Directors of several other companies including Dex Media, Inc. (Vice Chairman), SuperMedia, prior to its merger with Dex One (Chairman), Playtex Products (Chairman), Dr. Pepper/Seven-Up Companies, Inc., Dr. Pepper Bottling of the Southwest, Inc., Walls Industries, Inc., Alliance Imaging, Inc., Thermadyne Industries, Inc., Sybron International Corporation, Nebraska Book Corporation, ALC Communications Corporation, Mother’s Cookies, Inc., and Stella Cheese Company


Mr. Wheat brings to the Board significant healthcare staffing industry knowledge as well as extensive expertise in corporate finance and mergers and acquisitions, all of which are critical to the successful design and implementation of our growth strategy. Additionally, Mr. Wheat has significant experience serving AMN Healthcare under different operating environments, management teams and financial market cycles strengthening the Board’s collective knowledge, perspective, and capabilities to guide the Company through both anticipated and unexpected environments.

2023 Proxy Statement29

Table of Contents

Corporate Governance

Our Corporate Governance Program

Shareholder Corporate Governance Outreach

Accountability to AMN Healthcare shareholders is an essential component of our success, which is why we engage with our shareholders in a variety of ways throughout the year to discuss and obtain feedback on a range of important topics. Management will engage with shareholders to solicit their views on corporate governance, industry leadership, human capital management, corporate social responsibility and diversity, equality, equity, and inclusion. In addition, our Investor Relations team also meets regularly with shareholders, prospective investors, and investment analysts to discuss company performance, strategy, and sustainable growth.

Our outreach efforts have evolved into a robust program with a customized approach to each shareholder and the topics and initiatives that are most important to them. We believe this results in more meaningful dialogue on relevant topics, builds stronger relationships with our shareholders and ultimately a more successful company. With this customized strategy in place, we conduct a formal outreach in the fall of each year. We look forward to the opportunity to connect with our shareholders and find these engagements to be enlightening and productive. Each shareholder we met six times,with expressed appreciation for our interest in their views, and took two actionswe certainly appreciated their time and insight.

Additionally, in 2022, we conducted a comprehensive ESG materiality assessment through engagement with key internal and external constituencies, including our shareholders, that identified and prioritized environmental, social and governance issues likely to have meaningful long-term impact on our Company. Among the top issues identified by unanimous written consent. In 2019, no memberinvestor respondents as internal and external priorities are healthcare professional pipeline, recruitment, retention and engagement, workplace health and safety, and diversity, equity and inclusion of our corporate team members.

2022 Engagement Summary

We sent letters to our largest shareholders representing approximately

55%

of our shares outstanding

Included Shareholders representing over

50%

of our shares outstanding in our ESG Materiality Assessment

We met with shareholders representing approximately

17%

of our outstanding stock on corporate governance matters in 2022 and the first quarter of 2023

Shareholders representing over

19%

of our outstanding stock provided feedback to our ESG Materiality Assessment

   Strategy and Culture

   Human Capital Management

   Healthcare Professional Shortage

   DEI and Pay Equity

   Publication of second ESG Report aligned with the UN SDGs, SASB & TCFD frameworks in April 2023

   Continued investments in human capital management infrastructure

   Increased financial support to organizations focused on diversity, equality, equity and inclusion efforts, mental health, and wellbeing

●   Increased efforts for healthcare professional pipeline development in partnership with clients and universities

Although the focus of each of our shareholders may differ, AMN’s purpose, long-term strategy, commitment to elimination of equity barriers, pay for performance approach to executive compensation and emphasis on corporate governance and social responsibility were well received.

30

Table of Contents

Corporate Governance

Communications With the Board of Directors

The Board has established the following procedure for shareholders and other interested parties to communicate with members of the Board, attended fewer than 75%its Chair or the independent directors as a group. All such communications should be addressed to the attention of our Corporate Secretary at our offices located at 2999 Olympus Blvd., Suite 500, Dallas, Texas 75019. The Corporate Secretary opens and reviews all written communications to the Board, one of its committees or specific director(s) and promptly forwards to the Chair of the aggregateBoard and/or the appropriate Committee Chairperson. The Corporate Secretary will also periodically provide the Chair of the Board, the Committee Chairperson, and the Company’s Chief Executive Officer (if appropriate) with a summary of all such communications and any actions taken if not previously forwarded.

Factors that will be considered when determining whether or not the matter requires immediate attention include, but are not limited to, whether the matter relates to a pressing governance, compliance or legal issue, and whether the matter could have a material impact on the Company’s performance or stock price and the stakeholder(s) making the request.

Enterprise Risk Oversight

The Board is responsible for overseeing our enterprise-wide risk management program. In conjunction with this responsibility, the Board addresses our key risks, risk capacity and risk appetite levels that provide the foundation for our overall business strategy and annual goals. The Board believes that overseeing processes for assessing and managing the various risks we face is important to value creation and value preservation for our shareholders. As a result, the Board meets with executive management to oversee the Company’s enterprise risk governance framework and discuss how the Company’s identified key risks impact its long-term strategies and operational execution. This includes (i) at least an annual review by the Board of our Enterprise Risk Management Program and Crisis Management Plan, (ii) at least a quarterly review by the Audit Committee of reports on significant cybersecurity risks and material breaches, if any, (iii) an annual review by the Audit Committee of the Company’s Risk Management program, (iv) quarterly review by the Governance and Compliance Committee of its compliance, ESG and clinical quality programs, and, (v) quarterly reviews of human capital trends by the Compensation Committee.

Purposeful and calculated risk taking is important for us to be competitive and to achieve our long-term goals. Our enterprise risk governance framework reflects a collaborative process where the Board, executive management and other team members apply a disciplined approach to our strategic planning and operational decisions that is designed to balance the opportunities and threats to our business.

As part of our annual strategic planning process, Executive Management and the Board identify the key risks that jeopardize achievement of our strategic plan. Executive Management and the Board discuss our risk tolerance in light of our (i) existing risk capacity, (ii) appetite, if any, to take on additional risk or lessen our risk, (iii) risk velocity and (iv) mitigation factors. The Board’s determination of our key risks and our tolerance for each ultimately influences how we operate our business, including how we allocate resources and make strategic and operational decisions. We also have designed and maintain internal processes and an internal control environment that further facilitates the identification and management of risks, including response readiness processes, such as planning, disaster recovery and business continuity. As an example, in response to a cybersecurity tabletop exercise with the Board, the Company implemented a technology tool to improve business continuity plans and enhance program efficiencies and oversight and created stand-alone crisis communication channels for clients, healthcare professionals and team members. Additionally, in 2022, we reviewed with the Board a crisis notification and board engagement framework, including escalation process levels based on the type and severity of the issue.

In addition to the foregoing, the responsibilities of each of the Board’s standing committees are designed to focus attention on risk areas implicated by its area of expertise, and each committee reports regularly to the Board on its identification and assessment of such risks. For example, throughout 2021 and 2022, the Compensation Committee provided oversight of a human capital infrastructure project designed to mitigate an identified key risk related to talent. All committees play significant roles in carrying out the risk oversight function that typically focus in their areas of expertise. The general risk and oversight functions among the Board and its Committees is as follows. For more detail on the specific oversight and responsibilities of each Committee, see pages 48 - 52.

CORPORATE GOVERNANCE AND COMPLIANCE COMMITTEE:AUDIT COMMITTEE:COMPENSATION COMMITTEE:

   Ethics and Compliance Program

   Clinical Quality Program

●   ESG Program

●   Accounting, auditing and financial Controls and Disclosure

●   Technology related risks, including cybersecurity

   Enterprise Risk Management process

   Compensation Program

●   Human Capital Management

2023 Proxy Statement31

Table of Contents

Corporate Governance

Information Security, Cybersecurity and Data Privacy

Maintaining the privacy and security of the information we create and receive about the Company, our employees, clients, vendors and others is a component of the Company’s enterprise risk management program. We have systems in place to safely receive and store that information and to detect, contain and respond to data security incidents. While everyone at AMN Healthcare plays a part in information security and data privacy, oversight responsibility is shared by the Board, its committees and management.

Responsible PartyOversight area
BoardOversight of these topics within AMN Healthcare’s enterprise risks
Audit CommitteePrimary oversight responsibility for information security and cybersecurity, including internal controls designed to mitigate risks related to these topics
Corporate Governance andCompliance CommitteePrimary oversight responsibility for data privacy, including legal and regulatory compliance
ManagementOur Chief Information and Digital Officer, Chief Legal Officer and senior members of our information security, risk management and privacy compliance teams are responsible for identifying and managing risks related to these topics and reporting to the respective committee and/or full Board.

Our program and practices in these areas include the following:

Frequent Board and Committee Education. Management provides regular updates to the Board, Audit Committee and/ or Governance and Compliance Committee on these topics throughout the year and, at least annually, an information security program review is presented to the full board. In addition, the directors attend educational sessions offered through third party services.
Systems and processes. We use a combination of industry-leading tools and technologies to protect AMN Healthcare and the personal information we maintain and operate a proactive threat intelligence program to identify and assess risk.
Understanding evolving threats. Our information security team works to understand evolving threats and industry trends.
Collaboration with organizations across all industries. We share information and collaborate with organizations across different industries to fight cybercrime and advance capabilities in these areas.
Tabletop Exercises involving the Board and Management. We engage in regular tabletop exercises to simulate real-life cybersecurity and data privacy threats to provide our Board and/or management team with the opportunity to practice crisis response and implement policies and processes.
Operations Based on Best Practices. We have adopted the National Institute of Standards and Technology (NIST) Cybersecurity Framework to better understand, manage, and reduce our cybersecurity risk and protect our networks and data.
Data Privacy Program. We have invested in resources and technology to meet the evolving data privacy regulatory requirements.
Regular training and compliance activities for our team members. Our team members receive annual training to understand the behaviors necessary to protect company and personal information and receive annual training on privacy laws and requirements. We also offer ongoing practice and education for team members to recognize and report suspicious activity, including phishing campaigns.
Use of third parties. Beyond our in-house capabilities we engage with security and technology vendors to assess our program and test our technical capabilities.
Risk Transfer. We maintain insurance coverage to limit our exposure to certain events, including network security matters.

We continuously assess the risks and changes in the cyber environment and dynamically adjust our program and investments as appropriate. The Company has experienced cyber threats resulting in immaterial cyber incidents and expects cyber threats to continue with varying levels of sophistication. The Audit Committee receives quarterly reports on any notable incidents that may have occurred during the quarter.

32

Table of Contents

Corporate Governance

Our Strategic Approach to ESG

We envision a healthy, just, equitable, and sustainable world where all can thrive. We believe it is our responsibility to do our part in bringing this vision to life, which includes fostering a diverse and thriving workforce, leveraging the core of our business to advance health and health equity, and serving as a catalyst in partnership with our stakeholders to get further, faster, together. Recognizing that responsibility, AMN Healthcare is committed to using its unique reach and resources to advance social change and contribute to meet the demands of a more sustainable future. Our approach is premised on our core belief that achieving measurable results in ESG initiatives provides us with a competitive advantage by improving key stakeholder engagement, supporting talent acquisition, engagement, and retention, driving innovation and costs savings while reducing financial and non-financial risks, and improving the health of our workforce and communities. In working to achieve these results, we have embedded health, diversity, equity and inclusion and an ongoing commitment to sustainability into the core of our business strategy to drive shared value and position AMN Healthcare as the employer and strategic partner of choice. As a company steeped in our core values of customer focus, passion, trust, respect, continuous improvement, and innovation, we have always held our operations to high standards, and we are excited to share the progress we have made on our ESG initiatives and commitments.

Our ESG Pillars

Our ESG strategy is focused on four priority areas that matter most to our business and society and where we see the most meaningful opportunities to create a measurable impact in the coming years: (1) Corporate Governance; (2) Health & Wellness, (3) Diversity, Equality, Equity and Inclusion (“DEI”), and (4) Sustainability.

2023 Proxy Statement33

Table of Contents

Corporate Governance

34

Table of Contents

Corporate Governance

CORPORATE GOVERNANCE

CORPORATE GOVERNANCE
COMMITMENTSPROGRESS IN 2022

1.  Strong ethics, human rights, data privacy and cybersecurity

2.  Comprehensive reporting of financial performance and social & environmental impact

3.  Board diversity reflects value chain

4.  Political advocacy aligns with our values and ESG goals

COMPLETED MATERIALITYASSESSMENT

  Conducted first materiality assessment integrating feedback from internal and external stakeholders to focus and prioritize ESG issues

ENHANCED TCFD DISCLOSURES AND ESG REPORTING

  Enhanced TCFD disclosures and conducted scenario analysis

  Published first ESG report in 2022 aligned with GRI, SASB and TCFD frameworks

ESG EDUCATION

  Provided ESG training for the full Board to promote understanding and alignment on the issues that matter most to our company and the communities in which we conduct business

AWARD-WINNING BOARDDIVERSITY

  56% of our Board members are women

  33% of our Board members are BIPOC

COMMITMENT TO ADVANCINGHEALTH EQUITY

  Inaugural signatory to Healthcare Leadership Council commitment to shared principles aimed at eliminating health disparities

BOARD OVERSIGHT

The AMN Healthcare Board of Directors sets the tone for our Company’s commitment to our values, ethics, compliance, DEI and other ESG initiatives. The Board exercises active oversight of ESG matters, and the Board and its committees regularly and carefully review key governance documents, including our Corporate Governance Guidelines, Code of Conduct, and Code of Ethics for Senior Financial Officers, to ensure they contain practices that are relevant and support our ESG objectives and the values-based culture we strive to maintain. The foundation of our corporate governance strategy is to promote transparent disclosure to our stakeholders on an ongoing and consistent basis, so we publish these documents, among others, under the “Governance” section of the “Investors Relations” page on the Company’s website at https://ir.amnhealthcare.com/governance/governance-documents. We are happy to provide these materials in print for any stakeholder upon request.

Risk management is an integral component of AMN Healthcare’s business strategy, culture, and operations, so our Board’s oversight role and governance practices continue to evolve to support the resilience of our business and sustainability of our operations. Our strategy focuses on identifying the risks and opportunities, including ESG, that are most relevant to our business and then prioritizing those areas where we can achieve the greatest impact. To support the continuous evolution of these practices, we develop strategies to monitor or mitigate ESG risks, capitalize on opportunities, and disclose our progress to stakeholders on an ongoing and consistent

2023 Proxy Statement35

Table of Contents

Corporate Governance

basis. Our Governance and Compliance Committee regularly reviews ESG disclosure frameworks, initiatives, policies and disclosures from management. Our Governance and Compliance Committee oversees, and the Board is engaged and receives regular updates on our ESG initiatives. Our Board continues to invest in increasing their collective ESG acumen and expertise. For example, in 2022, the Conference Board ESG Center gave an Expert Briefing to our full Board on “Stakeholder Expectations & the Roles of the Board in ESG.”

Our executive management team sets the tone each day to foster a culture that represents the AMN Healthcare Difference and functions as the foundation for advancing our long-term ESG strategy. To help support our strategy, we have a dedicated team of cross-functional professionals who are focused on ensuring that our day-to-day operations are aligned with our ESG goals and principles.

ETHICS AND COMPLIANCE

Our core values are put into motion and reinforced by our ethics and compliance program’s many components, purposely designed to instill accountability at all levels of the organization. In this regard, our Ethics in Action program manages compliance training and monitors the development and completion of department operational compliance audit plans which are a key risk mitigation tool. For more than a decade, our leadership has appointed Ethics Champions and Records Champions throughout the company to serve as ambassadors of ethics and compliance requirements.

HEALTH AND WELLNESS

As a healthcare total talent solutions company, AMN Healthcare is empowering the future of care. Critical to our success in helping our clients improve patient outcomes and equal access to healthcare is continually enhancing the well-being of our own team members and other healthcare professionals. Prioritizing the health, safety and wellbeing of our colleagues and healthcare professionals is essential to delivering on our business objectives and is a pillar of our ESG strategy.

HEALTH AND WELLNESS
COMMITMENTSPROGRESS IN 2022

1.  Drive health & wellness for our team members & healthcare professionals

2.  Increase availability & quality of healthcare for communities

3.  Meaningfully help our clients optimize talent management and improve patient experience & outcomes

4.  Positively impact social & environmental determinants of health

HEALTHCARE ACCESS, QUALITY AND EQUITY

  Over 250,000 healthcare professional placements in 2022

  Increased supply of healthcare professionals through Connetics acquisition, which along with our O’Grady Peyton business, enabled us to place 1,700 nurses from 32 countries globally

  Over 3,000 interpreters worked over 200 million minutes to provide language services for over 14 million patient encounters

  Partnered with Remote Area Medical to provide free care clinic to Dallas-Fort Worth area residents

  In partnership with the International Esperanza Project, our clinicians treated 1,300 patients and provided 127 life changing surgeries, and our team members installed 280 smoke free stoves and 280 water filters, advancing health for families in rural Guatemala

CARING FOR OUR TEAM

  Launched and invested $3 million in AMN Caring for Caregivers Fund

  Invested additional $2 million in the AMN Team Member Hardship Fun

  Enhanced company match to 401(k) contributions

  Health insurance premium waivers

36

Table of Contents

Corporate Governance

CULTURE OF TEAM MEMBER WELLBEING

Throughout the pandemic, we have worked hard to support our front-line healthcare professionals and other team members as our healthcare system was placed under an unprecedented strain. Our commitment to supporting our colleagues’ mental, physical, and economic well-being continued throughout 2022.

To reward our team members’ exceptional performance and provide for their future, during the first six months of 2022, AMN Healthcare enhanced its employer match to 100% of 401(k) and deferred compensation contribution on up to 10% of each team member’s salary for eligible team members and provided a one-time contribution of $3,300 to each of our team members with an active 401(k) or deferred compensation plan financial account as of December 31, 2022. We also demonstrated our support for our team members’ physical well-being by waiving 100% of health insurance premiums for all team members for four months.

We recognize that our team members and healthcare professionals may need extra support in times of crisis. During 2022, we also contributed an additional $2 million into our AMN Team Member Hardship Fund, which we launched in 2021 to provide financial support for team members experiencing extreme financial hardship. In 2022, the AMN Team Member Hardship Fund provided $363,232 to 87 grantees experiencing financial hardship. Also in 2022, we invested $3 million into and launched our AMN Caring for Caregivers Fund to provide similar support to our healthcare professionals. In 2022, its inaugural year, the AMN Caring for Caregivers Fund provided $221,221 to 97 grantees experiencing financial hardship. Through these funds, corporate team members and healthcare professionals can receive financial support for qualifying events such as life-threatening or serious illnesses, natural disasters, funeral costs, or other events causing financial strain. This support is in addition to the insurance and other benefits and employee assistance programs available to support our team members and healthcare professionals.

COMMUNITY HEALTH AND WELLNESS

AMN Healthcare is committed to driving health equity by removing barriers and enhancing patient access to quality healthcare. In 2022, our AMN Healthcare Language Services team continued to meet the demand for language and interpretation services for patients with Limited English Proficiency and hearing-impaired patients, promoting equitable access to healthcare. In 2022, over 3,000 interpreters provided services in over 14 million patient interactions, breaking down language and communication barriers to support access to healthcare and improved outcomes.

AMN Healthcare strives to have a positive impact on health in our global community, which is why we partner with the International Esperanza Project (IEP), a nonprofit dedicated to inspiring hope in developing countries through healthcare, community infrastructure, and education. In 2022, we were able to continue our support of IEP and once again send teams of corporate team members and healthcare professionals to provide essential healthcare services and install clean cookstoves and water purification systems in homes to help drive health and wellness for families in rural communities in Guatemala.

To support healthcare and wellness in our local communities, we continued our support for non-profits such as the Ronald McDonald House, Alzheimer’s Foundation, American Cancer Society and many more through volunteerism and financial contributions. In 2022, we piloted our partnership with Remote Area Medical (“RAM”) that works with healthcare organizations to create large pop-up healthcare clinics in areas with high levels of need. At the Dallas-Fort Worth RAM clinic in December 2022, we partnered with the University of North Texas Health Science Center at Fort Worth, where we provided funding and volunteers which helped serve 538 patients.

2023 Proxy Statement37

Table of Contents

Corporate Governance

DIVERSITY, EQUALITY, EQUITY AND INCLUSION

AMN Healthcare is living proof of the power of Diversity, Equality, Equity and Inclusion. We are passionate about bringing diversity to our team, promoting social justice and achieving equity, and are committed to actively engaging in building an organization and society where equality is the norm, equity is achieved, and inclusion is universal so that all can thrive. Our Diversity, Equality, Equity and Inclusion philosophy is grounded in the belief that we should respect all voices, seek diverse perspectives, and succeed when we act together as a positive force for all humanity. We have the opportunity to influence each other, our industry, and our communities by fostering a diverse team.

DIVERSITY, EQUALITY, EQUITY AND INCLUSION
COMMITMENTSPROGRESS IN 2022

1.  DEI excellence in all recruiting & hiring for team members & healthcare professionals

2.  Representative diversity at ALL levels

3.  Equity in compensation and promotion

4.  Deeply inclusive culture of belonging

5.  Significant diverse supplier spend & economic impact in communities

DIVERSE REPRESENTATION THROUGHOUT AMN

  Increased representation of Leader-level team members from historically underrepresented groups (any combination of BIPOC, LGBTQ+, Disabled, or Veterans) by 52%, from 23% in 2019 to 35% in 2022

  69% of our team members and 63% of our leaders are women

  Representation among team members is approaching parity with US Bureau of Labor statistics on race and ethnicity

  Initiated collection of EEO-1 data for the Healthcare professionals we employ and place

INCLUSION THROUGHERG PARTICIPATION

  Added two new Employee Resource Groups and increased participation to 39% of team members in 2022

PAY TRANSPARENCY AND EQUITY

  Implemented enterprise-wide infrastructure to align job functions and compensation

  Salary transparency for all job postings nationwide

INCREASED SPEND WITH DIVERSEAND SMALL SUPPLIERS

  Spent $961,271,590 with diverse and/or small suppliers in 2022, a 154% increase from 2021 and 472% increase from 2020, promoting economic growth in our communities

38

Table of Contents

Corporate Governance

Our strategy to advance and enhance Diversity, Equality, Equity and Inclusion is built on the three defining pillars of Workforce, Workplace and Marketplace.

CREATING A DIVERSE AND INCLUSIVE WORKFORCE

We would not be able to empower the future of care without our team members, who work tirelessly to ensure that our clients and healthcare professionals have everything they need to deliver quality patient care. As a company we are enriched by the unique voices, backgrounds and perspectives that our team members bring to the organization, and we are proud of the positive impact our diverse team has on the healthcare industry. To ensure workforce diversity that reflects U.S. demographics, we track progress on recruitment, promotion, and retention to ensure compositional diversity and representation of gender, race/ethnicity, sexual orientation, disability, age, and veteran status, across all levels of the organization.

DIVERSITY GROWTH: UNDERREPRESENTED GROUPS AT AMN HEALTHCARE

We believe that our diverse workforce and inclusive environment drives better outcomes which has made us the leader in total talent solutions. We are proud to have made significant progress in hiring and promoting historically underrepresented team members, i.e., BIPOC, LGBTQ+, people with disabilities and veterans, across all levels of AMN Healthcare. Our corporate workforce increasingly reflects the diversity of the communities that we serve, which strengthens us, our clients and our communities.

2023 Proxy Statement39

Table of Contents

Corporate Governance

Growth of Historically Underrepresented Groups Among AMN Healthcare Team Members 2019 to 2022

     
2019 2022 Change from
2019 to 2022
(%)
34%TEAM MEMBERS45%TEAM MEMBERS 32%
        
37%INDIVIDUAL CONTRIBUTORS47%INDIVIDUAL CONTRIBUTORS 27%
        
23%LEADERS35%LEADERS 52%
        
18%DIRECTORS & ABOVE29%DIRECTORS & ABOVE 61%
        

The diverse backgrounds and experiences we seek to represent are broad. As of January 2023, we are proud that: 69% of our team members are women; 63% of our leaders are women; 56% of our board of directors are women. Our team is 58% Millennials, 31% Generation X, 6% Baby Boomers, and 5% Generation Z. Additionally, team members that self-identified as veterans, disabled or LGBTQ+ represented approximately 3%, 2%, and 3% of our team, respectively.

For the last six years, AMN Healthcare has been named to the Bloomberg Gender-Equality Index and received a top ranking – 95 out of 100 – in the Human Rights Campaign’s Corporate Equality Index. AMN also received the 2022 National Association of Corporate Directors Diversity, Equity and Inclusion Award, which recognizes top companies and their boards for leveraging the power of DEI to enhance their organization and create long-term, measurable benefit for all stakeholders and communities. We believe that human capital management infrastructure, including our DEI commitment is fundamental to our continued recognition as one of America’s Most Responsible Companies in each of the last three years.

HIRING

AMN Healthcare strives to attract and retain the best talent that supports and aligns with our DEI goals based on the belief that a diverse, inclusive and healthy workforce enables us to best address the needs of our stakeholders. To maintain a diverse workforce reflective of the communities we serve, we are committed to sourcing candidates from historically underrepresented groups and focus our recruitment efforts on hiring team members with a wide range of diverse characteristics including gender, ethnicity, LGBTQ+, disability and military service. We also internally track our hiring, promotion and retention rates to inform our overall progress against achieving DEI targets and to guide our strategy in maintaining an inclusive workforce.

40

Table of Contents

Corporate Governance

Intentional Language in Job Postings
Routine review of job postings to ensure use of neutral language to eliminate unintended barriers to prospective applicants.
Diverse Candidate Slates
We increased our outreach to both passive and active candidate pools to ensure a diverse slate of candidates for all leadership positions.

PROMOTION, RETENTION AND TEAM MEMBER ENGAGEMENT

Throughout 2022, approximately 1,200 team members were promoted or transferred internally into new positions, representing one-third of our corporate workforce. Our professional development education assistance program provides reimbursement to our corporate team members to advance their knowledge and skills through certificate and degree programs. We offer leadership development curricula led by our team of learning and talent development professionals for new leaders, called LEAD at AMN, as well as a leadership curriculum for our individual contributors who are seeking leadership positions, our emerging leaders program. In 2022, we also partnered with a university to offer a virtual certificate program for high-potential leaders and expanded access to executive coaching programs. Additionally, we provide a mentorship program to provide a larger group of our team members the opportunity to connect with others across our company to support their development, strengthen their skills, and deepen relationships. Nearly 10% of our team members participated in the mentoring program during 2022 as either a mentor or mentee. These programs are supplemented with professional development resources from third-party vendors and our corporate memberships in large industry associations, to which every team member has access.

In 2022, we continued to prioritize engaging with our team members through live virtual question and answer sessions on a monthly basis, through AMN Live as well as other town halls throughout the year with our Chief Executive Officer and other senior executives. To assess the engagement of our team members and take action to mitigate risks associated with workforce engagement, development and retention, in 2022 we restarted the annual survey that we have historically conducted to assess team member engagement. Based on the feedback we received, which was discussed with our Board, we incorporated several initiatives and areas of focus into our human capital management strategic plan. We then followed up later in the year with a shorter pulse survey. Team member engagement helps to strengthen our retention rate, which was above 85% in 2022, and our highest in the past five years.

2018 2022 YoY Change (%)
78%2018 RETENTION87%2022 RETENTION 12%

FOSTERING A WORKPLACE CULTURE WHERE ALL CAN THRIVE

Because people are our greatest asset, we remain focused on embedding a culture of inclusion in every aspect of our work to drive engagement.

AMN HEALTHCARE INVESTS IN OUR ERGS

As a total talent solutions company, we understand how important it is to ensure all of our team members feel a deep sense of belonging in the workplace. In 2022, we continued to invest in and grow opportunities for team members to connect and build communities with colleagues. One of the key ways we continue to do this is through our growing Employee Resource Groups (“ERGs”) and our over 100+ Diversity Champions. Our goal in investing in our ERGs and our Diversity Champions is to increase our team members’ individual and collective visibility and leadership, empower inclusion, and strengthen a culture of belonging. Each of these groups is sponsored by members of our executive team who participate in meetings, provide guidance and professional development as well as amplify the voices of team members across levels of the organization.

Our ERGs hold a variety of events throughout the course of the year to raise awareness, enable team members to connect, and build greater understanding of the diverse mosaic that strengthens our company. Our directors and senior leadership understand the integral role ERGs play in driving our DEI priorities and are active participants in educational forums, our multicultural fair and community-based events sponsored by our ERGs and Diversity Champions. In 2022, to further drive our investment in DEI, we

2023 Proxy Statement41

Table of Contents

Corporate Governance

increased our investment in these groups to over $250,000. We also expanded the number of ERGs from 8 to 10, with the addition of Loving Our Bodies’ Existence (“LOBE”) and Black Women Leading in Inclusion, Excellence, Vision and Education (“BELIEVE”). We are proud that our ERGs enjoy robust participation, with approximately 39% of team members belonging to at least one ERG.

10 EMPLOYEE RESOURCE
GROUPS
 39% TEAM MEMBER PARTICIPATION
                         
    
         

OPEN

Mental Health

Advocacy &

Awareness

Advocating for mental health awareness and creating a work environment where everyone feels comfortable communicating authentically.

 

WISE

Wisdom + Insight +

Sincerity +

Experience

Creating positive intergenerational dialogue benefitting team members of the entire Company.

 

PRIDE

LGBTQ + Allies

Engaging with and supporting LGBTQ+ team members and their allies in an inclusive environment.

 

BRAVE

Be Ready Always

– Veterans

Enterprise

Serving and advocating for military veterans, deployed troops, their families and supporters.

 

LOBE

(Loving Our Bodies

Existence)

Promoting body image positivity in the workplace by raising awareness, encouraging openness, and supporting all team members.

         
    
         

PAVE

Power & Value in

Equality

Advancing gender diversity and equality enabling women to connect while developing professionally.

 

PACT

Parents & Caregivers

Together

Championing working parents and caregiver team members by cultivating an inclusive, welcoming, agile and flexible workplace that ultimately builds trust, improves retention, and fosters innovation.

 

SLIDE

Strength Lies

in Diversity &

Equity

Enhancing the professional development, career path prospects and leadership opportunities of BIPOC in the workplace.

 

LALA

Latin American

Legacy Alliance

Representing, advocating, and celebrating the unique experiences, challenges, and culture of the Latin community.

 

BELIEVE

Black Women Leading

in Inclusion, Excellence,

Vision and Education

Advancing equity and belonging with a focus on Black women by engaging a network of allies to attract, retain, empower and inspire Black women to achieve their fullest potential across the spectrum of professional development nurtured by AMN Healthcare leadership.

42

Table of Contents

Corporate Governance

DEI EDUCATION

We offer a variety of courses through our LinkedIn Learning Library on several DEI topics. Currently, new team members are assigned an Inclusive Communications course which includes elements of unconscious bias. Additionally, newly promoted and newly hired leaders are required to complete an Inclusive Leadership course that centers learning around diversity, equity, and inclusion within leadership

Inclusive Communication Training for all Team Members

  Working with team members to build awareness, recognize blind spots based on mistaken, incomplete, or inaccurate assumptions, and embrace diversity.

Inclusive Leadership Course for all Leaders

  Live, four-hour mandatory DEI training for all leaders at the Company on inclusive leadership.

ADVANCING DIVERSITY, EQUALITY, EQUITY AND INCLUSION IN THE MARKETPLACE

Our commitment to DEI extends to our supplier partners and our community health partners. We actively engage diverse suppliers and identify new opportunities to support and grow small, minority, women, LGBTQ+, and veteran-owned businesses. By prioritizing supplier diversity, we positively impact the overall socio-economic health of the communities we serve.

SUPPLIER DIVERSITY

AMN Healthcare is focused on economic growth and creating work opportunities in line with our purpose of helping others achieve their personal and professional goals. We believe that equitable business opportunities contribute to a more equitable world, so we actively facilitate business partnerships with diverse vendors and suppliers by identifying business opportunities and partnerships that support small, minority, women, veteran, and LGBTQ+ owned businesses.

We understand that through supplier diversity, we have an opportunity to benefit the overall socioeconomic health of the communities we serve, so we increased our diverse and small supplier spend to $961,271,589 for 2022, continued funding our pledge of 100 minority-owned business certifications, and expanded our Vendor Development Program. In recognition of AMN Healthcare’s efforts to increase our spend with Minority-owned Business Enterprises, we were named Prime Supplier of the Year by the Western Regional Minority Supplier Development Council in 2022.

GIVING BACK

In addition to the work we do every day at AMN Healthcare, we reinforce our mission to empower the future of care and foster a stronger, more cohesive society through community service and charitable giving. We are proud to support and partner with nonprofits that are dedicated to encouraging diversity and driving equity, as we share those values. We have committed to supporting nonprofits that align with our holistic approach and goals toward health equity. We also recognize that AMN Healthcare is at its best when team members have the opportunity to support causes they care about. That is why we offer eight hours of paid time off for volunteering to our team members and encourage them to give back to their communities in personally meaningful ways. Being a healthcare industry leader demands purpose, a commitment to serve our communities, and the drive to use our resources for the greater good. To this end, we strive to create a meaningful impact and actively engage in philanthropy and community service to create a stronger, more cohesive society that supports our purpose and mission. Our core values act as a compass to our commitment to corporate social responsibility, and we align our charitable giving efforts with these values to help organizations and communities flourish. In 2022, we committed an additional $1.8 million to advance healthcare workforce pipeline, diversity, resilience, and wellness, and we contributed $1.1 million to nonprofits focused on health equity, wellness, DEI, and healthcare workforce (including $200,000 of the $1.8 million commitment noted just above). Our goal is to have a positive impact on the health and well-being of all our stakeholders.

2023 Proxy Statement43

Table of Contents

Corporate Governance

Below are some of the additional non-profit organizations we supported over the past year:

Sustainability

SUSTAINABILITY
COMMITMENTSPROGRESS IN 2022

1.  Reduce our operational footprint to zero in market-based CO2 emissions (Scopes 1 and 2) by end of 2024

2.  Set Scope 3 (value chain) GHG emissions Science-Based Target by end of 2024

3.  Water & Waste footprints measured by 2023. Targets set by end of 2024

34% EMISSION REDUCTION

Reduced Scope 1 & 2 GHGE by 34% from 2019 baseline year

MEASURED
ENVIRONMENTAL IMPACT

Measured water and waste footprints for 2020, 2021, and 2022

Measured full Scope 1, 2, and 3 GHGE for 2020, 2021, and 2022

AMN Healthcare is committed to significantly reducing our environmental impact across our own operations, accelerating our value chain’s sustainability journey, and catalyzing a healthy, sustainable, and regenerative future where all can thrive. As part of our commitment to embed sustainability in our business, we monitor emerging ESG risks and opportunities. Building off our last two TCFD reports, we conducted a TCFD gap analysis, conducted a physical and transition risk analysis, identified business impact (risks and opportunities) to inform strategic planning and our enhanced 2022 TCFD report. For more detail, please see our 2022 TCFD report, which is located in our 2022 ESG Report.

44

Table of Contents

Corporate Governance

MEASURING SCOPE 1, 2 AND 3 GREENHOUSE GAS EMISSIONS

Addressing our shareholders’ and other stakeholders’ calls for greater transparency surrounding environmental and social impact, and building from our baseline (2019) operational greenhouse gas emissions (“GHGE”) inventory which we conducted in 2021, we have calculated our full operational (Scope 1 and Scope 2) and value chain (Scope 3) GHGE for 2020, 2021, and 2022 – as well as our operational waste and water footprints. Please see our 2022 ESG Report for more detail.

SELECT AWARDS AND RECOGNITION

NACDWOMEN’S FORUM OF NEW YORKBLOOMBERG

Winner – Diversity, Equity & Inclusion Award – Public Company – Mid-Cap 2022

Corporate Champion Honoree for Over 40% Female Board Representation, 2017-2023 (biennial)

Gender Equality Index
2018-2023

HUMAN RIGHTS CAMPAIGNNEWSWEEKFORBES

Corporate Equality Index
2018-2022

America’s Most Responsible
Companies 2020-2023

America’s Best Large Employers 2022 America’s Best Employers for Women 2022

ESG-Linked Performance Pay

At AMN Healthcare, we integrate ESG goals into executive compensation. Specifically, the Company holds leadership accountable for executing on our ESG-related commitments by integrating achievement of ESG-related objectives into leadership metrics that comprise a portion of the “Leadership” component that makes up 30% of our senior executives’ target annual cash incentive bonus. In determining the ESG component, the Compensation Committee considers the Company’s performance and progress on certain ESG initiatives.

For 2022, these initiatives included, among other things, increasing representation of historically underrepresented groups, including women, in leadership roles, overseeing an enterprise-wide review of pay equity, leadership of our Employee Resource Groups, philanthropic leadership through board service, and the completion of an ESG materiality assessment.

In 2022, AMN Healthcare made significant progress in each of these and other ESG initiatives which the Compensation Committee determined significantly exceeded our goals. Among other achievements for 2022, the Company under its executive leadership:

Received multiple national and regional awards and recognition for DEI leadership
Increased team member representation of underrepresented groups, including women, in management-level roles
Expanded the quantity and membership of our Employee Resource Groups
2023 Proxy Statement45

Table of Contents

Corporate Governance

Expanded philanthropic leadership through board service, giving and volunteering programs
Completed a materiality assessment to facilitate prioritization and implementation of ESG initiatives.

Political Activity and Trade Associations

Our executive management reports annually to the Governance and Compliance Committee regarding compliance and overall strategic priorities for political and policy lobbying and political contributions that align with AMN’s long-term corporate strategy.

AMN makes limited direct political contributions to U.S. state and local candidates in accordance with our Corporate Political Activities Policy. AMN occasionally participates in the political process by providing financial support to state or local ballot initiatives relating to specific issues that have a direct impact on our businesses. AMN did not make any such contributions in 2022. As with every other aspect of our political involvement, AMN’s participation is guided by our purpose and values and is fully reported in accordance with governing laws. AMN does not make political contributions outside the United States.

From time to time, we engage in discussions with all levels of governments, industry associations, and coalitions on public policy and regulatory issues. When we determine it is in the best interest of our company, we work with lobbyists, trade associations, and government officials to provide information and perspective to support our point of view.

As part of our engagement in the public policy process, we participate in certain industry trade organizations representing the interests of the healthcare, healthcare workforce, staffing industry, and the broader business community with purposes that include, but are not limited to education about the industry, issues affecting the industry, and industry best practices and standards. We may not always support every position taken by our trade associations or the other members, however, we believe our participation in these organizations makes us more effective and broadens our perspective on policy issues critical to our industry, our company, our customers, and our communities.

Our complete Corporate Political Activities Policy can be found on our website at https://ir.amnhealthcare.com/governance/governance-documents.com.

Policies and Procedures Governing Conflicts of Interest and Related Party Transactions

Our Corporate Governance Guidelines, Code of Conduct and Related Party Transactions Policy collectively establish the Company’s procedures related to conflicts of interest and related party transactions.

Under these policies, directors and executive officers must notify the Company’s Chief Legal Officer in advance of any potential “related party transaction” that the Company would be required to disclose publicly under Item 404 of Regulation S-K promulgated under the Securities Exchange Act of 1934. Potential related party transactions involving the Chief Legal Officer must be disclosed to the CEO. If the Chief Legal Officer or CEO, as the case may be, determines that a potential related party transaction would be an actual related party transaction, if consummated, such matter must be referred to the Governance and Compliance Committee for review and approval. Any transaction involving a director, regardless of amount, must be referred to the Governance and Compliance Committee. The Governance and Compliance Committee may approve the transaction if it determines that consummation of the transaction is in the best interests of the Company’s shareholders.

Further, our policies require our directors and executive officers to avoid any action, position or interest that conflicts with an interest of the Company or gives the appearance of a conflict. Any potential conflict of interest involving our directors or executive officers must be reported in advance to the Chairman of the Board and Chief Legal Officer. If the Chief Legal Officer determines that an actual conflict of interest may exist, then the matter must be referred to the Governance and Compliance Committee for review.

Certain Transactions

In determining whether directors are independent, the Board considered Ms. Fontenot’s role as an independent director at Orlando Health, Inc. The Board also considered Ms. Fontenot’s prior role as an independent director of LHC Group, Inc., where she served as an independent director from 2019 until the company was acquired by United Healthcare and the board was disbanded in February 2023. In 2022, we continued commercial relationships with LHC Group and Orlando Health that existed before Ms. Fontenot joined the Board under which the Company provides clinical staffing and language services to LHC Group and Orlando Health. The approximately $800 thousand and $6.5 million in fees that we received from LHC Group and Orlando Health, respectively, in 2022 were negotiated on an arm’s-length basis and are within the categorical independence standards that the Board has adopted. Neither relationship prevents Ms. Fontenot from qualifying as an independent director under the categorical independence standards, and the Board considers Ms. Fontenot to be an independent director.

46

Table of Contents

Corporate Governance

Board and Committee Structure

Board Leadership Structure

The Board has carefully considered its leadership structure, including whether the role of Chair should be a non-executive position or be combined with that of the CEO. Following due consideration, the Board continues to conclude that maintaining an independent chair best positions the Board to promote shareholders’ interests and contribute to the Board’s overall efficiency and effectiveness. As announced on October 31, 2022, Ms. Grace joined the Company on November 28, 2022, as our President and Chief Executive Officer and a member of our Board. As our CEO, Ms. Grace, is responsible for working with the Board in setting our strategic direction and our day-to-day leadership and performance, while the Chair of the Board, Mr. Wheat, leads the Board in overseeing our strategy, provides guidance to our CEO and presides over meetings of the Board (held during the period for which he or she has been a director) and (ii) the numberBoard.

Douglas D. Wheat

Chair of the Board

The Board has selected Douglas D. Wheat to serve as its independent Chair because he:

  Brings unique and extensive board leadership experience that effectively allows him to lead our high-performing Board by keeping it focused on key areas of oversight, coordinating across committees and facilitating effective communication among directors and the Company’s executive management;

●  Fosters a productive relationship between the Board and the Company’s CEO by providing a sounding board with candid, constructive feedback from the Board to the Company’s executive management team;

●  Is deeply committed to our values and mission while driving long-term shareholder value;

  Increases the independent oversight of the Company and partners with the Compensation Committee to oversee the performance and compensation of our CEO;

  Acts as an independent spokesperson for the Company to our shareholders; and

  Has significant experience serving AMN Healthcare under different operating environments, management teams and financial market cycles, affording a unique and valuable ability to provide support to the Company’s new CEO.


Duties of Our Chairman

  Serves as Chair of regular sessions of the Board and manages the overall Board process.

  Leads the Board in anticipating and responding to crises.

●  Oversees and monitors Board engagement to ensure our directors are in-tune with issues of our dynamic industry and the evolving landscape.

●  Supports the Governance and Compliance Committee with board refreshment and executive leadership succession.

●  Models the culture and values expected of all directors.

  Conducts individual meetings with other directors, including the CEO, to encourage open communication, collaboration and differences in perspective.

  Evaluates overall Board effectiveness, with emphasis on identifying areas of enhancement, development and/or furtherance and communicating these observations to the Board for discussion.

  Represents the Board on occasions where it is important for the Board to respond on matters independently from or in concert with the Company’s executive management team.

  Provides guidance and direction to the CEO and executive management team.

  Engages with shareholders and presides over the Company’s Annual Meeting of Shareholders. Also recommends to the Board an agenda to be followed at the Annual Meeting.

2023 Proxy Statement47

Table of meetings held by all committees of the Board (during the periods that he or she served on such committees). All of our then-serving directors attended our 2019 Annual Meeting of Shareholders.Contents

Corporate Governance

Committees of the Board

We have standing Audit, Corporate Governance and Compliance and Compensation Committees. We also have an Executive Committee that meets periodically, as necessary, to oversee the Company’s business development and Executive Committees.capital allocation strategy. Additionally, shortly after Ms. Salka announced her intention to retire on March 10, 2022, the Board formed a CEO Search Committee to oversee the CEO succession process and engage a search firm to evaluate internal and external candidates. The Board committeesCommittees are chaired by independent directors, each of whom report to the Board at meetings on the activities and decisions made by their respective committees. The Board makes committee assignments and designates committee chairs based on a director’s independence, knowledge, and areas of expertise. We believe this structure helps facilitate efficient decision-making and communication among our directors and fosters efficient Board functioning at Board meetings.

In line with our value of continuous improvement, the directors conduct an evaluation of the performance of the Board and each of the committees on an annual

basis. Additionally, on abi-annual basis, the Governance and Compliance Chairman has individual conversations with the directors specifically regarding their board performance and board composition. We describe the current functions and members of each committee below. A more detailed description of the function,functions, duties and responsibilities of the Audit, Corporate Governance and Compliance and Compensation Committees is included in each Committee’s charter and available in the link entitled “Corporate Governance”“Governance” located within the “Investor Relations” tab of our website atwww.amnhealthcare.com.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  29


            CORPORATE GOVERNANCE                

The table below provides current committee memberships and fiscal year 20192022 committee meeting information:

Director       Audit(1)       Compensation(2)       Corporate Governance
and Compliance(3)
       Executive(4)       CEO Search
Committee
Mark G. Foletta         
R. Jeffrey Harris      
Jorge A. Caballero        
Martha H. Marsh        
Cary Grace         
Teri G. Fontenot        
Sylvia Trent-Adams        
Douglas D. Wheat        
Daphne E. Jones        
Committee Meetings and Actions by Written Consent          
Total Committee Meetings 9 7 5 3 8
Actions by Written Consent 0 4 0 2 0

  Chair    Member

    

 

Director

  

 

Audit (1)

  

 

Compensation (2)

  

 

Governance &

Compliance(3)

  

 

Executive

Mark G. Foletta

  

Chair

       

R. Jeffrey Harris

      

Chair

  

Member

Michael M.E. Johns, M.D.

    

Member

  

Member

   

Martha H. Marsh

    

Chair

     

Susan R. Salka

        

Member

Andrew M. Stern(4)

  

Member

    

Member

   

Teri G. Fontenot

  

Member

       

Douglas D. Wheat

        

Chair

Daphne E. Jones

  

Member

  

Member

     

Committee Meetings and Actions by Written Consent

Total Committee Meetings

  

9

  

6

  

5

  

2

Actions by Written Consent

  

0

  

0

  

0

  

4

(1)

The Board has determined that all Audit Committee members (A) are financially literate, and (B) meet the criteria for independence set forth in Rule10A-3 under the Exchange Act, and Section 303A of the NYSE Listed Company Manual. The Board further determined that Jorge A. Caballero, Mark G. Foletta and Teri G. Fontenot are each an “Audit Committee Financial Expert” as defined by SEC Rules and Regulations.

(2)

The Board has determined that all members of the Compensation Committee meet the standards for independence required by the NYSE.

(3)

The Board has determined that all members of the Corporate Governance and Compliance Committee meet the standards for independence required by the NYSE.

(4)Ms. Salka served on the Executive Committee until she retired and resigned from the Board on November 27, 2022.
(4)

Mr. Stern is not standing for re-election upon the expiration of his current term that expires at the conclusion of the Company’s 2020 Annual Meeting.

48

AUDIT COMMITTEETable of Contents

Our Audit Committee Charter, which is reviewed annually, sets forth the duties of the Audit Committee. Generally, the Audit Committee is responsible for, among other things, overseeing our financial reporting process. In the course of performing its functions, the Audit Committee as provided by our Audit Committee Charter:

Corporate Governance

Mark G. Foletta (Chair)

Members

Teri G.
Fontenot

Jorge A.
Caballero

Daphne E.
Jones

(1)

Audit Committee

Total Committee Meetings: 9 | Attendance: 100%

The Audit Committee is responsible for, among other things, overseeing our financial reporting process and cybersecurity risk management. In performing its functions, the Audit Committee:

reviews our internal accounting controls and audited financial statements,

(2)

reviews with our independent registered public accounting firm the scope of its audit, its audit report, and its recommendations,

(3)

considers the possible effect on the independence of such firm in approvingnon-audit services requested of it,

(4)

reviews disclosures made by our CEO and CFO in connection with the certification of our periodic reports,

(5)

reviews and discusses with management significant technology strategic initiatives, operations, and risk,

(6)

reviews and discusses with management the Company’s process to manage our major enterprise risk exposures and the steps taken to monitor, control and manage such exposures,
receives and

(7)

reviews quarterly reports from the Chief Information & Digital Officer on the Company’s technology and cyber risk profile, and

appoints our independent registered public accounting firm, subject to ratification by our shareholders.

CORPORATE GOVERNANCE AND COMPLIANCE COMMITTEE

Our Corporate Governance and Compliance Committee Charter sets forth the duties of the Governance and Compliance Committee. Generally, the Governance and Compliance Committee:

 

(1)

identifiesKey 2022 Activities

Received quarterly updates and recommends qualified individuals with diverse backgroundsoversaw the continued investment in and experiences to become membersmaturity of the Board,

Company’s information security program and progress improvements on key initiatives.
Annual review of the Company’s risk management program and oversight of the enterprise risk management process.
Oversaw the relationship between the Company’s finance team and its independent auditor to ensure an effective audit process.

 

(2)

periodically evaluates the Code of Conduct and the Governance Guidelines,

(3)

reviews the Board’s performance on an annual basis,

(4)

oversees all aspects of the Company’s ethics and compliance programs, including the Company’s healthcare and employment regulatory compliance and risk oversight with respect to the credentialing of candidates,

(5)

reviews and evaluates succession planning for the CEO and other members of our executive management team,

(6)

recommends potential successors to the CEO, oversees our shareholder engagement program as it relates to corporate governance issues and considers feedback provided by our shareholders, and

30  Martha H. Marsh (Chair)

Members

R. Jeffrey
Harris

Sylvia
Trent-Adams

Daphne E.
Jones

 

 

AMN HEALTHCARE SERVICES, INC.  

Compensation Committee

  2020 Proxy StatementTotal Committee Meetings: 7 | Attendance: 95%


            CORPORATE GOVERNANCE                

(7)

reviews and discusses withThe Compensation Committee is responsible for, among other things, overseeing our executive team relevant quality metrics, compliance with certification standardscompensation and related laws and regulations as well as our enterprise riskhuman capital management process relating toprograms. In the qualitycourse of our services.performing its functions, the Compensation Committee:

With respect to director nominee procedures, the Governance and Compliance Committee utilizes a broad approach for identification of director nominees and may seek recommendations from our directors, management or shareholders or it may choose to engage a search firm. A detailed discussion of our Board composition evaluation and director nomination process is described in the “Board Composition Evaluation and Director Nomination Processes“ section located on page 6 above.

In evaluating and determining whether to ultimately recommend a person as a candidate for election as a director, the Governance and Compliance Committee considers the qualifications set forth in our Governance Guidelines, including:

judgment, business and management experience,

leadership,

strategic planning,

reputation for honesty and integrity,

diversity, and

independence from management.

It also takes into account specific characteristics, skills and expertise that it believes will enhance the collective composition of the Board to most effectively support our long-term strategic objectives. The Governance and Compliance Committee may engage a third party to conduct or assist with the evaluation.

The Governance and Compliance Committee considers shareholder recommendations of qualified nominees when such recommendations are submitted in accordance with the procedures described in the Bylaws. To have a nominee considered by the Governance and Compliance Committee for election at the 2021 Annual Meeting of Shareholders, a shareholder must submit the recommendation in writing to the attention of our Corporate Secretary at our corporate headquarters no later than January 22, 2021 and no sooner than December 23, 2020. Any such recommendation must include the information set forth onExhibit A to this proxy statement (pageA-1).

The Governance and Compliance Committee received no recommendations for a director nominee from any shareholder for the director election to be held at the Annual Meeting.

COMPENSATION COMMITTEE

The Compensation Committee Charter, last amended in April 2019 to more effectively delineate the Committee’s oversight of the Company’s human capital management and equal pay strategies, sets forth the Committee’s duties. Among other things, the Compensation Committee:

(1)

establishes the executive compensation philosophy for the Company,

(2)

designs executive compensation programs to attract, incent and retain executive talent,

(3)

reviews, and, when appropriate, administers and makes recommendations to the Board regardingregarding: (A) the compensation of our CEO, (including employment agreements or severance arrangements, if applicable, and executive supplemental benefits or perquisites, if any), all senior officersexecutives that report directly to our CEO, and our directors and (B) our incentive compensation plans and equity-based plans,

(4)

prepares the Compensation Committee Report, approves the financial performance measures that were used by the Company to link compensation paid to the Company’s executives to performance for the most recently completed fiscal year, and oversees the preparation of our compensation disclosure and analysis required by the SEC to be included in our annual proxy statement and recommends theirits inclusion in the annual proxy statement to the Board,

(5)

recommends the proposals on“say-on-pay” “say-on-pay” and the frequency of the“say-on-pay” “say-on-pay” vote that are required by SEC rules

(6)

reviews our incentive compensation arrangements generally to determine whether they encourage excessive risk-taking,

(7)

evaluates the performance of our CEO, and

(8)

oversees the Company’s human capital management strategy, including talent recruitment, retention and engagement and its diversity, equality, equity, and inclusion initiatives.

For further information about the responsibilities of the Compensation Committee, please see the Compensation Discussion and Analysis portion of this proxy statement below.

Key 2022 Activities

Oversaw human capital infrastructure project designed to mitigate key risks related to talent and support the Company’s growth strategies.
Oversight of DEI initiatives to increase representation of team members from historically underrepresented communities.
Approved the terms for a transition agreement with Ms. Salka upon her retirement from the Company.
Designed retention bonus program for key executives in recognition of the competitive labor environment and to promote stability and continued growth during CEO transition.
Approved compensation package for new CEO.

For further information about the responsibilities of the Compensation Committee, please see the Compensation Discussion and Analysis portion of this proxy statement below.

AMN HEALTHCARE SERVICES, INC.  

20202023 Proxy Statement

49  31


Table of Contents


            CORPORATE GOVERNANCE                Corporate Governance

Compensation Committee Interlocks and Insider Participation

The Compensation Committee, whose members are Ms. Marsh, Dr. Johns, andMr. Harris, Ms. Jones, and Dr. Trent-Adams consists exclusively ofnon-employee, independent directors, none of whom has a business relationship with us, other than in his or her capacity as director, or has any interlocking relationships with us that are subject to disclosure under the rules of the SEC related to proxy statements.

Compensation Committee Consultant Independence

The Compensation Committee retains an independent consultant to assist it in fulfilling its responsibilities. Since 2008, the Compensation Committee has utilized Frederic W. Cook & Co., Inc. as its compensation consultant. Our compensation consultant advises the Compensation Committee on a variety of topics, including, among others, our equity compensation program, the design of our cash incentive program, the evaluation of the alignment of our compensation program with our shareholders’ interests, the risks presented by our executive compensation program structure, the assessment of the program compared to our peers and director and executive compensation trends.

In retaining and utilizing Frederic W. Cook & Co., the Compensation Committee considers (1) our directors’ experience with its employees and representatives while serving on other boards, (2) knowledge and experience in executive compensation program design, corporate finance and legal and regulatory issues, (3) experience providing consultative services to boards, as well as its analysis of our existing program and proposal of key considerations in evaluating and strengthening our program and (4) factors affecting independence, including factors set forth by the NYSE for evaluating the independence of advisors. In connection with its consideration of Frederic W. Cook & Co.’s independence, the Compensation Committee factored in that Frederic W. Cook & Co. does provide consulting services to other companies that have a director who is also a director of ours, but it does not have any other relationship with or provide any other services to us. As a result of the Compensation Committee’s review of the factors affecting independence, it has determined that Frederic W. Cook & Co. is independent and has no conflicts of interest with us.

R. Jeffrey Harris (Chair)

Members

Jorge A.
Caballero.

Sylvia
Trent-Adams

Teri G.
Fontenot

Corporate Governance and Compliance Committee

Total Committee Meetings: 5 | Attendance: 95%

The Corporate Governance and Compliance Committee is responsible for, among other things, overseeing our board composition and refreshment strategies, corporate governance practices, ESG reporting strategies and ethics and compliance programs. In the course of performing its functions, the Corporate Governance and Compliance Committee:

identifies and recommends qualified individuals with diverse backgrounds and experiences to become members of the Board,
oversees the Company’s ESG strategies and practices, including its governance reporting frameworks
periodically evaluates the Code of Conduct and the Governance Guidelines,
reviews the performance of the Board and its committees on an annual basis,
oversees all aspects of the Company’s ethics and compliance programs, including the Company’s healthcare, employment and privacy regulatory compliance and risk oversight with respect to the credentialing of candidates,
reviews and evaluates succession planning for the CEO and other members of our executive management team,
oversees our shareholder engagement program as it relates to corporate governance issues and considers feedback provided by our shareholders,
reviews related party transactions, and
reviews and discusses with our executive team relevant quality metrics, compliance with certification standards and related laws and regulations as well as our enterprise risk management process relating to the quality of our services.

Key 2022 Activities

Oversaw the advancement of the Company’s ESG strategy, commitments, and initiatives, including the Company’s measurement of its full value chain (Scopes 1, 2 and 3) GHGe footprint.
Oversaw the continued development and effectiveness of the Company’s Enterprise Compliance Program utilizing an independent third-party assessment.
Received quarterly updates and oversaw the continued investment in and maturity of the Company’s Privacy Compliance program.
50

Table of Contents

EXECUTIVE COMMITTEECorporate Governance

Douglas D. Wheat (Chair)

Members

R. Jeffrey
Harris

Cary
Grace

Executive Committee

Total Committee Meetings: 3 | Attendance: 100%

The Executive Committee exercises the power of the Board between its meetings, including the approval of certain acquisitions within established parameters.

Key 2022 Activities

Oversaw the Company’s acquisition of Connetics Communications.
Oversaw the Company’s business development strategies and evaluated acquisition targets.

Douglas D. Wheat (Chair)

Members

R. Jeffrey
Harris

Martha H.
Marsh

Search Committee

Total Committee Meetings: 8 | Attendance: 100%

The CEO Search Committee was responsible for overseeing the CEO succession process and engaging a search firm to evaluate internal and external candidates.

Key 2022 Activities

Development of desired profile and characteristics for the Company’s next CEO.
Selection of Executive Search firm to conduct robust internal and external search for the Company’s next CEO.
Oversaw the search and recommended final candidates for the Board to interview.

Meetings and Attendance

We expect each of our directors to attend each meeting of the Board inand of the interval betweencommittees on which he or she serves. We also expect our directors to attend our annual meetings. Our Board has an excellent record of attendance and engagement. During 2022, the Board met 8 times and took 3 actions by unanimous written consent. In 2022, our directors attended (i) 100% of the aggregate of the total number of meetings of the Board including(held during the approvalperiod for which he or she has been a director) and the number of certain acquisitions within established parameters.meetings held by the Audit, Executive and CEO Search Committees of the Board (during the periods that he or she served on such committees) and (ii) 95% of the aggregate of the total number of meetings of the Corporate Governance and Compliance Committee and Compensation Committee of the Board (held during the period for which he or she served on such committee). All our then-serving directors also attended our 2022 Annual Meeting of Shareholders.

2023 Proxy Statement51

Table of Contents

Corporate Governance

Executive Sessions ofNon-Management Directors

The Board has executive sessions at each regularly scheduled Board meeting during the year, for which our management director, Ms. Grace (or Ms. Salka before her retirement), is not present. In addition, all independent directors met to unanimously appoint Cary Grace as the Company’s President and Chief Executive Officer and a member of the Board, effective November 28, 2022.

Communications withMore Information

You can learn more about our corporate governance by visiting https://www.amnhealthcare.com/, where you will find our Corporate Governance Guidelines, each standing committee charter, and Director Independence Standards. AMN Healthcare has adopted a comprehensive Code of Conduct that applies to the CEO, CFO, Controller, and other senior financial and executive officers, as well as the Board of Directors

The Board has established the following procedure for shareholders and other interested parties to communicate with membersemployees. It is also available at https://www.amnhealthcare.com/. Each of the Board, the presiding director, or the independent directors as a group. All such communications should be addressedabove documents is available in print upon written request to the attentionOffice of our Corporate Secretary at our offices located at 12400 High Bluff Drive, Suite 100, San Diego, California 92130. The Corporate Secretary collects and maintains a log of each such communication and forwards any that the Corporate Secretary, believes requires immediate attentionAMN Healthcare Services, Inc. 2999 Olympus Blvd, Suite 500, Dallas, TX 75019 (469) 524-1473, or by email request to the appropriate members of the Board, who then determine how such communication should be addressed.

officeofthecorporatesecretary@amnhealthcare.com Attn: Corporate Secretary.

32  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement

  


52

DIRECTOR COMPENSATION AND OWNERSHIP GUIDELINES   


Table of Contents

Director Compensation and Ownership Guidelines

DIRECTOR COMPENSATION

AND OWNERSHIP GUIDELINES

Members of the Board who are not employees of the Company (“Independent Directors”), receive compensation for their service in the form of cash and equity. We refer to these directors as “Independent Directors.” Each form of compensation is evaluated by the Compensation Committee on an annual basis. The Compensation Committee believes director pay should be aligned with the long-term interests of shareholders, so it has historically given substantial weight to the equity component, which represented approximately 66% of our Independent Directors median total compensation in 2019. As part of their

 

DIRECTOR COMPENSATION PHILOSOPHY AND PROCESS

The Compensation Committee believes director pay should be aligned with the long-term interests of our shareholders, so it gives substantial weight to the equity component, which represented approximately two-thirds of our Independent Directors median total compensation in 2022.

As part of its annual review process, the Compensation Committee evaluates a variety of sources and benchmarks the compensation we pay our Independent Directors against our executive compensation peer group and relevant market data. It also consults with our independent compensation consulting firm, Frederic W. Cook & Co., Inc., prior to issuing a recommendation to the Board, which it has historically done in conjunction with the election of directors at the Annual Shareholders Meeting. Following this process provides the Compensation Committee with more visibility into director pay trends based on the most recently disclosed public filings of peer companies included in its analysis.

Director Cash Compensation

We pay our Independent Director’s against our peer group and relevant market data. It also consults with an independent compensation consulting firm, Frederic W. Cook & Co., Inc., prior to issuing a recommendation to the Board, which it has historically done in April. Following this process provides the Compensation Committee with more visibility into director pay trends based on the most recently disclosed public filings of peer companies included in its analysis.

Director Cash Compensation

We pay our independent Directors an annual cash retainer.retainer that is paid in advance on a quarterly basis. We do not pay any meeting fees to our directors. The Chairman of the Board, Committee Chairpersons and one Executive Committee member receive an additional annual retainer for their services. We also reimburse directors forout-of-pocket expenses incurred in connection with their service. Annual retainers are paid in four equal quarterly installments.instalments. The table on the rightbelow sets forth the

current annual retainer schedule for our Independent Directors.

PositionAnnual
Retainer
($)
Independent Director75,000 

    Position

Annual     

Retainer ($) 

Independent Director

  70,000     

Chairperson of the Board

 

100,000     

150,000(1)

Chairperson of Audit Committee

 

30,000

Chairperson of Compensation Committee

 

  15,000     

20,000(2)
Chairperson of Corporate Governance and Compliance Committee  10,000     15,000

(1)Effective April 1, 2022, we approved an increase in the annual cash retainer for the Chairperson of the Board from $100,000 to $150,000.

Executive(2)

Effective April 1, 2022, we approved an increase in the annual cash retainer for the Chairperson of the Compensation Committee Member

from $15,000 to $20,000.
 

  10,000     

2023 Proxy Statement
53

Table of Contents

Director Compensation and Ownership Guidelines

Director Equity Compensation

We typically grant full-value equity awards tonon-management directors Independent Directors upon appointment or election to the Board, and annually thereafter during the director’s term. WeBecause we believe that director compensation should be weighted in equity, we anticipate that we will continue to grant annual equity awards to our independentnon-management directors at some levelIndependent Directors for the foreseeable future. The aggregate grant date fair value, which we refer to as AGD Fair Value, of such equity awards is $140,000,$160,059, which we believe aligns with the market for independent director compensation.

On April 17, 2019,21, 2022, each independentnon-management directorIndependent Director serving on the Board at such time received an equity award of 2,9071,458 restricted stock units, which we refer to as RSUs. The RSU awards issued to independent directorsour Independent Directors vest on the earlier of theone-year anniversary of the grant date or the 2020 annual meeting2023 Annual Meeting of shareholders,Shareholders, provided such director remains in service, and eachservice. Each director was also given the option to defer receipt of the shares underlying the RSUs until their separation of service from the Board. Independent Directors that are elected to the Board at a time other than in connection with our annual meeting receive an equity award upon election in an amount equal to the pro rata annual grant value approved for Independent Directors for the anticipated service time from his or her separationdate of service.election through the Company’s next annual meeting of shareholders. The chart on the right illustrates a breakdown of the current annual compensation of our Independent Directors, excluding committee retainers.

INDEPENDENT DIRECTORS

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  33

Cash vs. Equity Compensation


DIRECTOR COMPENSATION AND OWNERSHIP GUIDELINES   

Director Compensation Table

The following table reflects compensation that our directors earned during fiscal year 2019.2022. The table does not include Ms. Salka whoor Ms. Grace, neither of whom received no additional compensation for hertheir service as a director.

   

 

Name

  

Fees Paid

in Cash

($)

   

Fees Paid

in Stock

($)(1)

   

 

            Total

($)

 

Mark G. Foletta

  

 

100,000

 

  

 

140,001

 

  

 

240,001

 

R. Jeffrey Harris

  

 

77,500

 

  

 

140,001

 

  

 

217,501

 

Michael M.E. Johns, M.D.

  

 

72,500

 

  

 

140,001

 

  

 

212,501

 

Martha H. Marsh

  

 

85,000

 

  

 

140,001

 

  

 

225,001

 

Andrew M. Stern

  

 

70,000

 

  

 

140,001

 

  

 

210,001

 

Paul E. Weaver (2)

  

 

23,270

 

  

 

-

 

  

 

23,270

 

Douglas D. Wheat

  

 

170,000

 

  

 

140,001

 

  

 

310,001

 

Daphne E. Jones

  

 

70,000

 

  

 

140,001

 

  

 

210,001

 

Teri G. Fontenot

  

 

20,222

 

  

 

75,489

 

  

 

95,711

 

Name Fees Paid
in Cash
($)(1)
     Fees Paid
in Stock
($)(2)
     Total
($)
 
Mark G. Foletta  110,000  160,059  270,059 
R. Jeffrey Harris  100,000  160,059  260,059 
Martha H. Marsh  103,750  160,059  263,809 
Jorge A. Caballero  75,000  160,059  235,059 
Sylvia Trent-Adams  75,000  160,059  235,059 
Douglas D. Wheat  232,500  160,059  392,559 
Daphne E. Jones  75,000  160,059  235,059 
Teri G. Fontenot  75,000  160,059  235,059 

(1)

In addition to their annual cash retainer, on December 13, 2022, we approved a payment of $20,000 to Mr. Wheat, $10,000 to Mr. Harris, $10,000 to Ms. Marsh and $5,000 to Mr. Foletta for their services as directors in connection with additional work performed in 2022 as part of the CEO Search and evaluation of strategic initiatives.

(2)The amount set forth in this column represents the AGD Fair Value of the 2,9071,458 RSUs granted to each director elected to the Board on the date of the Annual Meeting of Shareholders held on April 17, 2019, and, for Ms. Teri Fontenot, it reflects thepro-rated AGD Fair Value of the 1,356 RSUs awarded to her on the date of her appointment to the Board on September 16, 2019.

May 6, 2022.
(2)

Mr. Weaver retired from the Board in April 2019.

54

Table of Contents

Director Compensation and Ownership Guidelines

Director Equity Ownership Requirement

Our Board believes that all directors should maintain a meaningful personal financial stake in the Company to further align their long-term interests with our shareholders. Accordingly, it is the Board’s desire that eachnon-management director will hold Common Stock and vested but unsettled RSUs of the Company equal to a value of at least five times the director’s annual cash retainer (i.e.(i.e., $350,000)$375,000). The Company does not take into account the value of unvested RSUs and vested or unvested stock appreciation rights (“SARs”) and options in determining whether a director meets our director equity ownership guidelines. As of December 31, 2019,2022, all ofAMN non-management directors satisfy our director equity ownership guidelines, except for our two newest directors, with the exception of Ms. JonesDr. Trent-Adams and Ms. Fontenot,Mr. Caballero, who were appointed to the Board in July 2018October 2020 and September 2019, respectfully,December 2021, respectively.

LevelShares Held
as Multiple of
Annual Cash
Retainer
Complies
Mark G. Foletta53.5x
R. Jeffrey Harris116.4x
Martha H. Marsh72.5x
Jorge A. Caballero2.6xN/A(1)
Sylvia Trent-Adams4.6xN/A(2)
Douglas D. Wheat47.7x
Daphne E. Jones13x
Teri G. Fontenot10.7x

(1)Mr. Caballero was appointed to the Board in December 2021 and does not yet satisfy the director equity ownership requirement.
(2)Dr. Trent-Adams was appointed to the Board in October 2020 and does not yet satisfy the director equity ownership requirement.
2023 Proxy Statement55

Table of Contents

Executive Officers

Our named executive officers as of December 31, 2022 are listed below. We provide information regarding the business experience, qualifications, and affiliations of our director equity ownership guidelines.currently employed named executive officers who are not directors below.

For Ms. Grace’s experience, qualifications, and affiliations, please see page 26 above.

Jeffrey R. Knudson |48

Chief Financial Officer and Treasurer

Mr. Knudson joined us as Chief Financial Officer and Treasurer in November 2021. In his role, Mr. Knudson oversees the Company’s accounting, finance, investor relations and internal audit functions.

Prior to his appointment as Chief Financial Officer and Treasurer, Mr. Knudson served as Chief Financial Officer and Executive Vice President, Supply Chain of At Home Group, Inc., in which capacity he oversaw accounting, financial planning and analysis, treasury, investor relations, and internal audit and supply chain activities.

Prior to Mr. Knudson’s tenure with At Home Group, Inc., he served in several leadership positions at CVS Health and CVS Caremark Corp., including as Senior Vice President of Finance and Retail Controller for their retail pharmacy segment. Prior to CVS, Mr. Knudson was a key member of the treasury and mergers and acquisition leadership teams at L Brands and Express Scripts.

Mr. Knudson received his bachelor’s degree in accounting and finance from the University of San Diego.

Mark C. Hagan | 54

Chief Information and Digital Officer

Mr. Hagan joined us as Chief Information Officer in June 2018. In March 2020, Mr. Hagan was promoted to Chief Information and Digital Officer and is responsible for our digital strategy, technology R&D, enterprise information technology infrastructure, operations, development, security, program management operations as well as certain customer support operations.

Prior to joining AMN, from 2014-2018, Mr. Hagan was Chief Information Officer and Senior Vice President of IT at Envision Healthcare, a diverse healthcare services and technology company and a leading provider of physician-led services, post-acute care, ambulatory surgery services, and related management services. Prior to Envision, Mr. Hagan was IT Director at TeleTech.

Mr. Hagan currently serves as a director of M&M Properties Colorado LLC and Wonolo, Inc.

Mr. Hagan holds a Master of Business Administration from the University of Colorado and a Bachelor of Science and Computing from Queensland University of Technology.


56

Table of Contents

Executive Officers

Denise L. Jackson | 58

Chief Legal Officer and Corporate Secretary

Ms. Jackson joined us as General Counsel and Vice President of Administration in October 2000 and we appointed her as our Corporate Secretary in May 2003. Ms. Jackson is responsible for our legal, environmental, social and governance functions, compliance, risk management, real estate, government affairs and equity compensation.

Ms. Jackson serves on the Board of Tractor Supply Company (TCSO: Nasdaq), the largest retailer of rural lifestyle products in the United States and is the Chair of its Corporate Governance Committee.

Prior to joining AMN, from 1995 to September 2000, Ms. Jackson worked for The Mills Corporation serving as Vice President and Senior Counsel from 1998 to 2000.

Ms. Jackson holds a Juris Doctorate degree from the University of Arizona, a Master of Public Health from The George Washington University and a Bachelor of Science in Liberal Studies from the University of Arizona. Ms. Jackson is licensed as an attorney in California, the District of Columbia, Arizona, and New York.


2023 Proxy Statement57

Table of Contents

Executive Compensation

 

 

PROPOSAL 2

 

34  

Advisory Vote on Executive Compensation

 

AMN HEALTHCARE SERVICES, INC.  

The board unanimously recommends a vote “FOR” the approval of the compensation of our named executive officers, as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC.

  2020 Proxy Statement

  

Section 14A of the Exchange Act, as amended by the Dodd-Frank Act, enables our shareholders to vote to approve, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC’s rules. As previously disclosed, the Board has determined that it will hold an advisory vote on executive compensation on an annual basis, and the next shareholder advisory vote will occur at our 2023 Annual Meeting of Shareholders.


Our Board believes that AMN Healthcare’s long-term success as the leading total talent healthcare solutions company depends in large part on the attraction and retention of our named executive officers and the alignment of their compensation with the overall performance of the Company. Our compensation programs are designed to attract, retain, and properly incentivize executives and focus on the creation of shareholder value. Under our executive compensation programs that are focused on aligning pay with performance, we reward our named executive officers for the Company’s short- and long-term performance, including the achievement of specific pre-established performance metrics tied to annual and long-term operational, financial and strategic goals. The compensation packages for our named executive officers are substantially tied to our strategic objectives, financial plan, and total shareholder return and align with the interests of our stakeholders and our commitment to values and purpose. In setting target levels of compensation and long-term incentive opportunities, the Compensation Committee closely monitors evolving best practices as well as the compensation programs and pay levels of executives at peer companies to ensure that our compensation programs fall within the relevant market practices.

The Compensation Discussion and Analysis that follows details our compensation philosophy and the implementation of that philosophy against goals, including how we set compensation targets and objectives and evaluate each named executive officer against those targets and objectives to ensure performance is appropriately rewarded.

We ask that you support the compensation of our named executive officers as disclosed in our Compensation Discussion and Analysis and the accompanying tables contained in this proxy statement. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we ask our shareholders to vote “FOR” the following resolution at the Annual Meeting:

“RESOLVED, that the Company’s shareholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s proxy statement for the 2023 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, Summary Compensation Table and the other related tables and narrative disclosure.”

Our Board and our Compensation Committee value the opinions of our shareholders and will review the voting results and take them into consideration when making future decisions regarding our executive compensation programs and policies. Because your vote is advisory, it will not bind us, the Compensation Committee, or our Board.

58

COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION   


Table of Contents

Executive Compensation

COMPENSATION COMMITTEE REPORT ON

EXECUTIVE COMPENSATION

20192022 PAY AND PERFORMANCE

In 2019,2022, the Company furthered its long-termdelivered strong financial and operational performance, including record high revenue of $5.24 billion and adjusted EBITDA of $847 million, a 32% and 33% increase over 2021, respectively. We are proud of how the entire AMN team supported our clients and clinicians amidst severe workforce shortages positively impacting our communities. The Compensation Committee believes the strength and diversity of experience across our leadership team, their continued focus on our strategic objectivepriorities, and our partnership with healthcare organizations to provide our full suite of total talent solutions to optimize their workforce were key to the Company’s outstanding performance in 2022 and demonstrates our ability to continue to diversify our portfolio of talent solutions. Through our acquisitions of Silversheet and b4health, we expanded our suite of technology solutions offered to clients as a total talent management and workforce solutions partner. Additionally, our acquisition of Advanced Medical allowed the Company to expand its footprint into schools and other nonacute settings, which are strategically significant toexecute on our long-term growth objectivesstrategy.

As part of our long-term strategy to create sustainable value for shareholders, AMN Healthcare acquired Connetics Communications in May 2022, which specializes in the direct hire recruitment and permanent placement of international nurse and allied health professionals with healthcare facilities in the United States. The addition of Connetics expanded our international nurse business, adding permanent placement to our nurse and allied solutions and will help us bring more qualified and experienced healthcare professionals to the U.S. and further assist our clients in filling their staffing needs as patient care continuesthe critical labor shortage continues. In 2022, we continued to extend beyondmake significant progress on our investments in digital capabilities to enhance our client and clinician experience. Our clinician mobile application, AMN Passport, was downloaded by 97% of our nurse and allied clinicians on assignment and received industry-leading user satisfaction scores.

This year’s Compensation Discussion and Analysis highlights decisions made by the traditional hospital walls.Compensation Committee in the context of AMN’s exceptional 2022 financial and operational performance. The Compensation Committee has primary oversight over the design and execution of the Company’s executive compensation program that is structured on a pay-for-performance model that leverages short-and long-term incentives to drive multiple dimensions of performance and aligns the interests of our executives with those of our shareholders and other stakeholders. More specifically, we have designed a total rewards program consisting of base salary, annual cash bonuses, and long-term equity incentive awards.

By aligning pay with performance, we motivate and reward our executives for increases in long-term shareholder value. We grant performance restricted stock units based on total shareholder return and Adjusted EBITDA performance over a three-year period. For our 2020 awards, whose performance period ended on December 31, 2022, our absolute TSR of 95% placed us in the 89th percentile versus the Russell 2000 and our adjusted EBITDA performance exceeded target by more than 120%, resulting in the maximum payout of both awards. We also grant restricted stock units, the inherent value of which, is directly tied to the value of the Company’s stock performance.

We designed our 2022 Senior Management Incentive Bonus Plan, which we refer to as the Bonus Plan, to ensure that 70% of each executive’s annual cash bonus target is based on annual revenue and pre-bonus adjusted EBITDA goals, which serve as two key financial metrics for the Company. The Compensation Committee believes that the combination of these longer-term equity and annual cash incentive vehicles are effective to motivate and reward our executives, which is why they make up a substantial majority of their total compensation packages. As a result of this compensation structure that is focused on aligning our pay with performance and our leadership’s strong contributions and results in 2022, the Company’s named executive officers earned the maximum amount possible under each of our performance incentive programs for the 2022 performance period, which we cap at either 175% or 200% of target.

In May 2022, in recognition of the competitive labor environment and to promote stability and continued growth during our CEO transition, we established a cash bonus program (the “2022 Performance and Retention Plan”) for our named executive officers (other than Ms. Grace and Ms. Salka) and other key executives based on achieving 121% to 140% of our pre-bonus adjusted EBITDA target. These awards pay out at a range of 0% to 100% based on the performance, and the executive remaining employed by the Company on May 1, 2023. As a result of the Company’s exceptional performance, the 2022 Performance and Retention Plan is expected to result in the maximum payout, provided that the executive is employed by the Company on May 1, 2023.

The Compensation Committee believes that the Company’s compensation structure properly aligns pay with performance and appropriately incentivizes executives without excessive risk. The Compensation Committee is comfortable that the outcomes under the Company’s incentive compensation plans reasonably reflectalign with the balance of short- and long-termCompany’s record financial performance, and that management continuesthe Company’s named executive officers continue to take the necessary actions today to achieve the Company’sour long-term strategic plan and deliver shareholder value.

Our total shareholder return performance restricted stock units paid out at the maximum of 175% of target, as management continuedcontinue to deliver strong shareholder returns. Our cumulative total shareholder return, which we refersustainable value to as TSR,our shareholders.

(1)For information on pre-bonus adjusted EBITDA and adjusted EBITDA, which means adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of it from our 2022 net income, please see Exhibit A to this proxy statement (page 113).

2023 Proxy Statement59

Table of 73.5% placed us in the 81st percentile of the Russell 2000 Index during the measurement period of January 1, 2017 through December 31, 2019.Contents

TheExecutive Compensation Committee has historically set stretch, but realistic, targets to achieve performance incentive payouts under its Senior Management Incentive Bonus Plan, which we refer to as the Bonus Plan. Thus, despite all of the strategic achievements that the Company delivered in 2019 and its strong TSR, the Company’s financial performance, excluding the financial impact of its largest 2019 acquisition, Advanced Medical, did not satisfy the levels necessary to achieve target payouts under our Bonus Plan or the adjusted EBITDA margin equity performance awards. The Company’s financial performance was negatively impacted by the disruption in our Locum Tenens segment from organization and technology changes in 2018 and a challenging nurse supply market. Our Bonus Plan performance measures and the adjusted EBITDA margin targets are described in more detail in the following Compensation Discussion and Analysis.

APPROVAL OF PERFORMANCE GOALS FOR 2020Performance Goals for 2023

Looking to 2020, in connection with the review of the long and short-term goals,2023, the Compensation Committee established financial goals for performance-based compensation with thresholds, targets and maximums for Bonus Plan compensation.over a three-year period (2023 through 2025). We set Bonus Plan targets based on our annual operating plan and intend that the achievement of our annual targets will contribute to achievementthe successful execution of our long-term strategy. The Compensation Committee determined there was a reasonable likelihood that our executives could achieve the goals and earn Bonus Plan compensation at the target performance level based on the Company’s 2020 annual operating plan, while at the same time encouraging stretch performance.

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis that follows with management,Management and has recommended to the Board that it be included in this proxy statement.

Compensation Committee Members

Martha H. Marsh

Daphne E. Jones

Michael M.E. Johns, M.D.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  35

Compensation Committee Members


COMPENSATION DISCUSSION AND ANALYSIS   

Martha H. Marsh, Chair
R. Jeffrey Harris
Daphne E. Jones
Sylvia Trent-Adams

COMPENSATION DISCUSSION AND ANALYSISCompensation Discussion and Analysis

Introduction

TheThis Compensation Discussion and Analysis, which we refer to as the CD&A, provides a detailed description of the compensation objectives, philosophy, design, practices, and programs for our named executive officers.officers, and we listed those who served in this capacity during the 2022 fiscal year below. The Compensation Committee takes great care in the development and refinement of a comprehensive package that reflectsexercising its oversight responsibility relatingof the design of our comprehensive compensation program to attracting, retainingattract, retain, and incentingprovide incentives for talent to lead our organization to achievein a manner consistent with our core values and aligns with stakeholder interests and the achievement of our short- and long-term strategic goals.

More specifically, this CD&A provides clear details related to each of the following aspects of the total rewards program for our named executive officers: (1) the objectives and philosophy, (2) the processes and criteria in place for proper oversight, (3) the design and components of our named executive officers’ total rewards program, and (4) how each component fits into our Compensation Committee’s overall objective to supportsupports the Company’s business strategy.

Cary Grace(1)

President
and Chief
Executive
Officer

Susan R.
Salka(2)
Jeffrey R.
Knudson
Mark C.
Hagan
Denise L.
Jackson
Former
President
and Chief
Executive
Officer
Chief Financial
Officer and
Treasurer
Chief
Information
and Digital
Officer
Chief Legal
Officer and
Corporate
Secretary

(1)Ms. Grace joined the Company as President and Chief Executive officer on November 28, 2022.
(2)Ms. Salka resigned from the Company effective November 27, 2022.

60

Table of Contents

TheExecutive Compensation Committee believes

Executive Summary

Our Executive Compensation Program Philosophy and Objectives

Our executive compensation philosophy is that our namedcompensation realized by executives should (i) align with shareholders’ interests, (ii) reflect the individual skills and contributions of the executive officers are collectively a strong, valuable, experienced, talentedin achieving the strategic, financial, and innovative team, with a passion foroperational goals of the Company its core values and delivering sustainable returns for(iii) reflect the leadership they demonstrate in promoting our shareholders. Our named executive officers for the 2019 fiscal year are listed below.values-based culture and commitment to corporate social responsibility.

OUR EXECUTIVE COMPENSATION PROGRAM OBJECTIVES

OUR COMPENSATION PROGRAM OBJECTIVES

●  Pay-for-performance, with variable pay constituting a significant portion of total compensation

Name●  Focus on propelling growth and the attainment of our long-term financial and strategic objectives

●  Provide equal pay based on performance

●  Build a strong talent base to reinforce our succession planning objectives

●  Create commonality of interest between our executives and shareholders by tying realized compensation directly to changes in shareholder value

 

●  Reward our executives for long-term improvement in shareholder value

Current Title●  Attract, retain, and motivate highly skilled and innovative executives who embrace and promote AMN’s values-based culture that fosters innovation, diversity, and inclusion

●  Provide compensation that is competitive with compensation paid by other similarly sized companies, including those in our executive compensation peer group

Susan R. Salka

Chief Executive Officer

Brian M. Scott

Chief Financial Officer, Chief Accounting Officer●  Align compensation with established corporate governance practices and Treasurer

Ralph S. Henderson

President, Professional Services and Staffing

Denise L. Jackson

Chief Legal Officer and Corporate Secretary

avoid excessive risk

Executive Summary

Ourpay-for-performance focusedWith these principles in mind, we have designed and continually evaluate and modify, as necessary, our executive compensation program is designed to motivatesupport our leaders to build long-term shareholder value. Among other things,strategic objectives of achieving above-market growth in revenue and profitability by (1) being the Compensation Committee premisesleader and innovator in healthcare total talent management solutions and services, (2) growing our executive compensation on the following guiding principles:overall revenue mix from strategic talent solutions and technology and (3) delivering a superior customer experience through operational excellence and agility.

support the attainment of our short- and long-term financial objectives in alignment with our business strategy;

attract, retain and motivate talented and innovative executives who will extend our leadership position as the driver of quality and innovation within our industry; align pay with performance, with variable pay constituting a significant portion of total compensation;

create commonality of interest between our executives and shareholders by tying realized compensation directly to increases in shareholder value; and

foster a culture of integrity, equality and ethics where team members are treated with respect and appreciation for their contributions.

To support AMN’s objectives, the Compensation Committee has designed a total rewards program for our named executive officers, that includesincluding the following primary features whichthat constitute the majority of our named executive officersofficer’s total pay:compensation: (1) base salary; (2) annual bonuses; and (3) long-term incentive awards.

2023 Proxy Statement61

Table of Contents

Executive Compensation

Executive Compensation Practices

WHAT WE DO

36  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

Below is a summary relating to our named executive officers’ total rewards compensation program.

What We Do

LOGO   

Executive Compensation Philosophythat referencesreflects our commitment to long-term shareholder value, equal pay, corporate social responsibility and fostering a culture of compliance and ethics.

LOGO   

Align Pay with Performance.Performance. In 2019,Design an executive compensation program that is focused on performance with variable pay constituted 80%comprising the majority of our CEO’s total compensation and more than 68% for each of our other named executive officers.

executive’s compensation.

LOGO   

Reward for Increases in Shareholder Value.Value. We grant performance restricted stock units, which we refer to as PRSUs, based on absolute and relative total shareholder return over a three-year performance period to reward named executive officers for above-market stock performance (relative to the Russell 2000 Index). We refer to the awards that vest based on total shareholder return as TSR PRSUs.

LOGO   

Focus on Our Long-term Goals.Goals. We utilize PRSUs that vest three years from grant based on the Company’s achievement of certain long-term adjusted EBITDA growthtargets with a three-year vesting period and margin expansion objectives. We referRSUs, the inherent value of which, is directly tied to these awards as our adjusted EBITDA margin PRSUs and adjusted EBITDA growth PRSUs, as the case may be. We also sometimes refer to adjusted EBITDA as AEBITDA.

value of the Company’s stock performance.

LOGO   

Strong Ownership Guidelines.Requirements. We have meaningful stock ownership requirements forguidelines requiring our nameddirectors and executive officers that require ownershipto hold significant multiples of unrestricted shares.

LOGO   their annual retainer or base salary.

Cap Incentive AwardsAwards. .We cap annual bonus awardspayouts for both our named executive officers under our Bonus Plan.

cash and equity incentive awards.

LOGO   

Incentives to Achieve Objective and Key Financial Metrics.Metrics. 70% of our Bonus Plan target for each named executive officerannual cash bonus incentive plan is based on achieving annual revenue and pre-bonus adjusted EBITDA targets, two key financial metrics for the Company. The remaining 30%

Competitive Peer Benchmarking. We review our executive compensation peer group on an annual basis to ensure that our compensation program is based on objectivenon-financial criteria such as execution on key initiatives, leadershipproperly aligned with companies of similar size within the healthcare and demonstration of our values.

recruitment and staffing industries.

LOGO   

Independent Compensation Consultant.Consultant. Our Compensation Committee utilizes the services of an independent and reputable compensation consultant, Frederic W. Cook, to provide pay recommendations.

LOGO   

Responsible Share Usage. We judiciously grant shares under the AMN Healthcare 2017 Equity Plan, which we refer to as the Equity Plan, and maintain a share usage rate that is below industry norms.

LOGO   

Appropriate Peer Group Selection. We regularly review our executive compensation peer group to ensure that our compensation program is properly aligned with the companies we compete for talent and business.

LOGO   

“Double-trigger” Change in Control Provisions.Provisions. Our equity award agreementsarrangements include “double-trigger” mechanics.

Recoupment Policy: Our Clawback policy authorizes the Board to recoup all or any portion of the bonus and equity or cash incentive compensation from all current or former executive officers in the event of a material restatement of the Company’s financial results due to misconduct.


WHAT WE DON’T DO

What We Don’t Do

  No Pledging or Hedging of Company Securities Permitted

LOGO   No Tax Gross-ups

No Single-Trigger Change in Control Agreements

No Risky Programs.Excessive Perquisites We do not engage in compensation programs that create undue risk.

LOGO   

No Pledges or Hedges. We prohibit hedging and the pledging of, or hypothecating, or otherwise placing a lien on, any of common stock or other equity interests of the Company.

LOGO   

No New TaxGross-ups. We have committed to not enter into new employment or other agreements with taxgross-ups for named executive officers. Ms. Salka’s employment agreement, which was entered into in 2005, contains a tax gross up.

LOGO   

No Options or SARs. We have not granted equity awards in the form of options or stock appreciation rights, which we refer to as SARs, since 2010.


62

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  37


Table of Contents


COMPENSATION DISCUSSION AND ANALYSIS   

Executive Compensation

2019 Financial, Operational and Stock2022 Performance Highlights

A long-standing principle of our executive compensation program is linking pay to performance. Accordingly, when making compensation decisions, we analyze our financial, operational, and stock performance and execution on strategic initiatives. The Company delivered revenue, profitability and share growth in 20192022(1)and continued to make significant progress on our short- and long-term objectives and overall business strategy.

Some We describe some of our 20192022 highlights include:

Our TSR ranked in the 81st percentile for the three-year period ended December 31, 2019 among companies comprising the Russell 2000 Index as of December 31, 2016 with a cumulative total shareholder return of 73.5%.

The price of our common stock increased 10% in 2019 to $62.31, the closing price on December 31, 2019.

Execution of our long-term strategic plan by consummating the following acquisitions:

In January 2019, we acquired Silversheet Inc., which we refer to as Silversheet, anall-in-one healthcare provider credentialing and privileging SaaS solution. We often hear from clients that the credentialing and privileging processes are some of their largest pain points, and we believe that our acquisition of Silversheet will help our clients solve some of the inefficiencies associated with these processes.

In June 2019, we acquired Advanced Medical Personnel Services, Inc., which we refer to as Advanced Medical. A key to achieving our long-term growth strategies is expanding our service footprint into nonacute settings. Our acquisition of Advanced Medical furthers this objective by expanding our offerings to include the placement of therapists and nurses in contract positions across multiple healthcare settings, including schools, clinics, skilled nursing facilities, home health and telehealth environments. Our acquisition of Advanced Medical also bolsters our clinician supply in a competitive labor market, which we has helped alleviate some of the supply challenges the Company has experienced in 2019.

In December 2019, we acquired B4Health, LLC, which we refer to as b4health. b4health is an innovative technology company and leading provider of aweb-based internal float pool management solution and vendor management system for healthcare facilities. Our acquisition of b4health further diversifies of our workforce solutions offerings by providing technology aimed at automating communication, time management, and scheduling for clients to increase their clinician fill rates. It also further differentiates our suite of total workforce solutions by offering float pool and independent contractor management capabilities.

We believe these acquisitions will allow us to continue to strengthen our position as the industry’s most trusted total talent solution partner by diversifying our offerings and expanding our footprint into nonacute care settings.

Increased our consolidated revenue year over year by approximately 4% from approximately $2.14 billion to approximately $2.22 billion.

Our Allied Staffing Solutions business was our best-performing staffing line in 2019, reaching $323 million in annual revenue, 29% higher than the previous year including 9% in year over year organic growth.

Revenue for our Other Workforce Solutions segment reached a record $477.5 million for 2019, with consolidated growth of 9% over 2018. Within this segment, we consolidated our interim leadership and permanent placement businesses into one Leadership Solutions division. This move strengthened ourgo-to-market strategy and bolstered support of key brands in leadership and physician permanent placement.

below.

Record consolidated
REVENUEof$5.24 Billion
increased from $3.98 billion in 2021  

Increased our consolidated adjustedReported
ADJUSTED EBITDA(2) year over year by approximately 3%, 33%
from $270.4 $635 million in 2021
to $277.4 million.

$847 million
Increased Reported
ADJUSTED EPS(2) by 48%
from $8.03 in 2021
to $11.90 in 2022
Deployed $577 million in
SHARE REPURCHASES
representing 13% of weighted average shares
outstanding in 2022(3)


(1)

For more detail regarding our financial results, please see our 20192022 annual report on Form10-K filed by us with the SEC on February 25, 202022, 2023 and provided to you concurrently with this proxy statement. We provide the summary financial information in this proxy statement solely to help you in your evaluation and review of our CD&A. It should not be used as a substitute for a review of the detailed financial information in our 20192022 annual report on Form 10-K.

(2)

ForMore information on our adjusted diluted EPS and adjusted EBITDA, which meansrefers to our adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of it from our 20192022 GAAP diluted net income please seeper share to adjusted diluted EPS and 2022 net income to adjusted EBITDA, can be found at Exhibit BA to this proxy statement (pageB-1) 113).

(3)For the year ended December 31, 2022.

38  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement

DEEPENED PARTNERSHIPS TO ADDRESS SUSTAINED WORKFORCE CHALLENGES


  COMPENSATION DISCUSSION AND ANALYSIS  

CapitalizedAs we began a new phase of challenges and change within healthcare, the Company remained focused on a favorable capital markets environmentour commitment to make a private offeringour team members, healthcare professionals, clients, and their patients. We supported our clients amidst extreme staffing shortages and growing demand for patient care by collaborating, innovating, and evolving our existing solutions and creating new ones. We supported the full spectrum of $300 millionour client’s staffing needs and partnered to use an array of Senior Notes due in 2027our total talent services and technology to provide for additional liquidityenhance workforce sustainability and improve patient outcomes. In 2022, the number of clients that utilized 10 or more of our workforce solutions increased 10% and more than 60% of our consolidated revenue was generated from managed services programs. Additionally, as part of our growth strategy to pursue strategic acquisitions and other investments that we believe enhance long-term shareholder value.

Continued to returnadd value to our shareholdersclients and increase the supply of healthcare workforce, we acquired Connetics Communications in May 2022, an international nurse and allied recruitment company that specializes in nursing and allied professional direct hire recruitment and placements. Throughout 2022, the Company deployed more than 60,000 healthcare professionals each quarter and increased our corporate workforce by 10%. Guided by our core purpose of helping to achieve personal and professional goals, we increased our investment in our healthcare professionals’ and team members’ wellness, resiliency, mental health, and professional development. We believe that the deeper relationships with our clients, healthcare professionals and team members created through these efforts was central to delivering record performance in 2022 and sets us up for success in executing on our long-term strategy.

ADVANCING THE OVERALL HEALTH OF OUR WORKFORCE, WORKPLACE AND MARKETPLACE

AMN’s Purpose is helping people achieve their professional and personal goals. We believe our commitment to advancing the repurchase of approximately 395,212 sharesoverall health and wellbeing of our common stock.workforce, workplace and marketplace is vital to our ability to be the employer and strategic partner of choice in healthcare total talent solutions.

2023 Proxy Statement63

Table of Contents

Continued executionExecutive Compensation

To advance our purpose and achieve our business strategy, we believe that we must foster a healthy and diverse workforce that will advance equity and inclusion in our workplaces and society. One way in which we measure this is the representation of our workforce and its reflections of the communities that we serve. As of January 2023, 69% of our team members are women, and 45% of our team members and 35% of our leaders are from other historically underrepresented communities. To ensure our ability to continue to attract and develop diverse talent, we also enhanced our human capital infrastructure to support pay equity, leadership development and professional connections. For the sixth consecutive year, we were named to the Bloomberg Gender Equality Index and received a top ranking in the Human Rights Campaign Foundation’s Corporate Equality Index. Our Board was recognized with the 2022 National Association of Corporate Directors Diversity, Equity & Inclusion Award. Our executive leaders continued to serve in important and influential roles within our industry and our communities. We believe our commitment to advancing the overall health and wellbeing of or workforce, workplace and marketplace is vital to our ability to be the employer and strategic partner of choice in healthcare total talent solutions.

EXECUTION ON TECHNOLOGY AND DIGITAL STRATEGIC INITIATIVES

Throughout 2022, we maintained a sharp focus on our investments in technology and digital capabilities to enhance our client, candidate, and analytical strategic initiativesteam member experience and to improveprepare for the recruitment, engagement and retentionfuture of healthcare delivery. We continued to execute on our digital business optimization strategy through our digital staffing platform, AMN Passport, enabling on-line and mobile touchpoints, self-service capabilities, and automated processes, resulting in high utilization and user satisfaction by healthcare professionals through developmenton assignment. We also improved ease of mobileuse, increased automation and enabled capabilities scheduling applicationsacross our suite of workforce technologies. We believe our investments in technology systems and artificial intelligence.digital capabilities will continue to drive innovation and position us to serve growing health systems and diverse care settings while reducing costs and complexities for our clients and more effectively engage our healthcare professionals on their entire career journey.

2022 COMPENSATION ELEMENTS

The following charts compare our year-over-year performance on key financial metrics that we utilized in making

compensation decisions for our named executive officers in 2019.for 2022.

CONSOLIDATED REVENUE (MM)CONSOLIDATED ADJUSTED EBITDA (MM)

LOGO

The Compensation Committee placed considerable emphasis on our total shareholder return as well as financial and operational performance over the past 12 months inas well as our 2022 total shareholder return when determining our CEO’s 2019named executive officers’ 2022 cash bonus and equity awards. When determining Ms. Salka’s 2022 cash bonus, we placed considerable emphasis on the months in 2022 prior to Ms. Salka’s Transition Agreement, as well as her 2019 equity awards.agreement to remain Chief Executive Officer until a new Chief Executive Officer was named. Because certain compensation information included in this proxy statement spans the last three fiscal years, we have set forth below our cumulative total shareholder return and compound annual growth rate for theone-,two- and three-year periods ended December 31, 2019.2022.

64

Table of Contents

Executive Compensation

    

 

 

Period

  

Cumulative Total    

Shareholder Return (1)    

   

 

Compound

Annual

    Growth Rate    

 

  

Common Stock Price

at Beginning of Period

 

One-Year Period Ended December 31, 2019

  

 

5%  

 

  

 

N/A

 

 

$

55.65

 

Two-Year Period Ended December 31, 2019

  

 

30%  

 

  

 

27%

 

 

$

49.60

 

Three-Year Period Ended December 31,2019

  

 

73%  

 

  

 

17%

 

 

$

39.20

 

(1)
Period     Cumulative Total
Shareholder
Return(3)
(%)
     Compound
Annual
Growth Rate
(%)
     Common
Stock Price
at Beginning
of Period
($)
One-Year Period Ended December 31, 2022 4 N/A 120.80
Two-Year Period Ended December 31, 2022 76 23 68.92
Three-Year Period Ended December 31, 2022 94 18 62.11

(3)The price of our common stock on December 31, 2022 (the last trading day of the year) was $102.82. The cumulative total shareholder return illustrated in this column is based upon the provisions of the Company’s TSR performance equity awards agreements, which measure the percentage increase in the 90-day average closing price of our common stock on the trading day at the end of the relevant investment period from the 90-day average closing price of our common stock on the last trading day of the year preceding the beginning of the applicable period. We did not pay any dividends during the periods set forth in this table.

The illustrations below provide an overview of the principal components of our common stock on December 31, 2019 (the last trading day of the year) was $62.31. Unlike the total return values illustrated in the Proxy Statement Summary section above on page 1, which calculates the return using the closing price of our common stock on the firstexecutive compensation program aimed at driving long-term shareholder value and last date of an applicable measurement period, the cumulative total shareholder return illustrated in this column is based upon the provisions of the Company’s TSR performance equity awards agreements, which measure the percentage increase in the 90 day average closing price of our common stock on the trading day at the end of the relevant investment period from the 90 day average closing price of our common stock on the last trading day of the year preceding the beginning of the applicable period. We did not pay any dividends during the periods set forth in this table.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  39


COMPENSATION DISCUSSION AND ANALYSIS   

2019 Compensation for Our Named Executive Officers

rewarding strong financial and operational performance. Numerous factors played a role in our 20192022 compensation decisions with the overarching goal of closely linking pay to performance. In 2019,2022, given the Company’s exceptional financial performance and long-term stock performance, performance-based cash incentives paid for 2022 performance and equity compensation (which is inherently linked to performance)granted in 2022 comprised 80%83% of our CEO’sMs. Salka’s total compensation, and 68%76% - 73%80% of the total compensation for each of our other named executive officers.

To illustrate this, the chart set forth below reflects the percentage breakdownofficers resulting in an average of 77% of total compensation for our CEO’s 2019 compensationother named executive officers at risk (other than with respect to Ms. Grace’s partial year of service), as set forth in the Summary Compensation Table.Table on page 85 below.

MS. GRACE’S COMPENSATION AT RISK

LOGOMS. SALKA’S COMPENSATION AT RISK

OTHER NEO COMPENSATION AT RISK(1)

2023 Proxy Statement65

Table of Contents

Executive Compensation

Components(1)PurposeKey Features
Base Salary

Ms. Salka’s:

40  

 

Other NEOs
(Average):

AMN HEALTHCARE SERVICES, INC.  

Attract and retain talent

  Fixed base of cash compensation

  Reviewed and approved annually

  Benchmarked annually to the median and 75th percentile of our peer group and other companies of similar revenue and market capitalization

Annual Cash Incentive Bonus

Ms. Salka’s:

 

  2020 Proxy StatementOther NEOs
(Average):

 


Drive achievement of annual strategic and financial objectives 

  COMPENSATION DISCUSSION AND ANALYSIS    70% of target values are directly tied to measurable financial measures (known as the “Financial” component)

  Consolidated revenue (30%)

  Consolidated adjusted EBITDA (40%)

  30% of target values are directly tied to non-financial factors (known as the “Leadership” component)

  One-year performance period, aligned with our strategic priorities

  Payout Range: 0-200% of target

Long-Term Incentive

Ms. Salka’s:

Other NEOs
(Average):

Align with shareholders interests and drive achievement of our long-term strategic objectives

  Equity mix of:

  Time-vested restricted stock units (35%)

  Performance-based restricted stock units based on total shareholder return (30%)

  Payout Range: 0-175% of target

  Performance-based restricted stock units based on adjusted EBITDA performance (35%)

  Payout Range: 0-200% of target

  Three-year performance/vesting period

  Actual payout dependent upon long-term financial and stock performance and retention


(1)Ms. Grace joined the Company as President and CEO on November 28, 2022 and was not eligible to participate in the Bonus Plan for 2022 and did not receive the mix of long-term incentive awards reflected in this chart. The components of Ms. Grace’s 2022 compensation are included below in the section “Named Executive Officer Compensation in 2022.” Other NEOs reflected in this chart include Mr. Hagan, Mr. Knudson, and Ms. Jackson.

As the Compensation Committee has consistently done, throughout the past several years, it based its 20192022 compensation decisions aroundon the Company’s 2022 financial goal setting for 2019goals and other actions influencing executive compensation based on the expectation that (1) we would achieve targeted revenue and adjusted EBITDA growthperformance on a consolidated basis, and (2) our named executive officers would lead their teams to successfully execute our business strategy in a manner that reflected our core values. As a result of our 2019 operational performance and financial results, each named executive officer earned approximately 69% of his or her target bonus that was tied to the Company’s 2019 financial performance. Below is a breakdown of each of our current named executive officer’sofficers’ actual compensation for 2019.2022, as set forth in the Summary Compensation Table on page 85 below.

66

Table of Contents

Executive Compensation

Named Executive Officer Compensation In 2022

Cary Grace

TOTAL: $3,305,296

Susan R. Salka

TOTAL: $8,468,824

Jeffrey R. Knudson

TOTAL: $3,255,853

Mark C. Hagan

TOTAL: $2,905,456

Denise L. Jackson

TOTAL: $2,550,745

2023 Proxy Statement67

Table of Contents

LOGOExecutive Compensation

Response to 2019Say-on-PayTo 2022 Say-On-Pay Vote

At our 20192022 Annual Meeting of Shareholders held on April 17, 2019,May 6, 2022, we received more than 97%approximately 90% support (based on shares voting) on our“say-on-pay” advisory “say-on-pay” proposal regarding the compensation of our named executive officers. Our compensation program has remained consistent with that set forth in our 20192022 proxy statement, and we believe the following four themes remain most important amongto our investors:shareholders: (1) compensation should correlate to company performance, (2) performance awardscompensation should constitute an important componenta majority of compensation (3) long-term incentiveperformance awards (3) performance measures beyond total shareholder returnto ensure sustainable value for shareholders should be considered,an integral part of compensation and (4) variable compensation should be designed to motivate, reward and retain executives.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  41


COMPENSATION DISCUSSION AND ANALYSIS   

The Compensation Committee believes that our executive compensation program in 20192022 satisfied each of the four themes identified above. In 2019,2022, the Compensation Committee took the following actions:

1.(1)

Used performance restricted stock unitsIssued PRSUs tied to total shareholder return and financial goals (i.e., adjusted EBITDA margin)performance over a three-year period,

 (2)
2.

Established performance goals of 5.3% and 2.5% year-over-year consolidated revenue and adjusted EBITDA growth, respectively,performance in orderline with our annual financial operating plan for the named executive officers to receive their target bonuses,

 (3)
3.

Adjusted base salaries, to more closely aligncash incentive annual bonus opportunity and long-term equity incentive grant values aligned with industrymarket and peer group pay practicesto reward strong performance and to retain our talent, and reward strong performance, and

 (4)
4.

Rewarded named executive officers for strong financial, operationalEstablished the 2022 Performance and common stockRetention Bonus to be paid to certain key executives who remain employed with the Company on May 1, 2023, based on adjusted EBITDA performance through the useexceeding 121% - 140% of reasonable, competitive amounts of incentive-based compensation.

previously established targets.

OurPrincipal Components of our Compensation Program Philosophy and Objectives

A guiding principleIn line with our core value of continuous improvement, we (1) listen to our Executive Compensation Philosophy is that compensation realized by executives should (i) align with shareholders’ interests; (ii) reflectshareholders, (2) review the individual skills and contributions of the executivelatest trends in achieving the strategic, financial and operational goals of the Company and (iii) reflect the leadership they demonstrate in promoting our values-based culture. Additionally, corporate governance best practices, input received from shareholders through our engagement discussions and the annual shareholder advisory vote on executive compensation are also considered in the design ofpractices, (3) evaluate whether shareholders or proxy advisory services view certain pay practices with disfavor and (4) review our executives’ total rewards package. Our philosophy embraces the following principles:

Pay-for-performance, with variable pay constituting a significant portion of total compensation,

Create commonality of interest between our executives and shareholders by tying realized compensation directlypractices to changes in shareholder value,

Focus on propelling growth in the attainment of our long-term financial and strategic objectives,

Reward our executives for long-term improvement in shareholder value,

Provide equal pay based on performance without regard to legal status and classification,

Attract, retain and motivate highly skilled and innovative executivesensure that embrace and promote AMN’s values-based culture that fosters innovation, diversity and inclusion,

Build a strong talent base to reinforce our succession plan objectives,

Be competitive with companies in our peer group,

Maximize the financial efficiency of the overall program from, including but not limited to tax, accounting, and cash flow perspectives, and

Ensure that corporate governance practices and the impact of oursay-on-pay proposals are upheld.

With these principles as our foundation, we have designed and continually evaluateimplemented compensation programs that we believe will create value for our shareholders that attract, incentivize, and modify, as necessary, our executive compensation program to support our strategic objectives of achieving above-market growth in revenue and profitability by (1) being the leader and innovator in healthcare total talent solutions and services, (2) growing our overall revenue mix from strategic workforce solutions and technology and (3) delivering a superior customer experience through operational excellence and agility.retain executives.

The primary components of our executive compensation program - (1) base salary, (2) annual cash performance bonuses, and (3) long-term equity incentive awards - reflect the implementation of our executive compensation philosophy. The Compensation Committee is provided with benchmarking information of each of these components at the 25th percentile, the median and 75th percentile utilizing companies, including all members of our peer group, that are similar to us in terms of business type, revenue and market capitalization. The Compensation Committee considers benchmarking data as a reference point rather than determinative data. Compensation for specific individuals may vary upward or downward from the median for individual named executive officers based on, among other things, individual performance, tenure, experience, scope of responsibilities, internal parity considerations, the recommendations of our CEO (for compensation other than her own) and succession considerations.

42  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PRINCIPAL COMPONENTS OF OUR EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS  PROGRAM

The illustration below provides a high level summary of the primary components of our executive compensation program.

   
  ComponentPurposeKey Features

●  Base salary,

Base Salary●  Short-term or annual performance awards in the form of cash bonuses, and

LOGO●  Long-term incentive awards in the form of restricted stock units and performance restricted stock units.

     

We also provide:

Attract●  benefits generally available to other employees, including a non-qualified deferred compensation plan,

●  severance agreements, and

retain talent●  reimbursement for each named executive officer up to $25,000 for certain financial, estate planning and personal health and wellness expenses.

Base Salary

Base salary serves as the first principal component of our executive compensation program. In setting base salaries, the Compensation Committee considers several factors.

FACTORS CONSIDERED BY THE COMPENSATION COMMITTEE IN SETTING BASE SALARIES

 

•   Fixed base of cash compensation

•   Reviewed and approved annually

•   Benchmarked annually to the median of●  The market salary for similarly situated executives within our peer group and other companies of similar revenue size and market capitalization,

•   Salaries determined based on individual●  Our operational and financial performance,

●  Individual performance, skills, knowledge, tenure, experience, and scoperesponsibilities, and

●  The recommendations of responsibilityour CEO for our other named executive officers.

We manage salary changes to fall within our annual budget. We evaluate our operational and financial performance against our annual strategic objectives and our annual operating plan. We evaluate our stock performance against our executive compensation peer group and the Russell 2000 Index. Our CEO recommendations are particularly helpful for the Compensation Committee to evaluate the other executive officers’ performance, knowledge, skills, experience and responsibilities.

68

Table of Contents

Executive Compensation

Annual Cash Performance Bonus

Annual cash performance bonus opportunities serve as the second principal component of our executive compensation program and are designed to incentivize and reward performance. The Company’s Bonus Plan is the mechanism by which the Compensation Committee provides cash bonus opportunities as a strong incentive for our executive officers to achieve annual financial targets that support our strategic objectives. Although certain details of the Bonus Plan may change from year to year, its principal elements remain consistent and include specific consolidated revenue and consolidated adjusted EBITDA financial goals tied to our annual operating plan. We refer to these financial metrics of the Bonus Plan as the Financial Component. The Compensation Committee sets threshold, “target” (i.e., 100% payout) and maximum amounts for bonuses and a weight for each metric that corresponds to the level of achievement required to trigger a threshold, target, or maximum bonus for the named executive officer under such metric.

The threshold level for each metric typically starts at a minimum performance level (i.e., 90% of targeted consolidated adjusted EBITDA). The maximum bonus typically requires a performance level of 110% to 120% of the target amount for each metric. We have typically used incremental hurdles (usually 1% increments for adjusted EBITDA and one-half percent increments for revenue) of performance between the threshold level and the maximum level that increase the amount of bonus that can be earned on a straight-line basis depending on the hurdle ultimately achieved. The leadership component of the bonuses, which we refer to as the Leadership Component in this CD&A, has been based on non-financial factors, such as performance relative to direct competition, leadership, achievement of strategic objectives, including Company’s diversity and ESG-related objectives and effective leadership in line with our core values.

In addition, in 2022 we established the 2022 Performance and Retention Plan to provide incentive compensation in the form of an additional cash bonus to our named executive officers (other than Ms. Grace and Ms. Salka) and other key employees that is directly related to 2022 consolidated adjusted EBITDA for performance beyond 121% of our annual operating plan. The 2022 Performance and Retention Plan has a payout range of 0% and 100%, upon the Company’s achievement of a minimum performance level of 121% of target consolidated adjusted EBITDA (with a cap at a maximum level of 140% of the target), provided that to receive the bonus the executive must remain employed by the Company on May 1, 2023.

In setting each named executive officer’s target bonus, the Compensation Committee evaluates benchmarking data for comparable positions generally and within our executive compensation peer group, the recommendations of our CEO (except with respect to her target bonus), individual performance, knowledge, experience and responsibilities.

PRINCIPLES GOVERNING THE DESIGN OF CASH INCENTIVE BONUSES

 
 

●  The metrics must be tied to key indicators of our success and our annual objectives,

Annual Cash Incentive Bonus●  The performance goals must be reasonably achievable and viewed as fair, while at the same time encouraging stretch performance,

LOGO●  The metrics must be simple to understand and can be influenced by the executive,

 

●  The portion of an individual’s target annual cash compensation attributable to target annual bonus should increase with successively higher levels of responsibility, and

Drive achievement●  Payouts should reflect our performance as well as the performance of annual strategic and financial objectives

•   Incentivizesthe executive, officers to achieve annual financial objectives that support our strategic objectives

•   70% of target values are directly tied to measurable financial measures

•   30% of target values are directly tied to non-financial factors, such asincluding performance relative to direct competition, leadership, achievement of strategicthe Company’s diversity, equality, equity, and inclusion objectives and furtherance of its culture of ethics.

The Compensation Committee may amend the Bonus Plan at any time and may also amend any outstanding award granted under the Bonus Plan.

Long-Term Incentives

Long-term incentives in the form of equity awards are the third principal component of our executive compensation program and serve to align the interests of our named executive officers with our shareholders. Under the Company’s 2017 Equity Plan, which we refer to in this CD&A as the Equity Plan, we grant equity awards with various vesting parameters, typically three years in length, to named executive officers and key employees to incentivize the achievement of our long-term strategic objectives. We also use them as an employee retention tool. We utilize PRSUs as part of our long-term incentive structure to strengthen the performance-based component of the long-term incentive component. In 2022, we utilized PRSUs that pay out based on (i) the Company’s total shareholder return over three years and (ii) adjusted EBITDA Performance PRSUs that vest and pay out at the end of three years that accrue value on a one year and then two-year performance period based on the Company’s achievement of a target at the end of the first year and then a certain year-over-year compounding adjusted EBITDA performance target in the remaining two years. We refer to these awards as our TSR PRSUs and Adjusted EBITDA Performance PRSUs, respectively.

2023 Proxy Statement69

Table of Contents

Executive Compensation

•   Target values benchmarked annually against comparable positions and within our peer group

•   Minimum payouts generally begin at 90% of the applicable financial performance measure, with maximum payouts generally requiring 100% to 120% of the targeted performance measurePRINCIPLES GOVERNING THE DESIGN OF LONG-TERM INCENTIVES

 
 

●  Performance periods should cover multiple years to create balance between short- and long-term objectives,

●  Long-term Incentives

LOGO

Align with shareholders’incentives should function to (a) align executive and shareholder interests, (b) enhance focus on improvements in operating performance and the creation of shareholder value and (c) drive achievement of our long-term strategic objectives, and

●  Awards should support retention.

 

•   Performance generally covers a three-year period

•   Target objectives focus on (i) enhancing improving operating performance, (ii) aligning executives’ interests with shareholder interests, (iii) and the creation●  Aggregate annual share usage should be carefully managed to avoid excessive levels of shareholder value transfer, and (iii) drive achievement

●  The aggregate cost of long-term objectives

•   Vesting schedules intendedincentives should be reasonable compared to support long-term retentionmembers of key contributors

•   Actual payout can range dependent upon performance

•   Our long-term incentive award vehicles include (i) time vested RSUs, (ii) PRSUs based on total shareholder return,our peer group, and (iii) PRSUs based onthe cost implications should be supported by our annual adjusted EBITDA margin and annual adjusted EBITDA growthoperating plan.

Our Compensation Determination Process

Roles and Responsibilities

Responsible Party Primary Roles and Responsibilities Relating to Compensation Decisions

Retirement

& Health Plans

LOGO

CompensationCommittee(Comprised solely ofindependent directors)
 

The primary responsibilities of the Compensation Committee include oversight of our executive compensation programs. Specifically, they include:

Attract●  Review the design of, and retain highly skilledrisks associated with, the Company’s compensation policies and practices, including our Equity Plan and Bonus Plan;

●  Approve annual performance goals and objectives for our Chief Executive Officer;

●  Determine the annual compensation of our Chief Executive Officer, including the performance metrics and goals for performance-based long-term and short-term incentive compensation;

●  Conduct an annual evaluation of our Chief Executive Officer’s performance and review such evaluation with the independent members of the Board;

●  Approve the annual compensation of our other named executive officers and executives that directly report to our CEO (we refer to this group of executives, including the Chief Executive Officer, as the CEO Committee), including performance metrics and goals for performance-based long-term and short-term incentive compensation;

●  Hire the Company’s independent compensation consultant; and

●  Approve the composition of our executive compensation peer group.

IndependentMembers of theBoard 

●  Participate in and consider the Compensation Committee’s annual evaluation of our Chief Executive Officer’s performance; and

•   Benchmarked regularly to compete with commonly offered market Benefits

•   Must be limited, reasonable in cost  Consider the Committee’s actions regarding the compensation of our Chief Executive Officer and, easy to administerif deemed appropriate or necessary, ratify such actions.

•   Align with our overall business and human resources strategies

Our Compensation Program Oversight

RESPONSIBILITIES OF THE COMPENSATION COMMITTEE

The primary responsibilities of the Compensation Committee include oversight of our executive compensation programs. Specifically, they include:

determining the compensation of our CEO and, in partnership with our CEO, establishing the compensation of all other executive officers, including salary, cash incentives and equity awards,

designing our incentive compensation programs and administering our Equity Plan and Bonus Plan,

establishing the financial metrics and performance targets under our Equity Plan and Bonus Plan, and

as set forth more fully above (see page 25 above), analyzing the risk associated with our compensation practices.

AMN HEALTHCARE SERVICES, INC.  

IndependentCompensationConsultant
(Frederic W. Cook &Co., Inc.)
 

●  Provide the Compensation Committee with advice regarding the design of all elements of the Company’s executive compensation program;

●  2020 Proxy StatementReview and provide an assessment of the material risks associated with the Equity Plan and Bonus Plan;

●  Provide advice to the Compensation Committee regarding the composition of the compensation peer groups;

●  Provide expert knowledge of marketplace trends and best practices relating to executive compensation and competitive pay levels;

●  Provide advice and recommendations regarding the compensation of the Company’s named executive officers; and

●  Regularly attend and actively participate in meetings of the Compensation Committee, including executive sessions.

Chief ExecutiveOfficer 

●  Recommend annual non-financial performance goals and objectives for the CEO Committee (other than herself);

●    43Conduct an annual performance evaluation for each member of the CEO Committee (other than herself) and discuss the results with the Committee; and

●  Make recommendations to the Compensation Committee with respect to the compensation of the members of the CEO Committee (other than herself) based on the final assessment of their performance.


COMPENSATION DISCUSSION AND ANALYSIS   

The Compensation Committee reviews all components of compensation of the named executive officers and other officers that directly report to our CEO (we refer to this group of executives as the CEO Committee) on an annual basis and will consider changes at other times if a change in the scope of an officer’s responsibilities justifies such consideration. In so doing, the Compensation Committee uses the services of an independent compensation consultant, Frederic W. Cook & Co., and considers the analysis and advice of its compensation consultant in discharging its responsibilities. Representatives of Frederic W. Cook & Co. attend Compensation Committee meetings and have direct access to the Compensation Committee members without management involvement. The Compensation Committee has the sole authority to hire and terminate its compensation consultant.

The Compensation Committee generally conducts its salary and bonus structure review for a particular year in the last quarter of the previous year or early in the subject year. At that time, the Compensation Committee evaluates compensation by, among other things, reviewing (1) peer benchmarking information, (2) the individual’s performance, duties, and experience, (3) analysis and advice from its compensation consultant, (4) our financial and operational performance, and (5) the recommendations of our CEO (who does not provide a recommendation for herself).

70

Table of Contents

Executive Compensation

With respect to our Bonus Plan, the Compensation Committee determines the performance metrics for the award each year. Prior to or at the beginning of each fiscal year,In December, the Board setsapproves our annual operating plan and financial targets for the upcoming year. Once our performance. Thereafter,annual operating plan is approved, the Compensation Committee sets the range of financial performance and corresponding targets for theour named executive officers’ cash incentive compensationofficers under the Bonus Plan.Plan in early January of each year. These financial targets set by the Compensation Committee correspond to our annual operating plan financial targets approved by the Board.

The Compensation Committee also grants annual equity awards under our Equity Plan. In addition to annual grants, the Compensation Committee utilizes the Equity Plan to grant equity awards to key employees upon their initial employment, promotion, or as special retention awards. To further serve this purpose, the Board also adopted our 2014 Employment Inducement Plan under which we may issue up to 200,000 shares of our common stock to certain prospective employees. The Company did not make any equity grants from this plan in 2019. In the Compensation Committee’s discretion, it may authorize our CEO to grant equity awards to employees that do not serve on the Company’s CEO Committee within certain individual and aggregate thresholds.thresholds that the Compensation Committee approved. The Compensation Committee regularly reviews any awards granted by our CEO.

OUR 2019 PEER GROUPPeer Group

The duties ofOn an annual basis, the Compensation Committee require knowledge regardingreviews potential peer companies to help assess the competitiveness of compensation and practices for our executives and approves an appropriate executive compensation market.peer group. Accordingly, to understand our position within the marketplace for management talent and to assist the Compensation Committee in makingmake compensation decisions that will help attract and retain a strong management team, the Compensation Committee reviews (1) compensation information for companies comparable in size and industry, (2) our financial performance against our internal financial targets, our designated peer group, and the Russell 2000, and (3) internal compensation comparability among senior executives.

Because the Compensation Committee compares our performance against that of our peer group as part of its oversight responsibilities, it must determine our peer group. The Compensation Committee believes that one of the mostan important factors it mustfactor to consider in ensuring that our compensation program remains competitive, is the proper identification and selection of our peers,the executive compensation peer group, as we oftenmay compete for executive talent with such peers. Accordingly, thepeer companies. The Compensation Committee evaluates the members of our peer group annually. We selectselects peers from the healthcare, commercial and professional services industries, and target thosetargets companies operating in the healthcare and employment services, healthcare technology and diversified support services sectors. Like us, many of our peers are in both the S&P SmallCap 600 Index and the S&P Composite 1500 Index. Our 20192022 executive compensation peer group, as determined by our Compensation Committee, was as follows:

Our 2022 Executive
Compensation Peer Group

OUR 2019 PEER GROUP

●  Veradigm Inc.(1)

●  Insperity, Inc.●  ASGN Incorporated
●  Amedisys, Inc.●  Kforce, Inc.●  Premier, Inc.
●  Cross Country Healthcare, Inc.●  Korn/Ferry International●  Robert Half International Inc.
●  Healthcare Services Group, Inc.●  LHC Group, Inc.●  TrueBlue, Inc.
●  TriNet Group, Inc.●  Pediatrix Medical Group, Inc.(2)●  R1 RCM, Inc.

(1)Effective January 1, 2023, Allscripts Healthcare Solutions, Inc.

Korn/Ferry International

changed its name to Veradigm, Inc.

Amedisys,(2)

Effective July 1, 2022, MEDNAX, Inc.

LHC changed its name to Pediatrix Medical Group, Inc.

Cross Country Healthcare, Inc.

MEDNAX, Inc.

Healthcare Services Group, Inc.

ASGN Incorporated

TriNet Group, Inc.

Premier, Inc.

Insperity, Inc.

Robert Half International Inc.

Kforce, Inc.

TrueBlue, Inc.

44  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

Our 2019 peer group ranged from approximately$800 million to $6 billion in revenues based on each peer’s most recently reported four fiscal quarters, and from approximately $425 million to $7.3 billion in market capitalization. For purposes of comparison, our consolidated revenue for our most recently reported last four fiscal quarters equaled $2.2 billion and our market capitalization as of December 31, 2019 equaled approximately $2.9 billion, placing us seventh in our 2019 peer group for revenue and sixth for market capitalization.

Annually, inEach July the Compensation Committee evaluates our executive compensation peer group for the upcoming year primarily using industry, annual revenue and market capitalization as well as competitors and other companies from whom the Company recruits talents.of companies. When evaluating our 20202022 executive compensation peer group, the Compensation Committee reviewed (1) our 20192022 executive compensation peer group, (2) the peers utilized bythat Institutional Shareholder Services lists for us that were not in our 20192022 executive compensation peer group, (3) peers utilized bythat Glass Lewis lists for us that were not in our 20192022 executive compensation peer group, (4) companies that were not in our 20192022 executive compensation peer group that disclosed us in their proxy statement as part of their peer group, and (5) companies within our GICS code that met Institutional Shareholder Services’ recommended revenue and market capitalization band criteria. Based on its evaluation,

Our 2022 executive compensation peer group of 15 companies ranged from approximately $1.3 billion to $7.2 billion in revenues for the Compensation Committee decided notyear ended December 31, 2022, and from approximately $641 million to make changes to$8 billion market capitalization as of December 31, 2022. For purposes of comparison, our 2019consolidated revenue for the year ending December 31, 2022 was approximately $5.24 billion while our market capitalization was $4.5 billion as of December 31, 2022, placing us third in our 2022 executive compensation peer group for 2020.revenue and fourth for market capitalization. This does not include Veradigm Inc., who reported on February 28, 2023 that internal control failures resulting in a mis-statement to the reported revenue over the prior six quarters had occurred and filed a Form 12b-25, extending the due date of the Company’s Form 10-K. For the same reason, Veradigm Inc. is not included in the revenue chart directly below.

2023 Proxy Statement71

Table of Contents

Executive Compensation

TRAILING TWELVE MONTHS REVENUE ($MM) AS OF DECEMBER 31, 2022

(1)Revenue is reflected as of December 31, 2022 with the exception of Korn Ferry, which is based on the trailing twelve months ending January 31, 2023.

LOGO

MARKET CAPITALIZATION ($MM) AS OF DECEMBER 31, 2022

LOGO

(1)Effective July 1, 2022, Mednax, Inc. changed its corporate name to Pediatrix Medical Group, Inc.

AMN HEALTHCARE SERVICES, INC.  

(2)

2020 Proxy Statement

  45


COMPENSATION DISCUSSION AND ANALYSIS   

Effective January 1, 2023, Allscripts Healthcare Solutions, Inc. changed its name to Veradigm, Inc.

Benchmarking

Components of Our Compensation Program

In line with our core value of continuous improvement, we (1) listen to our shareholders, (2) review the latest trends in executive compensation practices, (3) evaluate whether certain pay practices are viewed with disfavor by shareholders or proxy advisory services and (4) review our pay practices to ensure that we have designed and implemented compensation programs that we believe will create value for our shareholders with a balance of short- and long-term incentives. The principal components of our executive compensation program include:

(1)

- (1) base salary,

(2)

short-term or annual performance awards in the form of cash bonuses,

(3)

long-term incentive awards in the form of restricted stock units and performance restricted stock units,

(4)

anon-qualified deferred compensation plan as well as benefits generally available to all of our employees,

(5)

Reimbursement of each named executive officer for certain financial, estate planning and personal health and wellness expenses, and

(6)

for our CEO, an employment agreement with severance provisions and, for our other named executive officers, severance arrangements.

BASE SALARY

Base salary, serves as(2) annual cash performance bonuses, and (3) long-term equity incentive awards - reflect the first componentimplementation of our executive compensation program. In setting base salaries,philosophy. The Compensation Committee receives benchmarking information for each of these components at the median and 75th percentile utilizing a blend of companies, including those within our executive compensation peer group, that are similar in terms of business type, revenue, and market capitalization. The Compensation Committee considers benchmarking data as a number of factors, including:

(1)

the market salary for similarly situated executives within our peer group and other companies of similar revenue size and market capitalization,

(2)

our operational and financial performance,

(3)

our stock performance,

(4)

individual performance, skills, knowledge, tenure, experience and responsibilities, and

(5)

for those who report to her and are officers of the Company, the recommendations of our CEO.

We manage salary changes to fall within our annual budget. We evaluate our operational and financial performance in light of our annual internal objectives and our annual operating plan andreference point rather than determinative data. Compensation for specific individuals may vary upward or downward from the healthcare workforce solutions and staffing industry performance. We evaluate our stock performance against our peer group and the Russell 2000 Index. Our CEO bases her recommendations on the same factors the Compensation Committee considers, and her recommendations are particularly helpfulmedian for the Compensation Committee to evaluate the other executive officers’ performance, knowledge, skills, experience and responsibilities.

ANNUAL CASH INCENTIVE BONUS

Annual cash incentive bonus opportunities serve as the second component of our executive compensation program. The Bonus Plan is the mechanism by which the Compensation Committee provides such opportunities. We intend our Bonus Plan to provide a strong incentive for ourindividual named executive officers to achieve annual financial objectives that support our strategic objectives. Although certain detailsbased on, among other things, individual performance, tenure, experience, scope of the annual bonus incentive may change from year to year, key components include specific financial goals set forth in our annual operating plan such as consolidated revenue and consolidated adjusted EBITDA. The Compensation Committee sets threshold, “target” (i.e., 100%) and maximum amounts for bonuses and a weight for each metric that corresponds to the level of achievement we require to trigger a threshold, target or maximum bonus for the named executive officer under such metric.

The threshold level for each metric typically starts at a minimum performance level (e.g., 90% of targeted consolidated adjusted EBITDA). The maximum bonus typically requires a performance level of 110% to 120% of the target amount for each metric. We have typically used incremental hurdles (usually 1% increments for adjusted EBITDA andone-half percent increments for revenue) of performance between the threshold level and the maximum level that increase the amount of bonus that can be earned on a straight-line basis depending on the

46  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

hurdle ultimately achieved. The leadership component of the bonuses, which we refer to as the Leadership Component, have been based onnon-financial factors, such as performance relative to direct competition, leadership, achievement of strategic objectives, effective leadership in line with our core values and executive leadership competencies and total shareholder return.

In setting each named executive officer’s target bonus, the Compensation Committee evaluates benchmarking data for comparable positions generally and within our peer group,responsibilities, internal parity considerations, the recommendations of our CEO (except with respect to(for compensation other than her target bonus), individual performance, knowledge, experienceown) and responsibilities, and the amount of the potential bonus under various performance scenarios. As with base salary, the Compensation Committee considers these factors in the context of each individual’s total cash compensation as well as the total compensation package (i.e., equity and cash) generally.

As set forth in our Executive Compensation Philosophy, the principles governing the annual design include the following:

succession planning considerations.

 (1)

the metrics must be tied to key indicators of our success and our annual objectives,

(2)

the performance goals must be reasonably achievable and viewed as fair, while at the same time encouraging stretch performance,

(3)

the metrics must be simple to understand and can be influenced by the executive,

(4)

the portion of an individual’s target annual cash compensation attributable to target annual bonus should increase with successively higher levels of responsibility, and

(5)

payouts should reflect our performance as well as the performance of the executive.

The Compensation Committee may amend the Bonus Plan at any time and may also amend any outstanding award granted under the Bonus Plan, provided it may not amend the Bonus Plan without the approval of our shareholders if the amendment would affect the tax deduction of payments made under it.

LONG-TERM INCENTIVES

Long-term incentives in the form of equity awards serve as the third component of our executive compensation program. Under our Equity Plan, we grant equity awards with various vesting parameters, typically three years in length, to named executive officers and key employees as an incentive to have a long-term perspective in supporting and developing our strategic objectives. We also use them as an employee retention tool. We utilize PRSUs as part of our long-term incentive structure to strengthen the performance-based component of the long-term incentive program. In 2019, we utilized TSR PRSUs and adjusted EBITDA margin PRSUs for performance-based equity for all of our named executive officers.

In general, we believe long-term equity incentive opportunities should be targeted to approximately the market median so that when combined with base salary and target annual bonus, total compensation falls around the median of market levels.

The following principles govern the design of our long-term incentives:

(1)

performance periods should cover multiple years to create balance between short- and long-term objectives,

(2)

long-term incentives should function to (a) align executive and shareholder interests, (b) enhance focus on improvements in operating performance and the creation of shareholder value and (c) drive achievement of our long-term strategic objectives,

(3)

awards should support long-term retention of key contributors through vesting,

(4)

aggregate annual share usage should be carefully managed to avoid excessive levels of shareholder value transfer in relation to those of our peer group, and

(5)

the aggregate cost of long-term incentives should be reasonable compared to members of our peer group, and the cost implications should be supported by our annual and longer-term operating plans.

AMN HEALTHCARE SERVICES, INC.  

72

2020 Proxy Statement

  47


Table of Contents


COMPENSATION DISCUSSION AND ANALYSIS   

Executive Compensation

RETIREMENT AND HEALTH PLANS

Retirement plans and other customary employee benefits serve as the fourth component of our executive compensation program. We adopted our 2005 Amended and Restated Executive Nonqualified Excess Plan, which we refer to as the Deferred Compensation Plan, primarily as a result of a market review that indicated that a deferred compensation plan was a significant component of executive compensation. We exclude our named executive officers from participating in our 401(k) plan, primarily to assist us in satisfying discrimination testing performed on our 401(k) plan. The Deferred Compensation Plan serves as the only retirement plan for our named executive officers. The Deferred Compensation Plan is not intended to be tax qualified. We describe the Deferred Compensation Plan more fully in the section entitled “Nonqualified Deferred Compensation” below.

We also offer healthcare insurance and other employee benefit programs to our named executive officers, which are generally the same as those programs provided to all eligible employees. We offer these plans to support our objective of attracting and retaining strong talent.

PERQUISITES

In addition to the benefits detailed above, the Company reimburses each named executive officer up to $25,000 in connection with annual expenses incurred in connection with financial, estate planning and personal health and wellness services. The approval of these limited perquisites by the Compensation Committee, all of which were new beginning in 2019, was made to attract and retain talent and provide market competitive compensation. The Compensation Committee believes that its approval of these perquisites remains consistent with the Company’s philosophy and commitment to align pay with performance.

In addition, in 2019, the Company continued to pay Mr. Henderson a monthly housing allowance in connection with his 2018 relocation to our Dallas, Texas office to provide increased executive leadership to our more than 700 employees located there. In 2019, the Company paid $33,231 in housing allowances to Mr. Henderson. Mr. Henderson’s housing stipend ended as of May 31, 2019.

EMPLOYMENT AND SEVERANCE AGREEMENTS

Severance arrangements serve as the fifth component of our executive compensation program. We are party to an employment agreement with our CEO, which contains severance provisions, and have entered into severance agreements with each of our other named executive officers. We entered into these agreements in support of our objectives regarding attraction and retention of strong management. In determining the appropriate severance levels, we considered survey data, advice from our compensation consultant and the Compensation Committee’s experience. We describe the terms of these agreements more fully in the section entitled “Termination of Employment and Change in Control Arrangements” below.

48  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

Our 20192022 Compensation Program and Results

Our named executive officers’ 20192022 direct compensation consisted of: (1) a base salary; (2) cash incentive bonus based on performance; (3) long-term equity incentives,incentives; (4) reimbursement for certain financial, and estate planning and personal health and wellness expensesexpenses; and (4)(5) certain other additional compensation, such as matching deferred compensation contributions. We discuss each component of our 20192022 compensation program for our named executive officers in more detail below.

BASE SALARYBase Salary

In late 2018,2021, the Compensation Committee reviewed annual base salary levels for the named executive officers and, after careful consideration, approved increases effective January 1, 20192022 ranging from three

zero to elevenpercentfromfive percent from the previous year, as set forthreflected in the table immediately to the right.below. In December 2019, the Compensation Committee considered base salaries of our named executive officers for 2020. In making its determinations, the Compensation Committee considers, among other things, (1) the market salary for similarly situated executives within our executive compensation peer group benchmarking,and other companies of similar revenue size and market capitalization, (2) Company operational and financial performance, and (3) individual and Company performance.

When benchmarking Ms. Salka’s 20192022 base salary, it was slightly above the median among other CEOs amongwithin our peers.2022 executive compensation peer group. The Compensation Committee believed this base salary was appropriate for Ms. Grace as well.

Named Executive Officer      2021 Salary
($)
       2022 Salary
($)
       Increase
%
 
Cary Grace     1,060,000    
Susan R. Salka(1)  1,030,000   1,060,000   3 
Jeffrey R. Knudson  600,000   600,000    
Mark C. Hagan  510,000   525,000   3 
Denise L. Jackson  440,000   460,000   5 
(1)Ms. Salka retired from the Company effective November 27, 2022.

Senior Management Incentive Bonus Plan

    

 

Named Executive
Officer

 

 

 

2018 Salary

($)

 

  

 

2019 Salary

($)

 

  

 

Increase

%

 

 

Susan R. Salka

 

 

900,000

 

 

 

1,000,000

 

 

 

11

 

Brian M. Scott

 

 

490,000

 

 

 

505,000

 

 

 

3

 

Ralph S. Henderson

 

 

490,000

 

 

 

505,000

 

 

 

3

 

Denise L. Jackson

 

 

409,500

 

 

 

430,000

 

 

 

5

 

BONUS PLAN

Target Bonus. Levels

In January 2019,December 2021, the Compensation Committee reviewed the 2022 target bonus levellevels for eachour named executive officer,officers, which we express as a percentage of annual base salary. After careful considerationIn furtherance of peer group data and other benchmarking information,the Company’s pay-for-performance philosophy, the Compensation Committee decided to maintainadjusted the existing bonus percentage target for eachMr. Hagan and Ms. Jackson in 2022 due to an increase in their base salary, but did not change the bonus target as a percentage of Ms. Salka and Messrs. Henderson and Scott while increasing the target percentage for Ms. Jackson.salary.

The table below shows 20192022 target bonus information for each named executive officer both in dollar amount and as a percentage of salary together with, for comparative purposes, the same figures for 2018.2021.

Named Executive Officer     2021 Bonus Target
(% of Salary)
      2022 Bonus Target
(% of Salary)
      2021 Bonus
Target ($)
      2022 Bonus
Target ($)
 
Cary Grace(2)            
Susan R. Salka  120   125   1,236,000   1,325,000 
Jeffrey R. Knudson(3)      90      540,000 
Mark C. Hagan  90   90   459,000   472,500 
Denise L. Jackson  90   90   396,000   414,000 
(2)Ms. Grace joined the Company on November 28, 2022 but was not eligible to participate in the Bonus Plan in 2022.
(3)Mr. Knudson joined the Company on November 2, 2021 and assumed the role of Chief Financial Officer and Treasurer on November 8, 2021, but was not eligible to participate in the Bonus Plan in 2021.

     

 

Named Executive Officer

 

  

 

2018 Bonus Target

(% of Salary)

 

   

 

2019 Bonus Target

(% of Salary)

 

   

 

2018 Bonus

Target ($)

 

   

 

2019 Bonus

Target ($)

 

 

Susan R. Salka

  

 

120

 

  

 

120

 

  

 

1,080,000

 

  

 

1,200,000

 

Brian M. Scott

  

 

100

 

  

 

100

 

  

 

490,000

 

  

 

505,000

 

Ralph S. Henderson

  

 

100

 

  

 

100

 

  

 

490,000

 

  

 

505,000

 

Denise L. Jackson

  

 

60

 

  

 

75

 

  

 

245,700

 

  

 

322,500

 

We believe thatThe dollar amount of Ms. Salka’s 2019 dollar2022 cash bonus target fell aroundamount was generally aligned with the median50th percentile among CEOs within our 20192022 executive compensation peer group based on our peers’ filed 2019the most recent proxy statements filed by our executive compensation peer group, which the Compensation Committee believed was appropriate.

2023 Proxy Statement73

Table of Contents

Executive Compensation

Structure of Ourour Senior Management Incentive Bonus Plan.

In 2019,2022, and consistent with previous years, the Financial Component of our bonus plan comprised 70% of our named executive officers’ totaltarget bonuses and the Leadership Component comprised the remaining 30%.

For 2019,2022, consistent with prior years’ practice, the Compensation Committee tied the Financial Component of the bonusBonus Plan to the achievement of financial targetsour 2022 annual operating plan revenue and pre-bonus adjusted EBITDA targets. We use pre-bonus adjusted EBITDA, which we refer to as Pre-Bonus AEBITDA(1), solely to determine bonuses. Pre-bonus AEBITDA excludes from Adjusted EBITDA the payment of bonuses, the impact of acquisitions that were not included in our 2019the Company’s operating plan, and certain increases to the Company’s legal expense accruals not contemplated by its 2022 annual operating plan. AtFor information on the time we establishedcalculation of Pre-Bonus AEBITDA, and a reconciliation of our 2022 net income to adjusted EBITDA and Pre-bonus AEBITDA, please see Exhibit A to this plan, we believed that it reflected above market growth for our three business segments on a consolidated basis.proxy statement (page 113).

In 2019,2022, the weighting of the performance metrics wasreflected below were consistent for each of our named executive officers:

   

 

Consolidated
Revenue

 

  

 

Consolidated

AEBITDA

 

  

 

Leadership

Component

 

35%

  

35%

  

30%

Consolidated Revenue    Pre-Bonus AEBITDA    Leadership Component
30% 40% 30%

AMN HEALTHCARE SERVICES, INC.  

(1)

2020 Proxy Statement

  49


COMPENSATION DISCUSSION AND ANALYSIS   

Under no circumstances should Pre-Bonus adjusted EBITDA be used to substitute for any other financial metric and is used by us solely to determine bonus amounts.

Rationale for Annual2022 Senior Management Incentive Bonus Plan Performance Goals.Objectives The

In 2022, the Compensation Committee has continued to utilize financial,the Financial and Leadership Components as the annual performance and leadership goals in its annual incentive bonus program overmetrics under the last several years, including 2019,Bonus Plan for a variety of reasons. It chose revenue because it believes it remains one of the most reliable measurements to evaluate the success of our strategy, entry into new markets and growthreasons, which are described in our existing businesses. It also selected revenue because investors focus on revenue growth as a metric when evaluating our performance. The Compensation Committee chose adjusted EBITDA because of its widespread acceptance among management, the Board, shareholders and analysts as a measurement of our profitability and performance. Both revenue and adjusted EBITDA are routinely areas of focus during our earnings calls. Furthermore, the Compensation Committee believes adjusted EBITDA remains an objective measure of management’s performance, and it excludes items over which management has less control, such as amortization, interest expense and taxes. The Compensation Committee uses the Leadership Component to, among other things, distinguish among individuals with respect tonon-financial metrics, such as leadership, personal performance, contributions and execution on our strategic and operational initiatives.more detail below.

Financial Component
Consolidated Revenue (30%): The Compensation Committee believes revenue remains one of the most reliable measurements to evaluate the success of our growth strategy and operational performance. It also selected revenue because investors focus on revenue growth as a metric when evaluating our performance.
Pre-Bonus AEBITDA (40%): The Compensation Committee chose Pre-Bonus AEBITDA because adjusted EBITDA is widely accepted among management, the Board, shareholders, and financial analysts as a measurement of our profitability and performance.Revenue and adjusted EBITDA are routinely areas of focus during our earnings calls and meetings with investors. Furthermore, the Compensation Committee believes Pre-Bonus AEBITDA remains an objective measure of management’s performance because it excludes items over which management has less control, such as amortization, interest expense and taxes.
The actual consolidated revenue and consolidated Pre-Bonus AEBITDA targets that the Compensation Committee established as the basis for paying “target” pay outs under the 2022 Financial Component for each named executive officer represented performance that the Compensation Committee believed was at or above anticipated performance of those in our market sector. The threshold for a named executive officer to receive a bonus under the Financial Component required achievement of 90% of our 2022 annual operating plan target for each of Pre-Bonus AEBITDA and consolidated revenue. Receipt of the target bonus amount for each of the consolidated revenue and Pre-Bonus AEBITDA metrics required the Company to meet 100% of our 2022 annual operating plan for that metric.
Leadership Component (30%): The Compensation Committee uses the Leadership Component to focus on the executive’s contribution to achieving our strategic goals that will fuel our financial success and create long-term value. While the specific measures may differ slightly for each named executive officer, we generally measure the Leadership Component based upon our named executive officers’ leadership, personal performance, execution on our strategic and operational initiatives and achievement of ESG-related objectives.

The actual consolidated revenue and consolidated adjusted EBITDA targets that the Compensation Committee originally established as the basis for paying the Financial Component of the 2019 bonuses required the Company to reach the 100% target level and represented growth that the Compensation Committee believed was at or above organic growth rates in the markets we serve. The threshold for a named executive officer to receive a bonus on the consolidated financial metrics required achievement of 90% of our 2019 annual operating plan target for each ofpre-bonus adjusted EBITDA,(3)which we refer to asPre-Bonus AEBITDA,and consolidated revenue. For information on the calculation ofPre-Bonus AEBITDA, and a reconciliation of our 2019 net income to adjusted EBITDA, please seeExhibit B to this proxy statement (pageB-1). Receipt of the target bonus amount for each financial metric required the Company to meet 100% of our 2019 annual operating plan for that metric, which represented roughly 5% year-over-year consolidated revenue growth and 2.5% consolidated adjusted EBITDA growth. The Company’s lower consolidated adjusted EBITDA growth target for 2019 relative to its annual consolidated revenue growth target is reflective of the Company’s decision to make strategic investments in its digital and workforce solutions technology offerings necessary to drive long-term shareholder value and achieve the Company’s long-term strategic objectives.

20192022 Payouts Under Senior Management Incentive Bonus Plan Payouts. The 2019 annual operating plan did not reflect the potential financial impact of any acquisitions. As such, the Compensation Committee elected not to include the financial impact of the Company‘s Silversheet, Advanced Medical acquisitions when determining the Company’s 2019 bonus plan revenue and adjusted EBITDA performance. In addition, because the Company’s acquisition of b4health occurred in late December, it did not have an impact on the Company’s 2019 bonus plan revenue and adjusted EBITDA performance.

FINANCIAL COMPONENT

We have included a table below ($ in thousands) that summarizes how we performed against the target financial performance metrics that we utilized (i.e., the Company’s annual operating plan plus the estimated revenue and earnings before interest, taxes, depreciation and amortization contributions of the acquisitions) when determining the Financial Component portion of our named executive officers’ bonuses for 2019.2022.

Metric     2022
Target
      2022
Results
      $ Variance From
2022 Target
      % Variance From
2022 Target
 
Consolidated Revenue  3,575,000   5,243,242   1,668,242   47 
Pre-Bonus AEBITDA  545,100   846,687   301,587   55 
74

Table of Contents

Executive Compensation

     
Metric  

2019

Target

   

2019

Results

   

$ Variance From

2019 Target

   

% Variance From

2019 Target

 
Consolidated Revenue   2,250,319    2,138,719    (111,600   (5
Pre-Bonus AEBITDA   284,501    277,567    (6,934   (2.4

LEADERSHIP COMPONENT

With respect to the Leadership Component, the Compensation Committee believes our named executive officers demonstrated strong leadership in 20192022 resulting in solidexceptional financial and operational results for the Company on both an absolute and relative basis compared against the Russell 2000, as we delivered a cumulative three-year total shareholder return of 73%, which places our performance in the 81st percentile compared to the Russell 2000, respectively.

(3) We usePre-Bonus adjusted EBITDA solely to determine bonuses.Pre-Bonus adjusted EBITDA excludes from Adjusted EBITDA the payment of bonuses and other extraordinary items not contemplated in our 2019 annual operating plan. Under no circumstances shouldPre-Bonus adjusted EBITDA be used to substitute for any other financial metric and is used by us solely to determine bonus amounts.

50  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

Additionally,Company. Specifically, we (i) successfullyeffectively responded, and worked with our clients to help address the continued challenges and opportunities that arose as labor market shortages increased and became severe, (ii) continued to executefocus on our long-term strategic planpriorities and our partnerships with healthcare organizations to expand and diversifyprovide our full suite of total talent solutions offeringsto optimize their workforce, (iii) expanded our international nurse business, adding permanent placement to our nurse and expand our footprint into nonacute care settings by acquiring Silversheet, Advanced Medical and b4health, (ii) capitalized on a favorable capital markets environmentallied solutions, (iv) continued to make significant progress on our investments in digital capabilities, and (v) made significant progress in advancing our other ESG-related initiatives.

PAYOUTS

The 2022 annual operating plan did not reflect the potential financial impact of any acquisitions. As such, the Compensation Committee did not include the financial impact of the Company acquisition of Connectics when determining the Company’s 2022 bonus plan revenue and adjusted EBITDA. Excluding the impact of such acquisitions, the Company’s 2022 revenue and Pre-Bonus AEBITDA results exceeded its 2022 annual operating plan and the revenue and Pre-Bonus AEBITDA Bonus Plan targets approved by the Compensation Committee in January 2022 by 47% and 55%, respectively. As a private offeringresult of $300 millionour leadership’s strong performance, the Company’s named executive officers earned maximum payouts of Senior Notes due 2027 to provide for additional liquidity to pursue strategic acquisitions and other investments that we believe enhance200% above their target long-term shareholder value, and (iii) continued our strategic development of mobile technology platforms and artificial intelligence aimed at improving the recruitment, engagement and retention of healthcare professionals.incentive compensation based on Pre-Bonus AEBITDA targets.

Based on outcomes, the Company and its Compensation Committee believe that the Bonus Plan is working as designed and intended, with the payout of the Financial Component of the 2019 annual incentive bonus having been in line with performance.intended. The illustrations below demonstrate the Company’s reported performance compared to annual operating plan target for each of the elements of the Financial Component together with an illustration of the Company’s 20192022 bonus payout compared to the Financial Component targets.

LOGO

The tables below set forth metrics and summary calculations for each named executive officer’s bonus amounts under the Leadership Component together with the final amounts paid under the Financial Component, which makesmade up 70% of the total target bonus amount.

 

MS. SALKA’S BONUS METRICS

 
   Pre-Bonus AEBITDA  Revenue  Leadership 

Levels

  % of Target   

Pre-Bonus

AEBITDA

($ in 1000’s)

 

 

 

  

Bonus

Amount ($)

 

 

  % of Target   

Revenue

($ in 1000’s)

 

 

  

Bonus

Amount ($)

 

 

  % of Target   Target ($) 

Maximum

  120   341,401   840,000   120   2,475,351   840,000   200   720,000 

Target

  100   284,501   420,000   100   2,250,319   420,000   100   360,000 

Threshold

  90   256,051   210,000   90.5   2,036,539   210,000   None   N/A 

 

MS. SALKA’S BONUS METRICS ACHIEVED AND BONUS EARNED

 

Achieved

  87.8   277,567   368,817   50.4   2,138,719   211,710   150  $540,000 

Total Bonus Earned: $1,120,527

 

  

% of Target Bonus Earned

under Financial

Component: 69.1%

 

 

 

  

    % of Target Bonus Earned    

under Leadership

Component: 150%

 

 

 

 

MR. SCOTT’S BONUS METRICS

 
   Pre-Bonus AEBITDA  Revenue  Leadership 

Levels

  % of Target   

Pre-Bonus

AEBITDA

($ in 1000’s)

 

 

 

  

Bonus

Amount ($)

 

 

  % of Target   

Revenue

($ in 1000’s)

 

 

  

Bonus

Amount ($)

 

 

  % of Target   Target ($) 

Maximum

  120   341,401   353,500   110   2,475,351   353,500   200   265,125 

Target

  100   284,501   176,750   100   2,250,319   176,750   100   151,500 

Threshold

  90   256,051   88,375   90.5   2,036,539   8,837   None   N/A 

 

MR. SCOTT’S BONUS METRICS ACHIEVED AND BONUS EARNED

 

Achieved

  87.8   277,567   155,210   50.4   2,138,719   89,095   190   287,850 

Total Bonus Earned: $532,155

 

  

% of Target Bonus Earned

under Financial

Component: 69.1%

 

 

 

  

    % of Target Bonus Earned    

under Leadership

Component: 190%

 

 

 

Ms. Salka and Ms. Grace are not reflected in the tables below. For more information on compensation paid to Ms. Salka and Ms. Grace, see New CEO Compensation and Ms. Salka’s Retirement below.

2023 Proxy Statement75

Table of Contents

Executive Compensation

MR. KNUDSON BONUS METRICS

Threshold     Target  Maximum         
Revenue
($ in 1000’s)
% of Target
Bonus Amount ($)

% of Target
Bonus Earned under
Financial Component:

AMN HEALTHCARE SERVICES, INC.  200%

Pre-Bonus AEBITDA
($ in 1000’s)
% of Target
Bonus Amount ($)
Leadership Target
($)
% of Target
 

% of Target
Bonus Earned under
Leadership Component:

200%

Total Bonus Earned: $1,080,000
MR. HAGAN’S BONUS METRICS
Threshold     Target  Maximum         
Revenue
($ in 1000’s)
% of Target
Bonus Amount ($)

% of Target
Bonus Earned under
Financial Component:

200%

Pre-Bonus AEBITDA
($ in 1000’s)
% of Target
Bonus Amount ($)
Leadership Target
($)
% of Target

% of Target
Bonus Earned under
Leadership Component:

200%

Total Bonus Earned: $945,000
 
76

Table of Contents

Executive Compensation

MS. JACKSON’S BONUS METRICS

Threshold     Target  Maximum         
Revenue
($ in 1000’s)
% of Target
Bonus Amount ($)
 

% of Target
Bonus Earned under
Financial Component:

200%

2020Pre-Bonus AEBITDA
($ in 1000’s)
% of Target
Bonus Amount ($)
 
Leadership Target
($)
% of Target

% of Target
Bonus Earned under
Leadership Component:

200%

Total Bonus Earned: $828,000

2022 Performance and Retention Plan

In May 2022, we established the 2022 Performance and Retention Plan for our named executive officers (other than Ms. Grace and Ms. Salka) and other key executives based on heightened adjusted EBITDA goals, in recognition of the competitive labor environment and to promote stability and continued growth during our CEO transition. The awards were designed to pay out at a range of 0% to 100%, subject to the Company’s adjusted EBITDA performance exceeding target by 121% to 140% and the executive remaining employed by the Company on May 1, 2023. As a result of the Company’s exceptional performance, the 2022 Performance and Retention Plan is expected to result in the maximum pay out, provided that to receive the bonus the executive must remain employed by the Company on May 1, 2023. Neither Ms. Salka nor Ms. Grace received a 2022 Performance and Retention Bonus, as the bonus was established after Ms. Salka announced her retirement and before Ms. Grace joined the Company.

Pre-Bonus AEBITDA
($ in 1000’s)
% of Target
Mr. Knudson 2022 Performance and
Retention Bonus
Payout Range 
Mr. Hagan’s 2022 Performance and
Retention Bonus
Payout Range
Ms. Jackson’s 2022 Performance and Retention BonusPayout Range
2023 Proxy Statement

77  51


Table of Contents


Executive Compensation

New CEO Compensation

On March 10, 2022, the Company announced that Ms. Salka would retire as President and Chief Executive Officer but would stand for re-election to AMN Healthcare’s board and would remain as President and Chief Executive Officer until the hiring of her successor. On October 31, 2022, the Company announced the appointment of Cary Grace to succeed Ms. Salka as CEO of the Company, effective November 28, 2022.

The Board determined that Ms. Grace was the right candidate to build upon AMN Healthcare’s operational and organizational strengths and guide AMN Healthcare in the next phase of its evolution. Ms. Grace’s proven track record of leading dynamic, client-centric businesses positions her to lead AMN into the new environment of post-pandemic healthcare. She is the former CEO of Global Retirement, Investment and Human Capital at Aon where she also led their enterprise client management and oversaw the integration of all acquisitions for the company. Prior to joining Aon in 2011, she spent more than 14 years at Bank of America, where she led several institutional and private banking businesses, including their $9 billion Mass Affluent Client Business. Ms. Grace is a passionate advocate for Environmental, Social and Governance issues and connected to AMN Healthcare’s purpose and values.

In designing Ms. Grace’s compensation package, the Compensation Committee, advised by its independent compensation consultant, sought to deliver market-competitive compensation commensurate with Ms. Grace’s capabilities, experience, alignment with AMN’s values and culture and reflective of the challenging healthcare environment. Ms. Grace’s base salary of $1,060,000 and annual cash bonus target of 125% of base salary are both equal to those of her predecessor, which the Compensation Committee determined were market competitive and recognized Ms. Grace’s expertise and leadership experience. Upon her hire, Ms. Grace received (i) an equity grant in the form of restricted stock units valued at $2 million (the “Buy-Out Award”) and (ii) an equity grant in the form of RSUs valued at $1 million (the “Sign-On Award”) that, in each case, will vest ratably on each of the first three anniversaries of the grant date. Additionally, on December 16, 2022, the Company paid Ms. Grace a sign-on cash bonus of $200,000. Ms. Grace also received an annual long-term incentive award with a target value of $4.4 million comprised of a mix of RSUs and performance-based RSUs in accordance with the Company’s standard equity practices in January 2023.

In determining the size and structure of her one-time new hire equity awards and bonus payment, the Compensation Committee considered the following factors:

The importance of creating immediate alignment with AMN’s shareholders,

COMPENSATION DISCUSSION AND ANALYSIS   

The competitive market for a talented, experienced, transformational leader capable of leading AMN,
Ms. Grace’s unique skill-set and proven record as a successful executive at large organizations, and
Outstanding equity awards that would be forfeited.

 

MR. HENDERSON’S BONUS METRICS

 
   Pre-Bonus AEBITDA  Revenue  Leadership 

Levels

  % of Target   

Pre-Bonus

AEBITDA

($ in 1000’s)

 

 

 

  

Bonus

Amount ($)

 

 

  % of Target   

Revenue

($ in 1000’s)

 

 

  

Bonus

Amount ($)

 

 

  % of Target   Target ($) 

Maximum

  120   341,401   353,500   110   2,475,351   353,500   200   265,125 

Target

  100   284,501   176,750   100   2,250,319   176,750   100   151,500 

Threshold

  90   256,051   88,375   90.5   2,036,539   8,837   None   N/A 

 

MR. HENDERSON’S BONUS METRICS ACHIEVED AND BONUS EARNED

 

Achieved

  87.8   277,567   155,210   50.4   2,138,719   89,095   100   151,500 

Total Bonus Earned: $395,805

 

  

% of Target Bonus Earned

under Financial

Component: 69.1%

 

 

 

  

    % of Target Bonus Earned    

under Leadership

Component: 100%

 

 

 

 

MS. JACKSON’S BONUS METRICS

 
   Pre-Bonus AEBITDA  Revenue  Leadership 

Levels

  % of Target   

Pre-Bonus

AEBITDA

($ in 1000’s)

 

 

 

  

Bonus

Amount ($)

 

 

  % of Target   

Revenue

($ in 1000’s)

 

 

  

Bonus

Amount ($)

 

 

  % of Target   Target ($) 

Maximum

  120   341,401   225,750   110   2,475,351   197,531   200   169,313 

Target

  100   284,501   112,875   100   2,250,319   112,875   100   96,750 

Threshold

  90   256,051   56,438   90.5   2,036,539   5,644   None   N/A 

 

MS. JACKSON’S BONUS METRICS ACHIEVED AND BONUS EARNED

 

Achieved

  87.8   277,567   99,119   50.4   2,138,719   56,897   190   183,825 

Total Bonus Earned: $339,842

 

  

% of Target Bonus Earned

under Financial

Component: 69.1%

 

 

 

  

    % of Target Bonus Earned    

under Leadership

Component: 190%

 

 

 

LONG-TERM INCENTIVE COMPENSATIONMs. Salka’s Retirement

On November 27, 2022, Ms. Salka retired as President and Chief Executive Officer of the Company and resigned as a board member. Upon the announcement of her retirement, the Compensation Committee approved a Transition Agreement with Ms. Salka which included provisions related to her 2022 annual bonus, continued employment with the Company through her retirement date and future service to the Company in an advisory capacity. Specifically, the Transition Agreement provided that payment of the 2022 annual bonus would be made at the maximum payout amount of 250% (200% of the target bonus) of Ms. Salka’s base salary (i.e., $2,650,000) and would be paid in 2023 at the same time it would have been paid had she remained a Company employee. Additionally, to facilitate a smooth transition, Ms. Salka agreed to serve as an advisor to the Company from the date of retirement through the third anniversary of the separation date, pursuant to an Advisory Agreement, pursuant to which Ms. Salka will receive renumeration amounting to $300,000 on each of the three anniversaries following the effective date of the Advisory Agreement.

In 2019,designing the compensation-related provision of the Transition Agreement, the Compensation Committee considered the following factors:

Ms. Salka’s significant tenure and success while at AMN,
Ms. Salka’s strong client, industry and other stakeholder relationships,
The significant portion of 2022 for which Ms. Salka would be serving as President and CEO before retirement, and
Ms. Salka’s commitment to enabling a smooth and efficient CEO transition.

The Compensation Committee believes that this arrangement is beneficial to the Company and its shareholders given the duration Ms. Salka’s tenure as well as her commitment to enabling a smooth and efficient CEO transition. Ms. Salka also satisfies the requirement for retirement eligibility for equity awards granted, but not yet vested at the time of her retirement.

78

Table of Contents

Executive Compensation

Long-Term Incentive Compensation

2022 Long-Term Incentive Equity Awards

In 2022, the Compensation Committee granted equity awards to each named executive officer and the Committee believes it servesthese awards serve as a key component of our named executive officer’stheir total compensation package. The chart below reflects the aggregate grant date fair value,Consistent with prior years, we used a mix of time-based restricted stock units, which we refer to as AGD Fair Value, of each equity award type granted to each named executive officer. For allRSUs in this CD&A, and PRSUs. All equity awards that we granted in 2019, our Compensation Committee approved changes to all of our equity grant agreements for our named executive officers to (1) provide for “double trigger” vesting mechanics in the event of a change in control of the Company, and (2) allow for continued vesting of outstanding equity awards if a grantee terminates his or her employment after satisfying certain age (55) and service time (15 years) requirements, which theour equity agreements refer to as “retirement.”

Commencing in October 2019 and December 2019, Ms. Salka and Ms. Jackson will, respectfully,each satisfy the requirements for retirement eligibility under their 2019respective 2022 equity awards. In light of Ms. Salka’s announced retirement, we amended Mr. Knudson’s restricted stock unit agreements on May 5, 2022, for his outstanding awards granted in 2021 and 2022 to also provide for accelerated vesting if he is terminated from the Company without Cause or termination of his service for Good Reason at a time when he could not have been terminated for Cause.

The RSUs that Ms. Grace received when she joined the Company on November 28, 2022 will vest ratably on each of the first three anniversaries of the grant date. In the event of a termination of Ms. Grace’s service by the Company without Cause or by Ms. Grace for Good Reason, (a) the Buy-Out Award will vest in full, (b) the Sign-On Award will vest on a pro-rata basis based on the number of full calendar months elapsed between the grant date and the termination date, (c) each Annual Award granted prior to 2026 in the form of RSUs will vest on a pro-rata basis based on the number of full calendar months elapsed between the grant date and the termination date and (d) each Annual Award granted prior to 2026 in the form of PRSUs will be eligible to vest on a pro-rata basis based on the number of full calendar months elapsed between the beginning of the applicable performance period and the termination date, subject to actual performance as measured at the end of the applicable performance period. “Cause” and “Good Reason” as used in the section are defined below in Termination of Employment and Change in Control Arrangements.

     
Named Executive Officer 

      AGD Fair Value of

2019 TSR PRSU

Award ($)

   

AGD Fair Value of

2019 AEBITDA PRSU

Award ($)

   

AGD Fair Value of

2019 RSU Award ($)

   

Total AGD Fair Value

of 2019 Awards ($)

 
Susan R. Salka  989,992    1,155,016    1,237,828    3,382,836 
Brian M. Scott  302,982    353,489    353,489    1,009,959 
Ralph S. Henderson  302,982    353,489    353,489    1,009,959 
Denise L. Jackson  193,492    225,772    225,772    645,036 

AGGREGATE GRANT DATE FAIR VALUE

The chart below reflects the aggregate grant date fair value of each equity award type that we granted to each named executive officer in 2022.

Named Executive Officer     AGD Fair
Value of
2022 TSR
PRSU
Award(s)
($)
      AGD Fair
Value of 2022
Adjusted
EBITDA
Performance
PRSU
Award
($)
      AGD Fair
Value of
2022 RSU
Award(s)
($)
       Total AGD
Fair Value
of 2022
Awards
($)
 
Cary Grace        2,999,903   2,999,903 
Susan R. Salka  1,367,247   1,539,945   1,539,945   4,447,137 
Jeffrey R. Knudson  465,990   524,907   524,907   1,515,805 
Mark C. Hagan  388,374   437,477   437,477   1,263,328 
Denise L. Jackson  341,775   384,932   384,932   1,111,639 

Each of our named executive officers received PRSU grants in January 2022. The PRSUs represented 65% or more of the AGD Fair Value of the total equity grant value for Ms. Salka, Mr. Knudson, Mr. Hagan and Ms. Jackson.

Ms. Grace received equity grant of 8,164 and 16,329 RSUs in connection with her appointment as President and Chief Executive Officer on November 28, 2022, the Sign-On Award and Buy-Out Award, respectively. The Compensation Committee did not grant Ms. Grace PRSUs at that time, because it thought it would be more appropriate to wait until it approved equity awards for the other named executive officers in 2023.

2023 Proxy Statement79

Table of Contents

Executive Compensation

To provide further clarity on our equity compensation practices, the chart below reflects the change in the AGD Fair Value of all 2022 equity awards granted to our named executive officers against the AGD Fair Value of all 2021 equity awards.

Named Executive Officer     AGD Fair Value of
2021 Equity Awards
($)
      AGD Fair Value of
2022 Equity Awards
($)
      Variance
($)
      %
Increase
(Decrease)
 
Cary Grace     2,999,903        
Susan R. Salka  5,643,694   4,447,137   (1,196,557)   (21) 
Jeffrey R. Knudson  2,999,940   1,515,805   (1,484,135)   (49) 
Mark C. Hagan  2,841,104(1)   1,263,328   (1,577,776)   (56) 
Denise L. Jackson  2,495,210(1)   1,111,639   (1,383,571)   (55) 
Total  13,979,948   11,337,812         

(1)The AGD Fair Value of the 2021 equity awards for Mr. Hagan and Ms. Jackson were understated in the Company’s proxy statement filed on March 23, 2022 by $515,580, due to an administrative error. The AGD Fair Value of the 2021 equity awards for Mr. Hagan and Ms. Jackson were $2,841,104 and $2,495,210, respectively, not $2,325,524 and $1,979,630, as previously reported.

TSR PRSUs

TSR PRSUs represented approximately 30% of the total 20192022 equity grant value that waswe awarded to each named executive officer,Ms. Salka, Mr. Knudson, Mr. Hagan and Ms. Jackson based on the AGD Fair Value, andValue. Each of our executive officers received a TSR PRSU grant in January each year that will be earned at the end of an approximately three-year performance period based on our stock performance against two measures: (1) a relative basis (which we refer to as Relative TSR) against a broader market (companies in the Russell 2000 Index at the beginning of the performance period) and (2) an absolute total shareholder return basis (which we refer to as Absolute TSR). We

1.a relative basis, which we refer to as Relative TSR, against a broader market (companies in the Russell 2000 Index at the beginning of the performance period) and

52  

2.

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement

an absolute total shareholder return basis, which we refer to as Absolute TSR.


  COMPENSATION DISCUSSION AND ANALYSIS  

We refer to the determination of our Relative TSR and Absolute TSR collectively as the TSR Measurement. The number of PRSUs earned if the Company’s Relative TSR exceeds the 50th percentile but its Absolute TSR is negative is capped at the target number of PRSUs granted. For each one percentile above the 25th percentile, an additional 3% of the PRSUs vest, and the maximum payout cannot exceed 175% if Absolute TSR is positive or 100% if the Absolute TSR is negative.

The table set forth below discloses the percentage of the 2019January 2022 target PRSUs that may be earned depending on the actual results of the Company’s TSR Measurement as of December 31, 2021.2024.(4)(1)

   

 

Relative TSR Percentile Rank

 

% of 2019 TSR

PRSUs Earned

if Absolute TSR Is  Negative(1)

 

 

% of 2019 TSR

PRSUs that Are Earned

if Absolute TSR Is Positive

 

<25.0%00
25.0%25.0025.00
37.5%62.5062.50
50.0%100.00100.00
62.5%100.00137.50
75.0%100.00175.00

Relative TSR Percentile Rank     % of 2022 TSR PRSUs Earned if
Absolute TSR is Negative(2)
     % of 2022 TSR PRSUs that are Earned if
Absolute TSR is Positive
<25.0% 0 0
25.0% 25.00 25.00
37.5% 62.50 62.50
50.0% 100.00 100.00
62.5% 100.00 137.50
75.0% 100.00 175.00

(1)

As set forth in the Grants of Plan-Based Awards Table, the target number of TSR PRSUs that we granted in January 2022 for each named executive officer is as follows: (i) for Ms. Salka, 9,301; (ii) for Mr. Knudson, 3,170; (iii) for Mr. Hagan, 2,642 and (iv) for Ms. Jackson, 2,325. Due to the timing of Ms. Grace’s appointment, the Committee elected to wait until January 2023 to approve her TSR PRSUs awards.

(2)For each one percentile above the 25th percentile, an additional 3% of the TSR PRSUs will be earned if Absolute TSR is positive, and the maximum payout cannot exceed 175%. If Absolute TSR is negative, for each one percentile above the 25th percentile, an additional 1.5% of the TSR PRSUs will be earned up to the 50th percentile with the maximum payout of 100%.

AdjustedADJUSTED EBITDA PERFORMANCE PRSUs

In 2019,2022, the Compensation Committee once again determined it best to dedicate a significant portion of the restricted stock unitsPRSUs to focus our named executive officers on achieving a 13.3%an adjusted EBITDA marginperformance target of $537 million in 2022 with compound year-over-year adjusted EBITDA performance rate target of 4% for 2021.the two-year period of 2023 and 2024(5)(1) Theby issuing Adjusted EBITDA Performance PRSUs. For these awards, the number of shares that could ultimately be earned ranges from 0% to 200% of the target number of adjusted EBITDA margin PRSUs depending on actual adjusted EBITDA margin performance for 2021.in 2022 and compound year-over-year adjusted EBITDA performance in the two-year period of 2022 and 2023.

(1)As set forth in the Grants of Plan-Based Awards Table, the target number of adjusted EBITDA PRSUs that we granted in 2022 for each named executive officer is as follows: (i) for Ms. Salka, 14,214; (ii) for Mr. Knudson, 4,845 (iii) for Mr. Hagan, 4,038, and (iii) for Ms. Jackson, 3,553.
80

Table of Contents

Time-Vested RSUsExecutive Compensation

Restricted stock unit grants, whichTIME-VESTED RSUs

RSUs that we refer to as RSUs, granted in 20192022 vest ratably on each of the first three anniversaries of the grant date. As it has done historically, the Compensation Committee elected to wait to consider a grant of RSUs for Ms. Salka for 2019 until the end of 2019 when it had better visibility of ouryear-end financial, operational and stock performance. Based on our financial, operational and stock performance in 2019, the Compensation Committee granted Ms. Salka 20,755RSUs with an AGD Fair Value of $1,237,828on December 16, 2019.

Aggregate Grant Date Fair Value

PRSUs represented 65% of the AGD Fair Value of all 2019 equity awards for our named executive officers, other than our CEO. Due to the timing of Ms. Salka’s RSU award in December 2019 (rather than January 2019), she received PRSUs that represented 37% of her total 2019 equity award value. To provide further clarity on our equity compensation practices, the chart below details the change of the AGD Fair Value of all 2019 equity awards granted to our named executive officers against the AGD Fair Value of all 2018 equity awards.

The 17% increase in our CEO’s AGD Fair Value in 2019 from 2018 is driven in part by the Company’s strong financial, operational and stock performance in 2019, as well as peer group and other compensation benchmarking.We believe that the AGD Fair Value of her equity awards placed her below the median among CEOs within our 2019 peer group for long-term incentive compensation. On an aggregate basis, the combined AGD Fair ValueResults of our named executive officers’ equity awards increased 69% in 2019 from 2018.2020 Performance Restricted Stock Unit Awards

(4) As set forth in the Grant of Plan-Based Awards Table, the target number of TSR PRSUs granted in 2019 for each named executive officer is as follows: (1) for Ms. Salka, 13,400; (2) for Mr. Scott, 4,101; (3) for Mr. Henderson, 4,101; and (4) for Ms. Jackson, 2,619.

(5) As set forth in the Grant of Plan-Based Awards Table, the target number of adjusted EBITDA PRSUs granted in 2019 for each named executive officer is as follows: (i) for Ms. Salka, 20,755; (ii) for Mr. Scott, 6,352; (iii) for Mr. Henderson, 6,352; and (iv) for Ms. Jackson, 4,057.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  53


COMPENSATION DISCUSSION AND ANALYSIS   

     
Named Executive Officer 

AGD Fair Value of

2018 Equity Awards($)

  

AGD Fair Value of

2019 Equity Awards($)

               Variance ($)   % Increase 
  
Susan R. Salka  2,888,030   3,382,836    494,806    17 
  
Brian M. Scott  1,000,046   1,009,959    9,913    1 
  
Ralph S. Henderson  1,000,046   1,009,959    9,913    1 
  
Denise L. Jackson  430,001   645,036    215,035    50 
  
Total  5,318,123   6,047,7903    729,667    69 

RESULTS OF OUR 2017 PERFORMANCE RESTRICTED STOCK UNIT AWARDS

2017 TSR PRSU Award TSR Measurement

On January 6, 2020,In early 2023, the Compensation Committee performed the TSR Measurement for the 20172020 TSR PRSU awards. Our Relative TSR was atawards for the 81st percentile of the Russell 2000 Index and our Absolute TSR was 73.45% during the measurement period from January 1, 20172020 through December 31, 2019. Accordingly,2022.

2020 TSR PRSUS:

   
RELATIVE TSR PERCENTILE
RANK VS. RUSSELL 2000
ABSOLUTE
TSR %
% OF 2020 TSR PRSUs
EARNED
89th94%175%
   
Named Executive OfficerNumber of 2020
TSR PRSUs Earned
Cary Grace(1)
Susan R. Salka23,336
Jeffrey R. Knudson(1)
Mark C. Hagan4,204
Denise L. Jackson4,401

(1)Ms. Grace and Mr. Knudson were not employed by the Company when it issued the 2020 TSR PRSUs and therefore did not receive any of these awards.

Additional Compensation Practices

Other Compensation Elements

Retirement and Health Plans

Retirement plans and other customary employee benefits serve as the fourth component of our executive compensation program. We adopted our 2005 Amended and Restated Executive Nonqualified Excess Plan, which we refer to as the Deferred Compensation Plan, primarily based on our review of peer market data indicating that a deferred compensation plan was a significant component of executive compensation. Our named executive officers are not eligible to participate in our 401(k) if they exceed the compensation threshold set by the Internal Revenue Service, which is primarily designed to assist us in satisfying discrimination testing performed on our 401(k) plan.(1) The Deferred Compensation Plan serves as the only retirement plan for our named executive officers. The Deferred Compensation Plan is not intended to be tax qualified. We describe the Deferred Compensation Plan more fully in the section entitled “Nonqualified Deferred Compensation” below.

In addition, all equity awards allow for continued vesting of outstanding equity awards if a grantee terminates his or her employment (other than for cause or due to a change in control) after satisfying certain age and service time requirements, which our equity agreements refer to as “retirement eligible.”

We also offer healthcare insurance and other employee benefits to our named executive officers, which are generally the same as those programs provided to all eligible employees. We offer these plans to support our objective of attracting and retaining strong talent.

(1)Ms. Grace was eligible to participate in our 401(k) plan when she joined the Company in November 2022 but is not eligible to participate in 2023.
2023 Proxy Statement81

Table of Contents

Executive Compensation

Perquisites

In addition to the benefits described above, the Company reimburses each named executive officer up to $25,000 in connection with annual expenses incurred in connection with financial, estate planning and personal health and wellness services. The Compensation Committee approved this limited perquisite to attract and retain talent and provide market competitive compensation. Our named executive officers also received the maximum (175%) of his oran inflation stipend consistent with our other corporate employees. In connection with Ms. Grace’s appointment as President and Chief Executive Officer and her target amount of 2017 TSR PRSUs. Specifically,agreement to relocate to our headquarters in Dallas, Texas, we agreed to reimburse her for certain expenses consistent with our Company policy for executives. We additionally paid certain attorney’s fees for Ms. Salka Mr. Scott, Mr. Henderson and Ms. Jackson earned 20,701, 7,245, 7,245Grace in connection with Ms. Salka’s Transition Agreement and 4,242 PRSUs, respectively.related agreements and Ms. Grace’s compensation-related agreements. The Compensation Committee believes that its approval of these perquisites remains consistent with the Company’s philosophy and commitment to align pay with performance.

2017 Adjusted EBITDA PRSU Award MeasurementSeverance Arrangements

On February 13, 2020,Severance arrangements serve as the fifth component of our executive compensation program. We are party to a severance agreement with each of our current named executive officers. We entered into these agreements in support of our objectives regarding attraction and retention of strong management. In determining the appropriate severance levels, we considered survey data, advice from our compensation consultant and the Compensation Committee determined that our 2019 adjusted EBITDA margin equaled 12.5%. Accordingly, each named executive officer received 25%Committee’s experience. We describe the terms of his or her target amountthese agreements more fully in the section entitled “Termination of 2017 adjusted EBITDA margin PRSUs. Specifically, Ms. Salka, Mr. Scott, Mr. HendersonEmployment and Ms. Jackson earned 4,496, 1,574, 1,574 and 922 PRSUs, respectively.Change in Control Arrangements” below.

Equity Ownership, Requirements, Clawback and No Pledging or Hedging Policies

We maintain meaningful equity ownership requirements as well as clawback and pledging policies to which our named executive officers are subject. We have set forth a summary of these requirements and policies below. Additional details related to these requirements and policies are contained in the Governance Guidelines.

EQUITY OWNERSHIP REQUIREMENTS

The Board believes that all named executive officers should maintain a meaningful personal financial stake in the Company to align their long-term interests with those of our shareholders. Accordingly, our named executive officers are subject to meaningful equity ownership requirements require the followingas set forth below. Additionally, our named executive officers and other executives to maintain the following:

Equity Ownership Requirements

Level

Proposed

Board of Directors

5x Annual Cash Retainer

Chief Executive Officer

5x Base Salary

Named Executive Officers

2x Base Salary

Other CEO Committee Members

1.5x Base Salary

54  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  COMPENSATION DISCUSSION AND ANALYSIS  

The value of unvested RSUs and vested or unvested SARs and options are not taken into account in determining whether a named executive officer satisfies our equity ownership requirements. Individuals subject to a securities trading policy that prohibits trading in the equity ownershipCompany’s securities based on material information and engaging in inappropriate transactions such as pledging and hedging. We set forth a summary of these requirements above who have not metand policies below. Additional details related to these requirements and policies are contained in the applicable ownership requirements are required to retain 50% of net vested shares from equity awards issued subsequent toGovernance Guidelines posted on the initial assessment of ownership until they have reached the applicable ownership requirement. Company’s website.

As of the close of business on February 24, 2020,March 21, 2023, all of our named executive officers satisfysatisfied our equity ownership requirements with the exception of Ms. Grace, whose employment with the Company began on November 28, 2022, and Mr. Knudson, whose employment with the Company began on November 2, 2021.

LevelRequired
Ownership
as a Multiple
of Base
Salary
Shares Held
as Multiple of
Base Salary
(1)
Complies(2)
Cary Grace5x Base Salary
Jeffry R. Knudson2x Base Salary1.7
Mark C. Hagan2x Base Salary4.5 
Denise L. Jackson2x Base Salary3.0 

Additionally, other CEO Committee Members are subject to equity ownership requirements amounting to 1.5 times their annual base salary.

(1)The value of unvested RSUs and vested or unvested stock appreciation rights and options are not considered when determining whether a named executive officer satisfies our equity ownership requirements. Our Chief Executive Officer, Named Executive Officers and other CEO Committee Members are subject to equity ownership requirements, which requires them to retain 50% of net vested shares from equity awards issued by the Company until they have reached the applicable ownership requirements reflected above.
(2)Ms. Grace and Mr. Knudson joined the Company on November 28, 2022 and November 2, 2021, respectively, and do not yet meet the required equity ownership as a multiple of each of their base salary.

Clawback Policy

CLAWBACK POLICY

Under the Governance Guidelines, if we are required to prepare an accounting restatement due to material noncompliance with any financial reporting requirements under the securities laws caused by misconduct, we can seek recoupment from all of our current or former executive officers who participated in the misconduct of:

1.(1)

all or any portion of the bonus and equity or cash incentive compensation received by such individuals during the12-month period following the first public issuance or filing with the SEC (whichever first occurs) of the financial document embodying such defective financial statement; and

2.(2)

any profits realized by such individuals from the sale of securities of the Company during that12-month period.

NO PLEDGING POLICYThe Company intends to adopt a clawback policy consistent with the requirements of the Exchange Act Rule 10d-1 and in accordance with the final listing standards adopted by the New York Stock Exchange.

82

Table of Contents

Executive Compensation

No Pledging or Hedging Policy

The Governance Guidelines prohibit named executive officers (and directors) from pledging, hypothecating, or otherwise placing a lien on any shares of our common stock (or any other equity interests) that they own.

Tax Deductibility of Executive Compensation

Prior to December 22, 2017, when the Tax Cuts and Jobs Act of 2017, which we refer to as the TCJA, was signed into law, Section 162(m) of the Internal Revenue Code generally disallowed a tax deduction to publicly held companies for compensation paid to certain executive officers in excess of $1 million per officer in any year that did not qualify as performance-based. We refer to the Internal Revenue Code as the Code.

Under theThe TCJA repealed the performance-based exception, has been repealed and the $1 million deduction limit now applies to anyone serving as the chief executive officer or the chief financial officer at any time during the taxable year and the top three other highest compensated executive officers serving at fiscalyear-end. The new rules generally apply to taxable years beginning after December 31, 2017, but do2017. Because many different factors influence a well-rounded, comprehensive executive compensation program, some of the compensation we provide to our named executive officers is likely not apply to remuneration provided pursuantbe fully deductible for tax purposes due to a written binding contract in effect on November 2, 2017 that is not modified in any material respect after that date.Section 162(m).

Overview of Our 20202023 Executive Compensation Program

Overall, the Compensation Committee believes the Company performed well during 20192022 and continued to execute on the Company’s long-term strategic plan. WeIn 2022, we achieved year-over-year consolidated revenue and consolidated adjusted EBITDA growthperformance of approximately 4%32% and 3%33%, respectively. Performance of our common stock continued its strong performance in 2019, delivering a 10% price appreciation. The Compensation Committee believes it has designed the 20202023 compensation structure to provide for important short- and long-term performance components that are aligned with shareholders,shareholders’ interests, consistent with the market environment and tailored specifically to us. Additional discussion of the Company’s 2023 executive compensation decisions will be provided in next year’s proxy statement.

BASE SALARYBase Salary

The Compensation Committee approved the annual base salaries for the named executive officers for 20202023 as follows:

Named Executive Officer     2022
Salary
($)
      2023
Salary
($)
      %
Increase
 
Cary Grace  1,060,000   1,060,000    
Jeffrey R. Knudson  600,000   630,000   5 
Mark C. Hagan  525,000   550,000   4.8 
Denise L. Jackson  460,000   500,000   8.7 

    
Named Executive Officer    

2019

Salary ($)

   

2020

                Salary  ($)

   

%

                 Increase

 
Susan R. Salka     1,000,000    1,030,000    3 
Brian M. Scott     505,000    520,000    3 
Ralph S. Henderson (1)     505,000    505,000    0 
Denise L. Jackson     430,000    440,000    2 

(1)

Mr. Henderson has notified the Company that he intends to retire on or about May 1, 2020.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  55


COMPENSATION DISCUSSION AND ANALYSIS   

The base salaries of our named executive officers reflect a 0% to 3%8.7% increase. The 20202023 base salary for our named executive officers is based on executive compensation market and peer group benchmarkingcompetitive analyses, and the Compensation Committee’s recognition that the Company’s 2019 organic2022 growth and core business performance did not meetwell exceeded targeted expectations, the individual performance and its commitment to maintain a pay for performance environment.

BONUS PLANBonus Plan

Target Bonus.

In January 2020,2023, the Compensation Committee reviewed the target bonus level for each named executive officer, which we express as a percent of annual base salary. After careful consideration, the Compensation Committee determined thatnot to increase the 20202022 bonus target as a percentage of salary should not be increased for our namedMr. Hagan and Ms. Jackson but determined to slightly increase the bonus target for Mr. Knudson based on executive officers.compensation peer group and market competitive data. We set forth below the 20202023 target bonuses for each named executive officer as a percentage of salary which remained unchanged from 2019.below.

Named Executive Officer 2022
Bonus Target
(% of Salary)
      2023
Bonus Target
(% of Salary)
 
Cary Grace     125 
Jeffrey R. Knudson  90   100 
Mark C. Hagan  90   90 
Denise L. Jackson  90   90 
2023 Proxy Statement83

Table of Contents

Executive Compensation

   
Named Executive Officer  

2019 Bonus

Target

  (% of Salary)  

  

2020 Bonus

Target

  (%of Salary)  

Susan R. Salka    120    120
Brian M. Scott    100    100
Ralph S. Henderson    100    100
Denise L. Jackson    75    75

Structure.

After careful consideration of the factors set forth above in the subsection of this CD&A entitled “Components“Principal Components of Our Compensation Program — Annual Cash Incentive Performance Bonus,” the Compensation Committee decided to useretain the same bonus structure used in 2022 for each named executive officer as it did in 2019.officers, with 40% of the bonus earned for achieving 2023 pre-bonus adjusted EBITDA target and 30% earned for achieving 2023 revenue target. The target goals for each of the financial metrics are consistent with the targets under our 20192023 annual operating plan and generally require growth that exceeds our estimate of anticipated industry performance. For our CEO, we believeMs. Grace, her 20192023 bonus target in dollar amountpercentage falls near the median50th percentile among CEOs within our 20192022 peer group.

LONG-TERM EQUITY INCENTIVESLong-Term Equity Incentives

The Compensation Committee continues to believe that aligning its pay for performance philosophy, goals and objectives is the foundation upon which it evaluates its annual long-term incentive award strategy. In January 2020, it approved the issuance of a new long-term incentive award that vests at the end of a three year-period and accrues certain value annually during each year of the award based on the Company’s annual adjusted EBITDA growth rate. We refer to these awards as adjusted EBITDA growth PRSUs. In 2020, these adjusted EBITDA growth PRSUs replaced the use of the adjusted EBITDA margin PRSUs, which vested after three years based on the Company’s adjusted EBITDA margin at the end of the last year of the award. The Compensation Committee believes that the adjusted EBITDA growth PRSUs allows management to effectively manage the Company’s

long-term adjusted EBITDA growth objectives over a three-year period and serves as a talent retention and engagement tool by allowing a portion of the awards to accrue each year with the vesting occurring on the third anniversary of the grant date.

In 2020,2023, the Compensation Committee utilized a combination of (1) TSR PRSUs, (2) adjusted EBITDA performance PRSUs and (3) time-vested RSUs, and (3) adjusted EBITDA growth PRSUs,keeping the allocation attributable to performance awards at 65% which replaced adjusted EBITDA margin PRSUs. Thewas the same as 2022. In 2023, the Compensation Committee continued to targettargeted an allocation of 30% TSR PRSUs, 35% adjusted EBITDA growthperformance PRSUs and 35% time-vested RSUs (as a percentage of the estimated AGD Fair Value of all 20202023 equity awards) in 2020. For each named executive officer, other than Ms. Salka, approximately 65% of the AGD Fair Value of the January 2020 equity awards consisted of PRSUs, and the remaining 35% consisted of time-vested RSUs. All of Ms. Salka’s January 2020 equity awards were PRSUs, as2023.

Peer Group

Based on its evaluation, the Compensation Committee will make their decision on her equity grant of time-vested RSUsdecided to add Change Healthcare, Inc., Encompass Health Corporation, Kelly Services, Inc, Option Care Health, Inc. and Teladoc Health, Inc. to our peer group for 2023, and to remove Veradigm Inc., (formerly, Allscripts Healthcare Solutions, Inc.), Healthcare Services Group, Inc., KForce, Inc., LHC Group, Inc. and TrueBlue, Inc. from our peer group in the fourth quarter of 2020 when it has better visibility of the Company’s 2020 performance.

2023.

84

56  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


Table of Contents


      EXECUTIVE COMPENSATION DISCLOSURE       

Executive Compensation

EXECUTIVE COMPENSATION DISCLOSUREExecutive Compensation Disclosure

Our named executive officers for the 2019 fiscal year are listed below. We provide information regarding the business experience, qualifications and affiliations of our named executive officers who are not directors below. For Ms. Salka’s experience, qualifications and affiliations, please see page 15 above.

Name Executive OfficerPosition
Susan R. SalkaChief Executive Officer
Brian M. ScottChief Financial Officer, Chief Accounting Officer and Treasurer
Ralph S. HendersonPresident, Professional Services and Staffing
Denise L. JacksonChief Legal Officer and Corporate Secretary

OurNon-Director Executive Officers

LOGO

Ralph S. Henderson                

Age: 59

President, Professional

Services and Staffing

Business Experience,

Qualifications and Affiliations:

Mr. Henderson joined us as President, Nurse Staffing in September 2007. In February 2009, we appointed him President, Nurse and Allied Staffing and in February 2012, named him President, Healthcare Staffing. In January 2016, we appointed Mr. Henderson President, Professional Services and Staffing. He is responsible for leading the sales and financial performance of our nurse and allied solutions segment and our locum tenens solutions segment. Prior to September 2007, Mr. Henderson served as Senior Vice President, Group Executive for Spherion, Inc., one of the largest commercial and professional staffing companies in the United States. Mr. Henderson started with Spherion in 1995 and held several leadership positions, including Regional Vice President and General Manager, Vice President of National Accounts, and Senior Vice President, Western Division. Prior to Spherion, Mr. Henderson was employed by American Express for nine years where in his last role he served as Vice President of Sales and Account Management in the Travel Management Services Division. Mr. Henderson holds a Bachelor of Science degree in Business Administration from Northern Arizona University.

LOGO

Denise L. Jackson                  

Age: 55

Chief Legal Officer and

Corporate Secretary

Business Experience,

Qualifications and Affiliations:

Ms. Jackson joined us as General Counsel and Vice President of Administration in October 2000. Ms. Jackson is responsible for our legal, corporate governance, compliance, ethics, risk management, real estate and corporate social responsibility functions. We appointed her as our Secretary in May 2003 and Senior Vice President in November 2004. From 1995 to September 2000, Ms. Jackson worked for The Mills Corporation serving as Vice President and Senior Counsel from 1998 to 2000. Ms. Jackson serves on the Board of Tractor Supply Company, the largest retailer of rural lifestyle products in the United States, is Chair of its Corporate Governance Committee and is a member of its Audit Committee. Ms. Jackson holds a Juris Doctorate degree from the University of Arizona, a Masters of Public Health from The George Washington University and a Bachelor of Science in Liberal Studies from the University of Arizona. Ms. Jackson is licensed as an attorney in California, the District of Columbia, Arizona and New York.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  57


    EXECUTIVE COMPENSATION DISCLOSURE       

LOGO

Brian M. Scott

Age: 50

Chief Financial Officer, Chief

Accounting Officer and

Treasurer

Business Experience,

Qualifications and Affiliations:

Mr. Scott joined us in December 2003. We appointed him Chief

Financial Officer, Chief Accounting Officer, and Treasurer in January 2011. In his role, Mr. Scott oversees the Company’s accounting, finance, investor relations and internal audit functions as well as certain shared services operations. Prior to his appointment as Chief Financial Officer, Chief Accounting Officer and Treasurer, Mr. Scott served in a variety of financial and operational roles for us including most recently as Senior Vice President of Operations, Finance and Business Development, in which capacity he oversaw our corporate financial planning and analysis, capital

funding and business development activities. He has also served as President of our pharmacy staffing division and as Director, Senior Director and Vice President of Finance, where his roles have included overseeing all accounting operations and SEC reporting. Mr. Scott started his career in San Francisco with KPMG and later became a partner in amid-sized CPA firm. He also served as controller of a biotechnology company. Mr. Scott serves on the Board of Nova Health, a private equity-backed chain of urgent care centers in the Pacific Northwest. He also serves on thenon-profit boards of the YMCA of San Diego County and the RC Baker Foundation. Mr. Scott is a certified public accountant (inactive) in California, and received his bachelor’s degree in accounting from California Polytechnic State University, San Luis Obispo and a Masters of Business Administration from the McCombs School of Business at the University of Texas at Austin.

Summary Compensation Table

The following table shows the compensation earned or accrued by our named executive officers for the three fiscal years ended December 31, 2019, 20182022, 2021 and 2017.2020.

        
Named Executive Officer
and Position
  Year  

Salary

($)(1)

  

Bonus

($)  

  

Stock

Awards

($)(2)

  

Non-Equity

Incentive Plan

Compensation

($) (3)

  

All Other

Compensation

($)(4)

  Total ($) 
  
Susan R. Salka   2019   996,154      3,382,836  (5)   1,120,527   127,289   5,626,806 
  
PEO,(6) President & CEO   2018   897,592      2,888,030  (7)   1,105,721   197,689   5,089,032 
  
 

 

   2017   835,577      2,299,955  (8)   548,078   197,357   3,880,967 
  
Brian M. Scott   2019   504,423      1,009,959  (10)   532,155   60,416   2,106,953 
  
PFO,(9) CFO, CAO & Treasurer   2018   489,038      1,000,046  (11)   480,324   50,941   2,020,349 
  
 

 

   2017   464,423      699,969  (12)   235,174   84,643   1,484,209 
  
Ralph S. Henderson   2019   504,423      1,009,959  (10)   395,805   93,647   2,003,834 
  
President, Professional Services & Staffing   2018   489,038      1,000,046  (11)   480,324   113,605   2,083,013 
  
 

 

   2017   464,423      699,969  (12)   235,174   75,587   1,475,153 
  
Denise L. Jackson   2019   429,212      645,036  (13)   339,842   44,013   1,458,103 
  
Chief Legal Officer & Corporate Secretary   2018   408,750      430,001  (14)   270,596   38,570   1,147,917 
  
 

 

   2017   389,423      409,978  (15)   139,230   49,449   988,080 

Named Executive Officer and Position     Year     Salary
($)(1)
     Bonus
($)
     Stock
Awards
($)(2)
     Non-Equity
Incentive Plan
Compensation
($)(3)
     All Other
Compensation
($)(4)
     Total
($)
 
Cary Grace
PEO,(7) President & CEO
 2022 81,538 200,000(5)  2,999,903(6)   23,855 3,305,296 
 2021               
  2020               
Susan R. Salka
President & CEO
 2022 977,308   4,447,137(8)  2,650,000 394,379 8,468,824 
 2021 1,030,000   5,643,694(9)  2,472,000 326,857 9,472,551 
  2020 1,027,692   3,632,452(10)  1,236,000 129,155 6,025,299 
Jeffrey R. Knudson
PFO,(12) CFO & Treasurer
 2022 600,000    1,515,805(11)  1,080,000 60,048 3,255,853 
 2021 90,000 900,000(13)  2,999,940(14)   32,745 4,022,685 
  2020               
Mark C. Hagan
Chief Information & Digital Officer
 2022 524,423   1,263,328(15)  946,000 171,705 2,905,456 
 2021 510,000   2,841,104(16)  918,000 137,868 4,406,972 
  2020 498,731   830,405(17)  386,250 114,692 1,830,078 
Denise L. Jackson
Chief Legal Officer & Corporate Secretary
 2022 459,231   1,111,639(18)  828,000 151,875 2,550,745 
 2021 440,000   2,495,210(19)  792,000 119,811 3,847,021 
  2020 442,615   660,064(20)  339,900 55,529 1,498,108 

(1)

Salary includes all salary amounts deferred by the named executive officers under theDeferred Compensation Plan.

Plan.
(2)

This column reflects the dollar amounts for the years shown of the AGD Fair Value of RSUs and PRSUs granted to our named executive officers. For PRSUs, which are subject to performance conditions, we report the grant date fair value based upon the probable outcome of such conditions and that value is consistent with the estimate of aggregate compensation cost to be recognized over the service period as of the grant date, excluding the effect of estimated forfeitures. For additional information on the valuation assumptions used in the calculation of these amounts, refer to notes 1(o)1(p) and 11 to the financial statements included in our annual report on Form10-K for the fiscal year ended December 31, 2019,2022, as filed with the SEC on February 25, 2020.

22, 2023.
(3)

This column consists of cash awards paid to our named executive officers pursuant to our Bonus Plan and generally sets forth bonus amounts in the year in which they are earned, although we typically pay them in the following fiscal year. In addition, as we discussed in our 2018 proxy statement, in 2017 the Compensation Committee decided to tie the Leadership Component for each named executive officer in 2017 to the implementation of new front and back office enterprise information technology systems in the Company’s locum tenens segment, which, at the time, the Compensation Committee expected to be completed in the first half of 2018. As a result, this amount is inclusive of the Leadership Component amount achieved based on the named executive officer’s satisfaction of the Leadership Component criteria described in the “Our Compensation Program Philosophy and Objectives” section above for 2018 and for the achievement of his or her 2017 Leadership Component that was determined and paid in 2018.

58  

(4)

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


      EXECUTIVE COMPENSATION DISCLOSURE       

(4)

This column consists of compensation received by our named executive officers in the form of matching contributions to the Deferred Compensation Plan and Company-paid life insurance premiums. For 2019, we paid matching contributions under the Deferred Compensation Plan as follows: (1) $126,820$332,581.23 for Ms. Salka, (2) $60,182$36,828.61 for Mr. Scott,Knudson, (3) $60,182$137,488.49 for Mr. Henderson, which also included a housing allowance of $33,231 for his relocation to TexasHagan, and $43,807(4) $119,344.25 for Ms. Jackson.

This column also reflects Company-paid life insurance premiums and health insurance, reimbursements for certain financial and estate planning and personal health and wellness expenses incurred by our named executive officers as follows: (1) $0 for Ms. Grace, (2) $53,015 for Ms. Salka, (3) $21,540 for Mr. Knudson, (4) $31,937 for Mr. Hagan, and (4) $30,850 for Ms. Jackson. This column also consists of compensation for the $300,000 annual fee paid to Ms. Salka pursuant to the terms of her November 27, 2022 Advisory Agreement.
(5)

20,755Ms. Grace joined the Company on November 28, 2022, so she was not eligible to receive an annual cash incentive bonus under the Bonus Plan. The Compensation Committee took this and other considerations into account at that time and determined it would be more appropriate to offer Ms. Grace a $200,000 sign-on bonus, which was paid on December 16, 2022.

(6)8,164 RSUs with an AGD Fair Value of $1,237,828, 13,400$999,927 and 16,329 RSUs with an AGD Fair Value of $1,999,976 comprise the amount of Ms. Grace’s 2022 stock awards. For additional information on the valuation assumptions used in the calculation of these amounts, refer to notes 1(p) and 11 to the financial statements included in our annual report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 22, 2023.
(7)“PEO” refers to our principal executive officer.
(8)14,214 RSUs with an AGD Fair Value of $1,539,945, 9,301 TSR PRSU with an AGD Fair Value of $989,992$1,367,247 and 20,75514,214 adjusted EBITDA marginPerformance PRSUs with an AGD Fair Value of $1,155,016,$1,539,945 comprise the amount of Ms. Salka’s 20192022 stock awards. Assuming the highest level of performance conditions will be achieved for the 13,4009,301 TSR PRSU award and the 20,75514,214 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $1,732,486$2,392,682 and $2,310,032,$3,079,890, respectively.

(6)(9)

“PEO” refers to our principal executive officer.

(7)

22,18730,717 RSUs with an AGD Fair Value of $1,250,016, 11,528$3,443,683, 13,441 TSR PRSU with an AGD Fair Value of $1,200,012 and 14,652 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $756,006 and 17,927 adjusted EBITDA margin PRSUs with an AGD Fair Value of $882,008$999,999, comprise the amount of Ms. Salka’s 20182021 stock awards. Assuming the highest level of performance conditions will be achieved for the 11,52813,441 TSR PRSU award and the 17,92714,652 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $992,561$2,099,955 and $1,764,017,$1,999,998, respectively.

2023 Proxy Statement    85


Table of Contents

Executive Compensation

(8)(10)

20,42919,625 RSUs with an AGD Fair Value of $1,000,000, 11,829$1,357,461, 13,335 TSR PRSU with an AGD Fair Value of $1,049,998 and 19,625 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $599,967 and 17,983 adjusted EBITDA margin PRSUs with an AGD Fair Value of $699,988,$1,224,993, comprise the amount of Ms. Salka’s 20172020 stock awards. Assuming the highest level of performance conditions will be achieved for the 11,82913,335 TSR PRSU award and the 17,98319,625 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $805,786$1,837,477 and $1,224,970,$2,449,985, respectively.

(9)(11)

“PFO” refers to our principal financial officer.

(10)

6,3524,845 RSUs with an AGD Fair Value of $353,489, 4,101$524,907, 3,170 TSR PRSU with an AGD Fair Value of $465,990 and 4,845 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $302,982 and 6,352 adjusted EBITDA margin PRSUs with an AGD Fair Value of $353,489$524,907 comprise the amount of Mr. Scott’s and Mr. Henderson’s 2019Knudson’s 2022 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,1013,170 TSR PRSU award and the 6,3524,845 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $530,237$815,483 and $706,978,$1,049,815, respectively.

(11)(12)

7,114“PFO” refers to our principal financial officer.

(13)Mr. Knudson joined the Company on November 2, 2021, so he was not eligible to receive an annual cash incentive bonus under the Bonus Plan. The Compensation Committee took this and other considerations into account at that time and determined it would be more appropriate to offer Mr. Knudson a $900,000 sign-on bonus, which was paid on March 11, 2022.
(14)29,262 RSUs with an AGD Fair Value of $350,009, 4,575$2,999,940 comprise the amount of Mr. Knudson’s 2021 stock awards.
(15)4,038 RSUs with an AGD Fair Value of $437,477, 2,642 TSR PRSUs with an AGD Fair Value of $300,029, 7,114$388,374 and 4,038 adjusted EBITDA marginPerformance PRSUs with an AGD Fair Value of $350,009$437,477 comprise the amount of Mr. Scott’s and Mr. Henderson’s 2018Hagan’s 2022 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,5752,642 TSR PRSU award and the 7,1144,038 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $393,908$679,655 and $700,018,$874,954, respectively.

(12)(16)

6,2946,923 RSUs with an AGD Fair Value of $244,994, 4,140$472,495, 3,528 TSR PRSUs with an AGD Fair Value of $209,981 and 6,294 adjusted EBITDA margin$314,980, 13,000 TSR PRSUs with an AGD Fair Value of $244,994$1,791,140 and 3,846 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $262,490 comprise the amount of Mr. Scott’sHagan’s 2021 stock awards. The AGD Fair Value of the 13,000 TSR PRSUs was understated in the Company’s proxy statement filed on March 23, 2022 due to an administrative error. The correct AGD FV is $1,791,140, not $1,275,560, as previously reported. Assuming the highest level of performance conditions will be achieved for the 3,528 TSR PRSU award, the 13,000 TSR PRSU award, and the 3,846 adjusted EBITDA Performance PRSU award, the AGD Fair Value of such awards would equal $551,215, $3,134,495, and $524,979, respectively.

(17)3,535 RSUs with an AGD Fair Value of $220,655, 2,603 RSUs with an AGD Fair Value of $199,962, 2,402 TSR PRSUs with an AGD Fair Value of $189,133 and 3,535 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $220,655 comprise the amount of Mr. Henderson’s 2017Hagan’s 2020 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,1402,402 TSR PRSU award and the 6,2943,535 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $282,012$330,944 and $428,759,$441,309, respectively.

(13)(18)

4,0573,553 RSUs with an AGD Fair Value of $225,772, 2,619$384,932, 2,325 TSR PRSUs with an AGD Fair Value of $193,492$341,775 and 4,0573,553 adjusted EBITDA marginPerformance PRSUs with an AGD Fair Value of $225,772$384,932 comprise the amount of Ms. Jackson’s 20192022 stock awards. Assuming the highest level of performance conditions will be achieved for the 2,6192,325 TSR PRSU award and the 4,0573,553 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $338,592$598,106 and $451,544,$769,864, respectively.

(14)(19)

3,0594,642 RSUs with an AGD Fair Value of $150,502, 1,967$316,817, 2,366 TSR PRSUs with an AGD Fair Value of $128,996 and 3,059 adjusted EBITDA margin$211,236, 13,000 TSR PRSUs with an AGD Fair Value of $150,503$1,791,140 and 2,579 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $176,017 comprise the amount of Ms. Jackson’s 20182021 stock awards. The AGD Fair Value of the 13,000 TSR PRSUs was understated in the Company’s proxy statement filed on March 23, 2022 due to an administrative error. The correct AGD FV is $1,791,140, not $1,275,560, as previously reported. Assuming the highest level of performance conditions will be achieved for the 2,366 TSR PRSU award, the 13,000 TSR PRSU award, and the 2,579 adjusted EBITDA Performance PRSU award, the AGD Fair Value of such awards would equal $369,619, $3,134,495, and $352,034, respectively.

(20)3,701 RSUs with an AGD Fair Value of $231,016, 2,515 TSR PRSUs with an AGD Fair Value of $198,031 and 3,701 adjusted EBITDA Performance PRSUs with an AGD Fair Value of $231,016 comprise the amount of Ms. Jackson’s 2020 stock awards. Assuming the highest level of performance conditions will be achieved for the 1,9672,515 TSR PRSU award and the 3,0593,701 adjusted EBITDA marginPerformance PRSU award, the AGD Fair Value of such awards would equal $169,346$346,535 and $301,006,$462,033, respectively.

(15)

4,639 RSUs with an AGD Fair Value of $140,005, 3,233 TSR PRSUs with an AGD Fair Value of $119,427 and 4,638 adjusted EBITDA margin PRSUs with an AGD Fair Value of $139,975 comprise the amount of Ms. Jackson’s 2017 stock awards. Assuming the highest level of performance conditions will be achieved for the 3,233 TSR PRSU award and the 4,638 adjusted EBITDA margin PRSU award, the AGD Fair Value of such awards would equal $170,728 and $244,941, respectively.

AMN HEALTHCARE SERVICES, INC.  

86

2020 Proxy Statement

  59


Table of Contents


    EXECUTIVE COMPENSATION DISCLOSURE       

Executive Compensation

Grants of Plan-Based Awards

The following table contains information concerning grants of plan-based awards to our named executive officers under our cash and equity plans during the year ended December 31, 2019.2022.

      

Name and Type of

 

Equity Award

 

    

Estimated Future Payouts

UnderNon-Equity Incentive

Plan Awards

 

 

Estimated Future Payouts

Under Equity Incentive Plan

Awards(1)

 

  

All Other
Stock

Awards:

# of
Shares of

Stock or

Units

 

  

Grant

Date Fair

Value of

Stock Awards

($)(8)

 

 
 

Grant Date 

 

 

Threshold 

($)(2) 

 

 

Target 

($)(3) 

 

 

Maximum 

($)(4) 

 

 

Threshold

(#)(5)

 

  

    Target

(#)(6)

 

  

Maximum

(#)(7)

 

 
          
Susan R. Salka 

 

 249,000 1,200,000 2,400,000 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

TSR PRSU

 1/3/2019 

 

 

 

 

 

  3,350   13,400   23,450  

 

 

 

  989,992 
  

AEBITDA PRSU

 1/3/2019 

 

 

 

 

 

  5,189   20,755   41,510  

 

 

 

  1,155,016 
  

RSU

 12/16/2019  

 

  

 

  

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  20,755  (9)   1,237,828 
  
Brian M. Scott 

 

 104,788 505,000 1,010,000 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

TSR PRSU

 1/3/2019 

 

 

 

 

 

  1,025   4,101   7,177  

 

 

 

  302,982 
  

AEBITDA PRSU

 1/3/2019 

 

 

 

 

 

  1,588   6,352   12,704  

 

 

 

  353,489 
  

RSU

 1/3/2019  

 

  

 

  

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  6,352  (9)   353,489 
  
Ralph S. Henderson 

 

 104,788 505,000 1,010,000 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

TSR PRSU

 1/3/2019 

 

 

 

 

 

  1,025   4,101   7,177  

 

 

 

  302,982 
  

AEBITDA PRSU

 1/3/2019 

 

 

 

 

 

  1,588   6,352   12,704  

 

 

 

  353,489 
  

RSU

 1/3/2019  

 

  

 

  

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  6,352  (9)   353,489 
  
Denise L. Jackson 

 

 66,919 322,500 645,000 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

TSR PRSU

 1/3/2019 

 

 

 

 

 

  655   2,619   4,583  

 

 

 

  193,492 
  

AEBITDA PRSU

 1/3/2019 

 

 

 

 

 

  1,014   4,057   8,114  

 

 

 

  225,772 
  

RSU

 1/3/2019  

 

  

 

  

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  4,057  (9)   225,772 

            Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards
     Estimated Future Payouts
Under Equity Incentive
Plan Awards(1)
     All Other
Stock
Awards:
     Grant
Date Fair
Value of
 
Name and Type
of Equity
Grant Date Threshold
($)(2)
     Target
($)(3)
     Maximum
($)(4)
 Threshold
(#)(5)
     Target
(#)(6)
     Maximum
(#)(7)
 # of Shares
of Stock or
Units
 Stock
Awards
($)(8)
 
Cary Grace                 
RSU11/28/2022             24,493  2,999,903 
Susan R. Salka   265,000 1,325,000 2,650,000            
TSR PRSU1/15/2022       2,325 9,301 16,277    1,367,247 
Adjusted EBITDA PRSU1/15/2022       3,554 14,214 28,428    1,539,945 
RSU1/15/2022             14,214(10)  1,539,945 
Jeffrey R. Knudson   108,000 540,000 1,080,000            
TSR PRSU1/15/2022       793 3,170 5,548    465,990 
Adjusted EBITDA PRSU1/15/2022       1,211 4,845 9,690    524,907 
RSU1/15/2022             4,845(9)  524,907 
Mark C. Hagan   94,500 472,500 945,000            
TSR PRSU1/15/2022       661 2,642 4,624    388,374 
Adjusted EBITDA PRSU1/15/2022       1,010 4,038 8,076    437,477 
RSU1/15/2022             4,038(9)  437,477 
Denise L. Jackson   82,800 414,000 828,000            
TSR PRSU1/15/2022       581 2,325 4,069    341,775 
Adjusted EBITDA PRSU1/15/2022       888 3,553 7,106    384,932 
RSU1/15/2022             3,553(10)  384,932 

(1)

The columns comprising the “Estimated Future Payouts Under Equity Incentive Plan Awards” set forth information regarding PRSUs granted to our named executive officers in 2019:2022: (1) TSR PRSUs based on total shareholder return over a three-period ending on December 31, 20212024 and (2) adjusted EBITDA margin PRSUs based on our adjusted EBITDA marginperformance over a three year period. The ultimate number of PRSUs that vest under these awards depends on the results of the TSR Measurement or our adjusted EBITDA marginperformance over a three year period, each of which will be calculated approximately three years after the date of grant.three-year period. All equity awards reflected in this table were granted under the Equity Plan.

(2)

The amount set forth in this column represents the minimum amount that a named executive officer would receive under our Bonus Plan if we met our 2019 adjusted EBITDA bonus funding threshold (which we set just above our actual 2018 adjusted EBITDA) and the threshold for 20192022 pre-bonus adjusted EBITDA. For information on the calculation ofPre-Bonus AEBITDA, and a reconciliation of our 20192022 net income to adjusted EBITDA, please seeExhibit BA to this proxy statement (pageB-1) 113). We describe the Bonus Plan, including the 20192022 metrics utilized for each named executive officer, in our CD&A above. There is no minimum threshold for a named executive officer’s Leadership Component under the Bonus Plan, which is why we have not factored in that Component in determining a threshold in this table.

(3)

The amount set forth in this column represents the amount that a named executive officer would receive under our Bonus Plan if the named executive officer met the target of each metric upon which his or her bonus is based.

(4)

The Compensation Committee set the maximum bonus for 20192022 under the Bonus Plan at 200% of the target amount for each named executive officer. The amount set forth in this column represents the amount that a named executive officer would receive under our Bonus Plan if all financial metrics to which he or she is subject exceeded our target for each metric by 10% to 20% (depending on the metric) and the individual, in the sole discretion of the Compensation Committee, demonstrated superior leadership, made exceptional individual contributions to our success in 20192022 and our performance or the performance of the applicable division surpassed that of our direct competitors such that the Compensation Committee awarded him or her the maximum200% bonus for the Leadership Component.

(5)

For TSR PRSUs awards, the number of shares set forth in this column assumes that under the TSR Measurement, our relative TSR percentile rank equaledequals at least 25%, which establishes the minimum amount of performance that we must achieve for our named executive officers to earn a portion of the award. We describe Relative TSR in our CD&A above. For adjusted EBITDA margin PRSU awards, the number of shares set forth in this column assumes that our 2021the Company will achieve annual adjusted EBITDA margin willperformance equal 12.3%.

to 90% of the Company’s adjusted EBITDA targets. A more detailed discussion of targets and performance metrics applicable to the adjusted EBITDA Performance PRSUs is found in subsection titled “Adjusted EBITDA Performance PRSUs” on page 80 above.
(6)

For TSR PRSUs, the number of PRSUs set forth in this column assumes that under the TSR Measurement, our relative TSR percentile rank equaledequals at least 50%. For adjusted EBITDA margin PRSU awards, the number of shares set forth in this column assumes that the Company’s 2021Company will achieve annual adjusted EBITDA margin will beperformance equal to 13.3%.

100% of the Company’s adjusted EBITDA targets.
(7)

The number of TSR PRSUs set forth in this column assumes that under the TSR Measurement each of the following conditions hashave been satisfied: (1) Relative TSR percentile equals at least 75% and (2) Absolute TSR exceeds zero. For adjusted EBITDA margin PRSUs,PRSU awards, the number of shares set forth in this column assumes that our 2021the Company will achieve annual adjusted EBITDA margin will beperformance equal to 14.3%.

120% of the Company’s adjusted EBITDA targets.
(8)

This column represents the grant date fair value, calculated in accordance with SEC rules, of each equity award. For PRSUs, which are subject to performance conditions, we report the grant date fair value based upon the probable outcome of such conditions and that value is consistent

2023 Proxy Statement    87


Table of Contents

Executive Compensation

with the estimate of aggregate compensation cost to be recognized over the service period as of the grant date, excluding the effect of estimated forfeitures. These amounts do not necessarily correspond to the actual value that will be realized by our named executive officers. For additional information on the valuation assumptions used in the calculation of these amounts, refer to notes 1(o)1(p) and 1011 to the financial statements included in our annual report on Form10-K for the fiscal year ended December 31, 2019,2022, as filed with the SEC on February 25, 2020.

22, 2023.
(9)

The RSUs underlying this award vest in three tranches on each of the first, second and third anniversaries of the Grant Date.

Date and the Grantee’s provision of three periods of Credited Service.

60  

(10)
The RSUs underlying this award are retirement eligible as of July 15, 2022 and vest in three tranches on each of the first, second and third anniversaries of the Grant Date.

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement

  


88

      EXECUTIVE COMPENSATION DISCLOSURE       


Table of Contents

Executive Compensation

Outstanding Equity Awards at Fiscal Year End

The following table represents equity interests held by the named executive officers as of December 31, 2019,2022, which is comprised of RSU and PRSU awards.

   
  OPTION AWARDS  STOCK AWARDS(1) 
        

Name

 

Option

Grant Date

  

Number of

Securities

Underlying

Unexercised

Options

Exercisable

  

Option

Exercise

Price ($)

  

Option

Expiration

Date

  

RSU or PRSU

Award Grant

Date

  

Number

of Shares

or Units

of Stock

That

Have Not

Vested

  

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

($)(2)

  

Equity
Incentive

Plan Awards:

Number of

Unearned

Shares,
Units or

Other Rights

That Have

Not Vested (2)

  

Equity
Incentive

Plan Awards:

Market or
Payout Value

of Unearned

Shares,
Units or

Other Rights

That Have

Not Vested

($) (2)

 
  

Susan R. Salka

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(3)    

 

 

 

 

 

 

 

  20,701  (4)     1,289,879 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(5)    

 

 

 

 

 

 

 

  4,496  (6)     280,146 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  12/19/2017(7)     13,687   852,837  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(8)    

 

 

 

 

 

 

 

  20,174  (9)   1,257,042 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(10)  

 

 

 

 

 

 

 

  4,482  (11)   279,273 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  12/17/2018(17)   14,865   926,238  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(13)  

 

 

 

 

 

 

 

  13,400  (14)   834,954 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(15)  

 

 

 

 

 

 

 

  5,189  (16)   323,327 
  
 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  12/16/2019(17)   20,755   1,293,244   

 

 

 

 

 

  

 

 

 

 

 

  

Brian M. Scott

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(3)    

 

 

 

 

 

 

 

  7,245  (4)     451,436 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(5)    

 

 

 

 

 

 

 

  1,574  (6)     98,076 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(13)   2,077   129,418  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(8)    

 

 

 

 

 

 

 

  8,006  (9)   498,854 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(10)  

 

 

 

 

 

 

 

  1,779  (11)   110,849 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(17)   4,766   296,969  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(13)  

 

 

 

 

 

 

 

  4,101  (14)   255,533 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(15)  

 

 

 

 

 

 

 

  1,588  (16)   98,948 
  
 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  1/3/2019(17)   6,352   395,793   

 

 

 

 

 

  

 

 

 

 

 

  

Ralph S. Henderson

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(3)    

 

 

 

 

 

 

 

  7,245  (4)     451,436 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(5)    

 

 

 

 

 

 

 

  1,574  (6)     98,076 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(13)   2,077   129,418  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(8)    

 

 

 

 

 

 

 

  8,006  (9)   498,854 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(10)  

 

 

 

 

 

 

 

  1,779  (11)   110,849 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(17)   4,766   296,969  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(13)  

 

 

 

 

 

 

 

  4,101  (14)   255,533 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(15)  

 

 

 

 

 

 

 

  1,588  (16)   98,948 
  
 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  1/3/2019(17)   6,352   395,793   

 

 

 

 

 

  

 

 

 

 

 

  

Denise L. Jackson

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(3)    

 

 

 

 

 

 

 

  4,242  (4)     264,319 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(5)    

 

 

 

 

 

 

 

  922  (6)     57,450 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/4/2017(13)   1,216   75,769  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(8)    

 

 

 

 

 

 

 

  3,442  (9)   214,471 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(10)  

 

 

 

 

 

 

 

  765  (11)   47,667 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/5/2018(17)   2,050   127,736  

 

 

 

 

 

 

 

 

  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(13)  

 

 

 

 

 

 

 

  2,619  (14)   163,190 
  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1/3/2019(15)  

 

 

 

 

 

 

 

  1,014  (16)   63,182 
  
 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  

 

 

 

 

 

  1/3/2019(17)   4,057   252,792   

 

 

 

 

 

  

 

 

 

 

 

  Option Awards Stock Awards(1)
Name     Option
Grant
Date
     Number of
Securities
Underlying
Unexercised
Options
Exercisable
     Option
Exercise
Price
($)
     Option
Expiration
Date
     RSU or
PRSU
Award
Grant
Date
     Number
of Shares
or Units
 of Stock
That
Have Not
Vested
     Market
Value of
Shares or
Units of
Stock
That
Have Not
Vested
($)(2)
      Equity
Incentive
Plan Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested(2)
     Equity
Incentive
Plan Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(2)
 
Cary Grace        11/28/2022(3)  8,164 839,422      
         11/28/2022(3)  16,329 1,678,948      
Susan R. Salka        1/6/2020(4)      33,559(5)  3,450,536 
         1/6/2020(6)      23,336(7)  2,399,408 
         12/16/2020(8)  6,673 686,118      
         1/4/2021(9)      29,304(10)  3,013,037 
         1/4/2021(11)      23,522(12)  2,418,532 
         9/20/2021(8)  20,581 2,116,138      
         1/15/2022(13)      28,428(14)  2,922,967 
         1/15/2022(15)      16,277(16)  1,673,601 
         1/15/2022(8)  14,214 1,461,483      
Jeffrey R. Knudson        11/2/2021(3)  19,606 2,015,889      
         1/15/2022(13)      9,690(14)  996,326 
         1/15/2022(15)      5,548(16)  570,445 
         1/15/2022(3)  4,845 498,163      
Mark C. Hagan        1/6/2020(4)      6,045(5)  621,547 
         1/6/2020(6)      4,204(7)  432,255 
         1/6/2020(17)  1,203 123,692      
         3/9/2020(18)  2,603 267,640      
         1/4/2021(9)      7,692(10)  790,891 
         1/4/2021(11)      6,174(12)  634,811 
         1/4/2021(3)  4,639 476,982      
         8/15/2021(19)      11,375(20)  1,169,578 
         1/15/2022(13)      8,076(14)  830,374 
         1/15/2022(15)      4,624(16)  475,440 
         1/15/2022(3)  4,038 415,187      
Denise L. Jackson        1/6/2020(4)      6,329(5)  650,748 
         1/6/2020(6)      4,401(7)  452,511 
         1/6/2020(17)  1,259 129,450      
         1/4/2021(9)      5,158(10)  540,346 
         1/4/2021(11)      4,141(12)  425,778 
         1/4/2021(8)  3,111 319,873      
         8/15/2021(19)      11,375(20)  1,169,578 
         1/15/2022(13)      7,106(14)  730,639 
         1/15/2022(15)      4,069(16)  418,375 
         1/15/2022(8)  3,553 365,319      

(1)

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  61


    EXECUTIVE COMPENSATION DISCLOSURE       

(1)

These columns consist of RSUs and PRSUs granted under the Equity Plan.

(2)

The market value of stock awards and the equity incentive plan awards represents (i) the number of shares that had not vested as of December 31, 20192022 as set forth in the applicable column, multiplied by (ii) $62.31,$102.82, the closing price of our Common Stock on December 31, 201930, 2022 (the last

2023 Proxy Statement    89


Table of Contents

Executive Compensation

trading day of the year). For PRSUs, the number of shares set forth in the applicable column may be more than the target amount granted under the award as detailed in the footnotes below, and the amount ultimately received for each award may be different than the number of shares identified.

(3)

The RSUs underlying this award vest in three tranches on each of the first, second and third anniversaries of the Grant Date and the Grantee’s provision of three periods of credited service.

(4)The adjusted EBITDA PRSUs underlying this award vested on January 6, 2023 and settled on February 15, 2023 after the Compensation Committee determined the Company’s 2022 adjusted EBITDA.
(5)Because the number of shares earned under this award was based on the Company’s 2022 adjusted EBITDA, we set forth the number of shares earned. Based on the Company’s adjusted EBITDA in each of the three performance periods consisting of 2020, 2021 and 2022, 171% of the target amount for this award was earned.
(6)These PRSUs vested on January 4, 2020.

6, 2023.
(4)(7)

The Compensation Committee performed the TSR Measurement for this award for the measurement period ended December 31, 20192022 on January 6, 2020.4, 2023. Relative TSR measured at the 81st89th percentile and Absolute TSR was positive. Based on those results, the number of PRSUs set forth in this column for this award, which was the maximum amount that could have been received under the award, vested as of January 4, 2020.

2023.
(5)(8)

The RSUs underlying this award vest in three tranches on each of the first, second and third anniversaries of the Grant Date and are irrevocable by the Company in the event of the executive’s retirement.

(9)The adjusted EBITDA margin PRSUs underlying this award vestedvest on January 4, 20202024. The settlement date and settled on February 13, 2020 when the Compensation Committee determineddetermination of the Company’s 2019 adjusted EBITDA margin.

(6)

Because the numbertotal amount of shares earned under this award was based onwill take place when the Company’s 2019Compensation Committee determines our annual year-over-year adjusted EBITDA margin,performance rate for 2021, 2022 and 2023, which we believe will occur in February 2024.

(10)Pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, which provides that the number of shares actually earned. Basedreported in this column shall be based on achieving the Company’s 2019maximum performance goal, because our long-term adjusted EBITDA marginperformance rate is currently commensurate with the maximum performance of 12.5%, 25% of the targetamount for this award was awarded.

these awards.
(7)(11)

The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we were to achieve our adjusted EBITDA targets in 2018 or 2019. We achieved our 2018 adjusted EBITDA target, and, as a result 33% of the RSUs vested on January 19, 2019 (and are not reflected as unvested in this row). We did not achieve our 2019 adjusted EBITDA target; therefore, the remaining 67% unvested amount set forth in this row will vest on December 19, 2020.

(8)

The TSR PRSUs underlying this award vest on the date on which the Compensation Committee performs the TSR Measurement, which shall occur within 30 days after December 31, 2020.2023. We describe the TSR Measurement in detail in the CD&A section above.

(9)(12)

The ultimate number of TSR PRSUs that vest under this award depends on the results of the TSR Measurement. The target amount for each of Ms. Salka, Mr. Scott, Mr. HendersonHagan and Ms. Jackson for his or her equity incentive plan award granted on January 5, 20184, 2021 is 11,528, 4,575, 4,57513,441, 3,528 and 1,967, respectively. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile and Absolute TSR would have to exceed zero. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero to an amount equal to the product of (1) the target amount for such executive, multiplied by (2) 1.75. The threshold amount equals 12.5% of the target amount. If we were to have conducted the TSR Measurement on December 31, 2019 (1) Relative TSR would have measured at the 78th percentile, and (2) Absolute TSR would have been positive. Based on those results, TSR PRSUs equal to 175% of the target amount (i.e., 20,174, 8,006, 8,006 and 3,442 for Ms. Salka, Mr. Scott, Mr. Henderson and Ms. Jackson, respectively) would have been earned.

(10)

The adjusted EBITDA PRSUs underlying this award vest on January 5, 2021. The settlement date and the determination of the amount of shares actually vested under the award reflected in this row will take place when the Compensation Committee determines our 2020 adjusted EBITDA margin, which we believe will occur in February 2021.

(11)

Pursuant to the instructions set forth to Item 402(f)(2) of RegulationS-K, which provides that the number of shares reported in this column shall be based on achieving target performance goals because our 2019 adjusted EBITDA margin of 12.5% does not exceed the 2020 threshold adjusted EBITDA margin, we set forth the number of shares representing the threshold amount for the award in this column.

(12)

The RSUs underlying this award vest in three tranches on each of the first, second and third anniversaries of the Grant Date and the Grantee’s provision of three periods of Credited Service, but are still reflected on this table as unvested because they remained unvested as of December 31, 2019.

(13)

The TSR PRSUs underlying this award vest on the date on which the Compensation Committee performs the TSR Measurement, which shall occur within 30 days after December 31, 2021. We describe the TSR Measurement in detail in the CD&A section above.

(14)

The ultimate number of TSR PRSUs that vest under this award depends on the results of the TSR Measurement. The target amount for each of Ms. Salka, Mr. Scott, Mr. Henderson and Ms. Jackson for his or her equity incentive plan award granted on January 3, 2019 is 13,400, 4,101, 4,101 and 2,619,2,366, respectively. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero up to an amount equal to the product of (i) the target amount for such executive, multiplied by (ii) 1.75. The threshold amount equals 25% of the target amount. If we were to have conducted the TSR Measurement on December 31, 2019,2022, Relative TSR would have measured at the 54th88th percentile. Based on those results, TSR PRSUs equal to the175% of target amount would have been earned.

(15)(13)

The adjusted EBITDA margin PRSUs underlying this award vest on January 3, 2022.15, 2025. The settlement date and the determination of the total amount of shares actually vestedearned under this award will take place when the Compensation Committee determines our 2021annual year-over-year adjusted EBITDA margin,performance rate for 2022, and two-year performance for 2023 and 2024, which we believe will occur in February 2022.

2025.
(16)(14)

Pursuant to the instructions set forth to Item 402(f)(2) of RegulationS-K, which provides that the number of shares reported in this column shall be based on achieving the thresholdmaximum performance goal, because our 2019long-term adjusted EBITDA marginperformance rate is currently commensurate with the maximum performance of 12.5% does not exceedthese awards.

(15)The TSR PRSUs underlying this award vest on the 2021 threshold adjusted EBITDA margin, we set forthdate on which the Compensation Committee performs the TSR Measurement, which shall occur within 30 days after December 31, 2024. We describe the TSR Measurement in detail in the CD&A section above.
(16)The ultimate number of shares representingTSR PRSUs that vest under this award depends on the results of the TSR Measurement. The target amount for each of Ms. Salka, Mr. Hagan and Ms. Jackson for his or her equity incentive plan award granted on January 4, 2021 is 13,441, 3,528 and 2,366, respectively. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero up to an amount equal to the product of (i) the target amount for such executive, multiplied by (ii) 1.75. The threshold amount forequals 25% of the award.

target amount. If we were to have conducted the TSR Measurement on December 31, 2022, Relative TSR would have measured at the 88th percentile. Based on those results, TSR PRSUs equal to 175% of target would have been earned.
(17)

The RSUs underlying this award vest in three tranches on each of the first, second and third anniversaries of the Grant Date and the Grantee’s provision of three periods of Credited Service.

credited service, but are still reflected on this table as unvested because they remained unvested as of December 31, 2022.

62  

(18)
The RSUs underlying this award vest on the third anniversary of the grant date and the Grantee’s provision of three periods of credited service.
(19)

AMN HEALTHCARE SERVICES, INC.  

The ultimate number of TSR PRSUs that vest under this award depends on the results of the TSR Measurement for the first and second performance periods. The target amount for each of Mr. Hagan and Ms. Jackson for his or her equity incentive plan award granted on August 15, 2021 is 13,000. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero up to an amount equal to the product of (i) the target amount for such executive, multiplied by (ii) 1.75. The threshold amount equals 25% of the target amount.
(20)50% of the target TSR PRSUs underlying this award vested on August 16, 2022. The Compensation Committee performed the TSR Measurement for this award for the measurement period ended August 16, 2022 on August 16, 2022. Relative TSR measured at the 87th percentile and Absolute TSR was positive. Based on those results, the number of PRSUs for this award for the first performance period was the maximum amount that could have been received under the award, vested as of August 16, 2022. The Compensation Committee will perform the TSR Measurement following the end of the two-year performance period for the remainder of this award, which shall occur within 30 days after August 15, 2023. We describe the TSR Measurement in detail in the CD&A section above. If we were to have conducted the TSR Measurement on December 31, 2022, Relative TSR would have measured at the 86th percentile. Based on those results, TSR PRSUs equal to 175% of target would have been earned.

  2020 Proxy Statement

  


90

      EXECUTIVE COMPENSATION DISCLOSURE       


Table of Contents

Executive Compensation

Option Exercises and Stock Vested

The following table shows information regarding exercises of option awards to purchase our Common Stock and vesting of stock awards held by our named executive officers during 2019,2022, as of December 31, 2019.2022.

   
    OPTION AWARDS   STOCK AWARDS 
     
Name  

Number of Shares

Acquired on

Exercise (#)

   

Value Realized on

Exercise ($)

   

Number of Shares

Acquired on

Vesting (#)(1)

   

Value Realized on

Vesting ($)(2)

 

Susan R. Salka

  

 

193,949

 

  

 

$8,571,772

 

  

 

74,587

 

  

 

4,226,424

 

Brian M. Scott

  

 

 

  

 

 

  

 

59,148

 

  

 

3,304,694

 

Ralph S. Henderson

  

 

 

  

 

 

  

 

59,148

 

  

 

3,304,694

 

Denise L. Jackson

  

 

 

  

 

 

  

 

13,046

 

  

 

727,690

 

  Option Awards Stock Awards
Name     Number
of Shares
Acquired on
Exercise
(#)
     Value
Realized on
Exercise
($)
     Number
of Shares
Acquired on
Vesting
(#)
     Value
Realized
on Vesting
($)(1)
Cary Grace    
Susan R. Salka   88,629 9,339,720
Jeffrey R. Knudson   9,656 1,226,698
Mark C. Hagan   28,356 3,133,889
Denise. L. Jackson   28,203 3,107,581

(1)

The amounts for Mr. Scott and Mr. Henderson includes 38,486 shares of Common Stock underlying a special grant awarded in 2015.

(2)

We calculate the “Value Realized on Vesting” by multiplying (i) the gross number of shares acquired on vesting prior to shares being withheld to cover taxes and (ii) the closing price of our Common Stock on the day prior to the applicable vest dates.

Nonqualified Deferred Compensation

We adopted and maintain oura Deferred Compensation Plan which providesto provide our executives, including our named executive officers, with the opportunity to defer up to 80% of their base salary and up to 90% of their bonus. The Deferred Compensation Plan also permits executives to defer the settlement date of their RSUs or PRSUs. Our named executive officers are excluded from participating in our 401(k) plan.plan, with exception to Ms. Grace and Mr. Knudson, who were eligible to participate in 2022, because they did not exceed the compensation threshold for at least a portion of 2022. In 2019,2022, we matched 100% up to 50% of the first 6% and 100% of the next 4%10% of the executive’s eligible compensation for a maximum match of 7%10% of the executive’s cash compensation.compensation through June 25, 2022 and then 50% of their contribution up to 6% and 100% of the next 4% contribution for the remainder of 2022. The Deferred Compensation Plan credits deferrals (other than deferrals of RSUs or PRSUs) with earnings or losses based upon the executive’s selection of 12 publicly traded mutual funds, which may change from time to time. The current list of measurement funds, through September 30, 2019 were: Vanguard VIF Total Bond Market Index, Fidelity VIP Investment Grade Bond, PIMCO VIT Real Return Portfolio, MFS VIT Value, Dreyfus Stock Index, American Funds ISwhich were available throughout all of 2022 are as follows: Hartford Small Cap Growth JPMorgan IT Mid Cap Value, Janus Henderson VIT Enterprise, DFA VA U.S. Targeted Value, Vanguard VIF Small Company Growth, American Funds IS International and NVIT Government Money Market. Starting on October 1, 2019, the measurement funds are: BNY Mellon Bond Market Index, PGIM Total Return Bond Z, Invesco Diversified Dividend R5, Principal LargeCap Growth I R5, MFS Mid Cap Value R4,Y, MassMutual Select Mid Cap Growth R5, Dodge & Cox International Stock, Invesco Diversified Dividend R5, and the Mid Cap Growth Fund Fee Class I1. In addition to these, there is a series of target date funds, which include several underlying funds. For the first half of 2022, these funds included the following underlying funds: T. Rowe Price New Horizons, T. Rowe Price Small-Cap Stock, T. Rowe Price Small-Cap Value, T. Rowe Price Growth Stock, T. Rowe Price Mid-Cap Growth, T. Rowe Price Equity Index 500, T. Rowe Price Mid-Cap Value, T. Rowe Price International Stock, T. Rowe Price US Large-Cap Core Z, T. Rowe Price Overseas Stock, T. Rowe Price Real Assets, T. Rowe Price Value, T. Rowe Price International Value Eq, T. Rowe Price Emerging Markets Stock, T. Rowe Price Em Mkts Discv Stk Z, T. Rowe Price High Yield, T. Rowe Price Emerging Markets Bond, T. Rowe Price US Treasury Long-Term, T. Rowe Price Floating Rate, T. Rowe Price Intl Bd USD Hdgd, T. Rowe Price New Income, T. Rowe Price Dynamic Global Bond Inv, T. Rowe Price Ltd Dur Infl Focus Bd, T. Rowe Price US Treasury Money. Effective August 8, 2022, the target date funds were replaced with the Blackrock Lifepath target date series which as the following underlying funds: iShares Core MSCI Total Intl Stk ETF (IXUS), iShares Developed Real Estate Idx K (BKRDX), iShares Russell 1000 Large-Cap Idx K (BRGKX), iShares Russell 2000 Small-Cap Idx K (BDBKX), iShares TIPS Bond ETF (TIP), iShares US Intermediate Credit Bond Idx (BICBX), iShares US Intermediate Gov Bd Idx (BIGBX), iShares US Long Credit Bond Index (BLCBX), iShares US Long Government Bond Idx (BLGBX) and the iShares US Securitized Bond Index (BISBX). Effective August 8, 2022, the following funds were replaced: MFS Mid Cap Value Fund Class R4 was replaced with MFS Mid Cap Value Fund Class R6; PGIM Total Return Bond Fund – Class Z was replaced with PGIM Total Return Bond Fund – Class R6; Principal LargeCap Growth Fund I R-5 Class was replaced with Principal LargeCap Growth Fund I Class R-6; Principal LargeCap S&P 500 Index Fund Institutional Class was replaced with Fidelity 500 Index Fund; Victory Sycamore Small Company OppOpportunity Fund Class I Hartfordwas replaced with Victory Sycamore Small Company Opportunity Fund R6; BNY Mellon Bond Market Index Fund – Class I was replaced with Fidelity U.S. Bond Index Fund; Large Cap Value Fund CL I2 was replaced with Large Cap Value Fund CL I1; Principal International Equity Index Fund Institutional Class was replaced with Fidelity International Index Fund; Principal MidCap S&P 400 Index Fund Institutional Class was replaced with Fidelity Mid Cap Index Fund; Principal SmallCap S&P 600 Index Fund Institutional Class was replaced with Fidelity Small Cap Index Fund; and the Small Cap Growth Y and Principal International Equity Index.II I2 was replaced with Small Cap Growth Fund II Fee Class I1.

Executives may change their election of measurement funds on a daily basis. Additionally, beginning in 2014, the Deferred Compensation Plan permitted executives to invest in a Deferred Compensation Fixed Rate Fund, which provides an annual fixed rate of return that is generally set by the Company on January 1 of each year at 120% of the long-term Applicable Federal Rate. For 2019,2022, the Company set the rate of return at 3.1%2.2% per annum. In 2019, the Company changed the rate

2023 Proxy Statement91

Table of return to 3.9% per annum.Contents

Executive Compensation

Benefits under the Deferred Compensation Plan are payable in a lump sum or in annual installments for a period of up to ten years beginning sixseven months after the named executive officer’s separation from service. Executives may also select at the time of deferral to be paid upon separation from service, a change in control or a fixed distribution date, which must be at least two years after the date of deferral. Benefits under the Deferred Compensation Plan are also payable if the executive experiences an unforeseen financial emergency. Deferrals of RSUs or PRSUs are settled in shares upon a fixed date selected by the executive or upon a separation from service or change in control.

The following table reflects contributions made by the named executive officers and matching contributions made by us under the Deferred Compensation Plan in fiscal year 20192022 as well as the named executive officers’ aggregate earnings, withdrawals, and balance information.

Name     Executive
Contribution
in Last FY
($)(1)
     Registrant
Contributions
in Last FY
($)(2)
     Aggregate
Earnings
(Loss) in
Last FY
($)(3)
     Aggregate
Withdrawals or
Distributions
($)
     Aggregate
Balance at
FYE
($)(4)
Cary Grace          
Susan R. Salka 345,074 332,581 (1,269,601)  17,248,607(5) 
Jeffrey R. Knudson 30,084 36,829 ($1,968)  64,945 
Mark C. Hagan 1,089,252 137,488 (540,239)  2,965,323 
Denise L. Jackson 125,291 119,344 (424,912)  2,313,610 

(1)

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  63


    EXECUTIVE COMPENSATION DISCLOSURE       

NONQUALIFIED DEFERRED COMPENSATION TABLE

      
Name  

Executive

Contribution

in Last FY ($)  (1)

   

Registrant

Contributions

in Last FY ($)  (2)

   

Aggregate

Earnings

in Last FY ($) (3)

   

Aggregate

Withdrawals or

Distributions ($)

   

Aggregate

Balance

at FYE ($) (4)

 
  
Susan R. Salka   197,483      126,820    792,386        11,441,143  (5) 
  
Brian M. Scott   96,063    60,182    274,248        1,540,803 
  
Ralph S. Henderson   179,404    60,182    236,264        1,951,635 
  
Denise L. Jackson   62,581    43,807    344,449        1,865,590 

(1)

The 20192022 “Salary” and 2018“Non-Equity“Non-Equity Incentive Compensation” columns of the Summary Compensation Table include the contributions, as applicable, of the named executive officers set forth in this table.

(2)

We include the matching contributions made by us set forth in this column in the 20192022 “All Other Compensation” column of the Summary Compensation Table.

(3)

Aggregate earnings are not reflected in the Summary Compensation Table. Additionally, any changes in the value of Common Stock underlying deferred vested awards are not included in this column.

(4)

To the extent our named executive officers made contributions, or we made matching contributions to our named executive officers, for the periods set forth in the Summary Compensation Table, such amounts are included (subject to increases or decreased earnings on such amounts) in this column.

(5)

This amount includes $6,308,451$10,409,805 representing the value of 101,243 shares of Common Stock underlying Ms. Salka’s deferred vested equity awards in her deferred compensation account, which is calculated based on our Common Stock price of $62.31$102.82 per share, the closing price on December 31, 2019.

2022.

Termination of Employment and Change in Control Arrangements

Ms. Grace’s Severance Agreement

MS. SALKA’S EMPLOYMENT AGREEMENT

We are party to an employmenta severance agreement with Ms. Salka(the “Severance Agreement”), dated May 4, 2005, as amended February 6, 2008. The employment agreement providesNovember 28, 2022 providing that Ms. Salka will serve as our President and CEO. For her services in that capacity, Ms. Salka (1) receives a base salary that we may increase annually at our discretion, (2) is eligible to receive an annual bonus subject to meeting certain performance-based criteria, and (3) is eligible to participate in our equity plans, employee benefit plans and other benefits programs provided in the same manner and to the same extent as our other senior management. The term of Ms. Salka’s employment agreement ends May 4, 2020 and automatically renews unless a party gives notice 120 days prior to the expiration date that such party does not wish to extend the term of the employment agreement.

The employment agreement provides that Ms. SalkaGrace will receive severance benefits undershould (1) the following three circumstances:Company terminate her employment without Cause(1), or (2) Ms. Grace resigns for Good Reason(2) (both deemed an “Involuntary Termination”).

(1)(1)

Death or Disability. In the event of her disability or death, Ms. Salka or her estate, as applicable, would be entitled to a severance payment equal to the sum of (A) two times her then-current annual base salary (payable not later than 30 days following termination of employment), and (B) an amount equal to the average of bonuses earned for the three most

recent fiscal years (“Average Bonus”) by her (payable when bonuses are paid to our other executive officers).

(2)

Termination for Reason Other than for Cause or Resignation for Good Reason. If we terminate Ms. Salka’s employment for any reason other than for “cause,” (6)or if she terminates her employment for “good reason,” (7)Ms. Salka would be entitled to receive from us, not later than 30 days following termination of employment, a lump sum amount equal to the sum of (A) two times her then-current annual base salary, and (B) two times her Average Bonus.

(3)

Change in Control. If, within one year following a “change in control,”(8) we terminate Ms. Salka for any reason other than for cause, or if she terminates her employment for good reason, she would be entitled to receive, as soon as reasonably practicable following her termination, a lump sum amount equal to the sum of (A) three times her then-current annual base salary, and (B) three times her Average Bonus. In addition, any unvested shares of RSUs, PRSUs, unvested options or other equity-based compensation awards held by Ms. Salka would automatically become 100% vested upon any “change in control” (as defined in Ms. Salka’s equity award agreements and the Equity Plan).

64  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


      EXECUTIVE COMPENSATION DISCLOSURE       

Additionally, under each of the above scenarios, Ms. Salka and her eligible dependents are entitled to continue to participate for two years in our medical, life, dental and disability insurance plans to the extent such plans permit continued participation (with Ms. Salka continuing to pay premiums in respect of such coverage that she was paying prior to termination).

Under some circumstances, amounts payable under Ms. Salka’s employment agreement are subject to a full“gross-up” payment to make her whole if she is deemed to have received “excess parachute payments” under Section 4999 of the Code. The

employment agreement has not been amended in recent years; however, in 2009, we committed to cease entering into employment agreements with taxgross-ups. Payment of all or a portion of the amounts set forth above may be delayed six months following her termination, if necessary to comply with the requirements of Section 409A of the Code. The employment agreement requires Ms. Salka to release any claims against us. The employment agreement also contains a confidentiality provision and a provision requiring Ms. Salka not to solicit our employees during its term and for a period of two years thereafter.

(6)

“Cause” is defined as (A) Executive’s failure to perform in any material respect his or her duties as an employee of the employment agreement as a terminationCompany, (B) violation of employmentthe Company’s Code of Business Conduct, Code of Ethics for Senior Financial Officers and Principal Executive Officer, and/or Securities Trading Policy, (C) the engaging by us dueExecutive in willful misconduct or gross negligence which is injurious to Ms. Salka’s (i)the Company or any of its affiliates, monetarily or otherwise, (D) the commission by Executive of an act of fraud or embezzlement against usthe Company or any of our subsidiariesits affiliates, or (E) the conviction inof Executive of a courtcrime which constitutes a felony or any lesser crime that involves Company property or a pleading of law,guilty or guilty plea or no contest plea, of any charge involving an act of fraud or embezzlement; (ii) conviction in a court of law, or guilty plea or no contest plea,nolo contendere with respect to a crime which constitutes a felony charge; (iii) willful misconductor any lesser crime that involves Company property. The Executive shall not be deemed to have been terminated for Cause unless the Company shall have given or delivered to the Executive (1) reasonable notice setting forth the basis for termination for Cause, and (2) a reasonable opportunity for the Executive to cure such alleged Cause, to the extent curable as our employeedetermined in the Company’s sole discretion. For purposes of this Agreement, no act, or as an employee for any of our subsidiaries that is reasonably likely to result in injury or financial loss to us or our subsidiaries; (iv) willful failure to render servicesact, on the Executive’s part shall be deemed “willful” unless done, or omitted to usbe done, by the Executive not in good faith and without reasonable belief that the Executive’s action or any of our subsidiariesomission was in accordance with her employment duties, which amounts to a material neglect of duties to us and does not result from physical illness, injury or incapacity, and which failure is not cured promptly after adequate notice; or (v) material breach of certain covenantsthe best interest of the employment agreement, if not cured within 30 days after written notice.

Company.
(7)(2)

“Good Reason” is defined inas the employment agreement asoccurrence of any of the following events without the Executive’s express written consent: (i) a material breach by usreduction in the Executive’s base salary or target annual bonus compensation; provided, however that a reduction in the Executive’s base salary or target annual bonus compensation that is commensurate with reductions simultaneously made to similarly situated executives shall not constitute a material reduction, (ii) the Company’s assignment to the Executive of duties that are both materially inconsistent with and materially adverse to the Executive’s position, in effect on the Effective Date (iii) any failure to nominate the Executive as a member of the Board or (iv) the Company’s relocation of Executive’s principal place of employment, agreementother than to the Company’s headquarters that is designated in its filings with the exceptionSecurities and Exchange Commission, to a locale that is more than fifty (50) miles from the Executive’s principal place of certain provisions thereto not cured within 30 daysemployment as of the Effective Date.

92

Table of Contents

Executive Compensation

In the event of an Involuntary Termination, except due to a Change-in-Control(3), Ms. Grace’s severance benefits will include: (1) a one-time cash payment equal to the sum of (A) 2 times Ms. Grace’s then-current annual base salary and (B) a prorated portion of her Average Bonus (an amount equal to the average of the annual performance bonus payments received by Ms. Grace for the three most recent fiscal years (or such fewer number of fiscal years during which Ms. Grace was employed)) and (2) reimbursement for COBRA health coverage for her health insurance for an 18-month period following the Involuntary Termination (or until such time as Ms. Grace becomes eligible for comparable coverage under another employer’s health plans, whichever is earlier), less her share of premiums.

Involuntary Termination due to Change-in-Control. If an Involuntary Termination occurs within one year of a Change in Control, Ms. Grace’s severance benefits will include (1) a one-time cash payment equal to 2.5 times her then-current annual base salary, (2) a one-time cash payment equal to 2.5 times her Average Bonus, (3) a one-time cash payment equal to a prorated portion of her Average Bonus, and (4) reimbursement for COBRA health coverage for her health insurance for an 18-month period following the Involuntary Termination (or until such time as Ms. Grace becomes eligible for comparable coverage under another employer’s health plans, whichever is earlier), less her share of premiums. The following table sets forth illustrative examples of the payments and benefits Ms. Grace would have received if any of the circumstances described above occurred as of December 31, 2022.

Termination Reason     Cash
Severance
($)
     Bonus
($)
     Benefits
($)
     Value of
Accelerated
Equity
Awards
($)
     Tax
Gross-Up
($)
     Total
($)
Termination of Employment by Us without Cause or by Ms. Grace for Good Reason Absent a Change in Control 2,120,000  15,201 1,702,265(1)  3,837,466
Termination of Employment by Us without Cause or by Ms. Grace for Good Reason with Change in Control 2,650,000  15,201 2,518,370(2)   5,183,571

(1)Represents the value of full acceleration of unvested RSUs pursuant to the RSU grant agreement for the buy-out award in addition to the vesting of a pro-rated portion of RSUs pursuant to the RSU grant agreement for the sign-on award based on the number of full calendar months elapsed between the grant date and the termination date. For the purpose of calculating the value of the vesting of the accelerated RSUs, we used $102.82, the closing price of our Common Stock on December 31, 2022, as the fair market value.
(2)Represents the value of full acceleration of unvested RSUs pursuant to the respective RSU grant agreements for the buy-out and sign-on awards. For the purpose of calculating the value of the vesting of the accelerated RSUs, we used $102.82, the closing price of our Common Stock on December 31, 2022, as the fair market value.

On or after a Change in Control and ending on the Board’s receiptfirst anniversary thereof, “Good Reason” is defined as the occurrence of any of the following events without the Executive’s express written notice of suchnon-compliance;consent: (i) a material reduction in the Executive’s base salary or target annual bonus compensation, as in effect on the date immediately prior to a Change in Control, (ii) the Company’s assignment to Ms. Salkathe Executive without herthe Executive’s consent of duties materially and adversely inconsistent with herthe Executive’s position, duties or responsibilities as in effect immediately before the Change in Control, including, but not limited to, any material reduction in such position, duties or responsibilities, or a change in herthe Executive’s title or office, as then in effect, or any removal of herthe Executive from any of such positions, titles or offices including Executive ceasing to be the Chief Executive Officer of the surviving company, or any failure to elect or reelect hernominate the Executive as a member of the Board or any removal of her as such a member, subject to certain exceptions; or (iii) the Company’s relocation of our corporate headquartersExecutive’s principal place of employment to a locale that is more than 50fifty (50) miles from San Diego, California without her approval.

the Executive’s principal place of employment immediately prior to the Change in Control.
(8)(3)

“Change in control”Control” is defined in the employment agreement as occurring upon: (1)(i) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning of Rule13d-3 promulgated under the Exchange Act) of a majority of the combined voting power of our then outstanding voting securities entitled to vote generally in the election of directors; (2)(ii) our dissolution or liquidation; (3)(iii) the sale of all or substantially all of our business or assets; or (4)(iv) the consummation of a merger, consolidation or similar form of corporate transaction involving the Company that requires the approval of our shareholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), if immediately following such Business Combination: (x) a Person is or becomes the beneficial owner, directly or indirectly, of a majority of the combined voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation), or (y) our shareholders cease to beneficially own, directly or indirectly, in substantially the same proportion as they owned the then outstanding voting securities immediately prior to the Business Combination, a majority of the combined voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation). “Surviving Corporation” means the corporation resulting from a Business Combination, and “Parent Corporation” means the ultimate parent corporation that directly or indirectly has beneficial ownership of a majority of the combined voting power of the then outstanding voting securities of the Surviving Corporation entitled to vote generally in the election of directors.

AMN HEALTHCARE SERVICES, INC.  

20202023 Proxy Statement

  65

93

Table of Contents


    EXECUTIVE COMPENSATION DISCLOSURE       

Executive Compensation

TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROLExecutive Officer Severance Agreements

ARRANGEMENTS FOR CHIEF EXECUTIVE OFFICER

The following table sets forth illustrative examples of the payments and benefits Ms. Salka would have received if any of the circumstances described above occurred as of December 31, 2019.

       
Termination Reason 

Cash

Severance ($)

   Bonus ($)  Benefits ($) (1)   

Value of

Accelerated
Equity

Awards ($) (2)

     TOTAL ($) 
  
Termination of Employment by Us without Cause or by Ms. Salka for Good Reason Absent a Change in Control  2,000,000    1,849,551   41,211      

 

   3,890,762 
  
Death or Disability  2,000,000    924,775   16,264      

 

   2,941,039 
  
Termination of Employment by Us without Cause or by Ms. Salka for Good Reason with a Change in Control  3,000,000    2,774,326   41,211    9,223,812   

 

   15,039,349 
(1)

Under the terms of Ms. Salka’s employment agreement, she and her eligible dependents may continue to participate for two years in our medical, life, dental and disability insurance plans to the extent such plans permit continued participation (with Ms. Salka continuing to pay premiums in respect of such coverage that she was paying prior to termination). For purposes of this column, we assume that all plans would permit continued participation and that Ms. Salka (or her eligible dependents in the event of her death) would continue to participate. We value the benefit at our estimated cost of two years of her and her dependents’ continued participation in the applicable plans.

(2)

We computed the value of accelerated equity awards using a share price of $62.31, the closing price of our Common Stock on December 31, 2019, the last trading day of the year. This column does not reflect awards that had already vested as of December 31, 2019. As set forth in the applicable equity award agreements, for TSR PRSUs, we have utilized the number of shares Ms. Salka would have received if the applicable TSR Measurements were performed on December 31, 2019; for adjusted EBITDA margin PRSUs we have utilized the target number underlying the awards based on 2020 or 2021 adjusted EBITDA margin and for the award based on 2019 adjusted EBITDA margin we have utilized the amount she would received based on our 2019 adjusted EBITDA margin.

EXECUTIVE OFFICER SEVERANCE AGREEMENTS

As of December 31, 2019,2022, we were party to executive severance agreements with each of Mr. Knudson, Mr. Hagan and Ms. Jackson Mr. Henderson and Mr. Scott, which are all virtually identical and provide that the applicable named executive officer will receive severance benefits if we terminate his or her employment without “cause,”(1) or relocate his or her position to a locale, other than to the Company’s SEC-designated headquarters, that is beyond a50-mile radius of their current office location (inexecutive officer resigns for “good reason”(2) (in either case, an involuntary termination).

If an involuntary termination occurs, but not within one year of a “change in control” (defined as(as defined in Ms. Salka’s employment agreement, see footnote 8 on the pageGrace’s Severance Agreement above), benefits include a cash payment equal to the applicable named executive officer’s then-current annual base salary, payment of a prorated portion of his or her Average Bonus and reimbursement for the COBRA health coverage for his or her health insurance for aone-year period (or until he or she becomes eligible for comparable coverage under another employer’s health plans, if earlier), less his or her share of premiums. If an involuntary termination occurs within one year of a change in control, the applicable named executive officer’s severance payment equals two times the sum of (A) his or her then-current annual base salary, plus (B) an amount equal to his or her Average Bonus. Each severance agreement contains a requirement that the named executive officer execute a general release in our favor as a condition to receiving the severance payments.

In addition, the named executive officers can resign their employment for “good reason(9)reason” after a “change in control” and generally receive the same severance benefits described in the preceding paragraph.

(9)(1)

“Cause” is defined as (A) Executive’s failure to perform in any material respect his or her duties as an employee of the Company, (B) violation of the Company’s Code of Business Conduct, Code of Ethics for Senior Financial Officers and Principal Executive Officer, and/or Securities Trading Policy, (C) the engaging by Executive in willful misconduct or gross negligence which is injurious to the Company or any of its affiliates, monetarily or otherwise, (D) the commission by Executive of an act of fraud or embezzlement against the Company or any of its affiliates, or (E) the conviction of Executive of a crime which constitutes a felony or any lesser crime that involves Company property or a pleading of guilty or nolo contendere with respect to a crime which constitutes a felony or any lesser crime that involves Company property.

(2)“Good Reason” for purposes of an involuntary termination not within one year after a “change in control” means the occurrence of any of the following events without the named executive officer’s express written consent: (i) a material reduction in the executive’s base salary or target annual bonus compensation unless such reduction is commensurate with reductions simultaneously made to similarly situated executives, (ii) the Company’s assignment to the executive of duties that are materially inconsistent and adverse to his or her position, or (iii) our relocation of the named executive officer’s principal place of employment to a locale that is more than fifty (50) miles from his or her principal place of employment immediately prior to the change in control; provided, however, that a relocation to the Company’s Dallas, Texas offices shall not trigger any severance obligation by the Company. On and after a “change in control,” “good reason” means the occurrence of any of the following events without the named executive officer’s express written consent: (i) a material reduction in his or her base salary or target annual bonus compensation as in effect on the date immediately prior to a change in control, (ii) the Company’s assignment to the named executive officer without his or her consent of duties materially and adversely inconsistent with the named executive officer’s position, duties or responsibilities as in effect immediately before the change in control, including, but not limited to, any material reduction in such position, duties or responsibilities, or a change in the named executive officer’s title or office, as then in effect, or any removal of the named executive officer from any of such positions, titles or offices, or (iii) our relocation of the named executive officer’s principal place of employment to a locale that is more than fifty (50) miles from his or her principal place of employment to a locale that is more than fifty (50) miles from his or her principal place of employment immediately prior to the change in control; provided, however that a relocation to the Company’s Dallas, Texas offices shall not trigger any severance obligation by the Company.

control.

66  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement

  


94

      EXECUTIVE COMPENSATION DISCLOSURE       


Table of Contents

Executive Compensation

The following table sets forth illustrative examples of the payments and benefits Mr. Scott,Knudson, Mr. HendersonHagan, and Ms. Jackson would have received if any of the circumstances described above occurred as of December 31, 2019.2022. Ms. Salka is not reflected below as she retired as President and Chief Executive Officer of the Company on November 27, 2022 and as a result, would not be entitled to any payments as of the measurement date as the result of severance or a change in control.

TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROLJEFFREY R. KNUDSON

ARRANGEMENTS OTHER EXECUTIVE OFFICERS

 
BRIAN M. SCOTT 
     
Termination Reason  

Cash

Severance
($)

   Bonus ($)   

Benefits

($)

  

Value of

Accelerated

Equity

Awards ($)
(1)

   

TOTAL

($)

 

Involuntary Absent a Change in Control

  

 

505,000

 

  

 

415,884

 

  

 

10,864

 

 

 

 

  

 

931,748

 

Involuntary Within One Year of a Change in Control

  

 

1,010,000

 

  

 

831,769

 

  

 

10,864

 

 

 

3,029,014

 

  

 

4,881,646

 

 
RALPH S. HENDERSON 
     
Termination Reason  

Cash

Severance
($)

   Bonus ($)   

Benefits

($)

  

Value of

Accelerated

Equity

Awards ($)
(1)

   

TOTAL

($)

 

Involuntary Absent a Change in Control

  

 

505,000

 

  

 

370,434

 

  

 

11,890

 

 

 

 

  

 

887,324

 

Involuntary Within One Year of a Change in Control

  

 

1,010,000

 

  

 

740,869

 

  

 

11,890

 

 

 

3,029,014

 

  

 

4,791,772

 

 
DENISE L. JACKSON 
     
Termination Reason  

Cash

Severance
($)

   Bonus ($)   

Benefits

($)

  

Value of

Accelerated

Equity

Awards ($)
(1)

   

TOTAL

($)

 

Involuntary Absent a Change in Control

  

 

430,000

 

  

 

249,889

 

  

 

11,316

 

 

 

 

  

 

691,205

 

Involuntary Within One Year of a Change in Control

  

 

860,000

 

  

 

499,779

 

  

 

11,316

 

 

 

1,639,937

 

  

 

3,011,032

 

Termination Reason     Cash
Severance
($)
     Bonus
($)
     Benefits
($)
     Value of Accelerated
Equity Awards
($)(1)
    Total
($)
Involuntary Absent a Change in Control 630,000 1,080,000 18,977 4,080,720 5,809,697
Involuntary Within One Year of a Change in Control 1,260,000 2,160,000 18,977 4,080,720 7,519,697
           

MARK C. HAGAN

         
           
Termination Reason     Cash
Severance
($)
     Bonus
($)
     Benefits
($)
     Value of Accelerated
Equity Awards
($)(1)
     Total
($)
Involuntary Absent a Change in Control 525,000 666,125 18,977  1,210,102
Involuntary Within One Year of a Change in Control 1,050,000 1,332,250 18,977 6,238,089 8,639,317
           

DENISE L. JACKSON

          
           
Termination Reason     Cash
Severance
($)
     Bonus
($)
     Benefits
($)
     Value of Accelerated
Equity Awards
($)(1)
     Total
($)
Involuntary Absent a Change in Control 500,000 653,300 13,347  1,116,647
Involuntary Within One Year of a Change in Control 1,000,000 1,306,600 13,347 5,013,092 7,333,039

(1)

PursuantRepresents the value of the full acceleration of unvested RSUs pursuant to the terms of therespective equity award agreements with each of our named executive officers, upon a change in controlofficers. For the purpose of the Company, all of their unvested equity awards become vested and exercisable regardless of whether there is a termination of employment. We have includedcalculating the value of acceleratedthe vesting of each named executive officer’s equity awards in the table above. For this purpose,accelerated RSUs, we used $62.31,$102.82, the closing price of our Common Stock on December 31, 2019.2022, as the fair market value. This column does not reflect awards that had already vested as of December 31, 2019. As2022.As set forth in the applicable equity award agreements, for TSR PRSUs, we have utilized the number of shares the named executive officers would have received if the applicable TSR Measurements were performed on December 31, 2019;2022; and for adjusted EBITDA margin PRSUs we have utilized the targetmaximum number underlying the awards based on 20192023 and 20202024 adjusted EBITDA margin and for the award based on 2019 adjusted EBITDA margin we have utilized the amount the executive received based on our 2019 adjusted EBITDA margin.

performance.

AMN HEALTHCARE SERVICES, INC.  

20202023 Proxy Statement

  67

95

Table of Contents


    EXECUTIVE COMPENSATION DISCLOSURE       

Executive Compensation

CEO Pay Ratio

At AMN,As required by Item 402(u) of Regulation S-K, we are committed to internal pay equity and equal pay based on role, qualifications, experience and merit, without regard to any legally-protected classifications. We design our compensation programs to be consistent and internally equitable to motivate employees to continue to perform in ways that enhance shareholder value. To this end, our Compensation Committee monitorsproviding the relationship between the pay of our executive officers and the pay of ournon-executive employees and takes into consideration the substantial amount of variable compensation that is tied to the Company’s performance. In 2019, 80% of our CEO’s compensation was at risk in the form of performance-based incentive cash and equity. For more details surrounding our executive compensation practices, please visit the subsection titled “Compensation Program Philosophy and Objectives” within the Compensation Discussion and Analysis above.

In August 2015, the SEC adopted rules implementing the “CEO pay ratio” disclosure requirements that were mandated by Congress pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”). The new rules require registrants to disclosefollowing information about the ratio of the median employee’s annual total compensation of our median employee to the CEO’s annualannualized total compensation. Ourcompensation of our CEO, Ms. Grace, for fiscal year 2022.

Pursuant to SEC rules, we are permitted to calculate our 2022 CEO pay ratio is calculatedusing the same median employee that we identified in accordance with the SEC’s final rules regarding the CEO pay ratio disclosure requirements promulgated pursuant2020 because we do not believe there have been any changes to Item 402(u) of RegulationS-K.

In 2017, we identified our employee population for the purposes of calculatingor employee compensation arrangements during 2022 that would have a significant impact on our CEO pay ratio as of October 27, 2017. On this date,disclosure. Accordingly, we had approximately 2,879 corporate employees. Duringhave elected to use the fourth quarter of 2017, we had an average of (1)9,234 nurses, allied and other clinical healthcare professionals, (2) 384 executive and clinical leadership interim staff, and (3) 349 medical coding professionals and case managers contracted to work for us. This does not include our locum tenens, all of whom are independent contractors and not our employees.same median employee.

To identifyWe calculated our median employee, we examined the 2017 total cash and equity compensation for all full-time, part-time, temporary and seasonal employees, excluding our CEO and including the healthcare professionals mentioned above, as ofOctober 27, 2017. Wages were annualized for full-time corporate employees that were not employed by us for the entire calendar year. Compensation for our healthcare professionals was not annualized. Other than the

foregoing, we did not make any assumptions, adjustments or estimates with respect to our employees’ total cash and equity compensation and used this consistently applied compensation measure to identify our median employee.

After identifying the median employee, we calculated his/heremployee’s annual total compensation using the same SEC rules we use for calculating the annual total compensation of our named executive officers, as set forth in the Summary Compensation Table ofabove. In 2022, the Executive Compensation Disclosure section above.

Pursuant to SEC rules,we substituted a different employee whose compensation was substantially similar to the median employee we identified in 2017 for the purposes of calculating our 2018 CEO pay ratio because our previously identified median employee was no longer employed by the Company at the end of 2018. When calculating our 2019 CEO pay ratio, we analyzed the 2019 compensation for the same individual identified in 2018 and determined that this employee’s 2019 compensation was not a reasonable reflection of the Company’s median employee because of the impact that this employee’s commission compensation had on his 2019 compensation. As a result, we substituted a different employee whose compensation was substantially similar to the median employee that we identified in 2017 as our median employee for purposes of calculating our ratio in 2019, as permitted by SEC guidance.

In 2019, theannual total compensation of our median employee was $55,343,$75,764, and our CEO’s annualannualized total compensation was $5,714,525,$4,262,478, of which $3,993,751$2,999,903 was variable compensation based on the performance of the Company. Since Ms. Grace joined the Company on November 28, 2022, we used her total annual base salary of $1,060,000, rather than the $81,538.46 in base salary that she received for 2022. She was also not eligible to receive an annual cash incentive bonus under the Bonus Plan. The resulting ratio of the total annual compensation of our median employee compared to the total annualannualized compensation of our CEO in 2019 is 103:2022 was 56:1.

The pay ratio was calculated in accordance with SEC rules based upon our reasonable judgment and assumptions. The SEC rules do not specify a single methodology for identification of the median employee or calculation of the pay ratio, and other companies may use assumptions and methodologies that are different from those used by us in calculating their pay ratio. Accordingly, the pay ratio disclosed by other companies may not be comparable to the Company’s pay ratio as disclosed above.

68  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  PROPOSAL 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION  

PROPOSAL 2

ADVISORY VOTE ON EXECUTIVE

COMPENSATION

Section 14A of the Exchange Act, as amended by the Dodd-Frank Act, enables our shareholders to vote to approve, on an advisory(non-binding) basis, the compensation of our named executive officers as disclosed in this proxy statement inPay Versus Performance

In accordance with the SEC’s rules. As previously disclosed, the Board has determined that it will hold an advisory vote on executive compensation on an annual basis, and the next shareholder advisory vote will occur at our 2020 Annual Meeting of Shareholders.

As described in detail in the Compensation Discussion and Analysis section above, we design our executive compensation programs to, among other things, attract, motivate, and retain our named executive officers, who are critical to our success. Under these programs, we reward our named executive officers for the Company’s successful performance, the achievement of specific annual, long-term and strategic goals, and the realization of increased value for our shareholders. The executive compensation packages paid to our named executive officers are substantially tied to our key business objectives and total shareholder return, to align with the interests of our shareholders. The Board maintains oversight over our executive pay programs and adheres to the highest level of corporate governance with their design. To this end, they closely monitor evolving best practices, including the compensation programs and pay levels of executives at peer companies to ensure that our compensation programs do not fall outside of the normal range of relevant market practices.

We have two shareholder approved performance incentive plans; cash and equity. We use these performance incentive plans to motivate, retain and reward our executives. These performance incentive plans make up a majority of the pay we provide to our executives. As a result of thispay-for-performance focused structure, our named executive officers generally realized an amount above their target compensation from 2017 – 2019. During this three-year period, we delivered strong financial and

operational results and our Common Stock price appreciatedapproximately 62% on a cumulative basis during the three-year period ended December 31, 2019, compared to 28% and 53% during this same period for the Russell 2000 and S&P 500,(1) respectively. We believe our performance pay structure appropriately incents executives without excessive risk. In 2019, the Company, as it has done for the past several years, utilized TSR PRSUs and adjusted EBITDA growth PRSUs as its performance incentive vehicles.

We ask that you support the compensation of our named executive officers as disclosed in our Compensation Discussion and Analysis and the accompanying tables contained in this proxy statement. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we ask our shareholders to vote “FOR” the following resolution at the Annual Meeting:

“RESOLVED, that the Company’s shareholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s proxy statement for the 2020 Annual Meeting of Shareholders pursuant to the compensation disclosure rules ofadopted by the Securities and Exchange Commission includingpursuant to the Compensation DiscussionDodd-Frank Wall Street Reform and Analysis, Summary Compensation TableConsumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officers (“PEOs”) and Non-PEO NEOs and Company performance for the other related tables and narrative disclosure.”

Because your vote is advisory, it will not bind us, thefiscal years listed below. The Compensation Committee or our Board. However, our Board and our Compensation Committee valuedid not consider the opinionspay versus performance disclosure below in making its pay decisions for any of our shareholders and will review the voting results and take them into consideration when making future decisions regarding our executive compensation programs and policies.years shown.

                     
      Summary     Compensation     Summary     Compensation     Average
Summary
Compensation
     Average
Compensation
     Value of Initial
Fixed $100
Investment
based on:4
           Pre-Bonus
Year Compensation
Table Total for
Susan Salka1
($)
 Actually Paid
to Susan
Salka1,2,3
($)
 Compensation
Table Total for
Cary Grace1
($)
 Actually
Paid to Cary
Grace1,2,3
($)
 Table Total
for Non-PEO
NEOs1
($)
 Actually Paid
to Non-PEO
NEOs1,2,3
($)
     TSR
($)
     Peer
Group
TSR
($)
 Net
Income
($ Millions)
 Adjusted
EBITDA5
($ Millions)
(a) (b) (c) (b) (c) (d) (e) (f) (g) (h) (i)
2022 8,468,824 7,987,377 3,305,296 2,823,763 2,904,018 3,534,932 165.01 118.22 444 868
2021 9,472,551 22,502,459   2,972,826 3,451,653 196.32 147.19 327 660
2020 6,025,299 8,091,337   1,874,937 1,760,065 109.53 133.81 71 335
 
(1)Susan Salka was our PEO in 2020, 2021, and 2022. Cary Grace was our PEO in 2022. The individuals comprising the Non-PEO NEOs for each year presented are listed below.

    2020    2021    2022
 Brian M. Scott Brian M. Scott Jeffrey R. Knudson
 Ralph S. Henderson Christopher S. Schwartz Mark Hagan
 Mark Hagan Jeffrey R. Knudson Denise Jackson
 Denise Jackson Mark Hagan  
   Denise Jackson  


(2)The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
96

Table of Contents

Executive Compensation

(3)Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the totals from the Stock Awards column set forth in the Summary Compensation Table.

 

 Year     Summary Compensation
Table Total for Susan Salka
($)
     Exclusion of Stock
Awards for Susan Salka
($)
     Inclusion of Equity
Values for Susan Salka
($)
     Compensation Actually
Paid to Susan Salka
($)
 2022 8,468,824 (4,447,137) 3,965,690 7,987,377
 2021 9,472,551 (5,643,694) 18,673,602 22,502,459 
 2020 6,025,299 (3,632,452) 5,698,490 8,091,337 

 Year     Summary Compensation
Table Total for Cary Grace
($)
        Exclusion of Stock
Awards for Cary Grace
($)
       Inclusion of Equity
Values for Cary Grace
($)
     Compensation Actually
Paid to Cary Grace
($)
 2022 3,305,296 (2,999,903) 2,518,370 2,823,763
 2021     
 2020     

 Year     Average Summary
Compensation Table Total
for Non-PEO NEOs
($)
        Average Exclusion of
Stock Awards for
Non-PEO NEOs
($)
         Average Inclusion of
Equity Values for
Non-PEO NEOs
($)
     Average
Compensation Actually
Paid to Non-PEO NEOs
($)
 2022 2,904,018 (1,296,924) 1,927,838 3,534,932
 2021 2,972,826 (2,012,241) 2,491,068 3,451,653 
 2020 1,874,937 (900,110) 785,238 1,760,065 

The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:

Year        Year-End
Fair Value of
Equity Awards
Granted
During Year
That Remained
Unvested as
of Last Day of
Year for Susan
Salka
($)
     Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards
for Susan Salka
($)
       Vesting-Date
Fair Value
of Equity
Awards
Granted
During Year
that Vested
During Year
for Susan
Salka
($)
       Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for Susan
Salka
($)
     Fair Value
at Last Day
of Prior Year
of Equity
Awards
Forfeited
During Year
for Susan
Salka
($)
       Value of
Dividends
or Other
Earnings
Paid on
Equity
Awards Not
Otherwise
Included for
Susan Salka
($)
     Total -
Inclusion of
Equity Values
for Susan
Salka
($)
2022 5,424,177 (961,985)  (496,502)   3,965,690
2021 8,521,434 9,159,676  992,492   18,673,602
2020 4,013,649 1,508,995  175,846   5,698,490

Year     Year-End
Fair Value of
Equity Awards
Granted
During Year
That Remained
Unvested as
of Last Day of
Year for Cary
Grace
($)
     Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards
for Cary Grace
($)
     Vesting-Date
Fair Value
of Equity
Awards
Granted
During Year
that Vested
During Year
for Cary
Grace
($)
     Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for Cary
Grace
($)
     Fair Value
at Last Day
of Prior Year
of Equity
Awards
Forfeited
During Year
for Cary
Grace
($)
     Value of
Dividends
or Other
Earnings
Paid on
Equity
Awards Not
Otherwise
Included for
Cary Grace
($)
      
Total -
Inclusion of
Equity Values
for Cary
Grace
($)
2022 2,518,370      2,518,370
2021       
2020       
2023 Proxy Statement97

Table of Contents

Executive Compensation

Year     Average
Year-End
Fair Value of
Equity Awards
Granted
During Year
That Remained
Unvested as
of Last Day of
Year for
Non-PEO NEOs
($)
      Average
Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards
for Non-PEO
NEOs
($)
     Average
Vesting-Date
Fair Value
of Equity
Awards
Granted
During Year
that Vested
During Year
for Non-PEO
NEOs
($)
      
Average Change
in Fair Value
from Last Day
of Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for
Non-PEO NEOs
($)
      
Average
Fair Value
at Last Day
of Prior Year
of Equity
Awards
Forfeited
During Year
for Non-PEO
NEOs
($)
     Average
Value of
Dividends
or Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
Non-PEO
NEOs
($)
     Total -
Average
Inclusion of
Equity Values
for Non-PEO
NEOs
($)
2022 1,581,852 (69,081)  415,067 0  1,927,838
2021 1,966,827 832,469  37,890 (346,117)  2,491,068
2020 729,754 327,207  (24,011) (247,712)  785,238

 

(1)(4)

The total returns reflected are asPeer Group TSR set forth in this table utilizes the S&P Health Care Services Select Industry Index (“S&P Health Care Services Select Industry Index”), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and calculated by combining share price appreciation and dividends paid to showin the total return to shareholders expressed as an annual percentage. Sources include: S&P Dow Jones IndicesHealth Care Services Select Industry Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5)We determined Pre-Bonus Adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and FactSet.Non-PEO NEOs in 2022. More information on Pre-Bonus Adjusted EBITDA can be found at Exhibit A to this proxy statement (page 113) and in Exhibit A to our proxy statements filed in 2022 and 2021, respectively. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.

Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)

The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and the Company’s cumulative TSR over the three most recently completed fiscal years.

*The Company TSR summarized above is indexed to an initial $100 investment

 


98

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  69


Table of Contents


Executive Compensation

PROPOSAL 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION   

Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income

The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the three most recently completed fiscal years.

Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Pre-Bonus Adjusted EBITDA

The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our other NEOs, and our Pre-Bonus Adjusted EBITDA during the three most recently completed fiscal years.

 

 

2023 Proxy Statement99

Table of Contents

Executive Compensation

Description of Relationship Between Company TSR and Peer Group TSR

The following chart compares our cumulative TSR over the three most recently completed fiscal years to that of the S&P Health Care Services Select Industry Index over the same period.

COMPARISON OF CUMULATIVE TSR OF AMN HEALTHCARE SERVICES INC. AND

S&P HEALTH CARE SERVICES SELECT INDUSTRY INDEX (FYE 2019 = $100)

*The Company TSR summarized above is indexed to an initial $100 investment

Tabular List of Most Important Financial Performance Measures

The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEOs and other NEOs for 2022 to Company performance. The measures in this table are not ranked.

Pre-Bonus Adjusted EBITDA
Revenue
Adjusted EBITDA Performance
Relative TSR
Absolute TSR

100

Table of Contents

Audit Committee Matters


 

PROPOSAL 3

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THERatification of the Selection of Our Independent Public Accounting Firm

APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS,

AS DISCLOSED IN THIS PROXY STATEMENT PURSUANT TO THE

COMPENSATION DISCLOSURE RULES OF THE SEC.

70  

 

AMN HEALTHCARE SERVICES, INC.  

The board recommends a vote “FOR” the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. 

  2020 Proxy Statement

  

The Audit Committee appointed KPMG LLP (“KPMG”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The Board proposes and recommends that the shareholders ratify this appointment.


Selection and Engagement of KPMG as Our Independent Registered Public Accounting Firm

KPMG served as our principal independent registered public accounting firm for 2022. We expect representatives from KPMG to be present at the Annual Meeting. They will be given the opportunity to make a statement if they so desire and are expected to be available to respond to any appropriate questions.

Audit fees, Audit-Related fees, Tax fees and all other fees

The following sets forth the fees paid or accrued for audit services and the fees paid for audit-related, tax and all other services rendered by KPMG for each of the last two years:

      2022
($)
     2021
($)
Audit Fees(1) 2,430,890 2,000,000
Audit-Related Fees(2) 21,683 10,960
Tax Fees(3) 362,218 248,750
All Other Fees  

(1)Audit fees in 2022 consist of fees for professional services rendered in connection with the (i) annual audits of our consolidated financial statements, and the effectiveness of internal control over financial reporting and (ii) reviews of the interim consolidated financial statements included in quarterly reports.
(2)Audit-related fees in 2022 consist principally of fees not reported under the “Audit Fees” heading, including fees in respect of accounting consultations.
(3)

REPORT OF THE AUDIT COMMITTEE   

Tax fees in 2022 consist of professional services rendered primarily relating to consultations in connection with research and development credits, an audit of the Company by the California State Franchise Tax Board and state sales and use tax compliance as well as other tax-related consulting services.

Pursuant to the Audit Committee Charter, it is the policy of the Audit Committee to review in advance and grant any appropriate pre-approvals of all auditing services to be provided by the independent registered public accounting firm and all non-audit services to be provided by the independent registered public accounting firm as permitted by Section 10A of the Exchange Act, and in connection therewith, to approve all fees and other terms of engagement. In 2021 and 2022, the Audit Committee approved all fees billed by KPMG prior to the engagement.

2023 Proxy Statement101

Table of Contents

REPORT OF THE AUDIT COMMITTEEAudit Committee Matters

Report of the Audit Committee

Management is responsible for the Company’s financial reporting process, including establishing and maintaining disclosure controls and procedures, establishing and maintaining internal control over financial reporting, evaluating the effectiveness of disclosure controls and procedures, evaluating and expressing an opinion on the effectiveness of internal controlcontrols and the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America.

KPMG LLP (“KPMG”) is responsible for performing an independent audit of the consolidated financial statements and expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the United States of America, as well as expressing an opinion on the effectiveness of internal control over financial reporting. The Audit Committee’s responsibility is to monitor, evaluate and oversee these processes. The Audit Committee members are not employees of the Company and are not professional accountants or auditors. The Audit Committee’s primary purpose is to assist the Board to fulfill its oversight responsibilities by reviewing the financial information provided to shareholders and others, the systems of internal controls that management has established to preserve the Company’s assets, and the audit process.process, including the review of critical audit matters with the Company’s independent registered accounting firm, and technology-related risks, including cybersecurity risks. It is not the Audit Committee’s duty or responsibility to conduct auditing or accounting reviews or procedures or to determine that the Company’s financial statements are complete and accurate and in accordance with accounting principles generally accepted in the United States of America. The Audit Committee has reviewed and discussed the audited financial statements with management. In giving the Audit Committee’s recommendation to the Board, it has relied on management’s representations that the financial statements have been prepared with integrity and objectivity and in conformity with accounting principles generally accepted in the United States of America and on the representations of the independent registered public accounting firm, KPMG, included in its report on the Company’s consolidated financial statements.

The Audit Committee is responsible for the appointment, subject to shareholder ratification, of the Company’s independent registered public accounting firm. The members of the Audit Committee are independent as defined by Section 303A of the NYSE Listed Company Manual.

In this context, the Audit Committee has reviewed and discussed with management, its report on the effectiveness of the Company’s internal control over financial reporting as well as KPMG’s report related to its audit of (i) the consolidated financial statements; and (ii) the effectiveness of internal control over financial reporting. The Audit Committee has discussed with KPMG the matters required to be discussed by Statement on Auditing Standards No. 61 (Communication with Audit Committees).the applicable requirements of the Public Company Accounting Oversight Board and the SEC. In addition, the Audit Committee has received from KPMG the written disclosures and the letter from the independent registered accounting firm required by applicable requirements of the Public Company Accounting Oversight Board regarding KPMG’s communications with the Audit Committee concerning independence and has discussed with KPMG its independence. The Audit Committee also considered whether KPMG’s provision ofnon-audit services to the Company is compatible with KPMG’s independence. KPMG advised the Audit Committee that KPMG was and continues to be independent accountants with respect to the Company.

The Audit Committee discussed with KPMG the overall scope and plans for its audits. The Audit Committee has met with KPMG, with and without management present, to discuss the results of its audits, the evaluations of the Company’s internal controls and the overall quality of the Company’s financial reporting.

Based upon the Audit Committee’s discussions with management and KPMG, the Audit Committee’s review of the representations of management and the report of KPMG to the Audit Committee, the Audit Committee recommended that the Board include the audited consolidated financial statements in the Company’s Annual Report on Form10-K for the year ended December 31, 20192022 filed with the SEC.

Audit Committee Members

MARK G. FOLETTA

Financial Expert

TERI G. FONTENOT

Financial Expert

DAPHNE E. JONES

Financially Literate

JORGE A. CABALLERO

Financial Expert

102

Table of Contents

Shareholder Proposal


PROPOSAL 4

 

Audit Committee Members

Mark G. Foletta

Financial Expert

Andrew M. Stern

Financially Literate

(not standing for re-election)

Daphne E. Jones

Financially Literate

Teri G. Fontenot

Financial Expert

AMN HEALTHCARE SERVICES, INC.  

Shareholder Proposal2020 Proxy Statement

  71


  PROPOSAL 3: RATIFICATION OF THE SELECTION OF OUR  INDEPENDENT PUBLIC ACCOUNTING FIRM  

PROPOSAL 3

RATIFICATION OF THE SELECTION OF OUR

INDEPENDENT PUBLIC ACCOUNTING FIRM

The Audit Committee appointed KPMG LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2019. The Board proposes and recommends that the shareholders ratify this appointment.

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

KPMG served as our principal independent registered public accounting firm for 2019. We expect representatives from KPMG to be present at the Annual Meeting. They will be given the opportunity to make a statement if they so desire and are expected to be available to respond to any appropriate questions. The following sets forth the fees paid or accrued for audit services and the fees paid for audit-related, tax and all other services rendered by KPMG for each of the last two years:

Audit Fees

KPMG billed $2,307,320 and $2,204,925 for audit fees in 2019 and 2018, respectively. Audit fees consist of fees for professional services rendered in connection with the (i) annual audits of our consolidated financial statements, and the effectiveness of internal control over financial reporting and (ii) reviews of the interim consolidated financial statements included in quarterly reports.

Audit-Related Fees

KPMG billed $45,474 and $48,968 for audit-related services in 2019 and 2018, respectively. Audit-related fees consist principally of fees not reported under the “Audit Fees” heading, including fees in respect of accounting consultations.

Tax Fees

KPMG billed (1) $373,730 in 2019 for professional services rendered primarily relating to consultations in connection with an audit of the Company by the California State Franchise Tax Board, research and development credits and state sales and use tax compliance, and (2) $412,974 in 2018 for professional services rendered primarily relating to consultations in connection with an audit of the Company by the Internal Revenue Service and tax consultations related to research and development credits.

All Other Fees

We did not incur any other fees billed by KPMG in 2019 or 2018.

Pursuant to the Audit Committee Charter, it is the policy of the Audit Committee to review in advance, and grant any appropriatepre-approvals of all auditing services to be provided by the independent registered public accounting firm and allnon-audit services to be provided by the independent registered public accounting firm as permitted by Section 10A of the Exchange Act, and in connection therewith, to approve all fees and other terms of engagement. In 2017 and 2018, the Audit Committee approved all fees billed by KPMG prior to the engagement.

THE BOARD RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT

OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

FOR THE FISCAL YEAR ENDING DECEMBER 31, 2019.

72  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 4: REDUCE THE THRESHOLD NECESSARY TO CALL A  SPECIAL MEETING OF SHAREHOLDERS   

PROPOSAL 4

REDUCE THE THRESHOLD NECESSARY TO CALL A SPECIAL MEETING OF SHAREHOLDERS

After careful consideration, the Board recommends that shareholders voteFOR the amendment to the Company’s Bylaws to enable shareholders who continuously own at least 15% of the Company’s outstanding common stock for at least one year to call special meetings.

The Company is asking shareholders to approve an amendment (the “Special Meeting Bylaws Amendment”) to the Company’s Bylaws to permit shareholders of record who continuously for at least one year own, in the aggregate, at least 15% of the Company’s outstanding common stock to call a special meeting of shareholders. The Special Meeting Bylaws Amendment would (i) lower the ownership threshold to permit shareholders who own at least 15% of our outstanding common stock to call a special meeting of shareholders, and (ii) add a requirement that eligible shareholders continuously own their common stock for one year in order to satisfy the 15% threshold.

The Board believes that special meetings of shareholders should be extraordinary events that are held only when strategic concerns or other similar considerations require that the matters to be addressed not be delayed until the next annual meeting. Moreover, because special meetings are expensive and time-consuming for the Company and potentially disruptive to its normal business operations, the Board believes that a small percentage of shareholders should not be entitled to utilize the right to call a special meeting for their own interests, which may not be shared by the majority of the Company’s shareholders. The Board will continue to have the ability to call special meetings of the shareholders in other instances when they determine it is appropriate.

In light of these considerations and based on the fact that approximately 83% and 76% of all of the S&P and Russell 3000 companies, respectively, that offer a special meeting right to shareholders have a threshold that is equal to or greater than 15%, the Board believes that establishing an ownership threshold of at least 15% for shareholders to call a special meeting reflects best practices and achieves a reasonable balance between enhancing shareholder rights and adequately protecting the long-term interests of the Company and its shareholders. The Board believes that an ownership threshold of at least 15% is appropriate based on the Company’s current size and shareholder composition, as it would provide the Company’s shareholders with a meaningful right to request a special meeting, while mitigating the risk that corporate resources are wasted to serve the narrow self-interests of a few minority shareholders. The Board also believes that adding a one year holding requirement for eligible shareholders to satisfy the 15% special meeting threshold ensures that shareholders seeking to call a special meeting are doing so with the long-term interests of the Company and its shareholders in mind.

The Board has determined that the Special Meeting Bylaws Amendment is advisable and in the best interests of the Company and its shareholders and has directed that it be submitted to the Company’s shareholders for approval. The text of the Special Meeting Bylaws Amendment proposed by this Proposal is attached to this proxy statement as Annex A. If this Proposal 4 is approved by a majority of the shares entitled to vote and present or represented by proxy at the Annual Meeting and Proposal 5 is not, the Special Meeting Bylaws Amendment would become immediately effective. If, however, Proposals 4 and 5 are both approved by a majority of the shares entitled to vote and present or represented by proxy at the Annual Meeting, the Board intends to solicit feedback from our shareholders and then act in manner that it deems to be in the best interests of the Company and its shareholders to reasonably implement each proposal.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE

APPROVAL OF THE REDUCTION OF THE SPECIAL MEETING THRESHOLD IN THE COMPANY’S BYLAWS

TO 15% SUBJECT TO A ONE YEAR HOLDING REQUIREMENT

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  73


  PROPOSAL 5: SHAREHOLDER PROPOSAL  

PROPOSAL 5

SHAREHOLDER PROPOSAL

The Company has been advised that Mr. John Chevedden, 2215 Nelson Avenue, No. 205, Redondo Beach, CA 90278, who has indicated he is a beneficial owner of at least $2,000 in market value of AMN’s Common Stock, intends to submit the following proposal at the Annual Meeting.

AMN is not responsible for the accuracy or content of this shareholder proposal, which is presented as received from the proponent in accordance with SEC rules.

Proposal 5 – Make4 — Reform the Current Impossible Special Shareholder Right to Call Special Meeting More AccessibleRequirements

Shareowners 

Shareholders ask our board to take the steps necessary to amend the appropriate company governing documents to give the owners of a combined 10%15% of our outstanding common stock the power to call a special shareownershareholder meeting.

One of the main purposes of this proposal is to give all shares, including street name shares, the right to formally participate in calling for a special shareholder meeting (orto the lowest percentage under state law). The Boardfullest extent possible and to clear up any ambiguity on whether street name shares can formally participate in calling for a special shareholder meeting without converting their shares to another class of Directors would continuestock.

One of the main purposes of this proposal is to have its existing powergive all shares, regardless of the length of continuous stock ownership, the right to formally participate in calling for a special shareholder meeting to the fullest extent possible

It is important to adopt this proposal because all AMN shares held in street name are now 100% disqualified from formally participating in the call for a special shareholder meeting. Under this ill-conceived AMN rule management discriminates against shareholders who bought AMN stock in street name which is the most efficient form of ownership for most AMN shareholders.

Also all AMN shares not held for one continuous year are now 100% disqualified from formally participating in the call for a special shareholder meeting. Under this ill-conceived AMN rule management discriminates against shareholder who bought AMN stock during the past 12 months.

It currently takes 15% of shares that are not owed in street name to call a special shareholder meeting.

Adoption of this proposal topic This could include a provision that the current 20% stock ownership threshold would still apply if a single shareholder calling for a special meeting owned 10% or moredisqualified 50% of AMN Healthcare stock.

A 10% stock ownership threshold is also important becauseshares from participating in the current 20% stock ownership threshold for shareholders to call a special meeting may be unreachable due to time constraints and the detailed technical requirements that can trip up halfcalling of shareholders who want a special shareholder meeting. Thus it would take 30% of the 20%non street names shares to call for a special meeting.

Then the owners of 30% of the AMN non street name shares held for more than a continuous year could determine that they own 45% of AMN non street name stock when length of stock ownership is factored out. Thus for practical purposes we may be left with a 45% stock ownership threshold to call a special shareholder meeting.

The nominal 15% of shares to call for a special shareholder meeting canturns into a bait and switch 45% threshold – nothing for management to brag about.

I know of no shareholders who have succeeded in calling for a special shareholder meeting at any company that excludes all street name shares.

I know of no shareholders who have succeeded in calling for a special shareholder meeting at any company that excludes all shares owned for less than a continuous year.

Thus AMN seems to have 2 bullet-proof defences to make sure that a special shareholder meeting will never be called due to the enormous burden AMN places on shareholders by these 2 under the radar exclusions.

Please vote yes:

Reform the Current Impossible Special Shareholder Meeting Requirements — Proposal 4

2023 Proxy Statement103

Table of Contents

Shareholder Proposal

OPPOSITION

AMN Healthcare’s Statement in Opposition to Proposal No. 4

The Board has considered the proponent’s proposal to (i) permit beneficial shareholders of the Company’s common stock to call a 40%special meeting; and (ii) eliminate the requirement to hold the Company’s common stock ownership thresholdfor at least one year prior to calling for a special meeting.

The Board has given careful consideration to this shareholder proposal and has concluded for the reasons set forth below that the adoption of this resolution is unnecessary and otherwise not in the best interests of the Company and its shareholders. Among other things, the one-year holding requirement to call a special meeting for practical purposes after our company attorneys doof shareholders protects the screening out process.Company against abuses by shareholders with narrow short-term interests.

ThisIn 2020, the Company’s proposal topic with the 10% stock ownership threshold won 44%-support at our 2018 annual meeting. The 2018 proposal did not have the following provision that is in this proposal: Adoption of this proposal topic could include a provision thatto enact the current 20%threshold of 15% with a one year holding period, passed with 85.7% support. The Company’s enacted threshold provides holders of 15% of our common stock ownership threshold would still apply if a single shareholder calling for a special meeting owned 10% or more of AMN Healthcare stock.

Makingat least one year with the right to call a special meeting more accessiblegave shareholders meaningful rights, aligned with best practices and strikes an appropriate balance. While the Company’s 2020 proposal received overwhelming shareholder support, Mr. Chevedden’s proposal, which sought the reduction of the ownership threshold from 20% to shareholders is showing increased support. For instance this proposal topic won 51%10%, received just 31.5% support at O’Reilly Automotive, Inc. (ORLY) in 2019.from shareholders.

Please voteMr. Chevedden again sought to improve shareholder engagement:

Make Shareholder Right to Call Special Meeting More Accessible – Proposal 5”

The Board of Director’s

Statement in Opposition

The Board has carefully considered the proponent’s proposal to reducedecrease the threshold to call a special meeting from the current 20% threshold to 10% (orand also proposed the lowest percentage under state law or 20%, if a singleremoval of the one-year stock holding period. The proposal received just 26.2% shareholder requesting a special meeting holds 10% or more Company shares). support.

The Board does not find it to be inbelieves that the best interests of our shareholders for the following reasons: (1) it applies different thresholds for different shareholders (i.e., those holding more than 10% and those holding less than 10%) creating an implied class system of shareholders, (2) it is confusing and creates uncertainty regarding the threshold necessary given the reference to state law; (3) it would allow a small minority of shareholders to create a financial and administrative burden on all of our shareholders and the Company, and (4) we are committed to corporate governance and, in addition to thecurrent special meeting right providewith a number of other ways for shareholders,15% threshold, including the proponent, to express their views onone-year stock hold requirement, appropriately balances the Company and its Board.

In addition and in an effort to continually consider and implement corporate governance best practices, we engaged with the proponent of this Proposal and proposed terms that we believe constitute best practices, eliminates confusion associated with this Proposal’s multiple circumstantial thresholds, and promotes the long term interest of our shareholders. After coming to what we believed to be an agreement with the proponent, our Board acted in good faith to amend the Company’s bylaws as agreed and in full expectation that this Proposal would be withdrawn. However, after filing the Form on8-K disclosing the amendment, the proponent elected not to withdraw, as we believe we had agreed.

74  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


PROPOSAL 5: SHAREHOLDER PROPOSAL   

We also note that a similar proposal submitted by this same proponent to decrease the special meeting threshold to 10% was voted down only two years ago. At that time, we engaged with our shareholders to discuss the Company’s current threshold of 20%. Our shareholders did not express concern regarding the 20% threshold requirement, especially in light of the Company’s strong corporate governance record and consistent engagement and transparency with its shareholders.

For these and the other additional reasons set forth below, your Board unanimously recommends that you vote AGAINST this proposal 5.

Reducing the threshold to 10% (or another unspecified “lowest percentage under state law”) applies different thresholds for different shareholders resulting in classification of shareholders, is confusing and creates uncertainty, and would allow a small minority (i.e., 10%) to create a financial and administrative burden on all of our shareholders and the Company.

While the Board supports giving shareholders a meaningful ability to call special meetings, the Board believes that this proposal does not appropriately balance the interests of all shareholders. The lower 10% (or another “lowest percentage under state law”) threshold requested by this proposal would increase the risk that a small minority of shareholders with special interests could trigger the heavy expenses and distraction from the business to convene a special meeting on matters that are not widely viewed as important or could efficiently be addressed at the next annual meeting. The shareholder proposal attempts to remedy this by providing that if a shareholder with 10% or more of Company shares requests a special meeting, then a higher threshold would apply. However, this is inadequate and does not, for example, protect against the 9.9% shareholder who would only need to solicit the votes of additional 0.1% of shareholdersright to call a special meeting while a

10.1%protecting its shareholder would needbase against the risk that a narrow shareholder base will use the special meeting mechanism as a means to solicit voteadvance short-term interests adverse to the long-term interests of an additional 9.9%. We also believe that thisthe Company and its shareholders.

Special meetings require substantial resources, and the elimination of a holding requirement as requested by the proposal is confusingcould increase the potential for misuse of the special meeting right by special-interest shareholder groups with no long-term vested interest in the Company. Given the size of the Company and provides different thresholds for differentour large number of shareholders, which we do not believe to be a standard governance practice.

Of all the S&P 500 and Russell 3000 companies that offer a special meeting right, approximately 83%is a significant undertaking that requires substantial management and 76%, respectively, haveexpense resources. The Board and management would be required to divert time and focus from their responsibility of managing the Company on behalf of all shareholders to prepare for, and conduct, the meeting, consequently distracting from their primary focus of operating our business and maximizing long-term shareholder value. Accordingly, special meetings should be extraordinary events that occur only when there are urgent and important strategic matters or concerns.

In response to the proponent’s proposal, the Company has amended its By-laws to clarify that beneficial holders, or holders of the Company’s common stock in street name, as well as record holders, can call a thresholdspecial meeting subject to the other conditions and procedural requirements as set forth in the By-laws.

While the Company’s By-laws did not prohibit beneficial owners from calling a special meeting, the Company believes that is equalthe amendments serve to or greater than 15%.clarify the pre-existing ability of beneficial owners to call a special meeting.

We believe that the Company’s overall corporate governance reflects best practices and provides shareholders with meaningful rights to communicate their views and ensure Board and management accountability and responsiveness to shareholders.

Given the Company’s demonstrated commitment to effective corporate governance, there are a number of other ways for shareholders to express their views in addition to a special meeting right. Therefore, the changes requested by this Proposal are unnecessary.

The Board believes that the Company’s commitment to ongoing and consistent dialogue with shareholders, combined with the following corporate governance practices, sufficiently serve to protect shareholders. This includes allowing multiple paths for shareholders to express their views to the Board, all without the added risks and expenses associated with a 10% special meeting threshold:eliminating the holding requirement:

“Proxy access” right to nominate directors
Annual director elections
Action by written consent
A majority shareholder voting right
104

Table of Contents

Shareholder Proposal

“Proxy access” right to nominate directors

Annual director elections

Action by written consent

No supermajority voting requirement

No poison pill

No classified common stock

For all the above reasons, the proponent’s proposed 10% or unspecified lower threshold for shareholders to convene a special meeting, even with the applicationIn light of the 20% threshold for a singleBoard’s belief that the Company’s existing shareholder holding 10% or moremeeting right is aligned with best practices and strikes the appropriate balance between providing shareholders with meaningful rights while adequately protecting the long-term interests of the Company shares,and all its shareholders, and the Board’s demonstrated commitment to strong corporate governance and responsiveness to shareholders, the Board believes the adoption of this shareholder proposal is unnecessary and not in shareholders’ best interest.

Recommendation of the Board of Directors

For all the reasons set forth above, the Board of Directors recommends a vote AGAINST Proposal No. 4

2023 Proxy Statement105

Table of Contents

Security Ownership and Other Matters

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “AGAINST

THE SHAREHOLDER PROPOSAL

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  75


SECURITY OWNERSHIP AND OTHER MATTERS   

SECURITY OWNERSHIP AND OTHER MATTERS

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information as of February 24, 2020 (the “Record Date”)March 21, 2023 regarding (i) each person known by us to be the beneficial owner of more than 5% of the outstanding shares of our Common Stock, (ii) each director and director nominee of the Company, (iii) the named executive officers and (iv) all executive officers and directors as a group. Except as otherwise indicated, each person has sole voting and dispositive power with respect to such shares.

Beneficial ownership includes shares for which a person, directly or indirectly, has or shares voting or investment power, or both, and also includes shares that each such person or group had the right to acquire within 60 days following the Record Date,March 21, 2023, including upon the exercise of options or warrants. Where applicable, we calculate the percentage of Common Stock beneficially owned by including the number of shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record DateMarch 21, 2023 in both the numerator and the denominator.

   
Name    

Number of Shares

of Common Stock

Beneficially Owned

   

        Percent of

Class

 

BlackRock, Inc. (1)

    

 

7,932,387

 

  

 

16.93

The Vanguard Group(2)

    

 

4,908,866

 

  

 

10.48

Susan R. Salka(3)

    

 

118,871

 

  

 

*

 

R. Jeffrey Harris(4)

    

 

99,034

 

  

 

*

 

Andrew M. Stern(5)

    

 

90,013

 

  

 

*

 

Dr. Michael M.E. Johns(6)

    

 

89,350

 

  

 

*

 

Martha H. Marsh(7)

    

 

76,115

 

  

 

*

 

Brian M. Scott(8)

    

 

40,989

 

  

 

*

 

Ralph S. Henderson(8)

    

 

20,013

 

  

 

*

 

Douglas D. Wheat(9)

    

 

37,645

 

  

 

*

 

Mark G. Foletta(10)

    

 

36,547

 

  

 

*

 

Denise L. Jackson(8)

    

 

20,152

 

  

 

*

 

Daphne E. Jones(11)

    

 

20,152

 

  

 

*

 

Teri G. Fontenot(12)

    

 

1,608

 

  

 

*

 

All directors, director nominees and executive officers as a group

    

 

634,600

 

  

 

1.35

NameNumber of Shares
of Common Stock
Beneficially
Owned(1)
     
Percent of
Class
BlackRock, Inc.(2)7,152,134 16.50%
The Vanguard Group(3)5,340,622 12.59%
R. Jeffrey Harris(4)86,335 *   
Susan R. Salka(5)10,588 *   
Martha H. Marsh(6)54,348 *   
Douglas D. Wheat(7)36,261 *   
Mark G. Foletta(8)40,170 *   
Denise L. Jackson(9)17,518 *   
Mark C. Hagan(9)29,283 *   
Jeffrey R. Knudson(9)12,474 *   
Daphne E. Jones(10)10,938 *   
Teri G. Fontenot(11)7,008 *   
Sylvia Trent-Adams(12)4,794 *   
Jorge A. Caballero(13)1,895 *   
Cary Grace(14)0 *   
All current directors, director nominees and executive officers as a group311,612 *   

*

Less than 1%.

(1)

Of the 7,932,387 shares of Common Stock BlackRock, Inc. beneficially owns, it has sole voting power over 7,680,649 shares of Common Stock and sole dispositive power over 7,932,387 shares. BlackRock, Inc.’s address is 55 East 52nd Street, New York, NY 10055. Ownership amount and other information contained in this table and accompanying footnote for BlackRock, Inc., including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 12) filed by BlackRock, Inc. with the SEC on February 4, 2020.

(2)

Of the 4,908,866 shares of Common Stock The Vanguard Group (“Vanguard”) beneficially owns, it has sole voting power over 97,202 shares, shared voting power over 7,948 shares, sole dispositive power over 4,809,668 shares and shared dispositive power over 99,198 shares. Vanguard’s address is 100 Vanguard Blvd., Malvern, Pennsylvania 19355. Ownership amount and other information contained in this table and accompanying footnote for Vanguard, including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 6) filed by Vanguard with the SEC on February 12, 2020.

(3)

Includes 118,871 shares of Common Stock owned directly by Ms. Salka and 101,243 vested RSUs that are deferred until her separation from service. Under the terms of the applicable award agreements, if Ms. Salka is a “specified employee” within the meaning of Section 409A of the Code, which she is, the distribution of her Common Stock would be delayed six months and one day. Accordingly, we have not included her 101,243 deferred vested RSUs and PRSUs in the table above because she would have no right to receive such shares within 60 days of the Record Date even if her employment with us terminated on the Record Date. If we were to include such amounts, the number of shares beneficially owned by her as set forth in this table would be increased by the corresponding amount.

76  

(1)

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  SECURITY OWNERSHIP AND OTHER MATTERS  

Additionally, inIn accordance with our policy, directors and named executive officers are not permitted to pledge, hypothecate or otherwise place liens on any equity securities of the Company that they own (or to engage in any hedging transactions involving our equity securities). Accordingly, no shares of Common Stock identified as beneficially owned in this table by our named executive officers and directors are pledged as security.

(2)Of the 7,152,134 shares of Common Stock BlackRock, Inc. beneficially owns, it has sole voting power over 7,051,024 shares of Common Stock, shared voting power over 0 shares, and sole dispositive power over 7,152,134 shares. BlackRock, Inc.’s address is 55 East 52nd Street, New York, NY 10055. Ownership amount and other information contained in this table and accompanying footnote for BlackRock, Inc., including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 1) filed by BlackRock, Inc. with the SEC on January 26,2023.
(3)Of the 5,456,661 shares of Common Stock The Vanguard Group (“Vanguard”) beneficially owns, it has sole voting power over 0 shares, shared voting power over 73,511 shares, sole dispositive power over 5,340,622 shares and shared dispositive power over 116,039 shares. Vanguard’s address is 100 Vanguard Blvd., Malvern, Pennsylvania 19355. Ownership amount and other information contained in this table and accompanying footnote for Vanguard, including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 9) filed by Vanguard with the SEC on February 9, 2023.
(4)

106

Table of Contents

Security Ownership and Other Matters

(4)Includes (A) 61,38950,139 shares of Common Stock owned directly by Mr. Harris and (B) 37,64536,196 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date,March 21, 2023, which 37,64536,196 shares consist of (i) 34,738 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (iii) 2,9071,458 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date.

March 21, 2023 on April 21, 2023.
(5)

Includes 90,013 shares of Common Stock deemed to be beneficially owned by Mr. Stern by reason of the right to acquire such shares within 60 days following the Record Date, which 90,013 shares consist of (i) 87,106 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 2,907 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date.

(6)

Includes (A) 40,00010,588 shares of Common Stock owned directly by Dr. JohnsMs. Salka and excludes 101,243 vested RSUs that she elected to defer until her separation from service. Under the terms of the applicable award agreements, if Ms. Salka is a “specified employee” within the meaning of Section 409A of the Code, which she is, the distribution of her Common Stock will be delayed six months and one day from her date of separation, and will be distributed on May 30, 2023. Accordingly, we have not included her 101,243 deferred vested RSUs in the table above because she will not have a right to receive such shares within 60 days from March 21, 2023. If we were to include such amounts, the number of shares beneficially owned by her as set forth in this table would be increased by the corresponding amount and be reflected as 111,831.

(6)Includes (A) 24,040 shares of Common Stock owned directly by Ms. Marsh and (B) 49,35030,308 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date,March 21, 2023, which 49,350 shares consist of (i) 46,443 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 2,907 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date.

(7)

Includes (A) 44,358 shares of Common Stock owned directly by Ms. Marsh and (B) 31,757 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which 31,75730,308 shares of Common Stock consist of (i) 28,850 shares of Common Stock underlying vested RSUs for which receipt has been deferred until her separation from service and (iii) 2,9071,458 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date.

from March 21, 2023 on April 21, 2023.
(8)(7)

All shares of Common Stock reflected in this row are owned directly by the named executive officer.

(9)

Includes 37,645 shares of Common Stock deemed to be beneficially owned by Mr. Wheat by reason of the right to acquire such shares within 60 days following the Record Date, which 37,645 shares consist of (A) 34,738 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (B) 2,907 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date.

(10)

Includes (A) 9,04365 shares of Common Stock owned directly by Mr. FolettaWheat and (B) 27,50436,196 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following March 21, 2023, which 36,196 shares of Common Stock consist of (i) 34,738 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (iii) 1,458 shares of Common Stock underlying RSUs that will vest within 60 days from March 21, 2023 on April 21, 2023.

(8)Includes (A) 14,415 shares of Common Stock owned directly by Mr. Foletta and (B) 26,055 shares of Common Stock deemed to be beneficially owned by reason of the Record Date,right to acquire such shares within 60 days following March 21, 2023, which 27,50426,055 shares consist of (i) 24,597 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 2,9071,458 shares of Common Stock underlying RSUs that will vest within 60 days from March 21, 2023 on April 21, 2023.
(9)All shares of Common Stock reflected in this row are owned directly by the Record Date.

named executive officer.
(11)(10)

Includes (A) 1,6087,341 shares of Common Stock owned directly by Ms. Jones and (B) 2,9073,597 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date,March 21, 2023, which 2,9073,597 shares consist of (i) 2,139 shares of Common Stock underlying vested RSUs for which receipt has been deferred until her separation from service and (ii) 1,458 shares of Common Stock underlying RSUs that will vest within 60 days from March 21, 2023 on April 21, 2023.

(11)Includes (A) 2,826 shares of Common Stock owned directly by Ms. Fontenot and (B) 4,182 shares of Common Stock deemed to be beneficially owned by reason of the Record Date.

right to acquire such shares within 60 days following March 21, 2023, which 4,182 shares consist of shares of Common Stock underlying vested RSUs for which receipt has been deferred until her separation from service.
(12)

Includes 1,356(A) 2,139 shares of Common Stock owned directly by Dr. Trent-Adams and (B) 2,655 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following March 21, 2023, which 2,655 shares consist of (i) 1,197 shares of Common Stock underlying vested RSUs for which receipt has been deferred until her separation from service and (ii) 1,458 shares of Common Stock underlying RSUs that were granted to Ms. Fontenot in connection with her appointment to the Board and will vest within 60 days from March 21, 2023 on April 21, 2023.

(13)Includes (A) 437 shares of Common Stock owned directly by Mr. Caballero and (B) 1,458 shares of Common Stock underlying RSUs deemed beneficially owned by reason of the Record Date.

right to acquire such shares within 60 days following March 21, 2023 on April 21, 2023.
(14)Ms. Grace joined the Company on November 30, 2022, so her equity awards have not vested as of March 21, 2023, nor will they vest within 60 days from March 21, 2023.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  77


SECURITY OWNERSHIP AND OTHER MATTERS   

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act generally requires our directors, executive officers and persons who own more than 10% of our Common Stock to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the SEC. Directors, executive officers and shareholders who own greater than 10% of our

Common Stock are required by SEC rules to furnish us with copies of Section 16(a) forms they file. We believe that all of our directors, named executive officers and greater than 10% beneficial owners complied with all filing requirements applicable to them in 2019.

2022 other than a Form 4 filing for Denise Jackson relating to a sale of common stock, which was filed late due to an administrative error and was corrected promptly following the identification of the error.

Shareholder Proposals for the 20212024 Annual Meeting of Shareholders

From time to time, shareholders present proposals, which may be proper subject for inclusion in the proxy statement and for consideration at the next annual meeting of shareholders. Any shareholder who desires to bring a proposal at our 20212024 Annual Meeting of Shareholders without including such proposal in our proxy statement must deliver written notice to our Secretary not before December 23, 2020January 18, 2024 and not later than January 22, 2021.February 17, 2024. We must receive shareholder proposals intended to be included in the 20212024 proxy statement no later than November 11, 2020.December 6, 2023.

2023 Proxy Statement107

Table of Contents

Security Ownership and Other Matters

The shareholder proposals must comply with the requirements of Rule14a-8 promulgated by the SEC under the Exchange Act.

If a shareholder proposal is not properly submitted for inclusion in the 20212024 proxy statement pursuant to the requirements described above (but otherwise complies with the advanced notice provisions of our Bylaws), management will be permitted to vote proxies in its discretion if it advises shareholders in the 20212024 proxy statement about the nature of the matter and how management intends to vote on such matter.

In addition, a shareholder who intends to solicit proxies in support of director nominees submitted under the advance notice provisions of our Bylaws must provide the notice required under Rule 14a-19 promulgated by the SEC under the Exchange Act to our Corporate Secretary no later than March 18, 2024.

Annual Report

Shareholders will receive with this proxy statement a copy of our Annual Report including the financial statements set forth in our annual report onForm 10-K, as filed with the SEC for the fiscal year ended December 31, 20192022 and certain exhibits thereto.

Shareholders may request additional copies by sending a written request to AMN Healthcare Services, Inc., 12400 High Bluff Drive,2999 Olympus Blvd., Suite 100, San Diego, California 92130,500, an, Texas 75019, Attn: Denise L. Jackson, Chief Legal Officer and Corporate Secretary.

Delivery of Proxy Statement, Annual Report or Notice of Internet Availability

We may satisfy SEC rules regarding delivery of our proxy materials, including our proxy statement, or delivery of the Notice of Internet Availability of Proxy Materials (the “Notice”) by delivering a single copy of these documents to an address shared by two or more shareholders. This process is known as “householding.” To the extent we have done so, we have delivered only one set of proxy materials or one Notice, as applicable, to shareholders who share an address with another shareholder, unless contrary instructions were received prior to the mailing date.

We undertake to deliver promptly upon written or oral request a separate copy of our proxy statement, our annual report and/or our Notice, as requested, to a shareholder at a shared address to which a single copy of these documents was delivered. To make such a request, please contact our Secretary at the

address set forth in the section immediately above entitled “Annual Report” or by calling our offices at866-871-8519. If your Common Stock is held by a brokerage firm or bank and you prefer to receive separate copies of our proxy statement, our annual report, or the Notice, either now or in the future, please contact your brokerage or bank. If your brokerage or bank is unable or unwilling to assist you, please contact us as indicated above.

Shareholders sharing an address who are receiving multiple copies of proxy materials and who want to receive a single copy of our annual reports, proxy statements and/or our Notices may do so by contacting our Secretary at the address set forth in the section immediately above entitled “Annual Report” or by calling our offices at866-871-8519.

78  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  SECURITY OWNERSHIP AND OTHER MATTERS  

Other Business

The Board does not know of any other matter that will come before the Annual Meeting other than those described in this proxy statement. If any other matters properly come up before the Annual Meeting, the persons named in the form of proxy intend to vote all proxies in accordance with their judgment on such matters.

108


Table of Contents

General Information

 

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  79


                GENERAL  INFORMATION                   

GENERAL INFORMATION

When and where is the Annual Meeting?

Our 20202023 Annual Meeting will be held at our offices located at 8840 Cypress Waters Boulevard, Suite 300, Dallas, Texas 75019virtually on Wednesday, April 22, 2020,

May 17, 2023, at 8:30 a.m.1:00 p.m. Central Time, or at any subsequent time that may be necessary by any adjournment or postponement of the Annual Meeting.

What is “Notice and Access” and whyWhy does AMN use it?

We are making the proxy solicitation materials available to our shareholders electronically via the Internet under the Notice and Access rules and regulations of the SEC. On or about March 11, 2020,April 4, 2023, we will mail to our shareholders the Notice in lieu of mailing a full set of proxy materials. Accordingly, our proxy materials are first being made available to our shareholders on or about March 11, 2020.April 4, 2023. The Notice includes information on how to access and review the proxy materials and how to vote online. All shareholders will have the ability to access the proxy materials on the website referred to in the Notice or request a printed set of the proxy materials.

Instructions on how to access the proxy materials on the Internet or to request a printed copy may be found

in the Notice. In addition, shareholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. Electronic delivery decreases costs, expedites distribution, and reduces our environmental impact. Environmental stewardship is aan important component of our Corporate Social Responsibility Program,ESG strategy, and we encourage shareholders to take advantage of the availability of the proxy materials on the Internet to help reduce the environmental impact of the Annual Meeting. Shareholders who received the Notice but would like to receive a printed copy of the proxy materials in the mail should follow the instructions in the Notice for requesting such materials.

Why am I receivingReceiving these proxy materials?Proxy Materials?

We are providing these proxy materials in connection with the solicitation of proxies on behalf of our Board for use at the Annual Meeting. This proxy statement includes information that we are required to provide under SEC rules and is designed to assist you in voting your shares.

Proxies in proper form received by us at or before the time of the Annual Meeting will be voted as specified. You may specify your choices by marking the appropriate boxes on your proxy card. If a proxy card

is dated, signed, and returned without specifying choices, the proxies will be voted in accordance with the recommendations of the Board set forth in this proxy statement, and, in their discretion, upon such other business as may properly come before the Annual Meeting. Business transacted at the Annual Meeting will be confined to the purposes stated in the Notice of Annual Meeting. Shares of our Common Stock cannot be voted at the Annual Meeting unless the holder is present in person or represented by proxy.

How can I get electronic accessGet Electronic Access to the proxy materials?Proxy Materials?

The Notice will provide you with instructions on how to (1) view our proxy materials for the Annual Meeting on the Internet, and (2) instruct us to send proxy materials to you by email. The proxy materials are also available under the “Investor Relations” tab on

our website atwww.amnhealthcare.com. Choosing to access our proxy materials electronically will save us the cost of printing and mailing documents to you and will reduce the impact of our annual meetings on the environment.

80  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


                   GENERAL INFORMATION                  

What is included in the proxy materials?Proxy Materials?

Our proxy materials include:

Our Notice of Annual Meeting of Shareholders,
This proxy statement, and
Our 2022 Annual Report including the financial statements set forth in our annual report on Form 10-K.

Our Notice of Annual Meeting of Shareholders,

This proxy statement, and

Our 2019 Annual Report including the financial statements set forth in our annual report onForm 10-K.

If you receive a paper copy of these materials by mail, the proxy materials will also include a proxy card.

2023 Proxy Statement109

Table of Contents

General Information

Who paysPays the costCost of soliciting proxiesSoliciting Proxies for the Annual Meeting?

Proxies will be solicited on behalf of the Board by mail, telephone, email, or other electronic means or in person, and we will pay the solicitation costs. We have retained Morrow Sodali LLC, a proxy solicitation

firm, to assist us in soliciting proxies and have agreed to pay them a fee of $9,000$9,500 for these services, plus reasonableout-of-pocket expenses.

Who is entitledEntitled to voteVote at the Annual Meeting?

In accordance with our Bylaws, the Board has fixed the close of business on February 24, 2020,March 21, 2023, as the record date for determining the shareholders entitled to notice of and to vote at the Annual Meeting or any adjournment or postponement thereof. At the close of business on the Record Date, the outstanding number

of our voting securities was 46,854,44440,447,414 shares. Each shareholder is entitled to one vote for each share of Common Stock he or she held as of the Record Date. Shares cannot be voted at the Annual Meeting unless the holder is present in person or represented by proxy.

What mattersMatters will be addressedAddressed at the Annual Meeting?

At the Annual Meeting, shareholders will be asked:

To elect the eight directors nominated by the Board and named in this proxy statement,

To approve, bynon-binding advisory vote, the compensation of our named executive officers,

To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020,

To approve the proposal to reduce the threshold necessary to call a special shareholders meeting to 15%, and

To transact such other business, including consideration of a shareholder proposal, if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

To elect the nine directors nominated by the Board and named in this proxy statement,

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

 81


                GENERAL  INFORMATION                   

What is the vote required for each proposal and what are my choices?

 

Proposal

Vote Required

Broker Discretionary

Voting Allowed

To approve, by non-binding advisory vote, the compensation of our named executive officers,
 
To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, and
To transact such other business, including consideration of a shareholder proposal, if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

What is the Vote Required for each Proposal and what are My Choices?

ProposalVote RequiredBroker Discretionary
Voting Allowed
Proposal 1:1: Election of eightnine directors     Majority of the votes cast     

No

Proposal 2:2: Advisory vote on the compensation of our named executive compensationofficers Majority of the shares entitled to vote and present or represented by proxy 

No

Proposal 3:3: Ratification of auditors for fiscal year 20202022 Majority of the shares entitled to vote and present or represented by proxy 

Yes

Proposal 4:Reduce the ownership threshold necessary to call a special meeting of shareholders to 15%4: Shareholder Proposal Majority of the shares entitled to vote and present or represented by proxy 

No

Proposal 5:Shareholder Proposal – Make Shareholder Right to Call Special Meeting More AccessibleMajority of the shares entitled to vote and present or represented by proxy

No

With respect to Proposal 1, the election of directors, you may vote FOR, AGAINST or ABSTAIN. Our Bylaws require that in an election where the number of director nominees does not exceed the number of directors to be elected, each director will be elected by the vote of the majority of the votes cast (in person during our virtual Annual Meeting or by proxy). A “majority of votes cast” means that the number of shares cast “FOR” a director’s election exceeds the number of votes cast “AGAINST” that director’s election. In accordance with our Bylaws, the following do not count as votes cast: (a) a share whose ballot is marked as withheld, (b) a share otherwise present at the meeting, but for which an ABSTAIN vote was cast, and (c) a share otherwise present at the meeting as to which a shareholder gives no authority or direction. In an uncontested election, a nominee who does not receive a majority of the votes cast will not be elected.

An incumbent director who is not elected because he or she does not receive a majority of the votes cast will continue to serve as a holdover director but will tender his or her resignation to the Board. Within 90 days after the date of the certification of the election results, the Governance and Compliance Committee will make a recommendation to the Board on whether to accept or reject the resignation, or whether other action should be taken, and the Board will act on the Governance and Compliance Committee’s recommendation and publicly disclose its decision and rationale.

With respect to Proposals 2, 3, 4 and 54 (or on any other matter to be voted on at the Annual Meeting), you may vote FOR, AGAINST or ABSTAIN. If you ABSTAIN from voting on Proposals 2, 3, 4 or 5,4, the ABSTAIN vote will have the same effect as an AGAINST vote.

110

Table of Contents

General Information

How does the Board recommendRecommend that I vote?Vote?

The Board recommends that you vote:

FOR:FOR: the election of the eightnine directors nominated by the Board and named in this proxy statement,

 

FOR: the approval, on aby non-binding advisory basis,vote, of the compensation of our named executive officers,

 

FOR:the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020,

2023,
 

FOR:the reduction of the ownership threshold necessary to call a special meeting of shareholders to 15%, and

AGAINST: the shareholder proposal entitled: “Make“Special Shareholder Right to Call a Special Meeting More Accessible”Improvement”.

HOW DO I VOTE MY SHARES?


ONLINE

82  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


                   GENERAL INFORMATION                  

How do I vote my shares?

ONLINE: byBy following the Internet voting instructions included in the proxy package sent to you (or by going towww.proxyvote.comand following the instructions) at any time up until 11:59 p.m. Eastern Time on the day before the date of the Annual Meeting.


CALL
:
by

By following the telephone voting instructions included in the proxy package sent to you (i.e., by(by calling 1 (800)690-6903and following the instructions) at any time up until 11:59 p.m. Eastern Time on the day before the date of the Annual Meeting.


MAIL

MAIL: ifIf you have elected to receive a printed copy of the proxy materials from us, by marking, dating, and signing your proxy card in accordance with the instructions on it and returning it by mail in thepre-addressed reply envelope provided with

the proxy materials. The proxy card must be received prior to the Annual Meeting.


DURING THE MEETING

IN PERSON: in personYou can also cast your vote at the meeting.our Virtual Shareholder Meeting. Even if you plan to attend, the Annual Meeting, we encourage you to vote in advance by Internet, telephone, or mail so your vote will be counted if for some reason you later decide notare unable to attend the Annual Meeting.attend.

If you are a beneficial owner and your shares are held through a broker, you should follow the instructions in the Notice provided by your broker, or your broker should provide instructions for voting your shares. In these cases, you may vote by Internet, telephone, or mail, as applicable. You may vote your shares beneficially held through your broker in person if you attend the Annual Meeting and you obtain a valid proxy card from your broker giving you the legal right to vote the shares at the Annual Meeting.

What is the difference between shareholder of record and beneficial owner?

Difference Between Shareholder of Record and Beneficial Owner?

Shareholder of Record. You are a shareholder of record if at the close of business on the Record Date your shares were registered directly in your name with American Stock Transfer & Trust Company, LLC, our transfer agent.

Beneficial Owner. You are a beneficial owner if at the close of business on the Record Date your shares were held by a brokerage firm or other nominee and

not in your name. Being a beneficial owner means that, like most of our shareholders, your shares are held in “streetname.“street name.” As the beneficial owner, you have the right to direct your broker or nominee on how to vote your shares by following the voting instructions your broker or other nominee provides. If you do not provide your broker or nominee with instructions on how to vote your shares, your broker or nominee will be able to vote your shares as described below.

What will happenHappen if I doDo not vote my shares?Vote My Shares?

Shareholders of Record.If you are the shareholder of record and you do not vote by proxy card, telephone, Internet or in person at the Annual Meeting, your shares will not be voted at the Annual Meeting.

Beneficial Owners. If you are the beneficial owner and you do not direct your broker or nominee on how to vote your shares, your broker or nominee may vote

your shares only on those proposals for which it hasdiscretionhas discretion to vote. Under the rules of the NYSE, your broker or nominee does not have discretion to vote your shares onnon-routine matters such as Proposals 1, 2, 4 and 5.4. We believe that Proposal 3 — ratification of our auditor — is a routine matter for which brokers and nominees can vote on behalf of their clients when voting instructions are not furnished by their clients.

AMN HEALTHCARE SERVICES, INC.  

20202023 Proxy Statement

111  83


Table of Contents


                GENERAL  INFORMATION                   

General Information

What is the effectEffect of a brokernon-vote?Broker Non-Vote?

Brokers or other nominees who hold shares for a beneficial owner have the discretion to vote on routine proposals when they have not received voting instructions from the beneficial owner at least ten days prior to the Annual Meeting. A brokernon-vote occurs when a broker or other nominee does not receive voting instructions from the beneficial owner and does not have the discretion to direct the voting of the shares. Brokernon-votes will be counted for purposes of calculating whether a quorum is present at the

Annual Meeting, but will not be counted for purposes of determining the number of votes present in person or represented by proxy and entitled to vote with respect to certain proposals. Accordingly, a brokernon-vote will not impact our ability to obtain a quorum nor will it impact any vote that requires a majority of the votes cast (Proposal(Proposals 1) or any proposal that requires the majority of the shares entitled to vote and present or represented by proxy (Proposals 2, 3, 4 and 5)4).

May I revoke my proxyRevoke My Proxy or change my vote?Change My Vote?

Yes, you may revoke a proxy you have given at any time before it is voted at the Annual Meeting by (1) sending our Corporate Secretary a letter revoking the proxy, which must be received prior to the Annual Meeting, or (2) attending the Annual Meeting and voting in person. Attendance at the Annual Meeting does not, standing alone, constitute your revocation of a proxy.

You may change your vote at any time prior to the voting of your shares at the Annual Meeting by (a) casting a new vote by telephone or over the Internet by 11:59 p.m. Eastern Time on the date before the day of the Annual Meeting, or (b) sending a new proxy card with a later date that is received prior to the Annual Meeting.

How Do I Attend the Virtual Annual Meeting?

Our Annual Meeting will be held virtually on Wednesday, May, 17, 2023, at 1:00 p.m. Central Time. Shareholders may sign-in to the virtual Annual Meeting starting at 12:45 p.m. (Central Time) by going to www.virtualshareholdermeeting.com/AMN2023. To register and attend the virtual Annual Meeting, you will need the control number included on your notice or proxy card voting instruction form or electronic notification. If you hold your shares through a securities broker (i.e., in “street name”), you should have received your notice or proxy card from your broker with your 16-digit control number. Only valid shareholders as of the record date, or their proxy holders, will be able to register for the meeting to participate and vote. The virtual Annual Meeting will start promptly at 1:00 p.m. (Central Time). A copy of the list of registered shareholders entitled to vote at the meeting will also be available for examination during the virtual Annual Meeting.

Will there be a Question and Answer Session?

Yes, as part of our virtual Annual Meeting, we will hold a Q&A session to allow shareholders the opportunity to ask questions similar to an in-person meeting. Once you have entered the virtual Annual Meeting platform, you will be able to type and submit your questions by using the applicable field provided in the web portal before the polls close. You or your proxy holder may participate, vote and ask questions at the virtual Annual Meeting subject to our Annual Meeting rules and procedures. We will post the Rules for Conduct of Meeting to our Investor Relations website at https://ir.amnhealthcare.comno later than one week prior to the Annual Meeting date of May 17, 2023 and will also make them available during the Annual Meeting through the virtual meeting platform. Only shareholders as of the record date or their proxy holders will be permitted to ask questions.

To make our virtual Annual Meeting more efficient, questions may be summarized and/or grouped topically for response and may also be omitted if inappropriate, not germane to the meeting agenda or in violation of any other rules and procedures, including, without limitation, our Annual Meeting Rules of Conduct. Any questions that comply with the Annual Meeting rules and procedures and are not addressed during the meeting will be published and answered as soon as practicable following the meeting on our Investor Relations website at https://ir.amnhealthcare.com.

What if I have Technical Questions?

Stockholders are encouraged to access the Annual Meeting early. If you encounter any difficulties accessing the Annual Meeting during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting log-in page.

How can I findFind the resultsResults of the Annual Meeting?

We will announce preliminary results at the Annual Meeting. We will publish the final voting results in a current report on Form8-K that we will file with the SEC within four business days after the Annual Meeting.

If the official results are not available at that time, we will provide preliminary voting results in the Form8-K and will providedisclose the final results in an amendment to the Form8-K as soon as they become available.

112

Table of Contents

84  Exhibit A to Proxy Statement

 

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  EXHIBIT A  

EXHIBIT A TO PROXY STATEMENT

Information Required to Have a Nominee of a Shareholder Considered by the Corporate Governance and Compliance Committee for Election at the 2021 Annual Meeting of Shareholders

To have a nominee considered by the Corporate Governance and Compliance Committee for election at the 2021 Annual Meeting of Shareholders, a shareholder must submit the recommendation with the information set forth below in writing to our Secretary at 12400 High Bluff Drive, San Diego, CA 92130 no later than January 22, 2021 and no sooner than December 23, 2020.

The name and address of the candidate; and

A brief biographical description of the candidate, including the candidate’s occupation for at least the last five years, and a statement of the qualifications of the candidate taking into account the qualifications requirements set forth in our Governance Guidelines as well as:

(1)

the name and address, as they appear on our books, of the shareholder and the name and address of any beneficial owner on whose behalf a nomination is being made and the names and addresses of their affiliates,

(2)

the class and number of shares of stock held of record and beneficially by such shareholder, and any such beneficial owner or affiliate, and the date such shares were acquired,

(3)

a description of any agreement, arrangement or understanding regarding such nomination between or among such shareholder, beneficial owners, affiliates or any other persons (including their names) acting in concert with any of the foregoing, and a representation that the shareholder will notify us in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting promptly following the later of the record date or the date notice of the record date is first publicly disclosed,

(4)

a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, hedging transactions and borrowed or loaned shares) that has been entered into as of the date of the notice of nomination by, or on behalf of, such shareholder, beneficial owners or affiliates the

effect or intent of which is to mitigate loss to, manage risk or benefit from share price changes for, or increase or decrease the voting power of such shareholder, beneficial owners or affiliates with respect to shares of our capital stock and a representation that the shareholder will notify us in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting promptly following the later of the record date or the date notice of the record date is first publicly disclosed,

(5)

a description in reasonable detail of any proxy (including revocable proxies), contract, arrangement, understanding or other relationship pursuant to which such shareholder, beneficial owners or affiliates have a right to vote any shares of our capital stock,

(6)

a representation that the shareholder is a holder of record of our capital stock entitled to vote at the meeting and intends to appear in person or by proxy at the meeting to propose such nomination,

(7)

all information regarding each shareholder nominee that would be required to be set forth in a definitive proxy statement filed with the SEC pursuant to Section 14 of the Exchange Act, and the written consent of each shareholder nominee to being named in a proxy statement as a nominee and to serve if elected,

(8)

a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such shareholder, beneficial owners, affiliates or others acting in concert therewith, including all information that would be required to be disclosed pursuant to Rule 404 promulgated under RegulationS-K if such shareholder, beneficial owner or any person acting in concert therewith, were the “registrant” for purposes of such rule and the shareholder nominee were a director or executive of such registrant,

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement

  A-1


EXHIBIT A   

(9)

a statement of whether the shareholder nominee agrees to tender a resignation if he or she fails to receive the required vote forre-election, in accordance with the Governance Guidelines and Section 3.3 of the Bylaws, and

(10)

all other information that would be required to be filed with the SEC if the shareholder, beneficial

owner or affiliate were a participant in a solicitation subject to Section 14 of the Exchange Act or any successor statute thereto.

We may require any shareholder nominee to furnish such other information as we may reasonably require to determine the eligibility of the shareholder nominee to serve as one of our directors.

A-2  

AMN HEALTHCARE SERVICES, INC.  

  2020 Proxy Statement


  EXHIBIT B  

EXHIBIT B TO PROXY STATEMENT

Non-GAAP Reconciliations Reconciliation for Consolidated Adjusted EBITDA and Consolidated Pre-Bonus Adjusted EBITDA for Purposes of 20192022 Bonus Achievement

  
   Year Ended
December 31,
 
  
(in thousands) 2019 

Net income

 

$

                113,988

 

Income tax expense

 

 

34,500

 

  

 

 

 

Income before income taxes

 

 

148,488

 

Interest expense, net, and other

 

 

28,427

 

  

 

 

 

Income from operations

 

 

176,915

 

Depreciation and amortization

 

 

58,520

 

Share-based compensation

 

 

16,241

 

Acquisition, integration, and other costs

 

 

25,723

 

  

 

 

 

Adjusted EBITDA

 

$

277,399

 

  
   

Year Ended

December 31,

 
  
(in thousands) 2019 

Revenue

  

Nurse and allied solutions

 

$

                1,419,965

 

Locum tenens solutions

 

 

324,653

 

Other workforce solutions

 

 

477,489

 

  

 

 

 
  

$

2,222,107

 

  

 

 

 

Segment operating income(1)

  

Nurse and allied solutions

 

$

199,806

 

Locum tenens solutions

 

 

25,108

 

Other workforce solutions

 

 

110,225

 

  

 

 

 
  

 

335,139

 

Unallocated corporate overhead(2)

 

 

57,740

 

  

 

 

 

AEBITDA(3)

 

$

277,399

 

  
   

Year Ended

December 31,

 
  
(in thousands) 

2019

 

AEBITDA

 

$

                 277,399

 

Adjustments(4)

 

 

168

 

  

 

 

 

Pre Bonus AEBITDA(5)

 

$

277,567

 

(1)(in thousands)

Year Ended December
31, 2022 ($)

Net income444,050
Income tax expense162,653
Income before income taxes606,703
Interest expense, net, and other40,398
Income from operations647,101
Depreciation and amortization133,007
Depreciation (included in cost of revenue)4,104
Share-based compensation30,066
Acquisition, integration, and other costs32,409
Adjusted EBITDA846,687

(in thousands)Year Ended December
31, 2022 ($)
Revenue
Nurse and allied solutions3,982,453
Physician and leadership solutions697,946
Technology and workforce solutions562,843
5,243,242
Segment operating income(1)
Nurse and allied solutions576,226
Physician and leadership solutions92,331
Technology and workforce solutions299,390
967,947
Unallocated corporate overhead(2)121,260
Adjusted EBITDA(3)846,687
Adjusted EBITDA846,687
Adjustments(4)21,245
Pre-bonus AEBITDA(5)867,932

Year Ended December
31, 2022 ($)
GAAP diluted net income per share (EPS)9.90
Adjustments2.00
Adjusted diluted EPS(6)11.90
2023 Proxy Statement113

Table of Contents

Exhibit A to Proxy Statement

(1)Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and integrationother costs, legal settlement accrual increases and share-based compensation expense.

(2)

Please note that the amount set forth in this line item excludes the amounts set forth in the line item below entitled “acquisition, integration, and other costs.” Acquisition, integration, costs” Acquisition and integrationother costs are subsets of unallocated corporate overhead.

(3)

AEBITDAAdjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, depreciation (included in cost of revenue), acquisition, integration, and integrationother costs, legal settlement accrual increases and share-based compensation expense. Management believes that AEBITDAAdjusted EBITDA provides an effective measure of our results, as it excludes certain items that management believes are not indicative of our operating performance and considers measures used in credit facilities. AEBITDAAdjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from AEBITDAAdjusted EBITDA are not indicative of our operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes AEBITDAAdjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income.

(4)

This amount represents the net adjustments to AEBITDA,Adjusted EBITDA, as decided by the Compensation Committee for bonus calculation and payout only. For the purposes of determiningPre-Bonus AEBITDA in connection with the bonus calculation and payout, the Compensation Committee excluded from AEBITDA the impact of the Company’s 2019 acquisitions of Silversheet and Advanced Medical as well as the expense associated with the payout of bonuses, and other extraordinary itemsthe impact of acquisitions that were not contemplatedincluded in the Company’s 2019operating plan and certain increases to the Company’s legal expense accruals not contemplated by its 2022 annual operating plan.

(5)

Pre-bonus AEBITDA represents the adjustments made to AEBITDAAdjusted EBITDA decided by the Compensation Committee.

(6)Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
114

Table of Contents

 

ABOUT AMN HEALTHCARE

AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the nation. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry. For more information about AMN Healthcare, visit www.amnhealthcare.com.

FORWARD-LOOKING STATEMENTS

This Proxy includes estimates, projections, statements related to our business plans, objectives, initiatives, strategies, practices, and expected operating Statement results that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, among others, the duration and severity of workforce shortages, the demand for healthcare services, the ability to grow our technology-enabled solutions and digital capabilities, our ability to innovate and improve patient outcomes, and performance for our company and our clients, our ability to accomplish our ESG commitments, our ability to attract and retain quality healthcare professionals and corporate team members, anticipated growth, acquisition and divestitures and their results on future operations, future economic conditions and performance, plans, objectives and strategies for future operations and growth, performance goals, actions related to our 2023 compensation, and other characterizations of future events or circumstances. The Company based these forward-looking statements on its current expectations, estimates, and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements contained in the shareholder letter are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and its other periodic reports as well as the Company’s current and other reports filed from time to time with the Securities and Exchange Commission. Be advised that developments subsequent to the shareholder letter are likely to cause these statements to become outdated with the passage of time. The Company makes available additional information regarding the non-GAAP financial measures on the Company’s website at https://ir.amnhealthcare.com/static-files/d5502550-cffc-47a5-a1ce-89af91f2bcc2.

This Proxy Statement includes several website addresses and references to additional materials found on those websites. These websites and materials are not incorporated by reference herein.

  

 

FOLLOW US ON


Table of Contents

Our Mission

AMN HEALTHCARE SERVICES, INC.  Deliver the best talent and insights to help healthcare organizations optimize their workforce

Give healthcare professionals opportunities to do their best work towards quality patient care

Create a values-based culture of innovation where our team members can achieve their goals

 

Our Values

2020 Proxy StatementOur six core values drive our culture and our strength as a company.

Customer Focus

Respect

Trust

Continuous Improvement

Passion

Innovation

 

Our Aspiration

  B-1We strive to be recognized as the most trusted, innovative, and influential force in helping healthcare organizations provide a quality patient care experience that is more human, more effective, and more achievable.

Awards List

AMNHealthcare.com
NYSE: AMN
Toll Free: (866) 871-8519


Table of Contents

AMN HEALTHCARE SERVICES, INC.
2999 OLYMPUS BLVD., SUITE 500
DALLAS, TEXAS 75019

     SCAN TO
VIEW MATERIALS & VOTE
     

 

ANNEX A TO PROXY STATEMENTVOTE BY INTERNET
Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above

Amendment

Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on May 16, 2023. Have your proxy card in hand when you access the Company’s Bylawsweb site and follow the instructions to Effectuate Proposal 4obtain your records and to create an electronic voting instruction form.

Below

During The Meeting - Go to www.virtualshareholdermeeting.com/AMN2023

You may attend the meeting via the Internet and vote during the meeting. Have the information that is reflection of the changes to Section 2.3 (Special Meetings) of the Company’s Bylaws that will be adopted if Proposal 4 of this Proxy Statement is approved by a majority of the shares entitled to vote and present or represented by proxy at the Annual Meeting.

2.3 Special Meetings.

(a)General. Unless otherwise prescribed by applicable law, special meetings of Stockholders may be called at any time by only (i) the Board, (ii) the Chairman or the Presiding Director (if one has been designated) or (iii) the holders of record whofor at least one year continuously“own” (as defined in Section 2.12(f))printed in the aggregate not less thanfifteentwenty percent (1520%) (the “Requisite Percentage”) ofbox marked by the outstanding shares of Common Stock priorarrow available and follow the instructions.

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on May 16, 2023. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date such request is delivered to the Secretary (the “Request Date”) (such request by Stockholders herein referred to as a “Stockholder Requested Special Meeting”), for any purpose or purposes prescribedyour proxy card and return it in the notice of the meeting and shall be held at such place (if any), on such date and at such time as the Board may fix. In lieu of holding a special meeting of Stockholders at a designated place, the Board may, in its sole discretion, determine that any special meeting of Stockholders may be held solely by means of remote communication. Business transacted at any special meeting of Stockholders shall be limitedpostage-paid envelope we have provided or return it to the purpose stated in the notice.Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

AMN HEALTHCARE SERVICES, INC.  

2020 Proxy Statement  

AX-1


LOGO

AMN HEALTHCARE SERVICES, INC.

12400 HIGH BLUFF DRIVE, SUITE 100

SAN DIEGO, CA 92130

VOTE BY INTERNET—www.proxyvote.com

Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on April 21, 2020. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.

VOTE BYPHONE—1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on April 21, 2020. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.


 

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

V03381-P86205                       KEEP THIS PORTION FOR YOUR RECORDS

DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

 

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
E92736-P33303                 KEEP THIS PORTION FOR YOUR RECORDS   

— — — — — — — — — — — — —  — — — — — — — — — — — — — — — — — — — —  — — — — — — — — — — — — — — — — — — — —  — — — — — — — —

        DETACH AND RETURN THIS PORTION ONLY   
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.                        

AMN HEALTHCARE SERVICES, INC.

 

 The Board of Directors recommends you vote FOR the election of each of the eight director nominees listed below:following:  
 1.Election of Directors   
 
 Nominees: For Against Abstain
  

1a.  Mark G. Foletta

Jorge A. Caballero   
  

1b.   TeriMark G. Fontenot

Foletta
   
  

1c.   R. Jeffrey Harris

Teri G. Fontenot   
  

1d.   Michael M.E. Johns, M.D.

Cary S. Grace   
  

1e.   Daphne E. Jones

R. Jeffrey Harris   
  

1f.   Martha H. Marsh

Daphne E. Jones   
  

1g.   Susan R. Salka

Martha H. Marsh   
  

1h.   DouglasSylvia D. Wheat

Trent-Adams
   

   
   

The Board of Directors recommends you vote FOR proposals 2, 3 and 4.     For    1i.AgainstAbstain  
2.    To approve, by non-binding advisory vote, the compensation of the Company’s named executive officersDouglas D. Wheat   
3.To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020☐  
4.To reduce the threshold necessary to call a Special Meeting of Shareholders☐  
The Board of Directors recommends you vote AGAINST the following proposal:  For     Against Abstain 
5. A shareholder proposal entitled: “Make Shareholder Right to Call Special Meeting More Accessible”  
  
NOTE: In their discretion, the proxies are authorized to vote upon such other business as may come before the Annual Meeting and at any adjournment or postponement of the Annual Meeting. This communication also serves as notice, which is hereby given, that the 2020 Annual Meeting of Shareholders of AMN Healthcare Services, Inc. will be held at the time, date and location set forth on the reverse side.   

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by an authorized officer.
 

     
The Board of Directors recommends you vote FOR proposals 2 and 3.ForAgainstAbstain
2. To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.
3. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
The Board of Directors recommends you vote AGAINST the following proposal:ForAgainstAbstain
4. A shareholder proposal entitled: “Reform the Current Impossible Special Shareholder Meeting Requirement”.
Note: Such other business as may properly come before the meeting or any adjournment thereof.


Signature [PLEASE SIGN WITHIN BOX]  

Date

 

Signature (Joint Owners)

Date


Table of Contents


 

 

 

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:

The Notice &and Proxy Statement and AnnualReport/10-K are available at www.proxyvote.com.

— — — — — — — — — — — — —  — — — — — — — — — — — — — — — — — — — —  — — — — — — — — — — — — — — — — — — — —  — — — — — — — — —

E92737-P33303            

 

AMN HEALTHCARE SERVICES, INC.

Annual Meeting of Shareholders

April 22, 2020 at 8:30 AM CDT

This proxy is solicited by the Board of Directors

The undersigned, revoking all previous proxies, hereby appoints Douglas D. Wheat, R. Jeffrey Harris and Mark G. Foletta, or any of them, as attorneys and proxies with full power of substitution and resubstitution to represent the undersigned and to vote all shares of Common Stock of AMN HEALTHCARE SERVICES, INC. (the “Company”) that the undersigned is entitled to vote at the Annual Meeting of Shareholders of the Company to be held at 8:30 AM Central Time on April 22, 2020, at the Company’s offices located at 8840 Cypress Waters Blvd., Suite 300, Dallas, Texas 75019, or at any adjournment or postponement thereof, with all powers which the undersigned would possess if personally present.

This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations.

In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting and at any adjournment or postponement of the Annual Meeting.

Continued and to be signed on reverse side

V03382-P86205     

AMN HEALTHCARE SERVICES, INC.
Annual Meeting of Shareholders
May 17, 2023 at 1:00 PM CDT
This proxy is solicited by the Board of Directors

The undersigned, revoking all previous proxies, hereby appoints Douglas D. Wheat, R. Jeffrey Harris and Mark G. Foletta, or any of them, as attorneys and proxies with full power of substitution and resubstitution to represent the undersigned and to vote all shares of Common Stock of AMN HEALTHCARE SERVICES, INC. (the “Company”), that the undersigned is entitled to vote at the Annual Meeting of Shareholders of the Company to be held virtually (www.virtualshareholdermeeting.com/AMN2023) at 1:00 PM Central Time on May 17, 2023 or at any adjournment or postponement thereof, with all the powers which the undersigned would possess if personally present.

This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations.

In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

Continued and to be signed on reverse side